Darell Doty Bigner
E. L. and Lucille F. Jones Cancer Distinguished Research Professor, in the School of Medicine
The Causes, Mechanisms of Transformation and Altered Growth Control and New Therapy for Primary and Metastatic Tumors of the Central Nervous System (CNS).
There are over 16,000 deaths in the United States each year from primary brain tumors such as malignant gliomas and medulloblastomas, and metastatic tumors to the CNS and its covering from systemic tumors such as carcinoma of the lung, breast, colon, and melanoma. An estimated 80,000 cases of primary brain tumors were expected to be diagnosed last year. Of that number, approximately 4,600 diagnosed will be children less than 19 years of age. During the last 20 years, however, there has been a significant increase in survival rates for those with primary malignant brain tumors.
For the last 44 years my research has involved the investigation of the causes, mechanism of transformation and altered growth control, and development of new methods of therapy for primary brain tumors and those metastasizing to the CNS and its coverings. In collaboration with my colleagues in the Preston Robert Tisch Brain Tumor Center, new drugs and those not previously thought to be active against CNS tumors have been identified. Overcoming mechanisms of drug resistance in primary brain tumors are also being pursued.
As the founding Director of the Preston Robert Tisch Brain Tumor Center, I help coordinate the research activities of all 37 faculty members in the Brain Tumor Center. These faculty members have projects ranging from very basic research into molecular etiology, molecular epidemiology, signal transduction; translational research performing pre-clinical evaluation of new therapies, and many clinical investigative efforts. I can describe any of the Brain Tumor Center faculty member’s research to third year students and then direct them to specific faculty members with whom the students would like a discussion.
We have identified through genome-wide screening methodology several new target molecules selectively expressed on malignant brain tumors, but not on normal brain. These include EGFRwt, EGFRvIII, and two lacto series gangliosides, 3'-isoLM1 and 3',6'-isoLD1 and chondroitin proteoglycan sulfate. We raised conventional and fully human monoclonal antibodies against most of these targets as well as having developed single fragment chain molecules from naïve human libraries.
My personal research focuses on molecularly targeted therapies of primary and metastatic CNS tumors with monoclonal antibodies and their fragments. Our study we conducted was with a molecule we discovered many years ago, the extracellular matrix molecule, Tenascin. We have treated over 150 malignant brain tumor patients with excellent results with a radiolabeled antibody we developed against Tenascin. We are collaborating with Dr. Ira Pastan at NIH to develop tumor-targeted therapies by fusing single fragment chain molecules from monoclonal antibodies or from naïve human libraries to the truncated fragment of pseudomonas exotoxin A. One example of this is the pseudomonas exotoxin conjugated to a single fragment chain antibody that reacts with wild type EGFR and EGFRvIII, two overexpressed proteins on glioblastoma. The immunotoxin, called D2C7-IT, is currently being investigated in an FDA dose-escalation study, in which patients undergoing treatment of this investigational new drug are showing positive responses. My laboratory is also working with Matthias Gromeier, creator of the oncolytic poliovirus - a re-engineered poliovirus that is lethal to cancer cells, but not lethal to normal cells. The oncolytic poliovirus therapeutic approach has shown such promising results in patients with glioblastoma, that it was recently featured on a on a special two-segment program of 60 Minutes. The next clinical step will be to combine both the virus and the immunotoxin with anti-PD1, an immune checkpoint blockade inhibitor and with anti-CD40, a fully human monoclonal antibody which converts tumor stimulant macrophages into tumor suppressive macrophages. We believe that regional tumor-targeted cytotoxic therapies, such as oncolytic poliovirus and the D2C7 immunotoxin, not only specifically target and destroy tumor cells, but in the process, initiate immune events that promote an in situ vaccine effect. That immune response can be amplified by human checkpoint blockade to engender a long-term systemic immune response that effectively eliminates recurrent and disseminated GBM cells. Ultimately, all three agents may be used together, providing different antigenic targets and cytotoxicity mechanisms.
We have identified through genome-wide screening methodology several new target molecules selectively expressed on malignant brain tumors, but not on normal brain. These include glycoprotein non-metastatic B (GPNMB), a molecule shared with malignant melanoma; MRP3, a member of the multidrug resistant family; and two lacto series gangliosides, 3'-isoLM1 and 3',6'-isoLD1 and chondroitin proteoglycan sulfate. We are raising conventional monoclonal antibodies against all of these targets as well as developing single fragment chain molecules from naïve human libraries. When necessary, affinity maturation in vitro is carried out and the antibodies and fragments are armed either with radioactive iodine, radioactive lutetium, or radioactive Astatine-211. Other constructs are evaluated for unarmed activity and some are armed with Pseudomonas exotoxin. After development of the constructs, they are evaluated in human malignant glioma xenograft systems and then all studies necessary for Investigational New Drug Permits from the Food and Drug Administration are carried out prior to actual clinical trial.
I was senior author on a New England Journal of Medicine paper that was the first to show markedly increased survival in low to intermediate grade gliomas with an isocitrate dehydrogenase mutation.
The first fully funded Specialized Research Center on Primary and Metastatic Tumors to the CNS funded by the National Institutes of Health, of which I was Principal Investigator, was funded for 30 years at which time the type of grant was discontinued. My NCI MERIT Award, which ranked in the upper 1.2 percentile of all NIH grants at the time of its last review, is currently in its 40th year of continuous funding. It is one of the few MERIT awards awarded three consecutive times, and it is the longest continually funded grant of the NCI Division of Cancer Diagnosis and Treatment. My last NCI Award was an Outstanding Investigator Award from 2014 to 2022.
In addition to the representative publications listed, I have made national presentations and international presentations during the past year.
My laboratory has trained over 50 third year medical students, residents, Ph.D. students, and postdoctoral fellows and I have a great deal of experience in career development with some students having advanced all the way from fellowship status to endowed professorships. A major goal with third year medical students is to perform work that can be presented in abstract form at national or international meetings and to obtain publication in major peer-reviewed journals.
There are over 16,000 deaths in the United States each year from primary brain tumors such as malignant gliomas and medulloblastomas, and metastatic tumors to the CNS and its covering from systemic tumors such as carcinoma of the lung, breast, colon, and melanoma. An estimated 80,000 cases of primary brain tumors were expected to be diagnosed last year. Of that number, approximately 4,600 diagnosed will be children less than 19 years of age. During the last 20 years, however, there has been a significant increase in survival rates for those with primary malignant brain tumors.
For the last 44 years my research has involved the investigation of the causes, mechanism of transformation and altered growth control, and development of new methods of therapy for primary brain tumors and those metastasizing to the CNS and its coverings. In collaboration with my colleagues in the Preston Robert Tisch Brain Tumor Center, new drugs and those not previously thought to be active against CNS tumors have been identified. Overcoming mechanisms of drug resistance in primary brain tumors are also being pursued.
As the founding Director of the Preston Robert Tisch Brain Tumor Center, I help coordinate the research activities of all 37 faculty members in the Brain Tumor Center. These faculty members have projects ranging from very basic research into molecular etiology, molecular epidemiology, signal transduction; translational research performing pre-clinical evaluation of new therapies, and many clinical investigative efforts. I can describe any of the Brain Tumor Center faculty member’s research to third year students and then direct them to specific faculty members with whom the students would like a discussion.
We have identified through genome-wide screening methodology several new target molecules selectively expressed on malignant brain tumors, but not on normal brain. These include EGFRwt, EGFRvIII, and two lacto series gangliosides, 3'-isoLM1 and 3',6'-isoLD1 and chondroitin proteoglycan sulfate. We raised conventional and fully human monoclonal antibodies against most of these targets as well as having developed single fragment chain molecules from naïve human libraries.
My personal research focuses on molecularly targeted therapies of primary and metastatic CNS tumors with monoclonal antibodies and their fragments. Our study we conducted was with a molecule we discovered many years ago, the extracellular matrix molecule, Tenascin. We have treated over 150 malignant brain tumor patients with excellent results with a radiolabeled antibody we developed against Tenascin. We are collaborating with Dr. Ira Pastan at NIH to develop tumor-targeted therapies by fusing single fragment chain molecules from monoclonal antibodies or from naïve human libraries to the truncated fragment of pseudomonas exotoxin A. One example of this is the pseudomonas exotoxin conjugated to a single fragment chain antibody that reacts with wild type EGFR and EGFRvIII, two overexpressed proteins on glioblastoma. The immunotoxin, called D2C7-IT, is currently being investigated in an FDA dose-escalation study, in which patients undergoing treatment of this investigational new drug are showing positive responses. My laboratory is also working with Matthias Gromeier, creator of the oncolytic poliovirus - a re-engineered poliovirus that is lethal to cancer cells, but not lethal to normal cells. The oncolytic poliovirus therapeutic approach has shown such promising results in patients with glioblastoma, that it was recently featured on a on a special two-segment program of 60 Minutes. The next clinical step will be to combine both the virus and the immunotoxin with anti-PD1, an immune checkpoint blockade inhibitor and with anti-CD40, a fully human monoclonal antibody which converts tumor stimulant macrophages into tumor suppressive macrophages. We believe that regional tumor-targeted cytotoxic therapies, such as oncolytic poliovirus and the D2C7 immunotoxin, not only specifically target and destroy tumor cells, but in the process, initiate immune events that promote an in situ vaccine effect. That immune response can be amplified by human checkpoint blockade to engender a long-term systemic immune response that effectively eliminates recurrent and disseminated GBM cells. Ultimately, all three agents may be used together, providing different antigenic targets and cytotoxicity mechanisms.
We have identified through genome-wide screening methodology several new target molecules selectively expressed on malignant brain tumors, but not on normal brain. These include glycoprotein non-metastatic B (GPNMB), a molecule shared with malignant melanoma; MRP3, a member of the multidrug resistant family; and two lacto series gangliosides, 3'-isoLM1 and 3',6'-isoLD1 and chondroitin proteoglycan sulfate. We are raising conventional monoclonal antibodies against all of these targets as well as developing single fragment chain molecules from naïve human libraries. When necessary, affinity maturation in vitro is carried out and the antibodies and fragments are armed either with radioactive iodine, radioactive lutetium, or radioactive Astatine-211. Other constructs are evaluated for unarmed activity and some are armed with Pseudomonas exotoxin. After development of the constructs, they are evaluated in human malignant glioma xenograft systems and then all studies necessary for Investigational New Drug Permits from the Food and Drug Administration are carried out prior to actual clinical trial.
I was senior author on a New England Journal of Medicine paper that was the first to show markedly increased survival in low to intermediate grade gliomas with an isocitrate dehydrogenase mutation.
The first fully funded Specialized Research Center on Primary and Metastatic Tumors to the CNS funded by the National Institutes of Health, of which I was Principal Investigator, was funded for 30 years at which time the type of grant was discontinued. My NCI MERIT Award, which ranked in the upper 1.2 percentile of all NIH grants at the time of its last review, is currently in its 40th year of continuous funding. It is one of the few MERIT awards awarded three consecutive times, and it is the longest continually funded grant of the NCI Division of Cancer Diagnosis and Treatment. My last NCI Award was an Outstanding Investigator Award from 2014 to 2022.
In addition to the representative publications listed, I have made national presentations and international presentations during the past year.
My laboratory has trained over 50 third year medical students, residents, Ph.D. students, and postdoctoral fellows and I have a great deal of experience in career development with some students having advanced all the way from fellowship status to endowed professorships. A major goal with third year medical students is to perform work that can be presented in abstract form at national or international meetings and to obtain publication in major peer-reviewed journals.
Current Appointments & Affiliations
- E. L. and Lucille F. Jones Cancer Distinguished Research Professor, in the School of Medicine, Neurosurgery, Neurosurgery 1987
- Professor of Neurosurgery, Neurosurgery, Neurosurgery 2017
- Chief, Division of Experimental Pathology, Pathology, Clinical Science Departments 1994
- Professor of Surgery, Surgery, Clinical Science Departments 1999
- Professor of Pathology, Pathology, Clinical Science Departments 2017
- Member of the Duke Cancer Institute, Duke Cancer Institute, Institutes and Centers 1972
Contact Information
- 177 Med Sci Res Bldg, Durham, NC 27710
- Duke Box 3156, Durham, NC 27710
-
bigne001@mc.duke.edu
(919) 684-5018
- Background
-
Education, Training, & Certifications
- Ph.D., Duke University 1971
- Clinical Associate, Medical Neurology, National Institutes of Health 1968 - 1970
- Fellow, Neurological Surgery, Duke University 1966 - 1968
- Intern, Surgery, Duke University 1965 - 1966
- M.D., Duke University 1965
-
Previous Appointments & Affiliations
- Professor of Pathology, Pathology, Clinical Science Departments 1978 - 2017
- Professor of Neurosurgery, Neurosurgery, Neurosurgery 2016 - 2017
- Vice-chair of Research in the Department of Surgery, Surgery, Clinical Science Departments 2003 - 2004
- Acting Director of the Duke Comprehensive Cancer Center in the School of Medicine, Duke Cancer Institute, Institutes and Centers 1995 - 2003
- Associate Professor of Experimental Surgery in the Department of Surgery, Surgery, Clinical Science Departments 1994 - 1999
- Assistant Professor of Experimental Surgery in the Department of Surgery, Surgery, Clinical Science Departments 1972 - 1977
- Associate Professor of Pathology with tenure, Pathology, Clinical Science Departments 1976 - 1977
- Associate Professor of Pathology, Pathology, Clinical Science Departments 1974 - 1976
- Assistant Professor of Pathology, Pathology, Clinical Science Departments 1972 - 1974
- Recognition
-
In the News
-
OCT 30, 2015 Duke Today -
OCT 30, 2015 -
MAR 31, 2015 Forbes -
MAR 31, 2015 Forbes -
JUL 21, 2014 -
JUL 21, 2014 Duke Today -
MAR 4, 2014 -
MAR 4, 2014 Duke Today
-
-
Awards & Honors
- Recipient, Feldman Founder's Award. National Brain Tumor Society. 2014
- Recipient, Lifetime Achievement Award. Society for Neuro-Oncology. 2014
- Team Leader AACR Team Science Award with Bert Vogelstein (Hopkins) and Ira Pastan (NCI). AACR. 2014
- International Prize for Translational Neuroscience of the Gertrud Reemstsma Foundation(Shared with David Louis, M.D., and awarded in Cologne, Germany) . Gertrud Reemstsma Foundation. 2008
- Doctor of Medicine, honoris causa. University of Lund, Sweden. 2007
- Honorary Member. American Association of Neurological Surgeons. 2007
- Brain Tumor Researcher of the Year. Tug McGraw Foundation. 2006
- Founding Editor. Neuro-Oncology. 1997
- Basic Science Lecture Award. American Society of Cytopathology. 1991
- President. American Association of Neuropathologists. 1988
- Honorary Member, Joint Section on Tumors, American Association of Neurological Surgeons and Congress of Neurological Surgeons. American Association of Neurological Surgeons and Congress of Neurological Surgeson. 1986
- Farber Foundation Brain Tumor Research Award. Farber Foundation. 1985
- Research
-
Selected Grants
- PVSRIPO in melanoma awarded by National Institutes of Health 2020 - 2025
- Regional Oncolytic Poliovirus Immunotherapy for Breast Cancer awarded by Department of Defense 2016 - 2024
- PRECLINICAL THERAPEUTIC SCREENING FOR NEW THERAPIES FOR GLIOBLASTOMA MULTIFORME awarded by Jewish Communal Fund 2022 - 2023
- Reviving cancer immune surveillance with CD4 T cell help awarded by National Institutes of Health 2021 - 2023
- PRECLINICAL THERAPEUTIC SCREENING FOR NEW THERAPIES FOR GLIOBLASTOMA MULTIFORME awarded by Jewish Communal Fund 2007 - 2023
- Innate Antiviral Signals for Cancer Immunotherapy awarded by National Institutes of Health 2018 - 2023
- Duke CTSA (TL1) Year 5 awarded by National Institutes of Health 2018 - 2023
- Translational Research in Surgical Oncology awarded by National Institutes of Health 2002 - 2022
- The Role of CD155 in Leptomeningeal Dissemination and Oncolytic Virus Susceptibility in the Medulloblastoma Microenvironment awarded by Department of Defense 2018 - 2022
- Validation of Novel Therapeutic Approach for Leptomeningeal Metastases awarded by Minnetronix, Inc 2016 - 2022
- Oncolytic Polovirus, Immunotoxin, and Checkpoint Inhibitor Therapy of Gliomas awarded by National Institutes of Health 2015 - 2022
- Is Low Tumor Mutational Burden Predictive of Response to Oncolytic Polio Virus Therapy in Recurrent Glioblastoma? awarded by National Institutes of Health 2019 - 2022
- Phase-1 clinical trial of PVSRIPO oncolytic immunotherapy in pediatric HGG awarded by Solving Kids' Cancer 2016 - 2021
- A novel sustained-release immunotoxin for treatment of glioblastoma multiforme awarded by National Institutes of Health 2019 - 2021
- Cancer Immunotherapy Through Intratumoral Activation of Recall Responses awarded by National Institutes of Health 2018 - 2021
- Organization and Function of Cellular Structure awarded by National Institutes of Health 1975 - 2020
- Anti-tumor efficacy of EGFR-targeting immunotoxin in combination with CCNU or PD-L1 blockade in glioma mouse models awarded by National Cancer Center 2018 - 2020
- The Role of IDH1 Mutations in Gliomagenesis and Metabolism awarded by National Institutes of Health 2009 - 2020
- Systemically administrered EGRFvIII-targeted bispecific antibody as an immunotherapeutic for glioblastoma. awarded by National Institutes of Health 2015 - 2019
- Vaccine Immunotoxin and Radioimmunotherapy of Primary and Metastatic CNS Tumors awarded by National Institutes of Health 2012 - 2018
- Targeting Translation Control in Malignant Glioma awarded by National Institutes of Health 2007 - 2018
- A Genetically Modified Poliovirus and Immunotoxin for Malignant Brain Tumors awarded by Brain Tumor Research Charity 2013 - 2017
- Determining the maximum tolerated dose of a recombinant immunotoxin targeting wildtype EGFR and Mutant EGFRvIII awarded by Uncle Kory Foundation 2016 - 2017
- Oncolytic PVSRIPO Expressing Tumor Antigens as a Cancer Vaccine awarded by Oligo Nation 2016 - 2017
- Enhancing dendritic cell migration to drive potent anti-tumor immune responses awarded by National Institutes of Health 2013 - 2017
- Immunosequencing of poliovirus and immunotoxin treated brain tumor samples awarded by Uncle Kory Foundation 2015 - 2016
- Research Training In Neuro-Oncology awarded by National Institutes of Health 1998 - 2016
- Oncolytic Poliovirus Immunotherapy of Malignant Glioma awarded by The Slomo and Cindy Silvian Foundation, Inc 2014 - 2015
- Clinical Oncology Research Career Development Program awarded by National Institutes of Health 2009 - 2015
- Oncolytic Virotherapy of Meningeal Cancer awarded by National Institutes of Health 2009 - 2015
- SRC on Primary Tumors of the CNS awarded by National Institutes of Health 1999 - 2015
- Adoptive Immunotherapy for GBM During Hematopoietic Recovery from Temozolomide awarded by National Institutes of Health 2009 - 2014
- Targeting EGFRvIII in Brain Tumors with Bispecific Antibodies awarded by National Institutes of Health 2013 - 2014
- Modulation of the blood-tumor barrier through targeted suppression of claudin 5 awarded by National Institutes of Health 2011 - 2013
- Reversal of CMV-specific immune deficits in patients with glioblastoma awarded by National Institutes of Health 2009 - 2013
- Brain Tumors - Immunological and Biological Studies awarded by National Institutes of Health 2001 - 2013
- Nuclear EGFR Signaling Network in Human Cancer awarded by National Institutes of Health 2006 - 2012
- Pre-clinical Translation of Regulatory T-cell Inhibition in Brain Tumors awarded by National Institutes of Health 2010 - 2012
- The Role of OTX2 in Molecular Pathogenesis of Medulloblastoma awarded by National Institutes of Health 2006 - 2012
- Small Animal PET / CT Molecular Imaging awarded by National Institutes of Health 2011 - 2012
- Meningioma: Risk Factors and Quality of Life awarded by National Institutes of Health 2006 - 2012
- SPORE in Brain Cancer awarded by National Institutes of Health 2004 - 2011
- Research Training In Neuro-Oncology awarded by National Institutes of Health 2005 - 2010
- Temodar Resistance in CNS Tumors awarded by National Institutes of Health 1992 - 2010
- Innovative Assays for Oncogenic Hedgehog Signaling awarded by National Institutes of Health 2006 - 2010
- Stem Cell-Like Glioma Cells in Angiogenesis awarded by National Institutes of Health 2008 - 2009
- TGFbeta-PTEN Interactions in Glioma Biology & Therapy awarded by National Institutes of Health 2006 - 2008
- Molecular Mechanisms of SPARC Mediated Glioma Invasion awarded by National Institutes of Health 2006 - 2008
- Phase II Study of 44Gy from 131I-81C6 for CNS Tumors awarded by National Institutes of Health 2003 - 2006
- High-Resolution CGH Characterization of Brain Tumors awarded by National Institutes of Health 2004 - 2006
- Regional AGT Depletion of CNS and Leptomeningeal Tumors awarded by National Institutes of Health 2002 - 2006
- Anti-Tenascin Antibody Constructs awarded by Department of Energy 1995 - 2005
- GCRC CAP awarded by National Institutes of Health 2000 - 2005
- Therapy of Temodar plus O6-Benzulguanine in Malignant Glioma awarded by National Institutes of Health 2003 - 2005
- SPORE in Brain Cancer awarded by National Institutes of Health 2002 - 2004
- Administrative Supplement: SRC on Primary and Metastatic Tumors of the CNS\ awarded by National Institutes of Health 2001 - 2004
- Astatine And Iodine Radiolabeled Monoclonal Antibodies awarded by National Institutes of Health 1999 - 2004
- ZD1839 Therapy of Glioblastoma Multiforme awarded by National Institutes of Health 2001 - 2003
- Development of Novel Tumor Imaging Agents awarded by National Institutes of Health 2000 - 2003
- The Role Of Tgfb In Brain Tumors awarded by National Institutes of Health 1998 - 2001
- Same awarded by National Institutes of Health 1999 - 2001
- Brain Tumors--Immunological and Biological Studies awarded by National Institutes of Health 1976 - 2001
- SRC on Primary and Metastatic Tumors of the CNS awarded by National Institutes of Health 2000 - 2001
- Administrative Supplement to NS20023-15 awarded by National Institutes of Health 1999 - 2000
- Brain Tumors - Immunological And Biological Studies awarded by National Institutes of Health 1997 - 1999
- Src On Primary And Matastatic Tumors Of The Cns awarded by National Institutes of Health 1994 - 1999
- Astatine And Iodine Radiolabeled Monoclonal Antibodies awarded by National Institutes of Health 1994 - 1999
- Src On Primary And Metastatic Tumors Of The Cns awarded by National Institutes of Health 1997 - 1999
- Cancer Center Core Support Grant awarded by National Institutes of Health 1976 - 1998
- Comprehensive Cancer Center Core Support Grant awarded by National Institutes of Health 1976 - 1998
- Comprehensive Cancer Center Core Support Grant awarded by National Institutes of Health 1976 - 1998
- Research Training In Neuro-Oncology awarded by National Institutes of Health 1987 - 1998
- Research Training In Neurology-Oncology awarded by National Institutes of Health 1992 - 1997
- Brain Tumors -- Immunological And Biological Studies awarded by National Institutes of Health 1994 - 1996
- Brain Tumors: Immunological And Biological Studies awarded by National Institutes of Health 1993 - 1996
- Intrathecal Therapy Of Melanoma Neoplastic Meningitis awarded by National Institutes of Health 1993 - 1995
- Src On Malignant Human Gliomas And Medulloblastomas awarded by National Institutes of Health 1993 - 1994
- Src On Malignant Human Gliomas And Medulloblastomas awarded by National Institutes of Health 1992 - 1994
- Src On Malignant Human Gliomas And Medulloblastoma awarded by National Institutes of Health 1989 - 1994
- Brain Tumors: Immunological And Biological Studies awarded by National Institutes of Health 1992 - 1993
- Brain Tumors; Immunological And Biological Studies awarded by National Institutes of Health 1990 - 1993
- Brain Tumor: Immunological And Biological Studies awarded by National Institutes of Health 1988 - 1993
- Malignant Human Gliomas And Medulloblastoma awarded by National Institutes of Health 1987 - 1989
- Malignant Human Gliomas And Medulloblastoma awarded by National Institutes of Health 1985 - 1989
- Sixth International Conference On Brain Tumor Research A awarded by National Institutes of Health 1985 - 1986
-
External Relationships
- Istari Oncology Inc.
- Publications & Artistic Works
-
Selected Publications
-
Books
-
Sampson, J. H., D. D. Bigner, A. H. Friedman, H. S. Friedman, and R. McLendon. The Duke glioma handbook: Pathology, diagnosis, and management, 2016. https://doi.org/10.1017/CBO9781107588721.Full Text
-
McLendon, R. E., M. K. Rosenblum, and D. D. Bigner. Russell and rubinstein's pathology of tumors of the nervous system, 2006.
-
-
Academic Articles
-
Low, Justin T., Vidyalakshmi Chandramohan, Michelle L. Bowie, Michael C. Brown, Matthew S. Waitkus, Aaron Briley, Kevin Stevenson, et al. “Epigenetic STING silencing is developmentally conserved in gliomas and can be rescued by methyltransferase inhibition.” Cancer Cell 40, no. 5 (May 9, 2022): 439–40. https://doi.org/10.1016/j.ccell.2022.04.009.Full Text Link to Item
-
Beasley, Georgia M., Smita K. Nair, Norma E. Farrow, Karenia Landa, Maria Angelica Selim, Carol Ann Wiggs, Sin-Ho Jung, et al. “Phase I trial of intratumoral PVSRIPO in patients with unresectable, treatment-refractory melanoma.” Journal for Immunotherapy of Cancer 9, no. 4 (April 2021): e002203. https://doi.org/10.1136/jitc-2020-002203.Full Text
-
Brown, Michael C., Mubeen M. Mosaheb, Malte Mohme, Zachary P. McKay, Eda K. Holl, Jonathan P. Kastan, Yuanfan Yang, et al. “Viral infection of cells within the tumor microenvironment mediates antitumor immunotherapy via selective TBK1-IRF3 signaling.” Nat Commun 12, no. 1 (March 25, 2021): 1858. https://doi.org/10.1038/s41467-021-22088-1.Full Text Link to Item
-
Gromeier, Matthias, Michael C. Brown, Gao Zhang, Xiang Lin, Yeqing Chen, Zhi Wei, Nike Beaubier, et al. “Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy.” Nat Commun 12, no. 1 (January 13, 2021): 352. https://doi.org/10.1038/s41467-020-20469-6.Full Text Open Access Copy Link to Item
-
Mosaheb, Mubeen M., Elena Y. Dobrikova, Michael C. Brown, Yuanfan Yang, Jana Cable, Hideho Okada, Smita K. Nair, Darell D. Bigner, David M. Ashley, and Matthias Gromeier. “Genetically stable poliovirus vectors activate dendritic cells and prime antitumor CD8 T cell immunity.” Nat Commun 11, no. 1 (January 27, 2020): 524. https://doi.org/10.1038/s41467-019-13939-z.Full Text Link to Item
-
Hansen, Landon J., Ran Sun, Rui Yang, Simranjit X. Singh, Lee H. Chen, Christopher J. Pirozzi, Casey J. Moure, et al. “MTAP Loss Promotes Stemness in Glioblastoma and Confers Unique Susceptibility to Purine Starvation.” Cancer Res 79, no. 13 (July 1, 2019): 3383–94. https://doi.org/10.1158/0008-5472.CAN-18-1010.Full Text Link to Item
-
Chandramohan, Vidyalakshmi, Xuhui Bao, Xin Yu, Scott Parker, Charlotte McDowall, Yen-Rei Yu, Patrick Healy, et al. “Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations.” J Immunother Cancer 7, no. 1 (May 29, 2019): 142. https://doi.org/10.1186/s40425-019-0614-0.Full Text Open Access Copy Link to Item
-
Diplas, Bill H., Heng Liu, Rui Yang, Landon J. Hansen, Alexis L. Zachem, Fangping Zhao, Darell D. Bigner, et al. “Sensitive and rapid detection of TERT promoter and IDH mutations in diffuse gliomas.” Neuro Oncol 21, no. 4 (March 18, 2019): 440–50. https://doi.org/10.1093/neuonc/noy167.Full Text Link to Item
-
Lipp, Eric S., Patrick Healy, Alan Austin, Alysha Clark, Tara Dalton, Kathryn Perkinson, James E. Herndon, et al. “MGMT: Immunohistochemical Detection in High-Grade Astrocytomas.” J Neuropathol Exp Neurol 78, no. 1 (January 1, 2019): 57–64. https://doi.org/10.1093/jnen/nly110.Full Text Link to Item
-
Yu, Xin, Mikhail Dobrikov, Stephen T. Keir, Matthias Gromeier, Ira H. Pastan, Ralph Reisfeld, Darell D. Bigner, and Vidyalakshmi Chandramohan. “Synergistic antitumor effects of 9.2.27-PE38KDEL and ABT-737 in primary and metastatic brain tumors.” Plos One 14, no. 1 (2019): e0210608. https://doi.org/10.1371/journal.pone.0210608.Full Text Open Access Copy Link to Item
-
Thompson, Eric M., Daniel Landi, David Ashley, Stephen T. Keir, and Darell Bigner. “Bevacizumab, irinotecan, temozolomide, tyrosine kinase inhibition, and MEK inhibition are effective against pleomorphic xanthoastrocytoma regardless of V600E status.” J Neurooncol 140, no. 2 (November 2018): 261–68. https://doi.org/10.1007/s11060-018-2975-5.Full Text Link to Item
-
Korkut, Anil, Sobia Zaidi, Rupa S. Kanchi, Shuyun Rao, Nancy R. Gough, Andre Schultz, Xubin Li, et al. “A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-β Superfamily.” Cell Syst 7, no. 4 (October 24, 2018): 422-437.e7. https://doi.org/10.1016/j.cels.2018.08.010.Full Text Link to Item
-
Poteet, Ethan, Gourav Roy Choudhury, Ali Winters, Wenjun Li, Myoung-Gwi Ryou, Ran Liu, Lin Tang, et al. “Correction: Reversing the Warburg effect as a treatment for glioblastoma.” J Biol Chem 293, no. 39 (September 28, 2018): 14973. https://doi.org/10.1074/jbc.AAC118.005625.Full Text Link to Item
-
Woroniecka, Karolina, Pakawat Chongsathidkiet, Kristen Rhodin, Hanna Kemeny, Cosette Dechant, S Harrison Farber, Aladine A. Elsamadicy, et al. “T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma.” Clin Cancer Res 24, no. 17 (September 1, 2018): 4175–86. https://doi.org/10.1158/1078-0432.CCR-17-1846.Full Text Link to Item
-
Lei, Kefeng, Ran Sun, Lee H. Chen, Bill H. Diplas, Casey J. Moure, Wenzhe Wang, Landon J. Hansen, et al. “Mutant allele quantification reveals a genetic basis for TP53 mutation-driven castration resistance in prostate cancer cells.” Sci Rep 8, no. 1 (August 21, 2018): 12507. https://doi.org/10.1038/s41598-018-30062-z.Full Text Link to Item
-
Gedeon, Patrick C., Teilo H. Schaller, Satish K. Chitneni, Bryan D. Choi, Chien-Tsun Kuan, Carter M. Suryadevara, David J. Snyder, et al. “A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma.” Clin Cancer Res 24, no. 15 (August 1, 2018): 3611–31. https://doi.org/10.1158/1078-0432.CCR-17-0126.Full Text Link to Item
-
Thompson, Eric M., Michael Brown, Elena Dobrikova, Vijay Ramaswamy, Michael D. Taylor, Roger McLendon, Jennifer Sanks, Vidya Chandramohan, Darell Bigner, and Matthias Gromeier. “Poliovirus Receptor (CD155) Expression in Pediatric Brain Tumors Mediates Oncolysis of Medulloblastoma and Pleomorphic Xanthoastrocytoma.” J Neuropathol Exp Neurol 77, no. 8 (August 1, 2018): 696–702. https://doi.org/10.1093/jnen/nly045.Full Text Link to Item
-
Desjardins, Annick, Matthias Gromeier, James E. Herndon, Nike Beaubier, Dani P. Bolognesi, Allan H. Friedman, Henry S. Friedman, et al. “Recurrent Glioblastoma Treated with Recombinant Poliovirus.” N Engl J Med 379, no. 2 (July 12, 2018): 150–61. https://doi.org/10.1056/NEJMoa1716435.Full Text Link to Item
-
Keir, Stephen T., Vidyalakshmi Chandramohan, Carlee D. Hemphill, Michael M. Grandal, Maria Carlsen Melander, Mikkel W. Pedersen, Ivan D. Horak, et al. “Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models.” J Neurooncol 138, no. 3 (July 2018): 489–98. https://doi.org/10.1007/s11060-018-2832-6.Full Text Open Access Copy Link to Item
-
Diplas, Bill H., Xujun He, Jacqueline A. Brosnan-Cashman, Heng Liu, Lee H. Chen, Zhaohui Wang, Casey J. Moure, et al. “The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma.” Nat Commun 9, no. 1 (May 25, 2018): 2087. https://doi.org/10.1038/s41467-018-04448-6.Full Text Link to Item
-
Liu, Yang, Nilay S. Sethi, Toshinori Hinoue, Barbara G. Schneider, Andrew D. Cherniack, Francisco Sanchez-Vega, Jose A. Seoane, et al. “Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas.” Cancer Cell 33, no. 4 (April 9, 2018): 721-735.e8. https://doi.org/10.1016/j.ccell.2018.03.010.Full Text Link to Item
-
Di, Chunhui, Nikol Mladkova, James Lin, Brian Fee, Miriam Rivas, Kang Chunsheng, Darell Bigner, and David Cory Adamson. “AJAP1 expression modulates glioma cell motility and correlates with tumor growth and survival.” Int J Oncol 52, no. 1 (January 2018): 47–54. https://doi.org/10.3892/ijo.2017.4184.Full Text Link to Item
-
Erdal, Serap, Bridget J. McCarthy, Natalia Gurule, Marianne Berwick, Emily Gonzales, Johanna Byrd, Kristina Flores, et al. “Application of mutagen sensitivity assay in a glioma case-control study.” Toxicol Rep 5 (2018): 183–88. https://doi.org/10.1016/j.toxrep.2017.12.010.Full Text Link to Item
-
Reap, Elizabeth A., Carter M. Suryadevara, Kristen A. Batich, Luis Sanchez-Perez, Gary E. Archer, Robert J. Schmittling, Pamela K. Norberg, et al. “Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma.” Cancer Res 78, no. 1 (January 1, 2018): 256–64. https://doi.org/10.1158/0008-5472.CAN-17-0469.Full Text Link to Item
-
Waitkus, Matthew S., Christopher J. Pirozzi, Casey J. Moure, Bill H. Diplas, Landon J. Hansen, Austin B. Carpenter, Rui Yang, et al. “Adaptive Evolution of the GDH2 Allosteric Domain Promotes Gliomagenesis by Resolving IDH1R132H-Induced Metabolic Liabilities.” Cancer Res 78, no. 1 (January 1, 2018): 36–50. https://doi.org/10.1158/0008-5472.CAN-17-1352.Full Text Link to Item
-
Xie, Liyi, Chen Lin, Qingfu Zhang, Hailan Piao, Darell D. Bigner, Zhen Zhang, and Xuhui Bao. “Elevated expression of podoplanin and its clinicopathological, prognostic, and therapeutic values in squamous non-small cell lung cancer.” Cancer Manag Res 10 (2018): 1329–40. https://doi.org/10.2147/CMAR.S163510.Full Text Link to Item
-
Chandramohan, Vidyalakshmi, Jeffrey D. Bryant, Hailan Piao, Stephen T. Keir, Eric S. Lipp, Michaela Lefaivre, Kathryn Perkinson, Darell D. Bigner, Matthias Gromeier, and Roger E. McLendon. “Validation of an Immunohistochemistry Assay for Detection of CD155, the Poliovirus Receptor, in Malignant Gliomas.” Arch Pathol Lab Med 141, no. 12 (December 2017): 1697–1704. https://doi.org/10.5858/arpa.2016-0580-OA.Full Text Link to Item
-
Yang, Rui, Lee H. Chen, Landon J. Hansen, Austin B. Carpenter, Casey J. Moure, Heng Liu, Christopher J. Pirozzi, et al. “Cic Loss Promotes Gliomagenesis via Aberrant Neural Stem Cell Proliferation and Differentiation.” Cancer Res 77, no. 22 (November 15, 2017): 6097–6108. https://doi.org/10.1158/0008-5472.CAN-17-1018.Full Text Link to Item
-
Xu, Cheng, Xiaoqing Liu, Yibo Geng, Qingran Bai, Changcun Pan, Yu Sun, Xin Chen, et al. “Patient-derived DIPG cells preserve stem-like characteristics and generate orthotopic tumors.” Oncotarget 8, no. 44 (September 29, 2017): 76644–55. https://doi.org/10.18632/oncotarget.19656.Full Text Link to Item
-
Brown, Michael C., Eda K. Holl, David Boczkowski, Elena Dobrikova, Mubeen Mosaheb, Vidya Chandramohan, Darell D. Bigner, Matthias Gromeier, and Smita K. Nair. “Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen-specific CTLs.” Sci Transl Med 9, no. 408 (September 20, 2017). https://doi.org/10.1126/scitranslmed.aan4220.Full Text Link to Item
-
Thompson, Eric M., Stephen T. Keir, Talaignair Venkatraman, Christopher Lascola, Kristen W. Yeom, Andrew B. Nixon, Yingmiao Liu, et al. “The role of angiogenesis in Group 3 medulloblastoma pathogenesis and survival.” Neuro Oncol 19, no. 9 (September 1, 2017): 1217–27. https://doi.org/10.1093/neuonc/nox033.Full Text Link to Item
-
Yu, Xin, Liang Qu, Darell D. Bigner, and Vidyalakshmi Chandramohan. “Selection of novel affinity-matured human chondroitin sulfate proteoglycan 4 antibody fragments by yeast display.” Protein Eng Des Sel 30, no. 9 (September 1, 2017): 639–47. https://doi.org/10.1093/protein/gzx038.Full Text Link to Item
-
Xu, Cheng, Xiaoqing Liu, Yibo Geng, Qingran Bai, Changcun Pan, Yu Sun, Xin Chen, et al. “Patient-derived DIPG cells preserve stem-like characteristics and generate orthotopic tumors.” Oncotarget, July 28, 2017. https://doi.org/10.18632/oncotarget.19656.Full Text Link to Item
-
Pirozzi, Christopher J., Austin B. Carpenter, Matthew S. Waitkus, Catherine Y. Wang, Huishan Zhu, Landon J. Hansen, Lee H. Chen, et al. “Mutant IDH1 Disrupts the Mouse Subventricular Zone and Alters Brain Tumor Progression.” Mol Cancer Res 15, no. 5 (May 2017): 507–20. https://doi.org/10.1158/1541-7786.MCR-16-0485.Full Text Link to Item
-
Batich, Kristen A., Elizabeth A. Reap, Gary E. Archer, Luis Sanchez-Perez, Smita K. Nair, Robert J. Schmittling, Pam Norberg, et al. “Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination.” Clin Cancer Res 23, no. 8 (April 15, 2017): 1898–1909. https://doi.org/10.1158/1078-0432.CCR-16-2057.Full Text Link to Item
-
Chandramohan, Vidyalakshmi, Charles N. Pegram, Hailan Piao, Scott E. Szafranski, Chien-Tsun Kuan, Ira H. Pastan, and Darell D. Bigner. “Production and quality control assessment of a GLP-grade immunotoxin, D2C7-(scdsFv)-PE38KDEL, for a phase I/II clinical trial.” Appl Microbiol Biotechnol 101, no. 7 (April 2017): 2747–66. https://doi.org/10.1007/s00253-016-8063-x.Full Text Link to Item
-
Hueckel, T., and L. Laloui. “Editorial.” Geomechanics for Energy and the Environment 9 (March 1, 2017): i. https://doi.org/10.1016/S2352-3808(17)30013-8.Full Text
-
Xie, Li-Yi, Hai-Lan Piao, Min Fan, Zhen Zhang, Chen Wang, Darell D. Bigner, and Xu-Hui Bao. “Immunotoxin Therapy for Lung Cancer.” Chinese Medical Journal 130, no. 5 (March 2017): 607–12. https://doi.org/10.4103/0366-6999.200540.Full Text
-
Yu, Xin, Charles N. Pegram, Darell D. Bigner, and Vidyalakshmi Chandramohan. “Development and validation of a cell-based fluorescent method for measuring antibody affinity.” J Immunol Methods 442 (March 2017): 49–53. https://doi.org/10.1016/j.jim.2016.12.004.Full Text Link to Item
-
Holl, Eda K., Michael C. Brown, David Boczkowski, Megan A. McNamara, Daniel J. George, Darell D. Bigner, Matthias Gromeier, and Smita K. Nair. “Recombinant oncolytic poliovirus, PVSRIPO, has potent cytotoxic and innate inflammatory effects, mediating therapy in human breast and prostate cancer xenograft models.” Oncotarget 7, no. 48 (November 29, 2016): 79828–41. https://doi.org/10.18632/oncotarget.12975.Full Text Link to Item
-
Li, Fang, Xinjian Liu, John H. Sampson, Darell D. Bigner, and Chuan-Yuan Li. “Rapid Reprogramming of Primary Human Astrocytes into Potent Tumor-Initiating Cells with Defined Genetic Factors.” Cancer Res 76, no. 17 (September 1, 2016): 5143–50. https://doi.org/10.1158/0008-5472.CAN-16-0171.Full Text Link to Item
-
Bao, Xuhui, Vidyalakshmi Chandramohan, Randall P. Reynolds, John N. Norton, William C. Wetsel, Ramona M. Rodriguiz, Dipendra K. Aryal, et al. “Preclinical toxicity evaluation of a novel immunotoxin, D2C7-(scdsFv)-PE38KDEL, administered via intracerebral convection-enhanced delivery in rats.” Invest New Drugs 34, no. 2 (April 2016): 149–58. https://doi.org/10.1007/s10637-015-0318-3.Full Text Link to Item
-
Thompson, Eric M., Thomas Hielscher, Eric Bouffet, Marc Remke, Betty Luu, Sridharan Gururangan, Roger E. McLendon, et al. “Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis.” Lancet Oncol 17, no. 4 (April 2016): 484–95. https://doi.org/10.1016/S1470-2045(15)00581-1.Full Text Open Access Copy Link to Item
-
Shiina, Satoshi, Masasuke Ohno, Fumiharu Ohka, Shunichiro Kuramitsu, Akane Yamamichi, Akira Kato, Kazuya Motomura, et al. “CAR T Cells Targeting Podoplanin Reduce Orthotopic Glioblastomas in Mouse Brains.” Cancer Immunol Res 4, no. 3 (March 2016): 259–68. https://doi.org/10.1158/2326-6066.CIR-15-0060.Full Text Link to Item
-
Hu, Jing, Tao Sun, Hui Wang, Zhengxin Chen, Shuai Wang, Lifeng Yuan, Tingyu Liu, et al. “MiR-215 Is Induced Post-transcriptionally via HIF-Drosha Complex and Mediates Glioma-Initiating Cell Adaptation to Hypoxia by Targeting KDM1B.” Cancer Cell 29, no. 1 (January 11, 2016): 49–60. https://doi.org/10.1016/j.ccell.2015.12.005.Full Text Open Access Copy Link to Item
-
Bao, Xuhui, Ira Pastan, Darell D. Bigner, and Vidyalakshmi Chandramohan. “EGFR/EGFRvIII-targeted immunotoxin therapy for the treatment of glioblastomas via convection-enhanced delivery.” Receptors Clin Investig 3, no. 4 (2016). https://doi.org/10.14800/rci.1430.Full Text Link to Item
-
Brown, Michael C., Eda K. Holl, David Boczkowski, Darell D. Bigner, Matthias Gromeier, and Smita K. Nair. “Abstract A157: Oncolytic poliovirus mediated immune events.” Cancer Immunology Research 4, no. 1_Supplement (January 1, 2016): A157–A157. https://doi.org/10.1158/2326-6074.cricimteatiaacr15-a157.Full Text
-
Svalina, Matthew N., Ken Kikuchi, Jinu Abraham, Sangeet Lal, Monika A. Davare, Teagan P. Settelmeyer, Michael C. Young, et al. “IGF1R as a Key Target in High Risk, Metastatic Medulloblastoma.” Scientific Reports 6 (2016). https://doi.org/10.1038/srep27012.Full Text Link to Item
-
Okamura, Tatsunori, Gamil Antoun, Stephen T. Keir, Henry Friedman, Darell D. Bigner, and Francis Ali-Osman. “Phosphorylation of Glutathione S-Transferase P1 (GSTP1) by Epidermal Growth Factor Receptor (EGFR) Promotes Formation of the GSTP1-c-Jun N-terminal kinase (JNK) Complex and Suppresses JNK Downstream Signaling and Apoptosis in Brain Tumor Cells.” J Biol Chem 290, no. 52 (December 25, 2015): 30866–78. https://doi.org/10.1074/jbc.M115.656140.Full Text Link to Item
-
Nair, Smita K., Timothy Driscoll, David Boczkowski, Robert Schmittling, Renee Reynolds, Laura A. Johnson, Gerald Grant, et al. “Ex vivo generation of dendritic cells from cryopreserved, post-induction chemotherapy, mobilized leukapheresis from pediatric patients with medulloblastoma.” J Neurooncol 125, no. 1 (October 2015): 65–74. https://doi.org/10.1007/s11060-015-1890-2.Full Text Link to Item
-
Cancer Genome Atlas Research Network, Jianan, Daniel J. Brat, Roel G. W. Verhaak, Kenneth D. Aldape, WK Alfred Yung, Sofie R. Salama, Lee A. D. Cooper, et al. “Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas.” N Engl J Med 372, no. 26 (June 25, 2015): 2481–98. https://doi.org/10.1056/NEJMoa1402121.Full Text Link to Item
-
Brown, Kristine E., Gustavo Chagoya, Shawn G. Kwatra, Timothy Yen, Stephen T. Keir, Mary Cooter, Katherine A. Hoadley, et al. “Proteomic profiling of patient-derived glioblastoma xenografts identifies a subset with activated EGFR: implications for drug development.” J Neurochem 133, no. 5 (June 2015): 730–38. https://doi.org/10.1111/jnc.13032.Full Text Link to Item
-
Schuster, James, Rose K. Lai, Lawrence D. Recht, David A. Reardon, Nina A. Paleologos, Morris D. Groves, Maciej M. Mrugala, et al. “A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study.” Neuro Oncol 17, no. 6 (June 2015): 854–61. https://doi.org/10.1093/neuonc/nou348.Full Text Link to Item
-
Mitchell, Duane A., Kristen A. Batich, Michael D. Gunn, Min-Nung Huang, Luis Sanchez-Perez, Smita K. Nair, Kendra L. Congdon, et al. “Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients.” Nature 519, no. 7543 (March 19, 2015): 366–69. https://doi.org/10.1038/nature14320.Full Text Open Access Copy Link to Item
-
Flores, Catherine, Christina Pham, David Snyder, Shicheng Yang, Luis Sanchez-Perez, Elias Sayour, Xiuyu Cui, et al. “Novel role of hematopoietic stem cells in immunologic rejection of malignant gliomas.” Oncoimmunology 4, no. 3 (March 2015): e994374. https://doi.org/10.4161/2162402X.2014.994374.Full Text Link to Item
-
Flores, Catherine, Christina Pham, David Snyder, Shicheng Yang, Luis Sanchez-Perez, Elias Sayour, Xiuyu Cui, et al. “Novel role of hematopoietic stem cells in immunologic rejection of malignant gliomas.” Oncoimmunology 4, no. 3 (2015). https://doi.org/10.4161/2162402X.2014.994374.Full Text Link to Item
-
Brown, Michael C., Elena Y. Dobrikova, Mikhail I. Dobrikov, Ross W. Walton, Sarah L. Gemberling, Smita K. Nair, Annick Desjardins, et al. “Oncolytic polio virotherapy of cancer.” Cancer 120, no. 21 (November 1, 2014): 3277–86. https://doi.org/10.1002/cncr.28862.Full Text Link to Item
-
Brown, Michael C., Jeffrey D. Bryant, Elena Y. Dobrikova, Mayya Shveygert, Shelton S. Bradrick, Vidyalakshmi Chandramohan, Darell D. Bigner, and Matthias Gromeier. “Induction of viral, 7-methyl-guanosine cap-independent translation and oncolysis by mitogen-activated protein kinase-interacting kinase-mediated effects on the serine/arginine-rich protein kinase.” J Virol 88, no. 22 (November 2014): 13135–48. https://doi.org/10.1128/JVI.01883-14.Full Text Link to Item
-
Desjardins, A., J. Sampson, K. Peters, G. Vlahovic, S. Threatt, J. Herndon, S. Boulton, et al. “AT-21 * FINAL RESULTS OF A PHASE 1 TRIAL OF AN ONCOLYTIC POLIO/RHINOVIRUS RECOMBINANT (PVSRIPO) AGAINST RECURRENT GLIOBLASTOMA (GBM).” Neuro Oncology 16, no. suppl 5 (November 1, 2014): v13–v13. https://doi.org/10.1093/neuonc/nou237.21.Full Text
-
Flores, C., C. Pham, D. Snyder, S. Yang, L. Sanchez-Perez, E. Sayour, X. Cui, et al. “IT-10 * SYNERGISTIC CELLULAR INTERACTIONS IN ADOPTIVE IMMUNOTHERAPY LEADS TO IMMUNOLOGIC REJECTION OF MALIGNANT GLIOMA.” Neuro Oncology 16, no. suppl 5 (November 1, 2014): v111–v111. https://doi.org/10.1093/neuonc/nou258.8.Full Text
-
Keir, S., M. Roskoski, D. Gasinski, H. Friedman, and D. Bigner. “ET-28 * COMBINATION THERAPY WITH MET TYROSINE KINASE INHIBITOR EMD1214063 AND BEVACIZUMAB.” Neuro Oncology 16, no. suppl 5 (November 1, 2014): v85–v85. https://doi.org/10.1093/neuonc/nou255.28.Full Text
-
Vlahovic, G., G. Archer, D. Lally-Goss, E. Reap, K. Batich, A. Desjardins, K. Peters, et al. “IT-34 * PILOT STUDY OF COMBINATION OF ANTITUMOR IMMUNOTHERAPY TARGETED AGAINST CYTOMEGALOVIRUS (CMV) PLUS REGULATORY T-CELL INHIBITION IN PATIENTS WITH NEWLY-DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM).” Neuro Oncology 16, no. suppl 5 (November 1, 2014): v117–v117. https://doi.org/10.1093/neuonc/nou258.32.Full Text
-
Wang, Hui, Tao Sun, Jing Hu, Rui Zhang, Yanhua Rao, Shuai Wang, Rui Chen, et al. “miR-33a promotes glioma-initiating cell self-renewal via PKA and NOTCH pathways.” J Clin Invest 124, no. 10 (October 2014): 4489–4502. https://doi.org/10.1172/JCI75284.Full Text Link to Item
-
Feng, Haizhong, Giselle Y. Lopez, Chung Kwon Kim, Angel Alvarez, Christopher G. Duncan, Ryo Nishikawa, Motoo Nagane, et al. “EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis.” J Clin Invest 124, no. 9 (September 2014): 3741–56. https://doi.org/10.1172/JCI73093.Full Text Open Access Copy Link to Item
-
Babu, Ranjith, Peter G. Kranz, Vijay Agarwal, Roger E. McLendon, Steven Thomas, Allan H. Friedman, Darell D. Bigner, and Cory Adamson. “Malignant brainstem gliomas in adults: clinicopathological characteristics and prognostic factors.” J Neurooncol 119, no. 1 (August 2014): 177–85. https://doi.org/10.1007/s11060-014-1471-9.Full Text Link to Item
-
Archer, G. E., E. Reap, P. Norberg, X. Cui, R. Schmittling, J. Herndon, V. Chandramohan, et al. “Idh1 mutations as a immunotherapeutic target for brain tumors.” Neuro Oncol 16 Suppl 3 (July 2014): iii40. https://doi.org/10.1093/neuonc/nou208.65.Full Text Link to Item
-
Keir, S. T., M. A. Roskoski, D. Gasinski, M. K. Kwatra, H. S. Friedman, and D. D. Bigner. “Identification and preliminary treatment data of xenografts representing tcga-defined subtypes.” Neuro Oncol 16 Suppl 3 (July 2014): iii35. https://doi.org/10.1093/neuonc/nou208.45.Full Text Link to Item
-
Kwatra, M. M., K. E. Brown, G. Chagoya, S. T. Keir, D. D. Bigner, and J. H. Sampson. “Patient-derived xenografts mirror the proteomic profile of human glioblastoma: implications for personalized drug development.” Neuro Oncol 16 Suppl 3 (July 2014): iii38. https://doi.org/10.1093/neuonc/nou208.57.Full Text Link to Item
-
Yan, H., P. J. Killela, Z. J. Reitman, Y. Jiao, C. Bettegowda, N. Agrawal, L. A. Diaz, et al. “Tert promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal.” Neuro Oncol 16 Suppl 3 (July 2014): iii5–6. https://doi.org/10.1093/neuonc/nou206.18.Full Text Link to Item
-
Zhang, Liwei, Lee H. Chen, Hong Wan, Rui Yang, Zhaohui Wang, Jie Feng, Shaohua Yang, et al. “Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas.” Nat Genet 46, no. 7 (July 2014): 726–30. https://doi.org/10.1038/ng.2995.Full Text Link to Item
-
Desjardins, A., J. H. Sampson, K. B. Peters, T. Ranjan, G. Vlahovic, S. Threatt, J. E. Herndon, et al. “Oncolytic polio/rhinovirus recombinant (pvsripo) in recurrent glioblastoma (gbm): first phase I clinical trial evaluating the intratumoral administration.” Neuro Oncol 16 Suppl 3 (July 2014): iii43. https://doi.org/10.1093/neuonc/nou209.5.Full Text Link to Item
-
Gromeier, M., E. Dobrikova, M. Dobrikov, M. Brown, J. Bryant, S. Threatt, S. Boulton, et al. “Oncolytic poliovirus immunotherapy of glioblastoma.” Neuro Oncol 16 Suppl 3 (July 2014): iii41. https://doi.org/10.1093/neuonc/nou208.69.Full Text Link to Item
-
Han, Lei, Kai-Liang Zhang, Jun-Xia Zhang, Liang Zeng, Chun-Hui Di, Brian E. Fee, Miriam Rivas, et al. “AJAP1 is dysregulated at an early stage of gliomagenesis and suppresses invasion through cytoskeleton reorganization.” Cns Neurosci Ther 20, no. 5 (May 2014): 429–37. https://doi.org/10.1111/cns.12232.Full Text Link to Item
-
Brennan, C. W., R. G. W. Verhaak, A. McKenna, B. Campos, H. Noushmehr, S. R. Salama, S. Zheng, et al. “Erratum: The somatic genomic landscape of glioblastoma (Cell (2013) 155 (462-477)).” Cell 157, no. 3 (April 24, 2014): 753. https://doi.org/10.1016/j.cell.2014.04.004.Full Text
-
Killela, Patrick J., Christopher J. Pirozzi, Zachary J. Reitman, Sian Jones, B Ahmed Rasheed, Eric Lipp, Henry Friedman, et al. “The genetic landscape of anaplastic astrocytoma.” Oncotarget 5, no. 6 (March 30, 2014): 1452–57. https://doi.org/10.18632/oncotarget.1505.Full Text Link to Item
-
Killela, Patrick J., Christopher J. Pirozzi, Patrick Healy, Zachary J. Reitman, Eric Lipp, B Ahmed Rasheed, Rui Yang, et al. “Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas.” Oncotarget 5, no. 6 (March 30, 2014): 1515–25. https://doi.org/10.18632/oncotarget.1765.Full Text Open Access Copy Link to Item
-
López, G. Y., G. A. Grant, H. E. Fuchs, L. G. Leithe, S. Gururangan, D. D. Bigner, H. Yan, R. E. McLendon, and Y. He. “Clinico-pathological description of three paediatric medulloblastoma cases with MLL2/3 gene mutations.” Neuropathol Appl Neurobiol 40, no. 2 (February 2014): 217–20. https://doi.org/10.1111/nan.12060.Full Text Link to Item
-
Choi, Bryan D., Carter M. Suryadevara, Patrick C. Gedeon, James E. Herndon, Luis Sanchez-Perez, Darell D. Bigner, and John H. Sampson. “Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma.” J Clin Neurosci 21, no. 1 (January 2014): 189–90. https://doi.org/10.1016/j.jocn.2013.03.012.Full Text Link to Item
-
Miao, Hongsheng, Bryan D. Choi, Carter M. Suryadevara, Luis Sanchez-Perez, Shicheng Yang, Gabriel De Leon, Elias J. Sayour, et al. “EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma.” Plos One 9, no. 4 (2014): e94281. https://doi.org/10.1371/journal.pone.0094281.Full Text Open Access Copy Link to Item
-
Zhang, L., L. H. Chen, H. Wan, R. Yang, Z. Wang, J. Feng, S. Yang, et al. “Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas.” Nature Genetics 46, no. 7 (January 1, 2014): 726–30. https://doi.org/10.1038/ng.2995.Full Text
-
Bota, Daniela A., Daniela Alexandru, Stephen T. Keir, Darell Bigner, James Vredenburgh, and Henry S. Friedman. “Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.” J Neurosurg 119, no. 6 (December 2013): 1415–23. https://doi.org/10.3171/2013.7.JNS1323.Full Text Link to Item
-
Chandramohan, V., and D. D. Bigner. “A novel recombinant immunotoxin-based therapy targeting wild-type and mutant EGFR improves survival in murine models of glioblastoma.” Oncoimmunology 2, no. 12 (December 1, 2013): 1–2. https://doi.org/10.4161/onci.26852.Full Text
-
Choi, B. D., P. C. Gedeon, L. Sanchez-Perez, D. D. Bigner, and J. H. Sampson. “Regulatory T cells are redirected to kill glioblastoma by an EGFRviii-targeted bispecific antibody.” Oncoimmunology 2, no. 12 (December 1, 2013): 1–2. https://doi.org/10.4161/onci.26757.Full Text
-
Choi, Bryan D., Patrick C. Gedeon, Luis Sanchez-Perez, Darell D. Bigner, and John H. Sampson. “Regulatory T cells are redirected to kill glioblastoma by an EGFRvIII-targeted bispecific antibody.” Oncoimmunology 2, no. 12 (December 1, 2013): e26757. https://doi.org/10.4161/onci.26757.Full Text Link to Item
-
Remke, M., V. Ramaswamy, J. Peacock, D. J. H. Shih, C. Koelsche, P. A. Northcott, N. Hill, et al. “TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma.” Acta Neuropathologica 126, no. 6 (December 1, 2013): 917–29. https://doi.org/10.1007/s00401-013-1198-2.Full Text
-
Chandramohan, Vidyalakshmi, and Darell D. Bigner. “A novel recombinant immunotoxin-based therapy targeting wild-type and mutant EGFR improves survival in murine models of glioblastoma.” Oncoimmunology 2, no. 12 (December 1, 2013): e26852. https://doi.org/10.4161/onci.26852.Full Text Open Access Copy Link to Item
-
Remke, Marc, Vijay Ramaswamy, John Peacock, David J. H. Shih, Christian Koelsche, Paul A. Northcott, Nadia Hill, et al. “TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma.” Acta Neuropathol 126, no. 6 (December 2013): 917–29. https://doi.org/10.1007/s00401-013-1198-2.Full Text Link to Item
-
Guo, Changcun, Lee H. Chen, Yafen Huang, Chun-Chi Chang, Ping Wang, Christopher J. Pirozzi, Xiaoxia Qin, et al. “KMT2D maintains neoplastic cell proliferation and global histone H3 lysine 4 monomethylation.” Oncotarget 4, no. 11 (November 2013): 2144–53. https://doi.org/10.18632/oncotarget.1555.Full Text Link to Item
-
Ramaswamy, Vijay, Marc Remke, Eric Bouffet, Claudia C. Faria, Sebastien Perreault, Yoon-Jae Cho, David J. Shih, et al. “Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis.” Lancet Oncol 14, no. 12 (November 2013): 1200–1207. https://doi.org/10.1016/S1470-2045(13)70449-2.Full Text Link to Item
-
Brennan, Cameron W., Roel G. W. Verhaak, Aaron McKenna, Benito Campos, Houtan Noushmehr, Sofie R. Salama, Siyuan Zheng, et al. “The somatic genomic landscape of glioblastoma.” Cell 155, no. 2 (October 10, 2013): 462–77. https://doi.org/10.1016/j.cell.2013.09.034.Full Text Link to Item
-
Frattini, Veronique, Vladimir Trifonov, Joseph Minhow Chan, Angelica Castano, Marie Lia, Francesco Abate, Stephen T. Keir, et al. “The integrated landscape of driver genomic alterations in glioblastoma.” Nat Genet 45, no. 10 (October 2013): 1141–49. https://doi.org/10.1038/ng.2734.Full Text Link to Item
-
Choi, Bryan D., Patrick C. Gedeon, Chien-Tsun Kuan, Luis Sanchez-Perez, Gary E. Archer, Darell D. Bigner, and John H. Sampson. “Rational design and generation of recombinant control reagents for bispecific antibodies through CDR mutagenesis.” J Immunol Methods 395, no. 1–2 (September 30, 2013): 14–20. https://doi.org/10.1016/j.jim.2013.06.003.Full Text Link to Item
-
Chandramohan, Vidyalakshmi, Xuhui Bao, Stephen T. Keir, Charles N. Pegram, Scott E. Szafranski, Hailan Piao, Carol J. Wikstrand, et al. “Construction of an immunotoxin, D2C7-(scdsFv)-PE38KDEL, targeting EGFRwt and EGFRvIII for brain tumor therapy.” Clin Cancer Res 19, no. 17 (September 1, 2013): 4717–27. https://doi.org/10.1158/1078-0432.CCR-12-3891.Full Text Link to Item
-
Choi, Bryan D., Patrick C. Gedeon, James E. Herndon, Gary E. Archer, Elizabeth A. Reap, Luis Sanchez-Perez, Duane A. Mitchell, Darell D. Bigner, and John H. Sampson. “Human regulatory T cells kill tumor cells through granzyme-dependent cytotoxicity upon retargeting with a bispecific antibody.” Cancer Immunol Res 1, no. 3 (September 2013): 163. https://doi.org/10.1158/2326-6066.CIR-13-0049.Full Text Link to Item
-
Gururangan, S., G. A. Grant, T. Driscoll, G. Archer, E. J. Sayour, J. E. Herndon, H. S. Friedman, et al. “ADOPTIVE LYMPHOCYTE THERAPY (ALT) PLUS DENDRITIC CELL VACCINATION (DCV) AFTER MYELOABLATIVE (MA) OR NON-MYELOABLATIVE (NMA) CONDITIONING IN PATIENTS WITH RECURRENT CENTRAL PNET (C-PNET).” Pediatric Blood & Cancer 60 (September 1, 2013): 13–13.Link to Item
-
Sampson, J. H., A. Desjardins, K. B. Peters, T. Ranjan, G. Vlahovic, D. Lally-Goss, S. Threatt, et al. “107 Dose-finding and safety study of an oncolytic polio/rhinovirus recombinant against recurrent glioblastoma.” Neurosurgery 60 Suppl 1 (August 2013): 155. https://doi.org/10.1227/01.neu.0000432699.02392.a4.Full Text Link to Item
-
Chandramohan, Vidyalakshmi, Duane A. Mitchell, Laura A. Johnson, John H. Sampson, and Darell D. Bigner. “Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors.” Future Oncol 9, no. 7 (July 2013): 977–90. https://doi.org/10.2217/fon.13.47.Full Text Link to Item
-
Gedeon, Patrick C., Bryan D. Choi, Tiffany R. Hodges, Duane A. Mitchell, Darell D. Bigner, and John H. Sampson. “An EGFRvIII-targeted bispecific T-cell engager overcomes limitations of the standard of care for glioblastoma.” Expert Rev Clin Pharmacol 6, no. 4 (July 2013): 375–86. https://doi.org/10.1586/17512433.2013.811806.Full Text Link to Item
-
Hodges, Tiffany R., Bryan D. Choi, Darell D. Bigner, Hai Yan, and John H. Sampson. “Isocitrate dehydrogenase 1: what it means to the neurosurgeon: a review.” J Neurosurg 118, no. 6 (June 2013): 1176–80. https://doi.org/10.3171/2013.3.JNS122282.Full Text Link to Item
-
Sayour, Elias, Luis Sanchez-Perez, Christina Pham, David Snyder, Catherine Flores, Hanna Kemeny, Weihua Xie, et al. “ENGINEERING RNA NANOPARTICLE VACCINES TO TARGET MALIGNANT PEDIATRIC BRAIN TUMORS.” Pediatric Blood & Cancer 60 (June 1, 2013): S4–S4.Link to Item
-
Sanchez-Perez, Luis, Bryan D. Choi, Elizabeth A. Reap, Elias J. Sayour, Pamela Norberg, Robert J. Schmittling, Gerald E. Archer, et al. “BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide.” Cancer Immunol Immunother 62, no. 6 (June 2013): 983–87. https://doi.org/10.1007/s00262-013-1405-y.Full Text Link to Item
-
Chandramohan, Vidyalakshmi, Xuhui Bao, Mika Kato Kaneko, Yukinari Kato, Stephen T. Keir, Scott E. Szafranski, Chien-Tsun Kuan, Ira H. Pastan, and Darell D. Bigner. “Recombinant anti-podoplanin (NZ-1) immunotoxin for the treatment of malignant brain tumors.” Int J Cancer 132, no. 10 (May 15, 2013): 2339–48. https://doi.org/10.1002/ijc.27919.Full Text Link to Item
-
Chandramohan, V., D. A. Mitchell, M. Gromeier, J. H. Sampson, and D. D. Bigner. “Current immunotherapeutic targets in gliomas,” May 1, 2013, 287–305.
-
Killela, Patrick J., Zachary J. Reitman, Yuchen Jiao, Chetan Bettegowda, Nishant Agrawal, Luis A. Diaz, Allan H. Friedman, et al. “TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal.” Proc Natl Acad Sci U S A 110, no. 15 (April 9, 2013): 6021–26. https://doi.org/10.1073/pnas.1303607110.Full Text Link to Item
-
Bettegowda, Chetan, Nishant Agrawal, Yuchen Jiao, Yuxuan Wang, Laura D. Wood, Fausto J. Rodriguez, Ralph H. Hruban, et al. “Exomic sequencing of four rare central nervous system tumor types.” Oncotarget 4, no. 4 (April 2013): 572–83. https://doi.org/10.18632/oncotarget.964.Full Text Link to Item
-
Choi, Bryan D., Ira Pastan, Darell D. Bigner, and John H. Sampson. “A novel bispecific antibody recruits T cells to eradicate tumors in the "immunologically privileged" central nervous system.” Oncoimmunology 2, no. 4 (April 1, 2013): e23639. https://doi.org/10.4161/onci.23639.Full Text Link to Item
-
Poteet, Ethan, Gourav Roy Choudhury, Ali Winters, Wenjun Li, Myoung-Gwi Ryou, Ran Liu, Lin Tang, et al. “Reversing the Warburg effect as a treatment for glioblastoma.” J Biol Chem 288, no. 13 (March 29, 2013): 9153–64. https://doi.org/10.1074/jbc.M112.440354.Full Text Link to Item
-
Gedeon, Patrick C., Bryan D. Choi, John H. Sampson, and Darell D. Bigner. “Rindopepimut: anti-EGFRvIII peptide vaccine, oncolytic.” Drugs Future 38, no. 3 (March 2013): 147–55. https://doi.org/10.1358/dof.2013.038.03.1933992.Full Text Link to Item
-
Jin, Genglin, Zachary J. Reitman, Christopher G. Duncan, Ivan Spasojevic, David M. Gooden, B Ahmed Rasheed, Rui Yang, et al. “Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas.” Cancer Res 73, no. 2 (January 15, 2013): 496–501. https://doi.org/10.1158/0008-5472.CAN-12-2852.Full Text Open Access Copy Link to Item
-
Choi, Bryan D., Chien-Tsun Kuan, Mingqing Cai, Gary E. Archer, Duane A. Mitchell, Patrick C. Gedeon, Luis Sanchez-Perez, Ira Pastan, Darell D. Bigner, and John H. Sampson. “Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma.” Proc Natl Acad Sci U S A 110, no. 1 (January 2, 2013): 270–75. https://doi.org/10.1073/pnas.1219817110.Full Text Link to Item
-
Epple, Laura M., Rebecca D. Dodd, Andrea L. Merz, Anjelika M. Dechkovskaia, Matthew Herring, Benjamin A. Winston, Alex M. Lencioni, et al. “Induction of the unfolded protein response drives enhanced metabolism and chemoresistance in glioma cells.” Plos One 8, no. 8 (2013): e73267. https://doi.org/10.1371/journal.pone.0073267.Full Text Link to Item
-
Frattini, V., V. Trifonov, J. M. Chan, A. Castano, M. Lia, F. Abate, S. T. Keir, et al. “The integrated landscape of driver genomic alterations in glioblastoma.” Nature Genetics 45, no. 10 (2013): 1141–49. https://doi.org/10.1038/ng.2734.Full Text
-
Sanchez-Perez, Luis A., Bryan D. Choi, Gary E. Archer, Xiuyu Cui, Catherine Flores, Laura A. Johnson, Robert J. Schmittling, et al. “Myeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in mice.” Plos One 8, no. 3 (2013): e59082. https://doi.org/10.1371/journal.pone.0059082.Full Text Open Access Copy Link to Item
-
Keir, Stephen T., Henry S. Friedman, David A. Reardon, Darell D. Bigner, and Lloyd A. Gray. “Mibefradil, a novel therapy for glioblastoma multiforme: cell cycle synchronization and interlaced therapy in a murine model.” J Neurooncol 111, no. 2 (January 2013): 97–102. https://doi.org/10.1007/s11060-012-0995-0.Full Text Link to Item
-
Piao, Hailan, Chien-Tsun Kuan, Vidya Chandramohan, Stephen T. Keir, Charles N. Pegram, Xuhui Bao, Jan-Eric Månsson, Ira H. Pastan, and Darell D. Bigner. “Affinity-matured recombinant immunotoxin targeting gangliosides 3'-isoLM1 and 3',6'-isoLD1 on malignant gliomas.” Mabs 5, no. 5 (2013): 748–62. https://doi.org/10.4161/mabs.25860.Full Text Link to Item
-
Duncan, Christopher G., Benjamin G. Barwick, Genglin Jin, Carlo Rago, Priya Kapoor-Vazirani, Doris R. Powell, Jen-Tsan Chi, Darell D. Bigner, Paula M. Vertino, and Hai Yan. “A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation.” Genome Res 22, no. 12 (December 2012): 2339–55. https://doi.org/10.1101/gr.132738.111.Full Text Link to Item
-
Mehta, Ankit I., Bryan D. Choi, Divya Ajay, Raghu Raghavan, Martin Brady, Allan H. Friedman, Ira Pastan, Darell D. Bigner, and John H. Sampson. “Convection enhanced delivery of macromolecules for brain tumors.” Curr Drug Discov Technol 9, no. 4 (December 2012): 305–10. https://doi.org/10.2174/157016312803305951.Full Text Link to Item
-
Shao, Huilin, Jaehoon Chung, Leonora Balaj, Alain Charest, Darell D. Bigner, Bob S. Carter, Fred H. Hochberg, Xandra O. Breakefield, Ralph Weissleder, and Hakho Lee. “Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy.” Nat Med 18, no. 12 (December 2012): 1835–40. https://doi.org/10.1038/nm.2994.Full Text Link to Item
-
Reitman, Zachary J., Bryan D. Choi, Ivan Spasojevic, Darell D. Bigner, John H. Sampson, and Hai Yan. “Enzyme redesign guided by cancer-derived IDH1 mutations.” Nat Chem Biol 8, no. 11 (November 2012): 887–89. https://doi.org/10.1038/nchembio.1065.Full Text Link to Item
-
Gurley, Steven N., Ammaar H. Abidi, Patrick Allison, Peihong Guan, Christopher Duntsch, Jon H. Robertson, Stanley D. Kosanke, et al. “Mechanism of anti-glioma activity and in vivo efficacy of the cannabinoid ligand KM-233.” J Neurooncol 110, no. 2 (November 2012): 163–77. https://doi.org/10.1007/s11060-012-0958-5.Full Text Link to Item
-
Guo, Changcun, Chun-Chi Chang, Matthew Wortham, Lee H. Chen, Dawn N. Kernagis, Xiaoxia Qin, Young-Wook Cho, et al. “Global identification of MLL2-targeted loci reveals MLL2's role in diverse signaling pathways.” Proc Natl Acad Sci U S A 109, no. 43 (October 23, 2012): 17603–8. https://doi.org/10.1073/pnas.1208807109.Full Text Link to Item
-
Reardon, D. A., J. E. Herndon, K. B. Peters, A. Desjardins, A. Coan, E. Lou, A. L. Sumrall, et al. “Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients.” Br J Cancer 107, no. 9 (October 23, 2012): 1481–87. https://doi.org/10.1038/bjc.2012.415.Full Text Open Access Copy Link to Item
-
Northcott, Paul A., David J. H. Shih, John Peacock, Livia Garzia, A Sorana Morrissy, Thomas Zichner, Adrian M. Stütz, et al. “Subgroup-specific structural variation across 1,000 medulloblastoma genomes.” Nature 488, no. 7409 (August 2, 2012): 49–56. https://doi.org/10.1038/nature11327.Full Text Link to Item
-
Jin, Genglin, Christopher J. Pirozzi, Lee H. Chen, Giselle Y. Lopez, Christopher G. Duncan, Jie Feng, Ivan Spasojevic, Darell D. Bigner, Yiping He, and Hai Yan. “Mutant IDH1 is required for IDH1 mutated tumor cell growth.” Oncotarget 3, no. 8 (August 2012): 774–82. https://doi.org/10.18632/oncotarget.577.Full Text Open Access Copy Link to Item
-
Jiao, Yuchen, Patrick J. Killela, Zachary J. Reitman, Ahmed B. Rasheed, Christopher M. Heaphy, Roeland F. de Wilde, Fausto J. Rodriguez, et al. “Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas.” Oncotarget 3, no. 7 (July 2012): 709–22. https://doi.org/10.18632/oncotarget.588.Full Text Open Access Copy Link to Item
-
Cory Adamsona, D., B. A. K. Rasheed, R. E. McLendon, and D. D. Bigner. “Central nervous system,” March 1, 2012, 193–210. https://doi.org/10.3233/978-1-61499-024-6-193.Full Text
-
Lin, Ningjing, Chunhui Di, Kathy Bortoff, Jinrong Fu, Peter Truszkowski, Patrick Killela, Chris Duncan, et al. “Deletion or epigenetic silencing of AJAP1 on 1p36 in glioblastoma.” Mol Cancer Res 10, no. 2 (February 2012): 208–17. https://doi.org/10.1158/1541-7786.MCR-10-0109.Full Text Link to Item
-
Wortham, Matthew, Genglin Jin, Julia Lailai Sun, Darell D. Bigner, Yiping He, and Hai Yan. “Aberrant Otx2 expression enhances migration and induces ectopic proliferation of hindbrain neuronal progenitor cells.” Plos One 7, no. 4 (2012): e36211. https://doi.org/10.1371/journal.pone.0036211.Full Text Link to Item
-
Chandramohan, Vidyalakshmi, John H. Sampson, Ira Pastan, and Darell D. Bigner. “Toxin-based targeted therapy for malignant brain tumors.” Clin Dev Immunol 2012 (2012): 480429. https://doi.org/10.1155/2012/480429.Full Text Open Access Copy Link to Item
-
Jones, Siân, Meng Li, D Williams Parsons, Xiaosong Zhang, Jelle Wesseling, Petra Kristel, Marjanka K. Schmidt, et al. “Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types.” Hum Mutat 33, no. 1 (January 2012): 100–103. https://doi.org/10.1002/humu.21633.Full Text Link to Item
-
Marshall, Deana, Duane A. Mitchell, Michael W. Graner, and Darell D. Bigner. “Immunotherapy of brain tumors.” Handb Clin Neurol 104 (2012): 309–30. https://doi.org/10.1016/B978-0-444-52138-5.00020-7.Full Text Link to Item
-
Sampson, John H., Robert J. Schmittling, Gary E. Archer, Kendra L. Congdon, Smita K. Nair, Elizabeth A. Reap, Annick Desjardins, et al. “A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma.” Plos One 7, no. 2 (2012): e31046. https://doi.org/10.1371/journal.pone.0031046.Full Text Open Access Copy Link to Item
-
Zalutsky, Michael R., Abraham Boskovitz, Chien-Tsun Kuan, Charles N. Pegram, Joanne Ayriss, Carol J. Wikstrand, Anne F. Buckley, et al. “Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptors.” Nucl Med Biol 39, no. 1 (January 2012): 23–34. https://doi.org/10.1016/j.nucmedbio.2011.06.005.Full Text Link to Item
-
Keir, Stephen T., David A. Reardon, Henry S. Friedman, and Darrel D. Bigner. “ACTIVITY OF THE PAN-HER INHIBITOR PF-00299804 AGAINST A PANEL OF BRAIN TUMOR XENOGRAFTS.” Neuro Oncology 13 (November 1, 2011): 164–164.Link to Item
-
Keir, Stephen T., David A. Reardon, Julia R. Saling, Lloyd S. Gray, Darell D. Bigner, and Henry S. Friedman. “MIBEFRADIL, A NOVEL THERAPY FOR GLIOBLATOMA MULTIFORME: INTERLACED THERAPY IN A MURINE MODEL.” Neuro Oncology 13 (November 1, 2011): 108–9.Link to Item
-
Kwatra, Madan M., Tara M. Porter, Kristine E. Brown, James E. Herndon, and Darell D. Bigner. “TRUNCATED NEUROKININ 1 RECEPTOR: EXPRESSION IN PRIMARY GLIOBLASTOMAS AND RELATIONSHIP WITH PATIENT SURVIVAL.” Neuro Oncology 13 (November 1, 2011): 82–82.Link to Item
-
Mitchell, Duane A., Gary E. Archer, Henry S. Friedman, James E. Herndon, Darell D. Bigner, and John H. Sampson. “DENDRITIC CELL VACCINES TARGETING CYTOMEGALOVIRUS IN GLIOBLASTOMA.” Neuro Oncology 13 (November 1, 2011): 39–39.Link to Item
-
Grant, Gerald A., Christy Wilson, Sara Salami, Paolo Macaroni, Shuqin Li, Ji-Young Park, David Needham, Darell Bigner, and Mark Dewhirst. “PRECLINICAL USE OF MILD HYPERTHERMIA TO ENHANCE DRUG DELIVERY TO BRAIN TUMORS.” Neuro Oncology 13 (November 1, 2011): 111–111.Link to Item
-
Mitchell, Duane A., Xiuyu Cui, Robert J. Schmittling, Luis Sanchez-Perez, David J. Snyder, Kendra L. Congdon, Gary E. Archer, et al. “Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans.” Blood 118, no. 11 (September 15, 2011): 3003–12. https://doi.org/10.1182/blood-2011-02-334565.Full Text Link to Item
-
Bettegowda, Chetan, Nishant Agrawal, Yuchen Jiao, Mark Sausen, Laura D. Wood, Ralph H. Hruban, Fausto J. Rodriguez, et al. “Mutations in CIC and FUBP1 contribute to human oligodendroglioma.” Science 333, no. 6048 (September 9, 2011): 1453–55. https://doi.org/10.1126/science.1210557.Full Text Link to Item
-
Sampson, John H., Raghu Raghavan, Martin Brady, Allan H. Friedman, and Darell Bigner. “Convection-enhanced delivery.” J Neurosurg 115, no. 3 (September 2011): 463–64. https://doi.org/10.3171/2010.11.JNS101801.Full Text Link to Item
-
Sampson, John H., Martin Brady, Raghu Raghavan, Ankit I. Mehta, Allan H. Friedman, David A. Reardon, Neil A. Petry, et al. “Colocalization of gadolinium-diethylene triamine pentaacetic acid with high-molecular-weight molecules after intracerebral convection-enhanced delivery in humans.” Neurosurgery 69, no. 3 (September 2011): 668–76. https://doi.org/10.1227/NEU.0b013e3182181ba8.Full Text Link to Item
-
Mehta, A. I., O. Persson, J. E. Herndon, G. E. Archer, R. McLendon, A. B. Heimberger, D. A. Mitchell, D. D. Bigner, and J. H. Sampson. “Reply to M.S. Lesniak.” Journal of Clinical Oncology 29, no. 22 (August 1, 2011): 3105–6. https://doi.org/10.1200/JCO.2011.35.0256.Full Text
-
Heaphy, Christopher M., Roeland F. de Wilde, Yuchen Jiao, Alison P. Klein, Barish H. Edil, Chanjuan Shi, Chetan Bettegowda, et al. “Altered telomeres in tumors with ATRX and DAXX mutations.” Science 333, no. 6041 (July 22, 2011): 425. https://doi.org/10.1126/science.1207313.Full Text Link to Item
-
Choi, Bryan D., Mingqing Cai, Darell D. Bigner, Ankit I. Mehta, Chien-Tsun Kuan, and John H. Sampson. “Bispecific antibodies engage T cells for antitumor immunotherapy.” Expert Opin Biol Ther 11, no. 7 (July 2011): 843–53. https://doi.org/10.1517/14712598.2011.572874.Full Text Link to Item
-
Kuan, Chien-Tsun, Kenji Wakiya, Stephen T. Keir, Jianjun Li, James E. Herndon, Ira Pastan, and Darell D. Bigner. “Affinity-matured anti-glycoprotein NMB recombinant immunotoxins targeting malignant gliomas and melanomas.” Int J Cancer 129, no. 1 (July 1, 2011): 111–21. https://doi.org/10.1002/ijc.25645.Full Text Link to Item
-
Vredenburgh, James J., Annick Desjardins, David A. Reardon, Katherine B. Peters, James E. Herndon, Jennifer Marcello, John P. Kirkpatrick, et al. “The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma.” Clin Cancer Res 17, no. 12 (June 15, 2011): 4119–24. https://doi.org/10.1158/1078-0432.CCR-11-0120.Full Text Link to Item
-
Heimberger, A. B., D. D. Bigner, J. E. Herndon, and J. H. Sampson. “Reply to M.C. Chamberlain.” Journal of Clinical Oncology 29, no. 17 (June 10, 2011). https://doi.org/10.1200/JCO.2010.34.1453.Full Text
-
Davis, Faith, Dora Il’yasova, Kristin Rankin, Bridget McCarthy, and Darell D. Bigner. “Medical diagnostic radiation exposures and risk of gliomas.” Radiat Res 175, no. 6 (June 2011): 790–96. https://doi.org/10.1667/RR2186.1.Full Text Link to Item
-
Liu, Irwin, Stephen Keir, B Ahmed Rasheed, and Darell Bigner. “Abstract 4417: Characterization of xenograft-derived EGFRvIII-positive GBM cell cultures reveals functional interactions between EGFRvIII, wild-type EGFR, and p53.” Cancer Research 71, no. 8_Supplement (April 15, 2011): 4417–4417. https://doi.org/10.1158/1538-7445.am2011-4417.Full Text
-
Reardon, David A., Scott Turner, Katherine B. Peters, Annick Desjardins, Sridharan Gururangan, John H. Sampson, Roger E. McLendon, et al. “A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma.” J Natl Compr Canc Netw 9, no. 4 (April 2011): 414–27. https://doi.org/10.6004/jnccn.2011.0038.Full Text Link to Item
-
Mehta, Ankit I., Bryan D. Choi, Raghu Raghavan, Martin Brady, Allan H. Friedman, Darell D. Bigner, Ira Pastan, and John H. Sampson. “Imaging of convection enhanced delivery of toxins in humans.” Toxins (Basel) 3, no. 3 (March 2011): 201–6. https://doi.org/10.3390/toxins3030201.Full Text Link to Item
-
Mehta, Ankit I., Charles W. Kanaly, Allan H. Friedman, Darell D. Bigner, and John H. Sampson. “Monitoring radiographic brain tumor progression.” Toxins (Basel) 3, no. 3 (March 2011): 191–200. https://doi.org/10.3390/toxins3030191.Full Text Link to Item
-
Liu, Quan, Gerald Grant, Jianjun Li, Yan Zhang, Fangyao Hu, Shuqin Li, Christy Wilson, Kui Chen, Darell Bigner, and Tuan Vo-Dinh. “Compact point-detection fluorescence spectroscopy system for quantifying intrinsic fluorescence redox ratio in brain cancer diagnostics.” J Biomed Opt 16, no. 3 (March 2011): 037004. https://doi.org/10.1117/1.3558840.Full Text Link to Item
-
Sampson, John H., Kenneth D. Aldape, Gary E. Archer, April Coan, Annick Desjardins, Allan H. Friedman, Henry S. Friedman, et al. “Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.” Neuro Oncol 13, no. 3 (March 2011): 324–33. https://doi.org/10.1093/neuonc/noq157.Full Text Link to Item
-
Reitman, Zachary J., Genglin Jin, Edward D. Karoly, Ivan Spasojevic, Jian Yang, Kenneth W. Kinzler, Yiping He, Darell D. Bigner, Bert Vogelstein, and Hai Yan. “Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome.” Proc Natl Acad Sci U S A 108, no. 8 (February 22, 2011): 3270–75. https://doi.org/10.1073/pnas.1019393108.Full Text Link to Item
-
Jin, Genglin, Zachary J. Reitman, Ivan Spasojevic, Ines Batinic-Haberle, Jian Yang, Oleg Schmidt-Kittler, Darell D. Bigner, and Hai Yan. “2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations.” Plos One 6, no. 2 (February 4, 2011): e16812. https://doi.org/10.1371/journal.pone.0016812.Full Text Link to Item
-
McCarthy, Bridget J., Kristin Rankin, Dora Il’yasova, Serap Erdal, Nicholas Vick, Francis Ali-Osman, Darell D. Bigner, and Faith Davis. “Assessment of type of allergy and antihistamine use in the development of glioma.” Cancer Epidemiol Biomarkers Prev 20, no. 2 (February 2011): 370–78. https://doi.org/10.1158/1055-9965.EPI-10-0948.Full Text Link to Item
-
Keir, Stephen T., Mark W. Dewhirst, John P. Kirkpatrick, Darell D. Bigner, and Ines Batinic-Haberle. “Cellular redox modulator, ortho Mn(III) meso-tetrakis(N-n-hexylpyridinium-2-yl)porphyrin, MnTnHex-2-PyP(5+) in the treatment of brain tumors.” Anticancer Agents Med Chem 11, no. 2 (February 2011): 202–12. https://doi.org/10.2174/187152011795255957.Full Text Link to Item
-
Parsons, D Williams, Meng Li, Xiaosong Zhang, Siân Jones, Rebecca J. Leary, Jimmy Cheng-Ho Lin, Simina M. Boca, et al. “The genetic landscape of the childhood cancer medulloblastoma.” Science 331, no. 6016 (January 28, 2011): 435–39. https://doi.org/10.1126/science.1198056.Full Text Link to Item
-
Kanaly, Charles W., Dale Ding, Ankit I. Mehta, Anthony F. Waller, Ian Crocker, Annick Desjardins, David A. Reardon, Allan H. Friedman, Darell D. Bigner, and John H. Sampson. “A novel method for volumetric MRI response assessment of enhancing brain tumors.” Plos One 6, no. 1 (January 26, 2011): e16031. https://doi.org/10.1371/journal.pone.0016031.Full Text Link to Item
-
Reardon, David A., James J. Vredenburgh, Annick Desjardins, Katherine Peters, Sridharan Gururangan, John H. Sampson, Jennifer Marcello, et al. “Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma.” J Neurooncol 101, no. 1 (January 2011): 57–66. https://doi.org/10.1007/s11060-010-0217-6.Full Text Link to Item
-
Barth, Rolf F., Virginia M. Sanders, and Darell D. Bigner. “Allan J. Yates, MD, PhD, FRCP(C) (1943–2010).” Journal of Neuropathology &Amp; Experimental Neurology 69, no. 12 (December 2010): 1272–73. https://doi.org/10.1097/nen.0b013e318200b662.Full Text
-
Kuan, Chien-Tsun, Jinli Chang, Jan-Eric Mansson, Jianjun Li, Charles Pegram, Pam Fredman, Roger E. McLendon, and Darell D. Bigner. “Multiple phenotypic changes in mice after knockout of the B3gnt5 gene, encoding Lc3 synthase--a key enzyme in lacto-neolacto ganglioside synthesis.” Bmc Dev Biol 10 (November 18, 2010): 114. https://doi.org/10.1186/1471-213X-10-114.Full Text Open Access Copy Link to Item
-
Cui, Bo, Stewart P. Johnson, Nancy Bullock, Francis Ali-Osman, Darell D. Bigner, and Henry S. Friedman. “Decoupling of DNA damage response signaling from DNA damages underlies temozolomide resistance in glioblastoma cells.” J Biomed Res 24, no. 6 (November 2010): 424–35. https://doi.org/10.1016/S1674-8301(10)60057-7.Full Text Link to Item
-
Sampson, John H., Amy B. Heimberger, Gary E. Archer, Kenneth D. Aldape, Allan H. Friedman, Henry S. Friedman, Mark R. Gilbert, et al. “Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.” J Clin Oncol 28, no. 31 (November 1, 2010): 4722–29. https://doi.org/10.1200/JCO.2010.28.6963.Full Text Link to Item
-
Grant, Gerald A., Christy Wilson, Matthew Campbell, Peter Humphries, Shuqin Li, Jianjun Li, Allan Johnson, Darell Bigner, and Mark Dewhirst. “REVERSIBLE OPENING OF THE BBB BY TARGETED SUPPRESSION OF CLAUDIN 5 TO ENHANCE DRUG DELIVERY TO BRAIN TUMORS.” Neuro Oncology 12 (November 1, 2010): 98–98.Link to Item
-
Hens, Marc, Ganesan Vaidyanathan, Xiao-Guang Zhao, Darell D. Bigner, and Michael R. Zalutsky. “Anti-EGFRvIII monoclonal antibody armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands.” Nucl Med Biol 37, no. 7 (October 2010): 741–50. https://doi.org/10.1016/j.nucmedbio.2010.04.020.Full Text Link to Item
-
Kato, Yukinari, Ganesan Vaidyanathan, Mika Kato Kaneko, Kazuhiko Mishima, Nidhi Srivastava, Vidyalakshmi Chandramohan, Charles Pegram, et al. “Evaluation of anti-podoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas.” Nucl Med Biol 37, no. 7 (October 2010): 785–94. https://doi.org/10.1016/j.nucmedbio.2010.03.010.Full Text Link to Item
-
Wheeler, S. E., S. Suzuki, S. M. Thomas, M. Sen, R. J. Leeman-Neill, S. I. Chiosea, C. -. T. Kuan, et al. “Epidermal growth factor receptor variant III mediates head and neck cancer cell invasion via STAT3 activation.” Oncogene 29, no. 37 (September 16, 2010): 5135–45. https://doi.org/10.1038/onc.2009.279.Full Text Link to Item
-
Kuan, Chien-Tsun, Kenji Wakiya, James E. Herndon, Eric S. Lipp, Charles N. Pegram, Gregory J. Riggins, Ahmed Rasheed, et al. “MRP3: a molecular target for human glioblastoma multiforme immunotherapy.” Bmc Cancer 10 (September 1, 2010): 468. https://doi.org/10.1186/1471-2407-10-468.Full Text Open Access Copy Link to Item
-
Jin, Genglin, Stephen Cook, Bo Cui, William C. Chen, Stephen T. Keir, Patrick Killela, Chunhui Di, et al. “HDMX regulates p53 activity and confers chemoresistance to 3-bis(2-chloroethyl)-1-nitrosourea.” Neuro Oncol 12, no. 9 (September 2010): 956–66. https://doi.org/10.1093/neuonc/noq045.Full Text Link to Item
-
Duncan, Christopher G., Patrick J. Killela, Cathy A. Payne, Benjamin Lampson, William C. Chen, Jeff Liu, David Solomon, et al. “Integrated genomic analyses identify ERRFI1 and TACC3 as glioblastoma-targeted genes.” Oncotarget 1, no. 4 (August 2010): 265–77. https://doi.org/10.18632/oncotarget.137.Full Text Link to Item
-
Kuan, Chien-Tsun, Nidhi Srivastava, Roger E. McLendon, Wayne A. Marasco, Michael R. Zalutsky, and Darell D. Bigner. “Recombinant single-chain variable fragment antibodies against extracellular epitopes of human multidrug resistance protein MRP3 for targeting malignant gliomas.” Int J Cancer 127, no. 3 (August 1, 2010): 598–611. https://doi.org/10.1002/ijc.25062.Full Text Link to Item
-
Lopez, Giselle Y., Zachary J. Reitman, David Solomon, Todd Waldman, Darell D. Bigner, Roger E. McLendon, Steven A. Rosenberg, Yardena Samuels, and Hai Yan. “IDH1(R132) mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain.” Biochem Biophys Res Commun 398, no. 3 (July 30, 2010): 585–87. https://doi.org/10.1016/j.bbrc.2010.06.125.Full Text Open Access Copy Link to Item
-
Zalutsky, M. R., D. A. Reardon, and D. D. Bigner. “Targeted Radiotherapy of Central Nervous System Malignancies,” July 15, 2010, 139–67. https://doi.org/10.1002/9780470613214.ch5.Full Text
-
Reitman, Zachary J., Natasha J. Olby, Christopher L. Mariani, Rachael Thomas, Matthew Breen, Darell D. Bigner, Roger E. McLendon, and Hai Yan. “IDH1 and IDH2 hotspot mutations are not found in canine glioma.” Int J Cancer 127, no. 1 (July 1, 2010): 245–46. https://doi.org/10.1002/ijc.25017.Full Text Link to Item
-
Ding, D., C. W. Kanaly, D. D. Bigner, T. J. Cummings, J. E. Herndon, I. Pastan, R. Raghavan, and J. H. Sampson. “Erratum: Convection-enhanced delivery of free gadolinium with the recombinant immunotoxin MR1-1 (Journal of Neuro-Oncology DOI 10.1007/s11060-009-0046-7).” Journal of Neuro Oncology 98, no. 1 (May 1, 2010): 9. https://doi.org/10.1007/s11060-010-0183-z.Full Text
-
Ding, Dale, Charles W. Kanaly, Darrell D. Bigner, Thomas J. Cummings, James E. Herndon, Ira Pastan, Raghu Raghavan, and John H. Sampson. “Convection-enhanced delivery of free gadolinium with the recombinant immunotoxin MR1-1.” J Neurooncol 98, no. 1 (May 2010): 1–7. https://doi.org/10.1007/s11060-009-0046-7.Full Text Link to Item
-
Adamson, D Cory, B Ahmed K. Rasheed, Roger E. McLendon, and Darell D. Bigner. “Central nervous system.” Cancer Biomark 9, no. 1–6 (2010): 193–210. https://doi.org/10.3233/CBM-2011-0177.Full Text Link to Item
-
Adamson, David C., Qun Shi, Matthew Wortham, Paul A. Northcott, Chunhui Di, Christopher G. Duncan, Jianjun Li, et al. “OTX2 is critical for the maintenance and progression of Shh-independent medulloblastomas.” Cancer Res 70, no. 1 (January 1, 2010): 181–91. https://doi.org/10.1158/0008-5472.CAN-09-2331.Full Text Link to Item
-
Kato, Yukinari, Chien-Tsun Kuan, Jinli Chang, Mika Kato Kaneko, Joanne Ayriss, Hailan Piao, Vidyalakshmi Chandramohan, et al. “GMab-1, a high-affinity anti-3'-isoLM1/3',6'-isoLD1 IgG monoclonal antibody, raised in lacto-series ganglioside-defective knockout mice.” Biochem Biophys Res Commun 391, no. 1 (January 1, 2010): 750–55. https://doi.org/10.1016/j.bbrc.2009.11.132.Full Text Link to Item
-
Nakahara, Yukiko, Paul A. Northcott, Meihua Li, Paul N. Kongkham, Christian Smith, Hai Yan, Sidney Croul, et al. “Genetic and epigenetic inactivation of Kruppel-like factor 4 in medulloblastoma.” Neoplasia 12, no. 1 (January 2010): 20–27. https://doi.org/10.1593/neo.91122.Full Text Link to Item
-
Kato, Yukinari, Genglin Jin, Chien-Tsun Kuan, Roger E. McLendon, Hai Yan, and Darell D. Bigner. “A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation.” Biochem Biophys Res Commun 390, no. 3 (December 18, 2009): 547–51. https://doi.org/10.1016/j.bbrc.2009.10.001.Full Text Link to Item
-
Yan, Hai, Darell D. Bigner, Victor Velculescu, and D Williams Parsons. “Mutant metabolic enzymes are at the origin of gliomas.” Cancer Res 69, no. 24 (December 15, 2009): 9157–59. https://doi.org/10.1158/0008-5472.CAN-09-2650.Full Text Link to Item
-
Reardon, D. A., A. Desjardins, J. J. Vredenburgh, S. Gururangan, J. H. Sampson, S. Sathornsumetee, R. E. McLendon, et al. “Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study.” Br J Cancer 101, no. 12 (December 15, 2009): 1986–94. https://doi.org/10.1038/sj.bjc.6605412.Full Text Open Access Copy Link to Item
-
Bigner, D. D. “In tribute to Mike Traynor (1939-2009).” Neuro Oncology 11, no. 6 (December 1, 2009): 724. https://doi.org/10.1215/15228517-2009-094.Full Text
-
Kuan, Chien-Tsun, Carol J. Wikstrand, Roger E. McLendon, Michael R. Zalutsky, Ujendra Kumar, and Darell D. Bigner. “Detection of amino-terminal extracellular domain of somatostatin receptor 2 by specific monoclonal antibodies and quantification of receptor density in medulloblastoma.” Hybridoma (Larchmt) 28, no. 6 (December 2009): 389–403. https://doi.org/10.1089/hyb.2009.0049.Full Text Open Access Copy Link to Item
-
Lu, Zheming, Lei Zhou, Patrick Killela, Ahmed B. Rasheed, Chunhui Di, William E. Poe, Roger E. McLendon, Darell D. Bigner, Christopher Nicchitta, and Hai Yan. “Glioblastoma proto-oncogene SEC61gamma is required for tumor cell survival and response to endoplasmic reticulum stress.” Cancer Res 69, no. 23 (December 1, 2009): 9105–11. https://doi.org/10.1158/0008-5472.CAN-09-2775.Full Text Link to Item
-
Choi, Bryan D., Gary E. Archer, Duane A. Mitchell, Amy B. Heimberger, Roger E. McLendon, Darell D. Bigner, and John H. Sampson. “EGFRvIII-targeted vaccination therapy of malignant glioma.” Brain Pathol 19, no. 4 (October 2009): 713–23. https://doi.org/10.1111/j.1750-3639.2009.00318.x.Full Text Link to Item
-
Sampson, John H., Gary E. Archer, Duane A. Mitchell, Amy B. Heimberger, James E. Herndon, Denise Lally-Goss, Sharon McGehee-Norman, et al. “An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme.” Mol Cancer Ther 8, no. 10 (October 2009): 2773–79. https://doi.org/10.1158/1535-7163.MCT-09-0124.Full Text Link to Item
-
Bektas, Meryem, Stewart P. Johnson, William E. Poe, Darell D. Bigner, and Henry S. Friedman. “A sphingosine kinase inhibitor induces cell death in temozolomide resistant glioblastoma cells.” Cancer Chemother Pharmacol 64, no. 5 (October 2009): 1053–58. https://doi.org/10.1007/s00280-009-1063-0.Full Text Link to Item
-
Graner, Michael W., Deborah A. Raynes, Darell D. Bigner, and Vince Guerriero. “Heat shock protein 70-binding protein 1 is highly expressed in high-grade gliomas, interacts with multiple heat shock protein 70 family members, and specifically binds brain tumor cell surfaces.” Cancer Sci 100, no. 10 (October 2009): 1870–79. https://doi.org/10.1111/j.1349-7006.2009.01269.x.Full Text Link to Item
-
Quinn, Jennifer A., Sara Xiaoyin Jiang, David A. Reardon, Annick Desjardins, James J. Vredenburgh, Jeremy N. Rich, Sridharan Gururangan, et al. “Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma.” Neuro Oncol 11, no. 5 (October 2009): 556–61. https://doi.org/10.1215/15228517-2009-007.Full Text Link to Item
-
Adamson, Cory, Okezie O. Kanu, Ankit I. Mehta, Chunhui Di, Ningjing Lin, Austin K. Mattox, and Darell D. Bigner. “Glioblastoma multiforme: a review of where we have been and where we are going.” Expert Opin Investig Drugs 18, no. 8 (August 2009): 1061–83. https://doi.org/10.1517/13543780903052764.Full Text Link to Item
-
Affronti, Mary Lou, Christopher R. Heery, James E. Herndon, Jeremy N. Rich, David A. Reardon, Annick Desjardins, James J. Vredenburgh, Allan H. Friedman, Darell D. Bigner, and Henry S. Friedman. “Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy.” Cancer 115, no. 15 (August 1, 2009): 3501–11. https://doi.org/10.1002/cncr.24398.Full Text Link to Item
-
Boskovitz, Abraham, Roger E. McLendon, Tatsunori Okamura, John H. Sampson, Darell D. Bigner, and Michael R. Zalutsky. “Treatment of HER2-positive breast carcinomatous meningitis with intrathecal administration of alpha-particle-emitting (211)At-labeled trastuzumab.” Nucl Med Biol 36, no. 6 (August 2009): 659–69. https://doi.org/10.1016/j.nucmedbio.2009.04.003.Full Text Link to Item
-
Solomon, David A., Jung-Sik Kim, Habtom W. Ressom, Zita Sibenaller, Timothy Ryken, Walter Jean, Darell Bigner, Hai Yan, and Todd Waldman. “Sample type bias in the analysis of cancer genomes.” Cancer Res 69, no. 14 (July 15, 2009): 5630–33. https://doi.org/10.1158/0008-5472.CAN-09-1055.Full Text Link to Item
-
Okamura, Tatsunori, Simendra Singh, John Buolamwini, Timothy Haystead, Henry Friedman, Darell Bigner, and Francis Ali-Osman. “Tyrosine phosphorylation of the human glutathione S-transferase P1 by epidermal growth factor receptor.” J Biol Chem 284, no. 25 (June 19, 2009): 16979–89. https://doi.org/10.1074/jbc.M808153200.Full Text Link to Item
-
Kanu, Okezie O., Ankit Mehta, Chunhui Di, Ningjing Lin, Kathy Bortoff, Darell D. Bigner, Hai Yan, and David Cory Adamson. “Glioblastoma multiforme: a review of therapeutic targets.” Expert Opin Ther Targets 13, no. 6 (June 2009): 701–18. https://doi.org/10.1517/14728220902942348.Full Text Link to Item
-
Cui, B., S. P. Johnson, N. Bullock, F. Ali-Osman, D. D. Bigner, and H. S. Friedman. “Bifunctional DNA alkylator 1,3-bis(2-chloroethyl)-1-nitrosourea activates the ATR-Chk1 pathway independently of the mismatch repair pathway.” Mol Pharmacol 75, no. 6 (June 2009): 1356–63. https://doi.org/10.1124/mol.108.053124.Full Text Link to Item
-
Heimberger, A. B., G. E. Archer, D. A. Mitchell, D. D. Bigner, R. J. Schmittling, J. E. Herndon, T. Davis, et al. “Epidermal growth factor receptor variant III (EGFRvIII) vaccine (CDX-110) in GBM.” J Clin Oncol 27, no. 15_suppl (May 20, 2009): 2021.Link to Item
-
Herndon, J., J. Vredenburgh, D. Reardon, A. Desjardins, K. Peters, S. Gururangan, J. Norfleet, A. Friedman, D. Bigner, and H. S. Friedman. “Phase I trial of vendetanib and oral etoposide for recurrent malignant gliomas.” J Clin Oncol 27, no. 15_suppl (May 20, 2009): e13016.Link to Item
-
Peters, K., A. Desjardins, D. A. Reardon, S. Perry, J. E. Herndon, L. Bailey, A. H. Friedman, H. S. Friedman, D. D. Bigner, and J. J. Vredenburgh. “Temozolomide (TMZ) and bevacizumab (BV) as initial treatment for unresectable or multifocal glioblastoma multiforme (GBM).” J Clin Oncol 27, no. 15_suppl (May 20, 2009): e13025.Link to Item
-
Sampson, J. H., G. E. Archer, D. D. Bigner, R. J. Schmittling, J. E. Herndon, T. Davis, H. S. Friedman, T. Keler, D. A. Reardon, and D. A. Mitchell. “Effect of daclizumab on TReg counts and EGFRvIII-specific immune responses in GBM.” J Clin Oncol 27, no. 15_suppl (May 20, 2009): 2034.Link to Item
-
Duncan, Christopher G., Rebecca J. Leary, Jimmy Cheng-Ho Lin, Jordan Cummins, Chunhui Di, Carl F. Schaefer, Tian-Li Wang, et al. “Identification of microbial DNA in human cancer.” Bmc Med Genomics 2 (May 8, 2009): 22. https://doi.org/10.1186/1755-8794-2-22.Full Text Link to Item
-
Graner, Michael W., Oscar Alzate, Angelika M. Dechkovskaia, Jack D. Keene, John H. Sampson, Duane A. Mitchell, and Darell D. Bigner. “Proteomic and immunologic analyses of brain tumor exosomes.” Faseb J 23, no. 5 (May 2009): 1541–57. https://doi.org/10.1096/fj.08-122184.Full Text Link to Item
-
Kanu, Okezie O., Betsy Hughes, Chunhui Di, Ningjing Lin, Jinrong Fu, Darell D. Bigner, Hai Yan, and Cory Adamson. “Glioblastoma Multiforme Oncogenomics and Signaling Pathways.” Clin Med Oncol 3 (April 8, 2009): 39–52. https://doi.org/10.4137/cmo.s1008.Full Text Link to Item
-
Archer, Gary E., Amy B. Heimberger, Darell D. Bigner, Tom Davis, Henry S. Friedman, Tibor Keler, Roger E. McLendon, et al. “INDUCTION OF IMMUNOLOGIC AND CLINICAL RESPONSES WITH EGFRVIII-TARGETED VACCINE (CDX-110) WITH CYCLES OF TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED EGFRVIII-POSITIVE GBM.” Neuro Oncology 11, no. 2 (April 1, 2009): 224–224.Link to Item
-
Chandramohan, Vidyalakshmi, Chien-Tsun Kuan, Charles N. Pegram, Ira Pastan, and Darell D. Bigner. “DUAL-SPECIFIC IMMUNOTOXIN, D2C7 (SCDSFV)-PE38KDEL, FOR BRAIN TUMOR TREATMENT.” Neuro Oncology 11, no. 2 (April 1, 2009): 223–223.Link to Item
-
Guruiangan, Sridharan, Hai Yan, Cory Adamson, Qun Shi, Roger McLendon, and Darell Bigner. “OTX2 IS ONCOGENIC AND PREDICTS DECREASED SURVIVAL IN MEDULLOBLASTOMA PATIENTS.” Neuro Oncology 11, no. 2 (April 1, 2009): 234–234.Link to Item
-
Il’yasova, Dora, Bridget McCarthy, Jennifer Marcello, Joellen M. Schildkraut, Patricia G. Moorman, Bhuma Krishnamachari, Francis Ali-Osman, Darell D. Bigner, and Faith Davis. “Association between glioma and history of allergies, asthma, and eczema: a case-control study with three groups of controls.” Cancer Epidemiol Biomarkers Prev 18, no. 4 (April 2009): 1232–38. https://doi.org/10.1158/1055-9965.EPI-08-0995.Full Text Link to Item
-
Kuan, Chien-Tsun, Kenji Wakiya, James E. Herndon, Carol J. Wikstrand, Roger E. McLendon, Michael R. Zalutsky, Ira H. Pastan, and Darell D. Bigner. “RECOMBINANT ANTIBODY-BASED MOLECULAR THERAPEUTICS FOR BRAIN TUMOR IMMUNOTHERAPY.” Neuro Oncology 11, no. 2 (April 1, 2009): 224–224.Link to Item
-
Northcott, Paul A., Yukiko Nakahara, Xiaochong Wu, Lars Feuk, David W. Ellison, Sid Croul, Stephen Mack, et al. “Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma.” Nat Genet 41, no. 4 (April 2009): 465–72. https://doi.org/10.1038/ng.336.Full Text Link to Item
-
Okamura, Tatsunori, Simendrah Singh, John K. Buolamwini, Henry S. Friedman, Darell D. Bigner, and Francis Ali-Osman. “EGF RECEPTOR TYROSINE KINASE MEDIATES A NOVEL PATHWAY OF DRUG RESISTANCE IN MALIGNANT GLIOMAS VIA TYROSINE PHOSPHORYLATION AND FUNCTIONAL ACTIVATION OF GLUTATHIONE S-TRANSFERASE P1.” Neuro Oncology 11, no. 2 (April 1, 2009): 218–218.Link to Item
-
Quinn, Jennifer A., Sara Xiaoyin Jiang, David A. Reardon, Annick Desjardins, James J. Vredenburgh, Jeremy N. Rich, Sridharan Gururangan, et al. “Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma.” J Clin Oncol 27, no. 8 (March 10, 2009): 1262–67. https://doi.org/10.1200/JCO.2008.18.8417.Full Text Link to Item
-
Il’yasova, Dora, Bridget J. McCarthy, Serap Erdal, Joanna Shimek, Jennifer Goldstein, Daniel R. Doerge, Steven R. Myers, et al. “Human exposure to selected animal neurocarcinogens: a biomarker-based assessment and implications for brain tumor epidemiology.” J Toxicol Environ Health B Crit Rev 12, no. 3 (March 2009): 175–87. https://doi.org/10.1080/10937400902894152.Full Text Link to Item
-
Bacolod, Manny D., Randy Fehdrau, Stewart P. Johnson, Nancy S. Bullock, Darell D. Bigner, Michael Colvin, and Henry S. Friedman. “BCNU-sequestration by metallothioneins may contribute to resistance in a medulloblastoma cell line.” Cancer Chemother Pharmacol 63, no. 4 (March 2009): 753–58. https://doi.org/10.1007/s00280-008-0792-9.Full Text Link to Item
-
Yan, Hai, D Williams Parsons, Genglin Jin, Roger McLendon, B Ahmed Rasheed, Weishi Yuan, Ivan Kos, et al. “IDH1 and IDH2 mutations in gliomas.” N Engl J Med 360, no. 8 (February 19, 2009): 765–73. https://doi.org/10.1056/NEJMoa0808710.Full Text Link to Item
-
Liu, Yingmiao, Chien-Tsun Kuan, Jing Mi, Xiuwu Zhang, Bryan M. Clary, Darell D. Bigner, and Bruce A. Sullenger. “Aptamers selected against the unglycosylated EGFRvIII ectodomain and delivered intracellularly reduce membrane-bound EGFRvIII and induce apoptosis.” Biol Chem 390, no. 2 (February 2009): 137–44. https://doi.org/10.1515/BC.2009.022.Full Text Link to Item
-
Quinn, Jennifer A., Sara Xiaoyin Jiang, James Carter, David A. Reardon, Annick Desjardins, James J. Vredenburgh, Jeremy N. Rich, et al. “Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme.” Clin Cancer Res 15, no. 3 (February 1, 2009): 1064–68. https://doi.org/10.1158/1078-0432.CCR-08-2130.Full Text Link to Item
-
Kato, Yukinari, Kazuhiko Mishima, Mika Kaneko, Michael Zalutsky, Chien-Tsun Kuan, and Darell Bigner. “Podoplanin is a novel antibody-based therapeutic target for glioblastoma.” Cancer Research 69 (2009).Link to Item
-
Solomon, David A., Jung-Sik Kim, Julia C. Cronin, Zita Sibenaller, Timothy Ryken, Steven A. Rosenberg, Habtom Ressom, et al. “Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma.” Cancer Res 68, no. 24 (December 15, 2008): 10300–306. https://doi.org/10.1158/0008-5472.CAN-08-3272.Full Text Link to Item
-
Schmittling, Robert J., Gary E. Archer, Duane A. Mitchell, Amy Heimberger, Charles Pegram, James E. Herndon, Henry S. Friedman, Darell D. Bigner, and John H. Sampson. “Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines.” J Immunol Methods 339, no. 1 (November 30, 2008): 74–81. https://doi.org/10.1016/j.jim.2008.08.004.Full Text Link to Item
-
Desjardins, Annick, David A. Reardon, James E. Herndon, Jennifer Marcello, Jennifer A. Quinn, Jeremy N. Rich, Sith Sathornsumetee, et al. “Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas.” Clin Cancer Res 14, no. 21 (November 1, 2008): 7068–73. https://doi.org/10.1158/1078-0432.CCR-08-0260.Full Text Link to Item
-
Cancer Genome Atlas Research Network, P. “Comprehensive genomic characterization defines human glioblastoma genes and core pathways.” Nature 455, no. 7216 (October 23, 2008): 1061–68. https://doi.org/10.1038/nature07385.Full Text Link to Item
-
Sampson, John H., Gary E. Archer, Duane A. Mitchell, Amy B. Heimberger, and Darell D. Bigner. “Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma.” Semin Immunol 20, no. 5 (October 2008): 267–75. https://doi.org/10.1016/j.smim.2008.04.001.Full Text Link to Item
-
Parsons, D Williams, Siân Jones, Xiaosong Zhang, Jimmy Cheng-Ho Lin, Rebecca J. Leary, Philipp Angenendt, Parminder Mankoo, et al. “An integrated genomic analysis of human glioblastoma multiforme.” Science 321, no. 5897 (September 26, 2008): 1807–12. https://doi.org/10.1126/science.1164382.Full Text Link to Item
-
Karakoula, Katherine, Nicola Potter, Steven T. Keir, Darell D. Bigner, Kim P. Phipps, William Harkness, Richard Hayward, et al. “GENETIC PROFILING IN TUMOR XENOGRAFTS FROM PAEDIATRIC GLIOMAS BY EXPRESSION AND HIGH RESOLUTION COMPARATIVE GENOMIC HYBRIDISATION MICROARRAYS.” Anticancer Research 28, no. 5C (September 1, 2008): 3341–3341.Link to Item
-
Maxwell, Jill A., Stewart P. Johnson, Roger E. McLendon, David W. Lister, Krystle S. Horne, Ahmed Rasheed, Jennifer A. Quinn, et al. “Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma.” Clin Cancer Res 14, no. 15 (August 1, 2008): 4859–68. https://doi.org/10.1158/1078-0432.CCR-07-4807.Full Text Link to Item
-
Sampson, John H., Gamal Akabani, Gerald E. Archer, Mitchel S. Berger, R Edward Coleman, Allan H. Friedman, Henry S. Friedman, et al. “Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors.” Neuro Oncol 10, no. 3 (June 2008): 320–29. https://doi.org/10.1215/15228517-2008-012.Full Text Link to Item
-
Mitchell, D., G. E. Archer, D. D. Bigner, H. S. Friedman, D. Lally-Goss, J. E. Herndon, S. McGehee, R. McLendon, D. A. Reardon, and J. H. Sampson. “Efficacy of a phase II vaccine targeting Cytomegalovirus antigens in newly diagnosed GBM.” Journal of Clinical Oncology 26, no. 15 (May 20, 2008).Link to Item
-
Sampson, J. H., G. E. Archer, D. D. Bigner, T. Davis, H. S. Friedman, T. Keler, D. A. Mitchell, D. A. Reardon, R. Sawaya, and A. B. Heimberger. “Effect of EGFRvIII-targeted vaccine (CDX-110) on immune response and TTP when given with simultaneous standard and continuous temozolomide in patients with GBM.” Journal of Clinical Oncology 26, no. 15_suppl (May 20, 2008): 2011–2011. https://doi.org/10.1200/jco.2008.26.15_suppl.2011.Full Text
-
Bacolod, M. D., S. M. Lin, S. P. Johnson, N. S. Bullock, M. Colvin, D. D. Bigner, and H. S. Friedman. “The gene expression profiles of medulloblastoma cell lines resistant to preactivated cyclophosphamide.” Curr Cancer Drug Targets 8, no. 3 (May 2008): 172–79. https://doi.org/10.2174/156800908784293631.Full Text Link to Item
-
Everson, Richard G., Michael W. Graner, Matthias Gromeier, James J. Vredenburgh, Annick Desjardins, David A. Reardon, Henry S. Friedman, Allan H. Friedman, Darell D. Bigner, and John H. Sampson. “Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma.” Expert Rev Anticancer Ther 8, no. 5 (May 2008): 717–32. https://doi.org/10.1586/14737140.8.5.717.Full Text Link to Item
-
Solomon, David A., Jung-Sik Kim, Sultan Jenkins, Habtom Ressom, Michael Huang, Nicholas Coppa, Lauren Mabanta, et al. “Identification of p18 INK4c as a tumor suppressor gene in glioblastoma multiforme.” Cancer Res 68, no. 8 (April 15, 2008): 2564–69. https://doi.org/10.1158/0008-5472.CAN-07-6388.Full Text Link to Item
-
Reardon, David A., Michael R. Zalutsky, Gamal Akabani, R Edward Coleman, Allan H. Friedman, James E. Herndon, Roger E. McLendon, et al. “A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost.” Neuro Oncol 10, no. 2 (April 2008): 182–89. https://doi.org/10.1215/15228517-2007-053.Full Text Link to Item
-
Heimberger, Amy B., Wei Sun, S Farzana Hussain, Mahua Dey, Lamonne Crutcher, Ken Aldape, Mark Gilbert, et al. “Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study.” Neuro Oncol 10, no. 1 (February 2008): 98–103. https://doi.org/10.1215/15228517-2007-046.Full Text Link to Item
-
Mott, Ryan T., Kristi C. Turner, Darell D. Bigner, and Roger E. McLendon. “Utility of EGFR and PTEN numerical aberrations in the evaluation of diffusely infiltrating astrocytomas. Laboratory investigation.” J Neurosurg 108, no. 2 (February 2008): 330–35. https://doi.org/10.3171/JNS/2008/108/2/0330.Full Text Link to Item
-
Yoshimoto, Koji, Julie Dang, Shaojun Zhu, David Nathanson, Tiffany Huang, Rebecca Dumont, David B. Seligson, et al. “Development of a real-time RT-PCR assay for detecting EGFRvIII in glioblastoma samples.” Clin Cancer Res 14, no. 2 (January 15, 2008): 488–93. https://doi.org/10.1158/1078-0432.CCR-07-1966.Full Text Link to Item
-
Ochiai, Hidenobu, Gary E. Archer, James E. Herndon, Chien-Tsun Kuan, Duane A. Mitchell, Darell D. Bigner, Ira H. Pastan, and John H. Sampson. “EGFRvIII-targeted immunotoxin induces antitumor immunity that is inhibited in the absence of CD4+ and CD8+ T cells.” Cancer Immunol Immunother 57, no. 1 (January 2008): 115–21. https://doi.org/10.1007/s00262-007-0363-7.Full Text Link to Item
-
Zalutsky, Michael R., David A. Reardon, Gamal Akabani, R Edward Coleman, Allan H. Friedman, Henry S. Friedman, Roger E. McLendon, Terence Z. Wong, and Darell D. Bigner. “Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6.” J Nucl Med 49, no. 1 (January 2008): 30–38. https://doi.org/10.2967/jnumed.107.046938.Full Text Link to Item
-
Johnson, Stewart P., Barton A. Kamen, Darell D. Bigner, and Henry S. Friedman. “O (4)-benzylfolic acid inactivates O (6)-alkylguanine-DNA alkyltransferase in brain tumor cell lines.” Cancer Chemother Pharmacol 60, no. 6 (November 2007): 883–89. https://doi.org/10.1007/s00280-007-0435-6.Full Text Link to Item
-
Vredenburgh, James J., Annick Desjardins, James E. Herndon, Jennifer Marcello, David A. Reardon, Jennifer A. Quinn, Jeremy N. Rich, et al. “Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.” J Clin Oncol 25, no. 30 (October 20, 2007): 4722–29. https://doi.org/10.1200/JCO.2007.12.2440.Full Text Link to Item
-
Graner, Michael W., R Ian Cumming, and Darell D. Bigner. “The heat shock response and chaperones/heat shock proteins in brain tumors: surface expression, release, and possible immune consequences.” J Neurosci 27, no. 42 (October 17, 2007): 11214–27. https://doi.org/10.1523/JNEUROSCI.3588-07.2007.Full Text Link to Item
-
Zalutsky, Michael R., David A. Reardon, Oscar R. Pozzi, Ganesan Vaidyanathan, and Darell D. Bigner. “Targeted alpha-particle radiotherapy with 211At-labeled monoclonal antibodies.” Nucl Med Biol 34, no. 7 (October 2007): 779–85. https://doi.org/10.1016/j.nucmedbio.2007.03.007.Full Text Link to Item
-
Hjelmeland, Anita B., Kathryn P. Lattimore, Brian E. Fee, Qing Shi, Sarah Wickman, Stephen T. Keir, Mark D. Hjelmeland, et al. “The combination of novel low molecular weight inhibitors of RAF (LBT613) and target of rapamycin (RAD001) decreases glioma proliferation and invasion.” Mol Cancer Ther 6, no. 9 (September 2007): 2449–57. https://doi.org/10.1158/1535-7163.MCT-07-0155.Full Text Link to Item
-
Badruddoja, Michael A., Stephen T. Keir, Ivan King, Joseph Zeidner, James J. Vredenburgh, Lawrence H. Muhlbaier, Darell D. Bigner, and Henry S. Friedman. “Activity of VNP40101M (Cloretazine) in the treatment of CNS tumor xenografts in athymic mice.” Neuro Oncol 9, no. 3 (July 2007): 240–44. https://doi.org/10.1215/15228517-2007-011.Full Text Link to Item
-
Sampson, John H., Raghu Raghavan, Martin L. Brady, James M. Provenzale, James E. Herndon, David Croteau, Allan H. Friedman, et al. “Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusions.” Neuro Oncol 9, no. 3 (July 2007): 343–53. https://doi.org/10.1215/15228517-2007-007.Full Text Link to Item
-
Shi, Q., S. Bao, L. Song, Q. Wu, D. D. Bigner, A. B. Hjelmeland, and J. N. Rich. “Targeting SPARC expression decreases glioma cellular survival and invasion associated with reduced activities of FAK and ILK kinases.” Oncogene 26, no. 28 (June 14, 2007): 4084–94. https://doi.org/10.1038/sj.onc.1210181.Full Text Link to Item
-
Shi, Qing, Anita B. Hjelmeland, Stephen T. Keir, Linhua Song, Sarah Wickman, Dowdy Jackson, Osamu Ohmori, Darell D. Bigner, Henry S. Friedman, and Jeremy N. Rich. “A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth.” Mol Carcinog 46, no. 6 (June 2007): 488–96. https://doi.org/10.1002/mc.20297.Full Text Link to Item
-
McLendon, Roger E., Gamal Akabani, Henry S. Friedman, David A. Reardon, Linda Cleveland, Ilkcan Cokgor, James E. Herndon, et al. “Tumor resection cavity administered iodine-131-labeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects.” Nucl Med Biol 34, no. 4 (May 2007): 405–13. https://doi.org/10.1016/j.nucmedbio.2007.01.009.Full Text Link to Item
-
Reardon, David A., Michael R. Zalutsky, and Darell D. Bigner. “Antitenascin-C monoclonal antibody radioimmunotherapy for malignant glioma patients.” Expert Rev Anticancer Ther 7, no. 5 (May 2007): 675–87. https://doi.org/10.1586/14737140.7.5.675.Full Text Link to Item
-
Fecci, Peter E., Hidenobu Ochiai, Duane A. Mitchell, Peter M. Grossi, Alison E. Sweeney, Gary E. Archer, Thomas Cummings, James P. Allison, Darell D. Bigner, and John H. Sampson. “Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function.” Clin Cancer Res 13, no. 7 (April 1, 2007): 2158–67. https://doi.org/10.1158/1078-0432.CCR-06-2070.Full Text Link to Item
-
Jones, Lee W., Bebe Guill, Stephen T. Keir, Karen Carter, Henry S. Friedman, Darell D. Bigner, and David A. Reardon. “Using the theory of planned behavior to understand the determinants of exercise intention in patients diagnosed with primary brain cancer.” Psychooncology 16, no. 3 (March 2007): 232–40. https://doi.org/10.1002/pon.1077.Full Text Link to Item
-
Vredenburgh, James J., Annick Desjardins, James E. Herndon, Jeannette M. Dowell, David A. Reardon, Jennifer A. Quinn, Jeremy N. Rich, et al. “Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.” Clin Cancer Res 13, no. 4 (February 15, 2007): 1253–59. https://doi.org/10.1158/1078-0432.CCR-06-2309.Full Text Link to Item
-
Sampson, John H., Martin L. Brady, Neil A. Petry, David Croteau, Allan H. Friedman, Henry S. Friedman, Terence Wong, et al. “Intracerebral infusate distribution by convection-enhanced delivery in humans with malignant gliomas: descriptive effects of target anatomy and catheter positioning.” Neurosurgery 60, no. 2 Suppl 1 (February 2007): ONS89–98. https://doi.org/10.1227/01.NEU.0000249256.09289.5F.Full Text Link to Item
-
Yordanov, Alexander T., Marc Hens, Charles Pegram, Darell D. Bigner, and Michael R. Zalutsky. “Antitenascin antibody 81C6 armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands.” Nucl Med Biol 34, no. 2 (February 2007): 173–83. https://doi.org/10.1016/j.nucmedbio.2006.11.003.Full Text Link to Item
-
Jones, Lee W., Bebe Guill, Stephen T. Keir, Karen Carter, Henry S. Friedman, Darell D. Bigner, and David A. Reardon. “Exercise interest and preferences among patients diagnosed with primary brain cancer.” Support Care Cancer 15, no. 1 (January 2007): 47–55. https://doi.org/10.1007/s00520-006-0096-8.Full Text Link to Item
-
Badruddoja, Michael A., Kara Penne, Annick Desjardins, David A. Reardon, Jeremy N. Rich, Jennifer A. Quinn, Sith Sathornsumetee, et al. “Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme.” Neuro Oncol 9, no. 1 (January 2007): 70–74. https://doi.org/10.1215/15228517-2006-022.Full Text Link to Item
-
Bao, Shideng, Qiulian Wu, Roger E. McLendon, Yueling Hao, Qing Shi, Anita B. Hjelmeland, Mark W. Dewhirst, Darell D. Bigner, and Jeremy N. Rich. “Glioma stem cells promote radioresistance by preferential activation of the DNA damage response.” Nature 444, no. 7120 (December 7, 2006): 756–60. https://doi.org/10.1038/nature05236.Full Text Link to Item
-
Bigner, D. D., W. K. A. Yung, C. D. James, and S. A. Cohn. “Neuro-Oncology: Editorial.” Neuro Oncology 8, no. 4 (October 1, 2006): 289. https://doi.org/10.1215/15228517-2006-018.Full Text
-
Maxwell, Jill A., Stewart P. Johnson, Jennifer A. Quinn, Roger E. McLendon, Francis Ali-Osman, Allan H. Friedman, James E. Herndon, et al. “Quantitative analysis of O6-alkylguanine-DNA alkyltransferase in malignant glioma.” Mol Cancer Ther 5, no. 10 (October 2006): 2531–39. https://doi.org/10.1158/1535-7163.MCT-06-0106.Full Text Link to Item
-
Boskovitz, A., H. Ochiai, T. Okamura, G. Akabani, S. Carlin, D. D. Bigner, and M. R. Zalutsky. “At-211-labeled trastuzumab: Evaluation of an alpha-particle emitting targeted radiotherapeutic for the treatment of breast carcinoma carcinomatous meningitis.” European Journal of Nuclear Medicine and Molecular Imaging 33 (September 1, 2006): S184–S184.Link to Item
-
Boskovitz, A., H. Ochiai, T. Okamura, G. Akabani, S. Carlin, D. D. Bigner, and M. R. Zalutsky. “At-211-labeled trastuzumab: Evaluation of an alpha-particle emitting targeted radiotherapeutic for the treatment of breast carcinoma carcinomatous meningitis.” European Journal of Nuclear Medicine and Molecular Imaging 33 (September 1, 2006): S378–S378.Link to Item
-
Reardon, D. A., M. R. Zalutsky, G. Akabani, R. E. Coleman, A. H. Friedman, R. E. McLendon, H. S. Friedman, J. E. Herndon, J. Kirkpatrick, and D. D. Bigner. “Radioimmunotherapy of patients with malignant brain tumors: patient-specific dosing of I-131-labeled anti-tenacin antibody to achieve 44 Gy boost dose to resection cavity margins.” European Journal of Nuclear Medicine and Molecular Imaging 33 (September 1, 2006): S194–S194.Link to Item
-
Sathornsumetee, Sith, Anita B. Hjelmeland, Stephen T. Keir, Roger E. McLendon, David Batt, Timothy Ramsey, Naeem Yusuff, et al. “AAL881, a novel small molecule inhibitor of RAF and vascular endothelial growth factor receptor activities, blocks the growth of malignant glioma.” Cancer Res 66, no. 17 (September 1, 2006): 8722–30. https://doi.org/10.1158/0008-5472.CAN-06-0284.Full Text Link to Item
-
Sok, John C., Francesca M. Coppelli, Sufi M. Thomas, Miriam N. Lango, Sichuan Xi, Jennifer L. Hunt, Maria L. Freilino, et al. “Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.” Clin Cancer Res 12, no. 17 (September 1, 2006): 5064–73. https://doi.org/10.1158/1078-0432.CCR-06-0913.Full Text Link to Item
-
Zalutsky, M. R., D. A. Reardon, J. A. Quinn, R. E. Coleman, G. Akabani, A. H. Friedman, H. S. Friedman, et al. “Chimeric murine/human IgG(2) anti-tenascin 81C6 monoclonal antibody: phase I trial in patients with malignant glioma of a construct with improved stability.” European Journal of Nuclear Medicine and Molecular Imaging 33 (September 1, 2006): S194–S194.Link to Item
-
Bao, Shideng, Qiulian Wu, Sith Sathornsumetee, Yueling Hao, Zhizhong Li, Anita B. Hjelmeland, Qing Shi, Roger E. McLendon, Darell D. Bigner, and Jeremy N. Rich. “Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor.” Cancer Res 66, no. 16 (August 15, 2006): 7843–48. https://doi.org/10.1158/0008-5472.CAN-06-1010.Full Text Link to Item
-
Fecci, Peter E., Alison E. Sweeney, Peter M. Grossi, Smita K. Nair, Christopher A. Learn, Duane A. Mitchell, Xiuyu Cui, et al. “Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells.” Clin Cancer Res 12, no. 14 Pt 1 (July 15, 2006): 4294–4305. https://doi.org/10.1158/1078-0432.CCR-06-0053.Full Text Link to Item
-
Heimberger, A. B., S. F. Hussain, K. Aldape, R. Sawaya, G. A. Archer, H. Friedman, D. Reardon, A. Friedman, D. Bigner, and J. H. Sampson. “Tumor-specific peptide vaccination in newly-diagnosed patients with GBM.” J Clin Oncol 24, no. 18_suppl (June 20, 2006): 2529.Link to Item
-
Rich, J. N., Q. Shi, A. B. Hjelmeland, S. T. Keir, S. Wickman, G. Wu, D. Jackson, O. Ohmori, D. D. Bigner, and H. S. Friedman. “A novel low molecular weight inhibitor of focal adhesion kinase and insulin-like growth factor-1 receptor, TAE226, inhibits glioma growth.” J Clin Oncol 24, no. 18_suppl (June 20, 2006): 11505.Link to Item
-
Reardon, David A., Jennifer A. Quinn, Gamal Akabani, R Edward Coleman, Allan H. Friedman, Henry S. Friedman, James E. Herndon, et al. “Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results.” J Nucl Med 47, no. 6 (June 2006): 912–18.Link to Item
-
Jones, Lee W., Bebe Guill, Stephen T. Keir, Karen Carter B S, Henry S. Friedman, Darrell D. Bigner, and David A. Reardon. “Patterns of exercise across the cancer trajectory in brain tumor patients.” Cancer 106, no. 10 (May 15, 2006): 2224–32. https://doi.org/10.1002/cncr.21858.Full Text Link to Item
-
Graner, Michael W., and Darell D. Bigner. “Therapeutic aspects of chaperones/heat-shock proteins in neuro-oncology.” Expert Rev Anticancer Ther 6, no. 5 (May 2006): 679–95. https://doi.org/10.1586/14737140.6.5.679.Full Text Link to Item
-
Sampson, John H., Gamal Akabani, Allan H. Friedman, Darell Bigner, Sandeep Kunwar, Mitchel S. Berger, and Krystof S. Bankiewicz. “Comparison of intratumoral bolus injection and convection-enhanced delivery of radiolabeled antitenascin monoclonal antibodies.” Neurosurg Focus 20, no. 4 (April 15, 2006): E14. https://doi.org/10.3171/foc.2006.20.4.9.Full Text Link to Item
-
Kuan, Chien-Tsun, Kenji Wakiya, Jeannette M. Dowell, James E. Herndon, David A. Reardon, Michael W. Graner, Gregory J. Riggins, Carol J. Wikstrand, and Darell D. Bigner. “Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme.” Clin Cancer Res 12, no. 7 Pt 1 (April 1, 2006): 1970–82. https://doi.org/10.1158/1078-0432.CCR-05-2797.Full Text Link to Item
-
Fecci, Peter E., Duane A. Mitchell, John F. Whitesides, Weihua Xie, Allan H. Friedman, Gary E. Archer, James E. Herndon, Darell D. Bigner, Glenn Dranoff, and John H. Sampson. “Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma.” Cancer Res 66, no. 6 (March 15, 2006): 3294–3302. https://doi.org/10.1158/0008-5472.CAN-05-3773.Full Text Link to Item
-
Reardon, David A., Jeremy N. Rich, Henry S. Friedman, and Darell D. Bigner. “Recent advances in the treatment of malignant astrocytoma.” J Clin Oncol 24, no. 8 (March 10, 2006): 1253–65. https://doi.org/10.1200/JCO.2005.04.5302.Full Text Link to Item
-
Reardon, David A., Jennifer A. Quinn, James J. Vredenburgh, Sridharan Gururangan, Allan H. Friedman, Annick Desjardins, Sith Sathornsumetee, et al. “Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma.” Clin Cancer Res 12, no. 3 Pt 1 (February 1, 2006): 860–68. https://doi.org/10.1158/1078-0432.CCR-05-2215.Full Text Link to Item
-
Davis, Faith G., Serap Erdal, Lori Williams, and Darell Bigner. “Work exposures to animal neurocarcinogens.” Int J Occup Environ Health 12, no. 1 (2006): 16–23. https://doi.org/10.1179/oeh.2006.12.1.16.Full Text Link to Item
-
Reardon, David A., Gamal Akabani, R Edward Coleman, Allan H. Friedman, Henry S. Friedman, James E. Herndon, Roger E. McLendon, et al. “Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results.” J Clin Oncol 24, no. 1 (January 1, 2006): 115–22. https://doi.org/10.1200/JCO.2005.03.4082.Full Text Link to Item
-
Shankar, Sriram, Ganesan Vaidyanathan, Chien-Tsun Kuan, Darell D. Bigner, and Michael R. Zalutsky. “Antiepidermal growth factor variant III scFv fragment: effect of radioiodination method on tumor targeting and normal tissue clearance.” Nucl Med Biol 33, no. 1 (January 2006): 101–10. https://doi.org/10.1016/j.nucmedbio.2005.08.004.Full Text Link to Item
-
Vaidyanathan, Ganesan, Kevin L. Alston, Darrel D. Bigner, and Michael R. Zalutsky. “Nepsilon-(3-[*I]Iodobenzoyl)-Lys5-Nalpha-maleimido-Gly1-GEEEK ([*I]IB-Mal-D-GEEEK): a radioiodinated prosthetic group containing negatively charged D-glutamates for labeling internalizing monoclonal antibodies.” Bioconjug Chem 17, no. 4 (2006): 1085–92. https://doi.org/10.1021/bc0600766.Full Text Link to Item
-
Hjelmeland, Anita B., Mark D. Hjelmeland, Qing Shi, Janet L. Hart, Darell D. Bigner, Xiao-Fan Wang, Christopher D. Kontos, and Jeremy N. Rich. “Loss of phosphatase and tensin homologue increases transforming growth factor beta-mediated invasion with enhanced SMAD3 transcriptional activity.” Cancer Res 65, no. 24 (December 15, 2005): 11276–81. https://doi.org/10.1158/0008-5472.CAN-05-3016.Full Text Link to Item
-
Yamaguchi, Keisuke, Mark D. Richardson, Darrell D. Bigner, and Madan M. Kwatra. “Signal transduction through substance P receptor in human glioblastoma cells: roles for Src and PKCdelta.” Cancer Chemother Pharmacol 56, no. 6 (December 2005): 585–93. https://doi.org/10.1007/s00280-005-1030-3.Full Text Link to Item
-
Rich, Jeremy N., Sith Sathornsumetee, Stephen T. Keir, Mark W. Kieran, Andrea Laforme, Arja Kaipainen, Roger E. McLendon, et al. “ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors.” Clin Cancer Res 11, no. 22 (November 15, 2005): 8145–57. https://doi.org/10.1158/1078-0432.CCR-05-0319.Full Text Link to Item
-
Friedman, Henry S., and Darell D. Bigner. “Glioblastoma multiforme and the epidermal growth factor receptor.” N Engl J Med 353, no. 19 (November 10, 2005): 1997–99. https://doi.org/10.1056/NEJMp058186.Full Text Link to Item
-
McLendon, Roger E., James E. Herndon, Bryan West, David Reardon, Rodney Wiltshire, BK Ahmed Rasheed, Jennifer Quinn, Henry S. Friedman, Allan H. Friedman, and Darell D. Bigner. “Survival analysis of presumptive prognostic markers among oligodendrogliomas.” Cancer 104, no. 8 (October 15, 2005): 1693–99. https://doi.org/10.1002/cncr.21362.Full Text Link to Item
-
Bigner, D. D., C. D. James, and S. A. Cohn. “Neuro-Oncology impact factor for 2004.” Neuro Oncology 7, no. 4 (October 1, 2005): 423–24. https://doi.org/10.1215/S1152851705200066.Full Text
-
Chang, Susan M., Sharon L. Reynolds, Nicholas Butowski, Kathleen R. Lamborn, Jan C. Buckner, Richard S. Kaplan, and Darell D. Bigner. “GNOSIS: guidelines for neuro-oncology: standards for investigational studies-reporting of phase 1 and phase 2 clinical trials.” Neuro Oncol 7, no. 4 (October 2005): 425–34. https://doi.org/10.1215/S1152851705000554.Full Text Link to Item
-
Rizzieri, David A., Martha Wadleigh, Carol J. Wikstrand, Karen P. Mann, Filiz Sen, Bercedis L. Peterson, Donna Niedzwiecki, Alan D. Proia, and Darell D. Bigner. “Tenascin and microvessel stromal changes in patients with non-Hodgkin's lymphoma are isolated to the sites of disease and vary in correlation to disease activity.” Leuk Lymphoma 46, no. 10 (October 2005): 1455–62. https://doi.org/10.1080/10428190500158060.Full Text Link to Item
-
Quinn, Jennifer A., Annick Desjardins, Jon Weingart, Henry Brem, M Eileen Dolan, Shannon M. Delaney, James Vredenburgh, et al. “Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.” J Clin Oncol 23, no. 28 (October 1, 2005): 7178–87. https://doi.org/10.1200/JCO.2005.06.502.Full Text Link to Item
-
Cheng, C Lynn, Stewart P. Johnson, Stephen T. Keir, Jennifer A. Quinn, Francis Ali-Osman, Csaba Szabo, Hongshan Li, et al. “Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft.” Mol Cancer Ther 4, no. 9 (September 2005): 1364–68. https://doi.org/10.1158/1535-7163.MCT-05-0128.Full Text Link to Item
-
Desjardins, Annick, Jeremy N. Rich, Jennifer A. Quinn, James Vredenburgh, Sridharan Gururangan, Sith Sathornsumetee, David A. Reardon, Allan H. Friedman, Darell D. Bigner, and Henry S. Friedman. “Chemotherapy and novel therapeutic approaches in malignant glioma.” Front Biosci 10 (September 1, 2005): 2645–68. https://doi.org/10.2741/1727.Full Text Link to Item
-
Graner, Michael W., and Darell D. Bigner. “Chaperone proteins and brain tumors: potential targets and possible therapeutics.” Neuro Oncol 7, no. 3 (July 2005): 260–78. https://doi.org/10.1215/S1152851704001188.Full Text Link to Item
-
Akabani, Gamal, David A. Reardon, R Edward Coleman, Terence Z. Wong, Scott D. Metzler, James E. Bowsher, Daniel P. Barboriak, et al. “Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study.” J Nucl Med 46, no. 6 (June 2005): 1042–51.Link to Item
-
Rich, Jeremy N., Christopher Hans, Beatrix Jones, Edwin S. Iversen, Roger E. McLendon, BK Ahmed Rasheed, Adrian Dobra, et al. “Gene expression profiling and genetic markers in glioblastoma survival.” Cancer Res 65, no. 10 (May 15, 2005): 4051–58. https://doi.org/10.1158/0008-5472.CAN-04-3936.Full Text Link to Item
-
Lyons, P., F. Davis, D. Bigner, H. Friedman, B. McCarthy, G. Rauscher, N. Vick, N. Paleologos, S. Tourt-Uhlig, and P. Lada. “Methods and outcomes for recruitment of cases and controls for a brain tumor epidemiology study.” Oncology Nursing Forum 32, no. 2 (March 1, 2005): 484–484.Link to Item
-
Di, Chunhui, Shaoxi Liao, David C. Adamson, Timothy J. Parrett, Daniel K. Broderick, Qun Shi, Christoph Lengauer, et al. “Identification of OTX2 as a medulloblastoma oncogene whose product can be targeted by all-trans retinoic acid.” Cancer Res 65, no. 3 (February 1, 2005): 919–24.Link to Item
-
Parekh, Kalpaj, Sabarinathan Ramachandran, Joel Cooper, Darell Bigner, Alexander Patterson, and T. Mohanakumar. “Tenascin-C, over expressed in lung cancer down regulates effector functions of tumor infiltrating lymphocytes.” Lung Cancer 47, no. 1 (January 2005): 17–29. https://doi.org/10.1016/j.lungcan.2004.05.016.Full Text Link to Item
-
Sampson, John H., David A. Reardon, Allan H. Friedman, Henry S. Friedman, R Edward Coleman, Roger E. McLendon, Ira Pastan, and Darell D. Bigner. “Sustained radiographic and clinical response in patient with bifrontal recurrent glioblastoma multiforme with intracerebral infusion of the recombinant targeted toxin TP-38: case study.” Neuro Oncol 7, no. 1 (January 2005): 90–96. https://doi.org/10.1215/S1152851703000589.Full Text Link to Item
-
Goudar, Ranjit K., Qing Shi, Mark D. Hjelmeland, Stephen T. Keir, Roger E. McLendon, Carol J. Wikstrand, Elizabeth D. Reese, et al. “Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition.” Mol Cancer Ther 4, no. 1 (January 2005): 101–12.Link to Item
-
Shi, Qing, Shideng Bao, Jill A. Maxwell, Elizabeth D. Reese, Henry S. Friedman, Darell D. Bigner, Xiao-Fan Wang, and Jeremy N. Rich. “Secreted protein acidic, rich in cysteine (SPARC), mediates cellular survival of gliomas through AKT activation.” J Biol Chem 279, no. 50 (December 10, 2004): 52200–209. https://doi.org/10.1074/jbc.M409630200.Full Text Link to Item
-
Purev, Enkhtsetseg, Dewei Cai, Eric Miller, Rolf Swoboda, Ted Mayer, Andres Klein-Szanto, Francesco M. Marincola, et al. “Immune responses of breast cancer patients to mutated epidermal growth factor receptor (EGF-RvIII, Delta EGF-R, and de2-7 EGF-R).” J Immunol 173, no. 10 (November 15, 2004): 6472–80. https://doi.org/10.4049/jimmunol.173.10.6472.Full Text Link to Item
-
Bigner, D. D., C. D. James, and S. A. Cohn. “Editorial.” Neuro Oncology 6, no. 4 (October 1, 2004): 273. https://doi.org/10.1215/S1152851704200163.Full Text
-
Shankar, Sriram, Ganesan Vaidyanathan, Donna J. Affleck, Katia Peixoto, Darell D. Bigner, and Michael R. Zalutsky. “Evaluation of an internalizing monoclonal antibody labeled using N-succinimidyl 3-[131I]iodo-4-phosphonomethylbenzoate ([131I]SIPMB), a negatively charged substituent bearing acylation agent.” Nucl Med Biol 31, no. 7 (October 2004): 909–19. https://doi.org/10.1016/j.nucmedbio.2004.04.007.Full Text Link to Item
-
Bacolod, Manny D., Stewart P. Johnson, Anthony E. Pegg, M Eileen Dolan, Robert C. Moschel, Nancy S. Bullock, Qingming Fang, et al. “Brain tumor cell lines resistant to O6-benzylguanine/1,3-bis(2-chloroethyl)-1-nitrosourea chemotherapy have O6-alkylguanine-DNA alkyltransferase mutations.” Mol Cancer Ther 3, no. 9 (September 2004): 1127–35.Link to Item
-
Boskovitz, Abraham, Carol J. Wikstrand, Chien-Tsun Kuan, Michael R. Zalutsky, David A. Reardon, and Darell D. Bigner. “Monoclonal antibodies for brain tumour treatment.” Expert Opin Biol Ther 4, no. 9 (September 2004): 1453–71. https://doi.org/10.1517/14712598.4.9.1453.Full Text Link to Item
-
Broderick, Daniel K., Chunhui Di, Timothy J. Parrett, Yardena R. Samuels, Jordan M. Cummins, Roger E. McLendon, Daniel W. Fults, Victor E. Velculescu, Darell D. Bigner, and Hai Yan. “Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas.” Cancer Res 64, no. 15 (August 1, 2004): 5048–50. https://doi.org/10.1158/0008-5472.CAN-04-1170.Full Text Link to Item
-
Rizzieri, David A., Gamal Akabani, Michael R. Zalutsky, R Edward Coleman, Scott D. Metzler, James E. Bowsher, Bonnie Toaso, et al. “Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma.” Blood 104, no. 3 (August 1, 2004): 642–48. https://doi.org/10.1182/blood-2003-12-4264.Full Text Link to Item
-
Wiltshire, Rodney N., James E. Herndon, Annie Lloyd, Henry S. Friedman, Darell D. Bigner, Sandra H. Bigner, and Roger E. McLendon. “Comparative genomic hybridization analysis of astrocytomas: prognostic and diagnostic implications.” J Mol Diagn 6, no. 3 (August 2004): 166–79. https://doi.org/10.1016/S1525-1578(10)60507-7.Full Text Link to Item
-
Badruddoja, M. A., D. A. Reardon, G. Akabani, A. H. Friedman, H. S. Friedman, J. N. Rich, J. A. Quinn, K. Penne, J. J. Vredenburgh, and D. D. Bigner. “Phase II trial of iodine 131-labeled murine anti-tenascin monoclonal anti-body 81C6 (M81C6) via surgically created resection cavity in the treatment of patients with recurrent malignant brain tumors.” J Clin Oncol 22, no. 14_suppl (July 15, 2004): 1569.Link to Item
-
Yung, A., J. Vredenburgh, T. Cloughesy, B. J. Klencke, P. S. Mischel, D. D. Bigner, K. Aldape, S. Vanderburg, M. Prados, and M. Accelerate Brain Cancer Cure Group. “Erlotinib HCL for glioblastoma multiforme in first relapse, a phase II trial.” J Clin Oncol 22, no. 14_suppl (July 15, 2004): 1555.Link to Item
-
Merrill, Melinda K., Guenter Bernhardt, John H. Sampson, Carol J. Wikstrand, Darell D. Bigner, and Matthias Gromeier. “Poliovirus receptor CD155-targeted oncolysis of glioma.” Neuro Oncol 6, no. 3 (July 2004): 208–17. https://doi.org/10.1215/S1152851703000577.Full Text Link to Item
-
Hjelmeland, Mark D., Anita B. Hjelmeland, Sith Sathornsumetee, Elizabeth D. Reese, Michael H. Herbstreith, Nicholas J. Laping, Henry S. Friedman, Darell D. Bigner, Xiao-Fan Wang, and Jeremy N. Rich. “SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motility.” Mol Cancer Ther 3, no. 6 (June 2004): 737–45.Link to Item
-
Learn, Chris A., Tristan L. Hartzell, Carol J. Wikstrand, Gary E. Archer, Jeremy N. Rich, Allan H. Friedman, Henry S. Friedman, Darell D. Bigner, and John H. Sampson. “Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme.” Clin Cancer Res 10, no. 9 (May 1, 2004): 3216–24. https://doi.org/10.1158/1078-0432.ccr-03-0521.Full Text Link to Item
-
Rich, Jeremy N., and Darell D. Bigner. “Development of novel targeted therapies in the treatment of malignant glioma.” Nat Rev Drug Discov 3, no. 5 (May 2004): 430–46. https://doi.org/10.1038/nrd1380.Full Text Link to Item
-
Quinn, Jennifer A., David A. Reardon, Allan H. Friedman, Jeremy N. Rich, John H. Sampson, James Vredenburgh, Sridharan Gururangan, et al. “Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma.” Neuro Oncol 6, no. 2 (April 2004): 145–53. https://doi.org/10.1215/S1152851703000498.Full Text Link to Item
-
Reardon, David A., Jennifer A. Quinn, Jeremy N. Rich, Sridharan Gururangan, James Vredenburgh, John H. Sampson, James M. Provenzale, et al. “Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma.” Neuro Oncol 6, no. 2 (April 2004): 134–44. https://doi.org/10.1215/s1152851703000413.Full Text Link to Item
-
Boskovitz, Abraham, Gamal H. Akabani, Charles N. Pegram, Darrell D. Bigner, and Michael R. Zalutsky. “Human/murine chimeric 81C6 F(ab')(2) fragment: preclinical evaluation of a potential construct for the targeted radiotherapy of malignant glioma.” Nucl Med Biol 31, no. 3 (April 2004): 345–55. https://doi.org/10.1016/j.nucmedbio.2003.10.008.Full Text Link to Item
-
Rich, Jeremy N., David A. Reardon, Terry Peery, Jeannette M. Dowell, Jennifer A. Quinn, Kara L. Penne, Carol J. Wikstrand, et al. “Phase II trial of gefitinib in recurrent glioblastoma.” J Clin Oncol 22, no. 1 (January 1, 2004): 133–42. https://doi.org/10.1200/JCO.2004.08.110.Full Text Link to Item
-
Castillo, Monette S., Faith G. Davis, Tanya Surawicz, Janet M. Bruner, Sandra Bigner, Stephen Coons, and Darell D. Bigner. “Consistency of primary brain tumor diagnoses and codes in cancer surveillance systems.” Neuroepidemiology 23, no. 1–2 (2004): 85–93. https://doi.org/10.1159/000073980.Full Text Link to Item
-
Grossi, Peter M., Hidenobu Ochiai, Gary E. Archer, Roger E. McLendon, Michael R. Zalutsky, Allan H. Friedman, Henry S. Friedman, Darell D. Bigner, and John H. Sampson. “Efficacy of intracerebral microinfusion of trastuzumab in an athymic rat model of intracerebral metastatic breast cancer.” Clin Cancer Res 9, no. 15 (November 15, 2003): 5514–20.Link to Item
-
Bigner, D. D. “Editorial.” Neuro Oncology 5, no. 4 (October 1, 2003): 227. https://doi.org/10.1215/S11520320053.Full Text
-
Sampson, John H., Gamal Akabani, Gary E. Archer, Darell D. Bigner, Mitchel S. Berger, Allan H. Friedman, Henry S. Friedman, et al. “Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors.” J Neurooncol 65, no. 1 (October 2003): 27–35. https://doi.org/10.1023/a:1026290315809.Full Text Link to Item
-
Heimberger, Amy B., Laura E. Crotty, Gary E. Archer, Kenneth R. Hess, Carol J. Wikstrand, Allan H. Friedman, Henry S. Friedman, Darell D. Bigner, and John H. Sampson. “Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors.” Clin Cancer Res 9, no. 11 (September 15, 2003): 4247–54.Link to Item
-
Rich, Jeremy N., Qing Shi, Mark Hjelmeland, Thomas J. Cummings, Chien-Tsun Kuan, Darell D. Bigner, Christopher M. Counter, and Xiao-Fan Wang. “Bone-related genes expressed in advanced malignancies induce invasion and metastasis in a genetically defined human cancer model.” J Biol Chem 278, no. 18 (May 2, 2003): 15951–57. https://doi.org/10.1074/jbc.M211498200.Full Text Link to Item
-
Vaidyanathan, Ganesan, Donna J. Affleck, Darell D. Bigner, and Michael R. Zalutsky. “N-succinimidyl 3-[211At]astato-4-guanidinomethylbenzoate: an acylation agent for labeling internalizing antibodies with alpha-particle emitting 211At.” Nucl Med Biol 30, no. 4 (May 2003): 351–59. https://doi.org/10.1016/s0969-8051(03)00005-2.Full Text Link to Item
-
Quinn, Jennifer A., David A. Reardon, Allan H. Friedman, Jeremy N. Rich, John H. Sampson, James M. Provenzale, Roger E. McLendon, et al. “Phase II trial of temozolomide in patients with progressive low-grade glioma.” J Clin Oncol 21, no. 4 (February 15, 2003): 646–51. https://doi.org/10.1200/JCO.2003.01.009.Full Text Link to Item
-
Fecci, Peter E., Duane A. Mitchell, Gary E. Archer, Michael A. Morse, H Kim Lyerly, Darell D. Bigner, and John H. Sampson. “The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors.” J Neurooncol 64, no. 1–2 (2003): 161–76. https://doi.org/10.1007/BF02700031.Full Text Link to Item
-
Akabani, Gamal, Roger E. McLendon, Darrell D. Bigner, and Michael R. Zalutsky. “Vascular targeted endoradiotherapy of tumors using alpha-particle-emitting compounds: theoretical analysis.” Int J Radiat Oncol Biol Phys 54, no. 4 (November 15, 2002): 1259–75. https://doi.org/10.1016/s0360-3016(02)03794-x.Full Text Link to Item
-
Heimberger, Amy B., Chris A. Learn, Gary E. Archer, Roger E. McLendon, Tracy A. Chewning, Frank L. Tuck, John B. Pracyk, et al. “Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa).” Clin Cancer Res 8, no. 11 (November 2002): 3496–3502.Link to Item
-
Bigner, D. D., and E. G. Shaw. “Editorial.” Neuro Oncology 4, no. 4 (October 1, 2002): 241. https://doi.org/10.1215/S1522851702200034.Full Text
-
Friedman, Henry S., Stephen Keir, Anthony E. Pegg, Peter J. Houghton, O Michael Colvin, Robert C. Moschel, Darell D. Bigner, and M Eileen Dolan. “O6-benzylguanine-mediated enhancement of chemotherapy.” Mol Cancer Ther 1, no. 11 (September 2002): 943–48.Link to Item
-
Huang, Li, Libing Feng, Limin Yang, Weiguo Zhou, Shouyuan Zhao, and Changben Li. “Screen and identification of proteins interacting with ADAM19 cytoplasmic tail.” Mol Biol Rep 29, no. 3 (September 2002): 317–23. https://doi.org/10.1023/a:1020409217215.Full Text Link to Item
-
Beauchesne, Patrick. “Promising survival and concomitant radiation plus temozolomide followed by adjuvant temozolomide.” J Clin Oncol 20, no. 14 (July 15, 2002): 3180–81. https://doi.org/10.1200/JCO.2002.20.14.3180.Full Text Link to Item
-
Reardon, D., and D. D. Bigner. “Promising survival and concomitant radiation plus temozolomide followed by adjuvant temozolomide - Reply.” Journal of Clinical Oncology 20, no. 14 (July 15, 2002): 3181–82.Link to Item
-
Nieder, Carsten. “Treatment of newly diagnosed glioblastoma multiforme.” J Clin Oncol 20, no. 14 (July 15, 2002): 3179–80. https://doi.org/10.1200/JCO.2002.20.14.3179.Full Text Link to Item
-
Bacolod, Manny D., Stewart P. Johnson, Francis Ali-Osman, Paul Modrich, Nancy S. Bullock, O Michael Colvin, Darell D. Bigner, and Henry S. Friedman. “Mechanisms of resistance to 1,3-bis(2-chloroethyl)-1-nitrosourea in human medulloblastoma and rhabdomyosarcoma.” Mol Cancer Ther 1, no. 9 (July 2002): 727–36.Link to Item
-
Davies, Helen, Graham R. Bignell, Charles Cox, Philip Stephens, Sarah Edkins, Sheila Clegg, Jon Teague, et al. “Mutations of the BRAF gene in human cancer.” Nature 417, no. 6892 (June 27, 2002): 949–54. https://doi.org/10.1038/nature00766.Full Text Link to Item
-
Rasheed, Ahmed, James E. Herndon, Timothy T. Stenzel, Jacqueline G. M. Raetz, Jason Kendelhardt, Henry S. Friedman, Allan H. Friedman, Darell D. Bigner, Sandra H. Bigner, and Roger E. McLendon. “Molecular markers of prognosis in astrocytic tumors.” Cancer 94, no. 10 (May 15, 2002): 2688–97. https://doi.org/10.1002/cncr.10544.Full Text Link to Item
-
Akabani, G., D. Rizzieri, R. E. Coleman, S. D. Metzler, M. R. Zalutsky, and D. D. Bigner. “Radioimmunotherapy of refractory non-Hodgkin's lymphoma with I-131-labeled chimeric 81C6 anti-tenascin monoclonal antibody: Dosimetry study.” Journal of Nuclear Medicine 43, no. 5 (May 1, 2002): 313P-313P.Link to Item
-
Quinn, Jennifer A., James Pluda, M Eileen Dolan, Shannon Delaney, Richard Kaplan, Jeremy N. Rich, Allan H. Friedman, et al. “Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma.” J Clin Oncol 20, no. 9 (May 1, 2002): 2277–83. https://doi.org/10.1200/JCO.2002.09.084.Full Text Link to Item
-
Aldosari, Naji, Rodney N. Wiltshire, Amalia Dutra, Evelin Schrock, Roger E. McLendon, Henry S. Friedman, Darell D. Bigner, and Sandra H. Bigner. “Comprehensive molecular cytogenetic investigation of chromosomal abnormalities in human medulloblastoma cell lines and xenograft.” Neuro Oncol 4, no. 2 (April 2002): 75–85. https://doi.org/10.1093/neuonc/4.2.75.Full Text Link to Item
-
Reardon, David A., Gamal Akabani, R Edward Coleman, Allan H. Friedman, Henry S. Friedman, James E. Herndon, Ilkcan Cokgor, et al. “Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas.” J Clin Oncol 20, no. 5 (March 1, 2002): 1389–97. https://doi.org/10.1200/JCO.2002.20.5.1389.Full Text Link to Item
-
Wikstrand, Carol J., Vanessa R. Cole, Laura E. Crotty, John H. Sampson, and Darell D. Bigner. “Generation of anti-idiotypic reagents in the EGFRvIII tumor-associated antigen system.” Cancer Immunol Immunother 50, no. 12 (February 2002): 639–52. https://doi.org/10.1007/s00262-001-0243-5.Full Text Link to Item
-
Heimberger, Amy B., Gary E. Archer, Laura E. Crotty, Roger E. McLendon, Allan H. Friedman, Henry S. Friedman, Darell D. Bigner, and John H. Sampson. “Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity and are effective against murine intracerebral melanoma.” Neurosurgery 50, no. 1 (January 2002): 158–64. https://doi.org/10.1097/00006123-200201000-00024.Full Text Link to Item
-
Vaidyanathan, Ganesan, Donna J. Affleck, Darell D. Bigner, and Michael R. Zalutsky. “Improved xenograft targeting of tumor-specific anti-epidermal growth factor receptor variant III antibody labeled using N-succinimidyl 4-guanidinomethyl-3-iodobenzoate.” Nucl Med Biol 29, no. 1 (January 2002): 1–11. https://doi.org/10.1016/s0969-8051(01)00277-3.Full Text Link to Item
-
Rizzieri, D. A., G. Akabani, R. E. Coleman, M. R. Zalutsky, D. Niedzwiecki, N. Payne, C. Wikstrand, and D. D. Bigner. “Radiolabeled anti-tenascin antibody for refractory non-Hodgkins lymphoma (NHL).” Blood 98, no. 11 (November 16, 2001): 247B-247B.Link to Item
-
Friedman, H. S., S. T. Keir, P. J. Houghton, A. A. Lawless, D. D. Bigner, and S. J. Waters. “Activity of irofulven (6-hydroxymethylacylfulvene) in the treatment of glioblastoma multiforme-derived xenografts in athymic mice.” Cancer Chemother Pharmacol 48, no. 5 (November 2001): 413–16. https://doi.org/10.1007/s002800100358.Full Text Link to Item
-
Zalutsky, M. R., X. G. Zhao, K. L. Alston, and D. Bigner. “High-level production of alpha-particle-emitting (211)At and preparation of (211)At-labeled antibodies for clinical use.” J Nucl Med 42, no. 10 (October 2001): 1508–15.Link to Item
-
Foulon, C. F., P. C. Welsh, D. D. Bigner, and M. R. Zalutsky. “Positively charged templates for labeling internalizing antibodies: comparison of N-succinimidyl 5-iodo-3-pyridinecarboxylate and the D-amino acid peptide KRYRR.” Nucl Med Biol 28, no. 7 (October 2001): 769–77. https://doi.org/10.1016/s0969-8051(01)00239-6.Full Text Link to Item
-
Cavazos, C. M., S. T. Keir, T. Yoshinari, D. D. Bigner, and H. S. Friedman. “Therapeutic activity of the topoisomerase I inhibitor J-107088 [6-N-(1-hydroxymethyla-2-hydroxyl) ethylamino-12,13-dihydro-13-(beta-D-glucopyranosyl) -5H-indolo[2,3-a]-pyrrolo[3,4-c]-carbazole-5,7(6H)-dione]] against pediatric and adult central nervous system tumor xenografts.” Cancer Chemother Pharmacol 48, no. 3 (September 2001): 250–54. https://doi.org/10.1007/s002800100347.Full Text Link to Item
-
Keir, S. T., F. Hausheer, A. A. Lawless, D. D. Bigner, and H. S. Friedman. “Therapeutic activity of 7-[(2-trimethylsilyl)ethyl)]-20 (S)-camptothecin against central nervous system tumor-derived xenografts in athymic mice.” Cancer Chemother Pharmacol 48, no. 1 (July 2001): 83–87. https://doi.org/10.1007/s002800000274.Full Text Link to Item
-
Kuan, C. T., C. J. Wikstrand, and D. D. Bigner. “EGF mutant receptor vIII as a molecular target in cancer therapy.” Endocr Relat Cancer 8, no. 2 (June 2001): 83–96. https://doi.org/10.1677/erc.0.0080083.Full Text Link to Item
-
McLendon, R. E., A. Rasheed, R. Wiltshire, J. Herndon, H. Friedman, A. Friedman, D. Bigner, and S. Bigner. “Molecular profiling of astrocytomas.” Journal of Neuropathology and Experimental Neurology 60, no. 5 (May 1, 2001): 535–535.Link to Item
-
Zalutsky, M. R., G. Akabani, H. S. Friedman, I. Cokgor, R. E. Coleman, A. H. Friedman, R. E. McLendon, X. G. Zhao, K. L. Alston, and D. D. Bigner. “Radioimmunotherapy of recurrent glioma patients using alpha-particle emitting astatine-211 labeled chimeric anti-tenascin monoclonal antibody.” Journal of Nuclear Medicine 42, no. 5 (May 1, 2001): 121P-122P.Link to Item
-
Cokgor, I., G. Akabani, H. S. Friedman, A. H. Friedman, M. R. Zalutsky, L. M. Zehngebot, J. M. Provenzale, C. D. Guy, C. J. Wikstrand, and D. D. Bigner. “Long term response in a patient with neoplastic meningitis secondary to melanoma treated with (131)I-radiolabeled antichondroitin proteoglycan sulfate Mel-14 F(ab')(2): a case study.” Cancer 91, no. 9 (May 1, 2001): 1809–13.Link to Item
-
Rich, J. N., C. Guo, R. E. McLendon, D. D. Bigner, X. F. Wang, and C. M. Counter. “A genetically tractable model of human glioma formation.” Cancer Res 61, no. 9 (May 1, 2001): 3556–60.Link to Item
-
McLendon, R., L. Cleveland, H. Friedman, M. Zalutsky, D. Bigner, and S. Bigner. “Beta emitter glioma therapy.” Modern Pathology 14, no. 1 (January 1, 2001): 209A-209A.Link to Item
-
McLendon, R., L. Cleveland, H. Friedman, M. Zalutsky, D. Bigner, and S. Bigner. “Beta emitter glioma therapy.” Laboratory Investigation 81, no. 1 (January 1, 2001): 209A-209A.Link to Item
-
Kuan, C. T., C. J. Wikstrand, G. Archer, R. Beers, I. Pastan, M. R. Zalutsky, and D. D. Bigner. “Increased binding affinity enhances targeting of glioma xenografts by EGFRvIII-specific scFv.” Int J Cancer 88, no. 6 (December 15, 2000): 962–69. https://doi.org/10.1002/1097-0215(20001215)88:6<962::aid-ijc20>3.0.co;2-u.Full Text Link to Item
-
Cokgor, I., G. Akabani, C. T. Kuan, H. S. Friedman, A. H. Friedman, R. E. Coleman, R. E. McLendon, et al. “Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas.” J Clin Oncol 18, no. 22 (November 15, 2000): 3862–72. https://doi.org/10.1200/JCO.2000.18.22.3862.Full Text Link to Item
-
Heimberger, A. B., G. E. Archer, R. E. McLendon, D. Price, A. H. Friedman, H. S. Friedman, D. D. Bigner, and J. H. Sampson. “Oral administration of the specific EGFR tyrosine kinase inhibitor, ZD1839 (Iressa (TM)), is active against EGFR-overexpressing intracranial tumors.” Clinical Cancer Research 6 (November 1, 2000): 4542S-4543S.Link to Item
-
Friedman, H. S., J. Pluda, J. A. Quinn, R. B. Ewesuedo, L. Long, A. H. Friedman, I. Cokgor, et al. “Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.” J Clin Oncol 18, no. 20 (October 15, 2000): 3522–28. https://doi.org/10.1200/JCO.2000.18.20.3522.Full Text Link to Item
-
Heimberger, A. B., G. E. Archer, R. E. McLendon, C. Hulette, A. H. Friedman, H. S. Friedman, D. D. Bigner, and J. H. Sampson. “Temozolomide delivered by intracerebral microinfusion is safe and efficacious against malignant gliomas in rats.” Clin Cancer Res 6, no. 10 (October 2000): 4148–53.Link to Item
-
Patel, V. J., G. B. Elion, P. J. Houghton, S. Keir, A. E. Pegg, S. P. Johnson, M. E. Dolan, D. D. Bigner, and H. S. Friedman. “Schedule-dependent activity of temozolomide plus CPT-11 against a human central nervous system tumor-derived xenograft.” Clin Cancer Res 6, no. 10 (October 2000): 4154–57.Link to Item
-
Loging, W. T., A. Lal, I. M. Siu, T. L. Loney, C. J. Wikstrand, M. A. Marra, C. Prange, D. D. Bigner, R. L. Strausberg, and G. J. Riggins. “Identifying potential tumor markers and antigens by database mining and rapid expression screening.” Genome Res 10, no. 9 (September 2000): 1393–1402. https://doi.org/10.1101/gr.138000.Full Text Link to Item
-
Campa, M. J., C. T. Kuan, M. D. O’Connor-McCourt, D. D. Bigner, and E. F. Patz. “Design of a novel small peptide targeted against a tumor-specific receptor.” Biochem Biophys Res Commun 275, no. 2 (August 28, 2000): 631–36. https://doi.org/10.1006/bbrc.2000.3347.Full Text Link to Item
-
Foulon, C. F., C. J. Reist, D. D. Bigner, and M. R. Zalutsky. “Radioiodination via D-amino acid peptide enhances cellular retention and tumor xenograft targeting of an internalizing anti-epidermal growth factor receptor variant III monoclonal antibody.” Cancer Res 60, no. 16 (August 15, 2000): 4453–60.Link to Item
-
McLendon, R. E., C. J. Wikstrand, M. R. Matthews, R. Al-Baradei, S. H. Bigner, and D. D. Bigner. “Glioma-associated antigen expression in oligodendroglial neoplasms. Tenascin and epidermal growth factor receptor.” J Histochem Cytochem 48, no. 8 (August 2000): 1103–10. https://doi.org/10.1177/002215540004800807.Full Text Link to Item
-
Wikstrand, C. J., J. H. Sampson, and D. D. Bigner. “EGFRvIII: An oncogene deletion mutant cell surface receptor target expressed by multiple tumour types.” Expert Opinion on Therapeutic Targets 4, no. 4 (August 1, 2000): 497–514. https://doi.org/10.1517/14728222.4.4.497.Full Text
-
Beers, R., P. Chowdhury, D. Bigner, and I. Pastan. “Immunotoxins with increased activity against epidermal growth factor receptor vIII-expressing cells produced by antibody phage display.” Clin Cancer Res 6, no. 7 (July 2000): 2835–43.Link to Item
-
Friedman, H. S., R. C. Castellino, G. B. Elion, S. T. Keir, P. J. Houghton, S. P. Johnson, and D. D. Bigner. “Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts (vol 45, pg 345, 1999).” Cancer Chemotherapy and Pharmacology 46, no. 1 (July 1, 2000): 84–84.Link to Item
-
Sampson, J. H., L. E. Crotty, S. Lee, G. E. Archer, D. M. Ashley, C. J. Wikstrand, L. P. Hale, et al. “Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors.” Proc Natl Acad Sci U S A 97, no. 13 (June 20, 2000): 7503–8. https://doi.org/10.1073/pnas.130166597.Full Text Link to Item
-
Akabani, G., R. E. McLendon, D. D. Bigner, and M. R. Zalutsky. “Microdosimetry of alpha-particle-emitting At-211-labelled monoclonal antibody (MAb) using histological images of malignant brain tumors.” Journal of Nuclear Medicine 41, no. 5 (May 1, 2000): 84P-84P.Link to Item
-
Aldosari, N., B. K. Rasheed, R. E. McLendon, H. S. Friedman, D. D. Bigner, and S. H. Bigner. “Characterization of chromosome 17 abnormalities in medulloblastomas.” Acta Neuropathol 99, no. 4 (April 2000): 345–51. https://doi.org/10.1007/s004010051134.Full Text Link to Item
-
Akabani, G., I. Cokgor, R. E. Coleman, D. González Trotter, T. Z. Wong, H. S. Friedman, A. H. Friedman, et al. “Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy.” Int J Radiat Oncol Biol Phys 46, no. 4 (March 1, 2000): 947–58. https://doi.org/10.1016/s0360-3016(99)00500-3.Full Text Link to Item
-
Heimberger, A. B., L. E. Crotty, G. E. Archer, R. E. McLendon, A. Friedman, G. Dranoff, D. D. Bigner, and J. H. Sampson. “Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma.” J Neuroimmunol 103, no. 1 (February 1, 2000): 16–25. https://doi.org/10.1016/s0165-5728(99)00172-1.Full Text Link to Item
-
Friedman, H. S., R. C. Castellino, G. B. Elion, S. T. Keir, P. J. Houghton, S. P. Johnson, and D. D. Bigner. “Erratum: Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts (Cancer Chemotherapy and Pharmacology 45 (345- 349)).” Cancer Chemotherapy and Pharmacology 46, no. 1 (January 1, 2000): 84.
-
Keir, S. T., M. E. Dolan, A. E. Pegg, A. Lawless, R. C. Moschel, D. D. Bigner, and H. S. Friedman. “O6-benzylguanine-mediated enhancement of nitrosourea activity in Mer- central nervous system tumor xenografts - Implications for clinical trials.” Cancer Chemotherapy and Pharmacology 45, no. 6 (2000): 437–40.
-
Castellino, R. C., G. B. Elion, S. T. Keir, P. J. Houghton, S. P. Johnson, D. D. Bigner, and H. S. Friedman. “Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts.” Cancer Chemother Pharmacol 45, no. 4 (2000): 345–49. https://doi.org/10.1007/s002800050050.Full Text Link to Item
-
Keir, S. T., M. E. Dolan, A. E. Pegg, A. Lawless, R. C. Moschel, D. D. Bigner, and H. S. Friedman. “O6-benzylguanine-mediated enhancement of nitrosourea activity in Mer- central nervous system tumor xenografts--implications for clinical trials.” Cancer Chemother Pharmacol 45, no. 6 (2000): 437–40. https://doi.org/10.1007/s002800051016.Full Text Link to Item
-
Kuan, C. T., C. J. Wikstrand, and D. D. Bigner. “EGFRvIII as a promising target for antibody-based brain tumor therapy.” Brain Tumor Pathol 17, no. 2 (2000): 71–78. https://doi.org/10.1007/BF02482738.Full Text Link to Item
-
Rich, J. N., M. Zhang, M. B. Datto, D. D. Bigner, and X. F. Wang. “Transforming growth factor-beta-mediated p15(INK4B) induction and growth inhibition in astrocytes is SMAD3-dependent and a pathway prominently altered in human glioma cell lines.” J Biol Chem 274, no. 49 (December 3, 1999): 35053–58. https://doi.org/10.1074/jbc.274.49.35053.Full Text Link to Item
-
Rizzieri, D. A., C. J. Wikstrand, K. P. Mann, F. Sen, A. D. Proia, D. Niedzwiecki, D. D. Bigner, and J. Vredenburgh. “Markers of angiogenesis, factor VIII and tenascin, correlate with disease activity in patients with Non-Hodgkin's Lymphoma.” Blood 94, no. 10 (November 15, 1999): 253B-253B.Link to Item
-
Archer, G. E., J. H. Sampson, I. A. Lorimer, R. E. McLendon, C. T. Kuan, A. H. Friedman, H. S. Friedman, I. H. Pastan, and D. D. Bigner. “Regional treatment of epidermal growth factor receptor vIII-expressing neoplastic meningitis with a single-chain immunotoxin, MR-1.” Clin Cancer Res 5, no. 9 (September 1999): 2646–52.Link to Item
-
Zalutsky, M. R., G. Akabani, I. Cokgor, H. S. Friedman, R. E. Coleman, A. H. Friedman, R. E. McLendon, and D. D. Bigner. “Astatine-211 labeled chimeric anti-tenascin antibody: Phase I trial in brain tumor resection cavity patients.” European Journal of Nuclear Medicine 26, no. 9 (September 1, 1999): 1215–1215.Link to Item
-
McLendon, R. E., G. E. Archer, R. H. Larsen, G. Akabani, D. D. Bigner, and M. R. Zalutsky. “Radiotoxicity of systemically administered 211At-labeled human/mouse chimeric monoclonal antibody: a long-term survival study with histologic analysis.” Int J Radiat Oncol Biol Phys 45, no. 2 (September 1, 1999): 491–99. https://doi.org/10.1016/s0360-3016(99)00206-0.Full Text Link to Item
-
Bigner, S. H., M. R. Matthews, B. K. Rasheed, R. N. Wiltshire, H. S. Friedman, A. H. Friedman, T. T. Stenzel, D. M. Dawes, R. E. McLendon, and D. D. Bigner. “Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization.” Am J Pathol 155, no. 2 (August 1999): 375–86. https://doi.org/10.1016/S0002-9440(10)65134-6.Full Text Link to Item
-
Kuan, C. T., C. J. Reist, C. F. Foulon, I. A. J. Lorimer, G. Archer, C. N. Pegram, I. Pastan, M. R. Zalutsky, and D. D. Bigner. “I-125-labeled anti-epidermal growth factor receptor-vIII single-chain Fv exhibits specific and high-level targeting of glioma xenografts.” Clinical Cancer Research 5, no. 6 (June 1, 1999): 1539–49.Link to Item
-
Kuan, C. T., C. J. Reist, C. F. Foulon, I. A. Lorimer, G. Archer, C. N. Pegram, I. Pastan, M. R. Zalutsky, and D. D. Bigner. “125I-labeled anti-epidermal growth factor receptor-vIII single-chain Fv exhibits specific and high-level targeting of glioma xenografts.” Clin Cancer Res 5, no. 6 (June 1999): 1539–49.Link to Item
-
Sampson, J. H., G. E. Archer, A. T. Villavicencio, R. E. McLendon, A. H. Friedman, W. R. Bishop, D. D. Bigner, and H. S. Friedman. “Treatment of neoplastic meningitis with intrathecal temozolomide.” Clin Cancer Res 5, no. 5 (May 1999): 1183–88.Link to Item
-
Friedman, H. S., W. P. Petros, A. H. Friedman, L. J. Schaaf, T. Kerby, J. Lawyer, M. Parry, et al. “Irinotecan therapy in adults with recurrent or progressive malignant glioma.” J Clin Oncol 17, no. 5 (May 1999): 1516–25. https://doi.org/10.1200/JCO.1999.17.5.1516.Full Text Link to Item
-
Rasheed, B. K., R. N. Wiltshire, S. H. Bigner, and D. D. Bigner. “Molecular pathogenesis of malignant gliomas.” Curr Opin Oncol 11, no. 3 (May 1999): 162–67. https://doi.org/10.1097/00001622-199905000-00004.Full Text Link to Item
-
Reist, C. J., C. F. Foulon, K. Alston, D. D. Bigner, and M. R. Zalutsky. “Astatine-211 labeling of internalizing anti-EGFRvIII monoclonal antibody using N-succinimidyl 5-[211At]astato-3-pyridinecarboxylate.” Nucl Med Biol 26, no. 4 (May 1999): 405–11. https://doi.org/10.1016/s0969-8051(98)00120-6.Full Text Link to Item
-
Akabani, G., C. J. Reist, I. Cokgor, A. H. Friedman, H. S. Friedman, R. E. Coleman, X. G. Zhao, D. D. Bigner, and M. R. Zalutsky. “Dosimetry of 131I-labeled 81C6 monoclonal antibody administered into surgically created resection cavities in patients with malignant brain tumors.” J Nucl Med 40, no. 4 (April 1999): 631–38.Link to Item
-
Foulon, C. F., C. J. Reist, D. D. Bigner, and M. R. Zalutsky. “Radioiodinated D-peptides as prosthetic groups for radiolabeling internalizing antibodies.” Journal of Labelled Compounds and Radiopharmaceuticals 42, no. SUPPL. 1 (January 1, 1999).
-
Kuan, C. T., C. J. Reist, C. F. Foulon, I. A. J. Lorimer, G. Archer, C. N. Pegram, I. Pastan, M. R. Zalutsky, and D. D. Bigner. “125I-labeled anti-epidermal growth factor receptor-vIII single-chain Fv exhibits specific and high-level targeting of glioma xenografts.” Clinical Cancer Research 5, no. 6 (1999): 1539–49.
-
Archer, G. E., J. H. Sampson, R. E. McLendon, A. H. Friedman, O. M. Colvin, M. Rose, H. Sands, et al. “Intrathecal busulfan treatment of human neoplastic meningitis in athymic nude rats.” J Neurooncol 44, no. 3 (1999): 233–41. https://doi.org/10.1023/a:1006304424346.Full Text Link to Item
-
Dong, Q., S. P. Johnson, O. M. Colvin, N. Bullock, C. Kilborn, G. Runyon, D. M. Sullivan, et al. “Multiple DNA repair mechanisms and alkylator resistance in the human medulloblastoma cell line D-283 Med (4-HCR).” Cancer Chemother Pharmacol 43, no. 1 (1999): 73–79. https://doi.org/10.1007/s002800050865.Full Text Link to Item
-
Foulon, C. F., D. D. Bigner, and M. R. Zalutsky. “Preparation and characterization of anti-tenascin monoclonal antibody-streptavidin conjugates for pretargeting applications.” Bioconjug Chem 10, no. 5 (1999): 867–76. https://doi.org/10.1021/bc990040w.Full Text Link to Item
-
Friedman, H. S., A. E. Pegg, S. P. Johnson, N. A. Loktionova, M. E. Dolan, P. Modrich, R. C. Moschel, et al. “Modulation of cyclophosphamide activity by O6-alkylguanine-DNA alkyltransferase.” Cancer Chemother Pharmacol 43, no. 1 (1999): 80–85. https://doi.org/10.1007/s002800050866.Full Text Link to Item
-
Wikstrand, C. J., I. Cokgor, J. H. Sampson, and D. D. Bigner. “Monoclonal antibody therapy of human gliomas: current status and future approaches.” Cancer Metastasis Rev 18, no. 4 (1999): 451–64. https://doi.org/10.1023/a:1006354102377.Full Text Link to Item
-
Friedman, H. S., R. E. McLendon, T. Kerby, M. Dugan, S. H. Bigner, A. J. Henry, D. M. Ashley, et al. “DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma.” J Clin Oncol 16, no. 12 (December 1998): 3851–57. https://doi.org/10.1200/JCO.1998.16.12.3851.Full Text Link to Item
-
Friedman, H. S., D. M. Kokkinakis, J. Pluda, A. H. Friedman, I. Cokgor, M. M. Haglund, D. M. Ashley, et al. “Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma.” J Clin Oncol 16, no. 11 (November 1998): 3570–75. https://doi.org/10.1200/JCO.1998.16.11.3570.Full Text Link to Item
-
Reist, C. J., D. D. Bigner, and M. R. Zalutsky. “Human IgG2 constant region enhances in vivo stability of anti-tenascin antibody 81C6 compared with its murine parent.” Clin Cancer Res 4, no. 10 (October 1998): 2495–2502.Link to Item
-
Wikstrand, C. J., and D. D. Bigner. “Prognostic applications of the epidermal growth factor receptor and its ligand, transforming growth factor-alpha.” J Natl Cancer Inst 90, no. 11 (June 3, 1998): 799–801. https://doi.org/10.1093/jnci/90.11.799.Full Text Link to Item
-
Ashley, D. M., J. H. Sampson, G. E. Archer, L. P. Hale, and D. D. Bigner. “Local production of TGF beta1 inhibits cerebral edema, enhances TNF-alpha induced apoptosis and improves survival in a murine glioma model.” J Neuroimmunol 86, no. 1 (June 1, 1998): 46–52. https://doi.org/10.1016/s0165-5728(98)00017-4.Full Text Link to Item
-
Lee, S. E., S. P. Johnson, L. P. Hale, J. Li, N. Bullock, H. Fuchs, A. Friedman, et al. “Analysis of DNA mismatch repair proteins in human medulloblastoma.” Clin Cancer Res 4, no. 6 (June 1998): 1415–19.Link to Item
-
Bigner, D. D., M. T. Brown, A. H. Friedman, R. E. Coleman, G. Akabani, H. S. Friedman, W. L. Thorstad, et al. “Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results.” J Clin Oncol 16, no. 6 (June 1998): 2202–12. https://doi.org/10.1200/JCO.1998.16.6.2202.Full Text Link to Item
-
Foulon, C. F., D. D. Bigner, and M. R. Zalutsky. “Pretargeted radioimmunotherapy using anti-tenascin 81C6-streptavidin conjugates and radiolabeled biotin: Preparation of reagents.” Journal of Nuclear Medicine 39, no. 5 (May 1, 1998): 105P-106P.Link to Item
-
Matthews, M. R., B. K. A. Rasheed, R. E. McLendon, C. J. Wikstrand, D. D. Bigner, and S. H. Bigner. “Molecular and immunohistologic (IHC) studies on oligodendroglial (O) tumors.” Journal of Neuropathology and Experimental Neurology 57, no. 5 (May 1, 1998): 473–473.Link to Item
-
McLendon, R. E., L. Cleveland, C. Pegram, S. H. Bigner, D. D. Bigner, and H. S. Friedman. “Immunohistochemical detection of the DNA repair enzyme O6-methylguanine-DNA methyltransferase in formalin-fixed, paraffin-embedded astrocytomas.” Lab Invest 78, no. 5 (May 1998): 643–44.Link to Item
-
Reist, C. J., D. D. Bigner, and M. R. Zalutsky. “Human IgG(2) constant region enhances the in vivo stability of monoclonal antibody 81C6 compared to its murine parent.” Journal of Nuclear Medicine 39, no. 5 (May 1, 1998): 77P-77P.Link to Item
-
Wikstrand, C. J., C. J. Reist, G. E. Archer, M. R. Zalutsky, and D. D. Bigner. “The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target.” J Neurovirol 4, no. 2 (April 1998): 148–58. https://doi.org/10.3109/13550289809114515.Full Text Link to Item
-
Ashley, D. M., F. M. Kong, D. D. Bigner, and L. P. Hale. “Endogenous expression of transforming growth factor beta1 inhibits growth and tumorigenicity and enhances Fas-mediated apoptosis in a murine high-grade glioma model.” Cancer Res 58, no. 2 (January 15, 1998): 302–9.Link to Item
-
Coggins, C. A., G. B. Elion, P. J. Houghton, C. B. Hare, S. Keir, O. M. Colvin, D. D. Bigner, and H. S. Friedman. “Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents.” Cancer Chemother Pharmacol 41, no. 6 (1998): 485–90. https://doi.org/10.1007/s002800050771.Full Text Link to Item
-
Hanley, M. L., G. B. Elion, O. M. Colvin, P. L. Modrich, S. Keir, D. J. Adams, D. D. Bigner, and H. S. Friedman. “Therapeutic efficacy of vinorelbine against pediatric and adult central nervous system tumors.” Cancer Chemother Pharmacol 42, no. 6 (1998): 479–82. https://doi.org/10.1007/s002800050848.Full Text Link to Item
-
Ashley, D. M., and D. D. Bigner. “Recent advances in the biology of central nervous system tumors.” Curr Opin Neurol 10, no. 6 (December 1997): 445–51. https://doi.org/10.1097/00019052-199712000-00002.Full Text Link to Item
-
Sampson, J. H., D. M. Ashley, G. E. Archer, H. E. Fuchs, G. Dranoff, L. P. Hale, and D. D. Bigner. “Characterization of a spontaneous murine astrocytoma and abrogation of its tumorigenicity by cytokine secretion.” Neurosurgery 41, no. 6 (December 1997): 1365–72. https://doi.org/10.1097/00006123-199712000-00024.Full Text Link to Item
-
Ashley, D. M., S. K. Batra, and D. D. Bigner. “Monoclonal antibodies to growth factors and growth factor receptors: their diagnostic and therapeutic potential in brain tumors.” J Neurooncol 35, no. 3 (December 1997): 259–73. https://doi.org/10.1023/a:1005812417638.Full Text Link to Item
-
Ashley, D. M., B. Faiola, S. Nair, L. P. Hale, D. D. Bigner, and E. Gilboa. “Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors.” J Exp Med 186, no. 7 (October 6, 1997): 1177–82. https://doi.org/10.1084/jem.186.7.1177.Full Text Link to Item
-
Rasheed, B. K., T. T. Stenzel, R. E. McLendon, R. Parsons, A. H. Friedman, H. S. Friedman, D. D. Bigner, and S. H. Bigner. “PTEN gene mutations are seen in high-grade but not in low-grade gliomas.” Cancer Res 57, no. 19 (October 1, 1997): 4187–90.Link to Item
-
Reist, C. J., S. K. Batra, C. N. Pegram, D. D. Bigner, and M. R. Zalutsky. “In vitro and in vivo behavior of radiolabeled chimeric anti-EGFRvIII monoclonal antibody: comparison with its murine parent.” Nucl Med Biol 24, no. 7 (October 1997): 639–47. https://doi.org/10.1016/s0969-8051(97)00080-2.Full Text Link to Item
-
Wikstrand, C. J., R. E. McLendon, A. H. Friedman, and D. D. Bigner. “Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII.” Cancer Res 57, no. 18 (September 15, 1997): 4130–40.Link to Item
-
Ashley, D. M., J. H. Sampson, G. E. Archer, S. K. Batra, D. D. Bigner, and L. P. Hale. “A genetically modified allogeneic cellular vaccine generates MHC class I-restricted cytotoxic responses against tumor-associated antigens and protects against CNS tumors in vivo.” J Neuroimmunol 78, no. 1–2 (September 1997): 34–46. https://doi.org/10.1016/s0165-5728(97)00080-5.Full Text Link to Item
-
Friedman, H. S., S. P. Johnson, Q. Dong, S. C. Schold, B. K. Rasheed, S. H. Bigner, F. Ali-Osman, et al. “Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft.” Cancer Res 57, no. 14 (July 15, 1997): 2933–36.Link to Item
-
Chu, C. T., K. D. Everiss, C. J. Wikstrand, S. K. Batra, H. J. Kung, and D. D. Bigner. “Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII).” Biochem J 324 ( Pt 3), no. Pt 3 (June 15, 1997): 855–61. https://doi.org/10.1042/bj3240855.Full Text Link to Item
-
Akabani, G., W. L. Thorstad, M. T. Brown, R. E. Coleman, M. R. Zalutsky, and D. D. Bigner. “Dosimetry methods for patients with malignant CNS tumors treated with I-131 81C6 via surgically created cystic resection cavity.” Journal of Nuclear Medicine 38, no. 5 (May 1, 1997): 395–395.Link to Item
-
Archer, G. E., J. H. Sampson, and D. D. Bigner. “Viruses and oncogenes in brain tumors.” J Neurovirol 3 Suppl 1 (May 1997): S76–77.Link to Item
-
Matthews, M., A. Friedman, C. Wikstrand, D. Bigner, and R. McLendon. “Extracellular matrix antigens in capillary hemangioblastoma.” Journal of Neuropathology and Experimental Neurology 56, no. 5 (May 1, 1997): 166–166.Link to Item
-
Reist, C. J., C. F. Foulon, D. D. Bigner, and M. R. Zalutsky. “A method for labeling internalizing antibodies with astatine-211.” Journal of Nuclear Medicine 38, no. 5 (May 1, 1997): 15–15.Link to Item
-
Reist, C. J., G. E. Archer, C. J. Wikstrand, D. D. Bigner, and M. R. Zalutsky. “Improved targeting of an anti-epidermal growth factor receptor variant III monoclonal antibody in tumor xenografts after labeling using N-succinimidyl 5-iodo-3-pyridinecarboxylate.” Cancer Res 57, no. 8 (April 15, 1997): 1510–15.Link to Item
-
Zalutsky, M. R., M. G. Stabin, R. H. Larsen, and D. D. Bigner. “Tissue distribution and radiation dosimetry of astatine-211-labeled chimeric 81C6, an alpha-particle-emitting immunoconjugate.” Nucl Med Biol 24, no. 3 (April 1997): 255–61. https://doi.org/10.1016/s0969-8051(97)00060-7.Full Text Link to Item
-
Bean, J. M., G. E. Archer, M. T. Munley, E. Ong, S. A. Snyder, Z. A. Haroon, R. E. McLendon, et al. “2013 The impact of hypoxia and oxygenation modification on the radiation response of an intracranial rat glioma.” International Journal of Radiation Oncology*Biology*Physics 39, no. 2 (January 1997): 247–247. https://doi.org/10.1016/s0360-3016(97)80782-1.Full Text
-
Hare, C. B., G. B. Elion, O. M. Colvin, F. Ali-Osman, O. W. Griffith, W. P. Petros, S. Keir, S. L. Marcelli, D. D. Bigner, and H. S. Friedman. “Characterization of the mechanisms of busulfan resistance in a human glioblastoma multiforme xenograft.” Cancer Chemother Pharmacol 40, no. 5 (1997): 409–14. https://doi.org/10.1007/s002800050678.Full Text Link to Item
-
Hare, C. B., G. B. Elion, P. J. Houghton, J. A. Houghton, S. Keir, S. L. Marcelli, D. D. Bigner, and H. S. Friedman. “Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts.” Cancer Chemother Pharmacol 39, no. 3 (1997): 187–91. https://doi.org/10.1007/s002800050558.Full Text Link to Item
-
Hauck, M. L., M. W. Dewhirst, D. D. Bigner, and M. R. Zalutsky. “Local hyperthermia improves uptake of a chimeric monoclonal antibody in a subcutaneous xenograft model.” Clin Cancer Res 3, no. 1 (January 1997): 63–70.Link to Item
-
Kurpad, S. N., M. E. Dolan, R. E. McLendon, G. E. Archer, R. C. Moschel, A. E. Pegg, D. D. Bigner, and H. S. Friedman. “Intraarterial O6-benzylguanine enables the specific therapy of nitrosourea-resistant intracranial human glioma xenografts in athymic rats with 1,3-bis(2-chloroethyl)-1-nitrosourea.” Cancer Chemother Pharmacol 39, no. 4 (1997): 307–16. https://doi.org/10.1007/s002800050577.Full Text Link to Item
-
Moynihan, K., G. B. Elion, C. Pegram, C. J. Reist, D. Wellner, D. D. Bigner, O. W. Griffith, and H. S. Friedman. “L-amino acid oxidase (LOX) modulation of melphalan activity against intracranial glioma.” Cancer Chemother Pharmacol 39, no. 3 (1997): 179–86. https://doi.org/10.1007/s002800050557.Full Text Link to Item
-
Lorimer, I. A., A. Keppler-Hafkemeyer, R. A. Beers, C. N. Pegram, D. D. Bigner, and I. Pastan. “Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: targeting with a single chain antibody variable domain isolated by phage display.” Proc Natl Acad Sci U S A 93, no. 25 (December 10, 1996): 14815–20. https://doi.org/10.1073/pnas.93.25.14815.Full Text Link to Item
-
Reist, C. J., P. K. Garg, K. L. Alston, D. D. Bigner, and M. R. Zalutsky. “Radioiodination of internalizing monoclonal antibodies using N-succinimidyl 5-iodo-3-pyridinecarboxylate.” Cancer Res 56, no. 21 (November 1, 1996): 4970–77.Link to Item
-
Reist, C. J., P. K. Garg, K. L. Alston, D. D. Bigner, and M. R. Zalutsky. “A method for the radiohalogenation of internalizing antibodies.” Journal of Nuclear Medicine 37, no. 10 (October 1, 1996): 1825–1825.Link to Item
-
Sampson, J. H., G. E. Archer, D. M. Ashley, H. E. Fuchs, L. P. Hale, G. Dranoff, and D. D. Bigner. “Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system.” Proc Natl Acad Sci U S A 93, no. 19 (September 17, 1996): 10399–404. https://doi.org/10.1073/pnas.93.19.10399.Full Text Link to Item
-
McCowage, G., R. Tien, R. McLendon, G. Felsberg, H. Fuchs, M. L. Graham, J. Kurtzberg, et al. “Successful treatment of childhood pilocytic astrocytomas metastatic to the leptomeninges with high-dose cyclophosphamide.” Med Pediatr Oncol 27, no. 1 (July 1996): 32–39. https://doi.org/10.1002/(SICI)1096-911X(199607)27:1<32::AID-MPO7>3.0.CO;2-V.Full Text Link to Item
-
Ashley, D. M., D. Longee, R. Tien, H. Fuchs, M. L. Graham, J. Kurtzberg, J. Casey, et al. “Treatment of patients with pineoblastoma with high dose cyclophosphamide.” Med Pediatr Oncol 26, no. 6 (June 1996): 387–92. https://doi.org/10.1002/(SICI)1096-911X(199606)26:6<387::AID-MPO3>3.0.CO;2-D.Full Text Link to Item
-
Brown, M. T., R. E. Coleman, A. H. Friedman, H. S. Friedman, R. E. McLendon, R. Reiman, G. J. Felsberg, et al. “Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results.” Clin Cancer Res 2, no. 6 (June 1996): 963–72.Link to Item
-
Fredman, P., C. J. Wikstrand, J. E. Månsson, G. Reifenberger, S. H. Bigner, A. Rasheed, L. Svennerholm, and D. D. Bigner. “In vivo growth conditions suppress the expression of ganglioside GM2 and favour that of lacto series gangliosides in the human glioma D-54MG cell line.” Glycoconj J 13, no. 3 (June 1996): 391–99. https://doi.org/10.1007/BF00731472.Full Text Link to Item
-
McLendon, R. E., K. M. Fung, R. C. Bentley, B. K. Ahmed Rasheed, J. Q. Trojanowski, S. H. Bigner, D. D. Bigner, and H. S. Friedman. “Production and characterization of two ependymoma xenografts.” J Neuropathol Exp Neurol 55, no. 5 (May 1996): 540–48. https://doi.org/10.1097/00005072-199605000-00007.Full Text Link to Item
-
Zalutsky, M. R., G. E. Archer, P. K. Garg, S. K. Batra, and D. D. Bigner. “Chimeric anti-tenascin antibody 81C6: increased tumor localization compared with its murine parent.” Nucl Med Biol 23, no. 4 (May 1996): 449–58. https://doi.org/10.1016/0969-8051(96)00021-2.Full Text Link to Item
-
McLendon, R. E., G. E. Archer, P. K. Garg, D. D. Bigner, and M. R. Zalutsky. “Radiotoxicity of systematically administered [211At]astatide in B6C3F1 and BALB/c (nu/nu) mice: a long-term survival study with histologic analysis.” Int J Radiat Oncol Biol Phys 35, no. 1 (April 1, 1996): 69–80. https://doi.org/10.1016/s0360-3016(96)85013-9.Full Text Link to Item
-
Barsky, D., Q. Dong, M. E. Colvin, C. F. Melius, S. M. Ludeman, O. M. Colvin, D. D. Bigner, P. Modrich, and H. S. Friedman. “A structural basis for a phosphoramide mustard-induced DNA interstrand cross-link at 5'd(GAC).” Biophysical Journal 70, no. 2 (February 1, 1996): MP447–MP447.Link to Item
-
Davis, F. G., N. Malinski, W. Haenszel, J. Chang, J. Flannery, S. Gershman, R. Dibble, and D. D. Bigner. “Primary brain tumor incidence rates in four United States regions, 1985-1989: a pilot study.” Neuroepidemiology 15, no. 2 (1996): 103–12. https://doi.org/10.1159/000109895.Full Text Link to Item
-
Dong, Q., N. Bullock, F. Ali-Osman, O. M. Colvin, D. D. Bigner, and H. S. Friedman. “Repair analysis of 4-hydroperoxycyclophosphamide-induced DNA interstrand crosslinking in the c-myc gene in 4-hydroperoxycyclophosphamide-sensitive and -resistant medulloblastoma cell lines.” Cancer Chemother Pharmacol 37, no. 3 (1996): 242–46. https://doi.org/10.1007/BF00688323.Full Text Link to Item
-
Moynihan, K., G. B. Elion, F. Ali-Osman, S. Marcelli, S. Keir, D. D. Bigner, and H. S. Friedman. “Enhancement of melphalan activity by inhibition of DNA polymerase-alpha and DNA polymerase-beta.” Cancer Chemother Pharmacol 38, no. 4 (1996): 349–54. https://doi.org/10.1007/s002800050494.Full Text Link to Item
-
Zalutsky, M. R., J. M. Schuster, P. K. Garg, G. E. Archer, M. W. Dewhirst, and D. D. Bigner. “Two approaches for enhancing radioimmunotherapy: alpha emitters and hyperthermia.” Recent Results Cancer Res 141 (1996): 101–22. https://doi.org/10.1007/978-3-642-79952-5_7.Full Text Link to Item
-
Zalutsky, M. R., and D. D. Bigner. “Radioimmunotherapy with alpha-particle emitting radioimmunoconjugates.” Acta Oncol 35, no. 3 (1996): 373–79. https://doi.org/10.3109/02841869609101654.Full Text Link to Item
-
Dong, Q., D. Barsky, M. E. Colvin, C. F. Melius, S. M. Ludeman, J. F. Moravek, O. M. Colvin, D. D. Bigner, P. Modrich, and H. S. Friedman. “A structural basis for a phosphoramide mustard-induced DNA interstrand cross-link at 5'-d(GAC).” Proc Natl Acad Sci U S A 92, no. 26 (December 19, 1995): 12170–74. https://doi.org/10.1073/pnas.92.26.12170.Full Text Link to Item
-
Bigner, D. D., G. E. Archer, R. E. McLendon, H. S. Friedman, H. E. Fuchs, L. H. Pai, J. E. Herndon, and I. H. Pastan. “Efficacy of compartmental administration of immunotoxin LMB-1 (B3-LysPE38) in a rat model of carcinomatous meningitis.” Clin Cancer Res 1, no. 12 (December 1995): 1545–55.Link to Item
-
Kurpad, S. N., X. G. Zhao, C. J. Wikstrand, S. K. Batra, R. E. McLendon, and D. D. Bigner. “Tumor antigens in astrocytic gliomas.” Glia 15, no. 3 (November 1995): 244–56. https://doi.org/10.1002/glia.440150306.Full Text Link to Item
-
Batra, S. K., S. Castelino-Prabhu, C. J. Wikstrand, X. Zhu, P. A. Humphrey, H. S. Friedman, and D. D. Bigner. “Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene.” Cell Growth Differ 6, no. 10 (October 1995): 1251–59.Link to Item
-
Reist, C. J., G. E. Archer, S. N. Kurpad, C. J. Wikstrand, G. Vaidyanathan, M. C. Willingham, D. K. Moscatello, A. J. Wong, D. D. Bigner, and M. R. Zalutsky. “Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies: use of the tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts.” Cancer Res 55, no. 19 (October 1, 1995): 4375–82.Link to Item
-
Kurpad, S. N., H. S. Friedman, G. E. Archer, R. E. McLendon, W. M. Petros, H. E. Fuchs, A. Guaspari, and D. D. Bigner. “Intraarterial administration of melphalan for treatment of intracranial human glioma xenografts in athymic rats.” Cancer Res 55, no. 17 (September 1, 1995): 3803–9.Link to Item
-
Moghrabi, A., H. Fuchs, M. Brown, S. C. Schold, M. Graham, J. Kurtzberg, R. Tien, G. Felsberg, D. H. Lachance, and O. M. Colvin. “Cyclophosphamide in combination with sargramostim for treatment of recurrent medulloblastoma.” Med Pediatr Oncol 25, no. 3 (September 1995): 190–96. https://doi.org/10.1002/mpo.2950250306.Full Text Link to Item
-
Lorimer, I. A., C. J. Wikstrand, S. K. Batra, D. D. Bigner, and I. Pastan. “Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors.” Clin Cancer Res 1, no. 8 (August 1995): 859–64.Link to Item
-
Wikstrand, C. J., L. P. Hale, S. K. Batra, M. L. Hill, P. A. Humphrey, S. N. Kurpad, R. E. McLendon, D. Moscatello, C. N. Pegram, and C. J. Reist. “Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas.” Cancer Res 55, no. 14 (July 15, 1995): 3140–48.Link to Item
-
Friedman, H. S., M. E. Dolan, A. E. Pegg, S. Marcelli, S. Keir, J. J. Catino, D. D. Bigner, and S. C. Schold. “Activity of temozolomide in the treatment of central nervous system tumor xenografts.” Cancer Res 55, no. 13 (July 1, 1995): 2853–57.Link to Item
-
Castellino, S. M., H. S. Friedman, G. B. Elion, E. T. Ong, S. L. Marcelli, R. Page, D. D. Bigner, and M. W. Dewhirst. “Flunarizine enhancement of melphalan activity against drug-sensitive/resistant rhabdomyosarcoma.” Br J Cancer 71, no. 6 (June 1995): 1181–87. https://doi.org/10.1038/bjc.1995.230.Full Text Link to Item
-
Foltz, R. M., R. E. McLendon, H. S. Friedman, R. K. Dodge, D. D. Bigner, and M. W. Dewhirst. “A pial window model for the intracranial study of human glioma microvascular function.” Neurosurgery 36, no. 5 (May 1995): 976–84. https://doi.org/10.1227/00006123-199505000-00014.Full Text Link to Item
-
Lachance, D. H., D. Oette, S. C. Schold, M. Brown, J. Kurtzberg, M. L. Graham, R. Tien, G. Felsberg, O. M. Colvin, and A. Moghrabi. “Dose escalation trial of cyclophosphamide with Sargramostim in the treatment of central nervous system (CNS) neoplasms.” Med Pediatr Oncol 24, no. 4 (April 1995): 241–47. https://doi.org/10.1002/mpo.2950240406.Full Text Link to Item
-
Pastan, I. H., G. E. Archer, R. E. McLendon, H. S. Friedman, H. E. Fuchs, Q. C. Wang, L. H. Pai, J. Herndon, and D. D. Bigner. “Intrathecal administration of single-chain immunotoxin, LMB-7 [B3(Fv)-PE38], produces cures of carcinomatous meningitis in a rat model.” Proc Natl Acad Sci U S A 92, no. 7 (March 28, 1995): 2765–69. https://doi.org/10.1073/pnas.92.7.2765.Full Text Link to Item
-
Batra, S. K., R. E. McLendon, J. S. Koo, S. Castelino-Prabhu, H. E. Fuchs, J. P. Krischer, H. S. Friedman, D. D. Bigner, and S. H. Bigner. “Prognostic implications of chromosome 17p deletions in human medulloblastomas.” J Neurooncol 24, no. 1 (1995): 39–45. https://doi.org/10.1007/BF01052657.Full Text Link to Item
-
Bigner, D. D., M. Brown, R. E. Coleman, A. H. Friedman, H. S. Friedman, R. E. McLendon, S. H. Bigner, X. G. Zhao, C. J. Wikstrand, and C. N. Pegram. “Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab')2--a preliminary report.” J Neurooncol 24, no. 1 (1995): 109–22. https://doi.org/10.1007/BF01052668.Full Text Link to Item
-
Friedman, H. S., S. H. Bigner, and D. D. Bigner. “Cyclophosphamide therapy of medulloblastoma: from the laboratory to the clinic and back again (and again and again).” J Neurooncol 24, no. 1 (1995): 103–8. https://doi.org/10.1007/BF01052667.Full Text Link to Item
-
Rich, J. N., G. B. Elion, D. Wellner, O. M. Colvin, D. R. Groothuis, J. H. Hilton, K. E. Schlageter, D. D. Bigner, O. W. Griffith, and H. S. Friedman. “The effect of L-amino acid oxidase on activity of melphalan against an intracranial xenograft.” Cancer Chemother Pharmacol 36, no. 5 (1995): 379–84. https://doi.org/10.1007/BF00686186.Full Text Link to Item
-
Schuster, J. M., M. R. Zalutsky, M. A. Noska, R. Dodge, H. S. Friedman, D. D. Bigner, and M. W. Dewhirst. “Hyperthermic modulation of radiolabelled antibody uptake in a human glioma xenograft and normal tissues.” Int J Hyperthermia 11, no. 1 (1995): 59–72. https://doi.org/10.3109/02656739509004948.Full Text Link to Item
-
Jen, J., J. W. Harper, S. H. Bigner, D. D. Bigner, N. Papadopoulos, S. Markowitz, J. K. Willson, K. W. Kinzler, and B. Vogelstein. “Deletion of p16 and p15 genes in brain tumors.” Cancer Res 54, no. 24 (December 15, 1994): 6353–58.Link to Item
-
Batra, S. K., B. K. Rasheed, S. H. Bigner, and D. D. Bigner. “Oncogenes and anti-oncogenes in human central nervous system tumors.” Lab Invest 71, no. 5 (November 1994): 621–37.Link to Item
-
Friedman, H. S., G. E. Archer, R. E. McLendon, J. M. Schuster, O. M. Colvin, A. Guaspari, R. Blum, P. A. Savina, H. E. Fuchs, and D. D. Bigner. “Intrathecal melphalan therapy of human neoplastic meningitis in athymic nude rats.” Cancer Res 54, no. 17 (September 1, 1994): 4710–14.Link to Item
-
Zalutsky, M. R., R. E. McLendon, P. K. Garg, G. E. Archer, J. M. Schuster, and D. D. Bigner. “Radioimmunotherapy of neoplastic meningitis in rats using an alpha-particle-emitting immunoconjugate.” Cancer Res 54, no. 17 (September 1, 1994): 4719–25.Link to Item
-
Friedman, H. S., M. E. Dolan, S. H. Kaufmann, O. M. Colvin, O. W. Griffith, R. C. Moschel, S. C. Schold, D. D. Bigner, and F. Ali-Osman. “Elevated DNA polymerase alpha, DNA polymerase beta, and DNA topoisomerase II in a melphalan-resistant rhabdomyosarcoma xenograft that is cross-resistant to nitrosoureas and topotecan.” Cancer Res 54, no. 13 (July 1, 1994): 3487–93.Link to Item
-
McLendon, R. E., and D. D. Bigner. “Immunohistochemistry of the glial fibrillary acidic protein: basic and applied considerations.” Brain Pathol 4, no. 3 (July 1994): 221–28. https://doi.org/10.1111/j.1750-3639.1994.tb00837.x.Full Text Link to Item
-
He, X., G. E. Archer, C. J. Wikstrand, S. L. Morrison, M. R. Zalutsky, D. D. Bigner, and S. K. Batra. “Generation and characterization of a mouse/human chimeric antibody directed against extracellular matrix protein tenascin.” J Neuroimmunol 52, no. 2 (July 1994): 127–37. https://doi.org/10.1016/0165-5728(94)90106-6.Full Text Link to Item
-
Friedman, H. S., G. Archer, and D. D. Bigner. “Re: Toxicity of intrathecal melphalan.” J Natl Cancer Inst 86, no. 11 (June 1, 1994): 870–71. https://doi.org/10.1093/jnci/86.11.870.Full Text Link to Item
-
Kurpad, S. N., C. J. Wikstrand, and D. D. Bigner. “Immunobiology of malignant astrocytomas.” Semin Oncol 21, no. 2 (April 1994): 149–61.Link to Item
-
Batra, S. K., M. L. Niswonger, C. J. Wikstrand, C. N. Pegram, M. R. Zalutsky, S. L. Morrison, and D. D. Bigner. “Mouse/human chimeric Me1-14 antibody: genomic cloning of the variable region genes, linkage to human constant region genes, expression, and characterization.” Hybridoma 13, no. 2 (April 1994): 87–97. https://doi.org/10.1089/hyb.1994.13.87.Full Text Link to Item
-
Rasheed, B. K., R. E. McLendon, J. E. Herndon, H. S. Friedman, A. H. Friedman, D. D. Bigner, and S. H. Bigner. “Alterations of the TP53 gene in human gliomas.” Cancer Res 54, no. 5 (March 1, 1994): 1324–30.Link to Item
-
Aaron, R. H., G. B. Elion, O. M. Colvin, M. Graham, S. Keir, D. D. Bigner, and H. S. Friedman. “Busulfan therapy of central nervous system xenografts in athymic mice.” Cancer Chemother Pharmacol 35, no. 2 (1994): 127–31. https://doi.org/10.1007/BF00686634.Full Text Link to Item
-
Friedman, H. S., P. J. Houghton, S. C. Schold, S. Keir, and D. D. Bigner. “Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts.” Cancer Chemother Pharmacol 34, no. 2 (1994): 171–74. https://doi.org/10.1007/BF00685936.Full Text Link to Item
-
Wikstrand, C. J., P. Fredman, L. Svennerholm, and D. D. Bigner. “Detection of glioma-associated gangliosides GM2, GD2, GD3, 3'-isoLM1 3',6'-isoLD1 in central nervous system tumors in vitro and in vivo using epitope-defined monoclonal antibodies.” Prog Brain Res 101 (1994): 213–23. https://doi.org/10.1016/s0079-6123(08)61951-2.Full Text Link to Item
-
Wikstrand, C. J., P. Fredman, R. R. McLendon, L. Svennerholm, and D. D. Bigner. “Altered expression of ganglioside phenotypes of human gliomas in vivo and in vitro.” Mol Chem Neuropathol 21, no. 2–3 (1994): 129–38. https://doi.org/10.1007/BF02815347.Full Text Link to Item
-
Garg, S., P. K. Garg, X. G. Zhao, H. S. Friedman, D. D. Bigner, and M. R. Zalutsky. “Radioiodination of a monoclonal antibody using N-succinimidyl 5-iodo-3-pyridinecarboxylate.” Nucl Med Biol 20, no. 7 (October 1993): 835–42. https://doi.org/10.1016/0969-8051(93)90149-o.Full Text Link to Item
-
Ibrahim, S. N., V. A. Lightner, J. B. Ventimiglia, G. K. Ibrahim, P. J. Walther, D. D. Bigner, and P. A. Humphrey. “Tenascin expression in prostatic hyperplasia, intraepithelial neoplasia, and carcinoma.” Hum Pathol 24, no. 9 (September 1993): 982–89. https://doi.org/10.1016/0046-8177(93)90112-t.Full Text Link to Item
-
Garcia de Palazzo, I. E., G. P. Adams, P. Sundareshan, A. J. Wong, J. R. Testa, D. D. Bigner, and L. M. Weiner. “Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas.” Cancer Res 53, no. 14 (July 15, 1993): 3217–20.Link to Item
-
Wikstrand, C. J., S. D. Stanley, P. A. Humphrey, C. N. Pegram, G. E. Archer, S. Kurpad, M. Shibuya, and D. D. Bigner. “Investigation of a synthetic peptide as immunogen for a variant epidermal growth factor receptor associated with gliomas.” J Neuroimmunol 46, no. 1–2 (July 1993): 165–73. https://doi.org/10.1016/0165-5728(93)90246-u.Full Text Link to Item
-
Schold, S. C., M. R. Zalutsky, R. E. Coleman, M. J. Glantz, A. H. Friedman, R. J. Jaszczak, S. H. Bigner, and D. D. Bigner. “Distribution and dosimetry of I-123-labeled monoclonal antibody 81C6 in patients with anaplastic glioma.” Invest Radiol 28, no. 6 (June 1993): 488–96.Link to Item
-
Schuster, J. M., H. S. Friedman, G. E. Archer, H. E. Fuchs, R. E. McLendon, O. M. Colvin, and D. D. Bigner. “Intraarterial therapy of human glioma xenografts in athymic rats using 4-hydroperoxycyclophosphamide.” Cancer Res 53, no. 10 Suppl (May 15, 1993): 2338–43.Link to Item
-
McLENDON, R. E., S. K. BATRA, H. S. FRIEDMAN, B. K. A. RASHEED, D. D. BIGNER, and S. H. BIGNER. “EXPRESSION OF C-MYC IN MEDULLOBLASTOMA XENOGRAFTS.” Journal of Neuropathology and Experimental Neurology 52, no. 3 (May 1993): 267–267. https://doi.org/10.1097/00005072-199305000-00030.Full Text
-
BATRA, S. K., M. NISWONGER, C. J. WIKSTRAND, M. R. ZALUTSKY, S. L. MORRISON, and D. D. BIGNER. “GENERATION AND CHARACTERIZATION OF MOUSE-HUMAN CHIMERIC MEL-14 ANTIBODY.” Journal of Immunology 150, no. 8 (April 15, 1993): A150–A150.Link to Item
-
Brent, T. P., M. A. von Wronski, C. C. Edwards, M. Bromley, G. P. Margison, J. A. Rafferty, C. N. Pegram, and D. D. Bigner. “Identification of nitrosourea-resistant human rhabdomyosarcomas by in situ immunostaining of O6-methylguanine-DNA methyltransferase.” Oncol Res 5, no. 2 (1993): 83–86.Link to Item
-
Castellino, S., G. B. Elion, O. W. Griffith, M. Dewhirst, J. Kurtzberg, R. C. Cattley, P. Scott, D. D. Bigner, and H. S. Friedman. “Development of a model of melphalan-induced gastrointestinal toxicity in mice.” Cancer Chemother Pharmacol 31, no. 5 (1993): 376–80. https://doi.org/10.1007/BF00686151.Full Text Link to Item
-
Schold, S. C., J. E. Herndon, P. C. Burger, E. C. Halperin, N. A. Vick, J. G. Cairncross, D. R. Macdonald, E. J. Dropcho, R. Morawetz, and D. D. Bigner. “Randomized comparison of diaziquone and carmustine in the treatment of adults with anaplastic glioma.” J Clin Oncol 11, no. 1 (January 1993): 77–83. https://doi.org/10.1200/JCO.1993.11.1.77.Full Text Link to Item
-
Wikstrand, C. J., D. C. Longee, R. E. McLendon, G. N. Fuller, H. S. Friedman, P. Fredman, L. Svennerholm, and D. D. Bigner. “Lactotetraose series ganglioside 3',6'-isoLD1 in tumors of central nervous and other systems in vitro and in vivo.” Cancer Res 53, no. 1 (January 1, 1993): 120–26.Link to Item
-
Schuster, J. M., H. S. Friedman, G. E. Archer, H. E. Fuchs, R. E. McLendon, and D. D. Bigner. “Intraarterial Therapy of Human Glioma Xenografts in Athymic Rats Using 4-Hydroperoxycyclophosphamide.” Cancer Research 53, no. 10 (January 1, 1993): 2338–43.
-
Friedman, H. S., M. E. Dolan, R. C. Moschel, A. E. Pegg, G. M. Felker, J. Rich, D. D. Bigner, and S. C. Schold. “Enhancement of nitrosourea activity in medulloblastoma and glioblastoma multiforme.” J Natl Cancer Inst 84, no. 24 (December 16, 1992): 1926–31. https://doi.org/10.1093/jnci/84.24.1926.Full Text Link to Item
-
Bigner, D. D. “M. Stephen Mahaley, Jr., M.D., Ph.D., 1932-1992.” J Neurosurg 77, no. 6 (December 1992): 829–31. https://doi.org/10.3171/jns.1992.77.6.0829.Full Text Link to Item
-
Groothuis, D. R., B. E. Lippitz, I. Fekete, K. E. Schlageter, P. Molnar, O. M. Colvin, C. R. Roe, D. D. Bigner, and H. S. Friedman. “The effect of an amino acid-lowering diet on the rate of melphalan entry into brain and xenotransplanted glioma.” Cancer Res 52, no. 20 (October 15, 1992): 5590–96.Link to Item
-
Friedman, H. S., O. M. Colvin, S. H. Kaufmann, S. M. Ludeman, N. Bullock, D. D. Bigner, and O. W. Griffith. “Cyclophosphamide resistance in medulloblastoma.” Cancer Res 52, no. 19 (October 1, 1992): 5373–78.Link to Item
-
Wikstrand, C. J., P. Fredman, L. Svennerholm, P. A. Humphrey, S. H. Bigner, and D. D. Bigner. “Monoclonal antibodies to malignant human gliomas.” Mol Chem Neuropathol 17, no. 2 (October 1992): 137–46. https://doi.org/10.1007/BF03159988.Full Text Link to Item
-
Garg, P. K., S. Garg, D. D. Bigner, and M. R. Zalutsky. “Localization of fluorine-18-labeled Mel-14 monoclonal antibody F(ab')2 fragment in a subcutaneous xenograft model.” Cancer Res 52, no. 18 (September 15, 1992): 5054–60.Link to Item
-
Moseley, R. P., V. Papanastassiou, M. R. Zalutsky, R. D. Ashpole, S. Evans, D. D. Bigner, and J. T. Kemshead. “Immunoreactivity, pharmacokinetics and bone marrow dosimetry of intrathecal radioimmunoconjugates.” Int J Cancer 52, no. 1 (August 19, 1992): 38–43. https://doi.org/10.1002/ijc.2910520109.Full Text Link to Item
-
Vaidyanathan, G., D. D. Bigner, and M. R. Zalutsky. “Fluorine-18-labeled monoclonal antibody fragments: a potential approach for combining radioimmunoscintigraphy and positron emission tomography.” J Nucl Med 33, no. 8 (August 1992): 1535–41.Link to Item
-
Rasheed, B. K., G. N. Fuller, A. H. Friedman, D. D. Bigner, and S. H. Bigner. “Loss of heterozygosity for 10q loci in human gliomas.” Genes Chromosomes Cancer 5, no. 1 (July 1992): 75–82. https://doi.org/10.1002/gcc.2870050111.Full Text Link to Item
-
Schuster, J. M., and D. D. Bigner. “Immunotherapy and monoclonal antibody therapies.” Curr Opin Oncol 4, no. 3 (June 1992): 547–52. https://doi.org/10.1097/00001622-199206000-00020.Full Text Link to Item
-
Wong, A. J., J. M. Ruppert, S. H. Bigner, C. H. Grzeschik, P. A. Humphrey, D. S. Bigner, and B. Vogelstein. “Structural alterations of the epidermal growth factor receptor gene in human gliomas.” Proc Natl Acad Sci U S A 89, no. 7 (April 1, 1992): 2965–69. https://doi.org/10.1073/pnas.89.7.2965.Full Text Link to Item
-
Kwatra, M. M., D. D. Bigner, and J. A. Cohn. “The ligand binding domain of the epidermal growth factor receptor is not required for receptor dimerization.” Biochim Biophys Acta 1134, no. 2 (March 16, 1992): 178–81. https://doi.org/10.1016/0167-4889(92)90042-a.Full Text Link to Item
-
He, X. M., L. E. Ostrowski, M. A. von Wronski, H. S. Friedman, C. J. Wikstrand, S. H. Bigner, A. Rasheed, S. K. Batra, S. Mitra, and T. P. Brent. “Expression of O6-methylguanine-DNA methyltransferase in six human medulloblastoma cell lines.” Cancer Res 52, no. 5 (March 1, 1992): 1144–48.Link to Item
-
Shiota, S., M. A. von Wronski, K. Tano, D. D. Bigner, T. P. Brent, and S. Mitra. “Characterization of cDNA encoding mouse DNA repair protein O6-methylguanine-DNA methyltransferase and high-level expression of the wild-type and mutant proteins in Escherichia coli.” Biochemistry 31, no. 7 (February 25, 1992): 1897–1903. https://doi.org/10.1021/bi00122a001.Full Text Link to Item
-
Laskowitz, D. T., G. B. Elion, M. W. Dewhirst, O. W. Griffith, P. M. Savina, M. R. Blum, D. M. Prescott, D. D. Bigner, and H. S. Friedman. “Hyperthermia-induced enhancement of melphalan activity against a melphalan-resistant human rhabdomyosarcoma xenograft.” Radiat Res 129, no. 2 (February 1992): 218–23.Link to Item
-
Halperin, E. C., D. M. Brizel, G. Honore, M. R. Sontag, O. W. Griffith, D. D. Bigner, and H. S. Friedman. “The radiation dose-response relationship in a human glioma xenograft and an evaluation of the influence of glutathione depletion by buthionine sulfoximine.” Int J Radiat Oncol Biol Phys 24, no. 1 (1992): 103–9. https://doi.org/10.1016/0360-3016(92)91028-l.Full Text Link to Item
-
Halperin, E. C., D. M. Brizel, G. Honore, M. R. Sontag, O. W. Griffith, D. D. Bigner, and H. S. Friedman. “The radiation dose-response relationship in a human glioma xenograft and an evaluation of the influence of glutathione depletion by buthionine sulfoximine.” International Journal of Radiation Oncology, Biology, Physics 24, no. 1 (1992): 103–9.
-
Laskowitz, D. T., G. B. Elion, M. W. Dewhirst, O. W. Griffith, R. A. Casero, P. A. Scott, N. Bullock, D. D. Bigner, and H. S. Friedman. “Effects of glutathione or polyamine depletion on in vivo thermosensitization.” Int J Hyperthermia 8, no. 2 (1992): 199–208. https://doi.org/10.3109/02656739209021775.Full Text Link to Item
-
Laskowitz, D. T., G. B. Elion, M. W. Dewhirst, O. W. Griffith, R. C. Cattley, D. D. Bigner, and H. S. Friedman. “Enhancement of melphalan-induced gastrointestinal toxicity in mice treated with regional hyperthermia and BSO-mediated glutathione depletion.” Int J Hyperthermia 8, no. 1 (1992): 111–20. https://doi.org/10.3109/02656739209052883.Full Text Link to Item
-
Ventimiglia, J. B., C. J. Wikstrand, L. E. Ostrowski, M. A. Bourdon, V. A. Lightner, and D. D. Bigner. “Tenascin expression in human glioma cell lines and normal tissues.” J Neuroimmunol 36, no. 1 (January 1992): 41–55. https://doi.org/10.1016/0165-5728(92)90029-k.Full Text Link to Item
-
Vick, W. W., J. W. Tello, C. J. Wikstrand, X. He, D. Longee, P. Fredman, L. Svennerholm, D. D. Bigner, W. W. Johnston, and S. H. Bigner. “Application of a panel of antiganglioside monoclonal antibodies to cytologic specimens.” Acta Cytol 36, no. 5 (1992): 697–705.Link to Item
-
Wronski, M. A. von, L. C. Harris, K. Tano, S. Mitra, D. D. Bigner, and T. P. Brent. “Cytosine methylation and suppression of O6-methylguanine-DNA methyltransferase expression in human rhabdomyosarcoma cell lines and xenografts.” Oncol Res 4, no. 4–5 (1992): 167–74.Link to Item
-
He, X., C. J. Wikstrand, P. Fredman, J. E. Mansson, L. Svennerholm, and D. D. Bigner. “GD3 expression by cultured human tumor cells of neuroectodermal origin. Acta Neuropathol (1989) 79 (317-325).” Acta Neuropathologica 82, no. 5 (November 21, 1991): 425. https://doi.org/10.1007/BF00296556.Full Text
-
Wikstrand, C. J., X. M. He, G. N. Fuller, S. H. Bigner, P. Fredman, L. Svennerholm, and D. D. Bigner. “Occurrence of lacto series gangliosides 3'-isoLM1 and 3',6'-isoLD1 in human gliomas in vitro and in vivo.” J Neuropathol Exp Neurol 50, no. 6 (November 1991): 756–69. https://doi.org/10.1097/00005072-199111000-00007.Full Text Link to Item
-
Bjerkvig, R., O. Engebraaten, O. D. Laerum, P. Fredman, L. Svennerholm, F. D. Vrionis, C. J. Wikstrand, and D. D. Bigner. “Anti-GM2 monoclonal antibodies induce necrosis in GM2-rich cultures of a human glioma cell line.” Cancer Res 51, no. 17 (September 1, 1991): 4643–48.Link to Item
-
Ostrowski, L. E., M. A. von Wronski, S. H. Bigner, A. Rasheed, S. C. Schold, T. P. Brent, S. Mitra, and D. D. Bigner. “Expression of O6-methylguanine-DNA methyltransferase in malignant human glioma cell lines.” Carcinogenesis 12, no. 9 (September 1991): 1739–44. https://doi.org/10.1093/carcin/12.9.1739.Full Text Link to Item
-
Saylors, R. L., D. Sidransky, H. S. Friedman, S. H. Bigner, D. D. Bigner, B. Vogelstein, and G. M. Brodeur. “Infrequent p53 gene mutations in medulloblastomas.” Cancer Res 51, no. 17 (September 1, 1991): 4721–23.Link to Item
-
Tano, K., S. Shiota, J. S. Remack, T. P. Brent, D. D. Bigner, and S. Mitra. “The origin of O6-methylguanine-DNA methyltransferase in Chinese hamster ovary cells transfected with human DNA.” Mutat Res 255, no. 2 (September 1991): 175–82. https://doi.org/10.1016/0921-8777(91)90051-p.Full Text Link to Item
-
Humphrey, P. A., L. M. Gangarosa, A. J. Wong, G. E. Archer, M. Lund-Johansen, R. Bjerkvig, O. D. Laerum, H. S. Friedman, and D. D. Bigner. “Deletion-mutant epidermal growth factor receptor in human gliomas: effects of type II mutation on receptor function.” Biochem Biophys Res Commun 178, no. 3 (August 15, 1991): 1413–20. https://doi.org/10.1016/0006-291x(91)91051-d.Full Text Link to Item
-
Schuster, J. M., P. K. Garg, D. D. Bigner, and M. R. Zalutsky. “Improved therapeutic efficacy of a monoclonal antibody radioiodinated using N-succinimidyl-3-(tri-n-butylstannyl)benzoate.” Cancer Res 51, no. 16 (August 15, 1991): 4164–69.Link to Item
-
Lilley, E. R., G. B. Elion, M. W. Dewhirst, S. C. Schold, M. R. Blum, P. M. Savina, D. T. Laskowitz, D. D. Bigner, and H. S. Friedman. “Therapeutic analysis of melphalan-resistant human rhabdomyosarcoma xenograft TE-671 MR.” Cancer Res 51, no. 15 (August 1, 1991): 3906–9.Link to Item
-
Friedman, H. S., W. J. Oakes, S. H. Bigner, C. J. Wikstrand, and D. D. Bigner. “Medulloblastoma: tumor biological and clinical perspectives.” J Neurooncol 11, no. 1 (August 1991): 1–15. https://doi.org/10.1007/BF00166992.Full Text Link to Item
-
Ostrowski, L. E., C. N. Pegram, M. A. Von Wronski, P. A. Humphrey, X. M. He, S. Shiota, S. Mitra, T. P. Brent, and D. D. Bigner. “Production and characterization of antipeptide antibodies against human O6-methylguanine-DNA methyltransferase.” Cancer Res 51, no. 13 (July 1, 1991): 3339–44.Link to Item
-
He, X. M., C. J. Wikstrand, H. S. Friedman, S. H. Bigner, S. Pleasure, J. Q. Trojanowski, and D. D. Bigner. “Differentiation characteristics of newly established medulloblastoma cell lines (D384 Med, D425 Med, and D458 Med) and their transplantable xenografts.” Lab Invest 64, no. 6 (June 1991): 833–43.Link to Item
-
FULLER, G. N., C. J. WIKSTRAND, X. HE, S. H. BIGNER, P. FREDMAN, L. SVENNERHOLM, and D. D. BIGNER. “EXPRESSION OF LACTO SERIES GANGLIOSIDES 3'-ISOLM1 AND 3',6'-ISOLD1 IN HUMAN GLIOMAS INSITU AND INVIVO.” Journal of Neuropathology and Experimental Neurology 50, no. 3 (May 1, 1991): 291–291.Link to Item
-
Schuster, J. M., H. S. Friedman, and D. D. Bigner. “Therapeutic analysis of in vitro and in vivo brain tumor models.” Neurol Clin 9, no. 2 (May 1991): 375–82.Link to Item
-
Garg, S., P. K. Garg, D. D. Bigner, and M. R. Zalutsky. “Radioiodination and astatination of monoclonal antibodies using heterocyclic acylation agents.” Journal of Labelled Compounds and Radiopharmaceuticals 30 (April 5, 1991).
-
Gottfries, J., A. K. Percy, J. E. Månsson, P. Fredman, C. J. Wikstrand, H. S. Friedman, D. D. Bigner, and L. Svennerholm. “Glycolipids and glycosyltransferases in permanent cell lines established from human medulloblastomas.” Biochim Biophys Acta 1081, no. 3 (February 5, 1991): 253–61. https://doi.org/10.1016/0005-2760(91)90279-q.Full Text Link to Item
-
Wronski, M. A. von, S. Shiota, K. Tano, S. Mitra, D. D. Bigner, and T. P. Brent. “Structural and immunological comparison of indigenous human O6-methylguanine-DNA methyltransferase with that encoded by a cloned cDNA.” J Biol Chem 266, no. 2 (January 15, 1991): 1064–70.Link to Item
-
Wikstrand, C. J., H. S. Friedman, and D. D. Bigner. “Medulloblastoma cell-substrate interaction in vitro.” Invasion Metastasis 11, no. 6 (1991): 310–24.Link to Item
-
Longee, D. C., C. J. Wikstrand, J. E. Månsson, X. He, G. N. Fuller, S. H. Bigner, P. Fredman, L. Svennerholm, and D. D. Bigner. “Disialoganglioside GD2 in human neuroectodermal tumor cell lines and gliomas.” Acta Neuropathol 82, no. 1 (1991): 45–54. https://doi.org/10.1007/BF00310922.Full Text Link to Item
-
Skapek, S. X., A. F. VanDellen, D. P. McMahon, D. G. Postels, O. W. Griffith, D. D. Bigner, and H. S. Friedman. “Melphalan-induced toxicity in nude mice following pretreatment with buthionine sulfoximine.” Cancer Chemother Pharmacol 28, no. 1 (1991): 15–21. https://doi.org/10.1007/BF00684950.Full Text Link to Item
-
Wang, A. M., G. B. Elion, H. S. Friedman, W. J. Bodell, D. D. Bigner, and S. C. Schold. “Positive therapeutic interaction between thiopurines and alkylating drugs in human glioma xenografts.” Cancer Chemother Pharmacol 27, no. 4 (1991): 278–84. https://doi.org/10.1007/BF00685112.Full Text Link to Item
-
Bigner, S. H., P. A. Humphrey, A. J. Wong, B. Vogelstein, J. Mark, H. S. Friedman, and D. D. Bigner. “Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts.” Cancer Res 50, no. 24 (December 15, 1990): 8017–22.Link to Item
-
Gottfries, J., P. Fredman, J. E. Månsson, V. P. Collins, H. von Holst, D. D. Armstrong, A. K. Percy, C. J. Wikstrand, D. D. Bigner, and L. Svennerholm. “Determination of gangliosides in six human primary medulloblastomas.” J Neurochem 55, no. 4 (October 1990): 1322–26. https://doi.org/10.1111/j.1471-4159.1990.tb03142.x.Full Text Link to Item
-
Lippitz, B. E., M. Kiessling, C. B. Ostertag, and D. D. Bigner. “[Significance of monoclonal antibodies in diagnosis and therapy of tumors of the central nervous system].” Nervenarzt 61, no. 10 (October 1990): 587–96.Link to Item
-
Barnard, R., and D. D. Bigner. “In memoriam Lucien J. Rubinstein, M.D. (1924-1990).” J Neurooncol 9, no. 2 (October 1990): III–VI. https://doi.org/10.1007/BF02427828.Full Text Link to Item
-
Lund-Johansen, M., R. Bjerkvig, P. A. Humphrey, S. H. Bigner, D. D. Bigner, and O. D. Laerum. “Effect of epidermal growth factor on glioma cell growth, migration, and invasion in vitro.” Cancer Res 50, no. 18 (September 15, 1990): 6039–44.Link to Item
-
Davidsson, P., P. Fredman, H. von Holst, C. J. Wikstrand, X. He, D. D. Bigner, and L. Svennerholm. “Circulating glycoconjugates in CSF of meningioma patients.” Acta Neurol Scand 82, no. 3 (September 1990): 203–8. https://doi.org/10.1111/j.1600-0404.1990.tb04489.x.Full Text Link to Item
-
Fredman, P., J. E. Månsson, S. H. Bigner, C. J. Wikstrand, D. D. Bigner, and L. Svennerholm. “Gangliosides in the human glioma cell line U-118 MG grown in culture or as xenografts in nude rats.” Biochim Biophys Acta 1045, no. 3 (August 6, 1990): 239–44. https://doi.org/10.1016/0005-2760(90)90126-i.Full Text Link to Item
-
Bigner, S. H., J. Mark, and D. D. Bigner. “Cytogenetics of human brain tumors.” Cancer Genet Cytogenet 47, no. 2 (July 15, 1990): 141–54. https://doi.org/10.1016/0165-4608(90)90024-5.Full Text Link to Item
-
Zalutsky, M. R., R. P. Moseley, J. C. Benjamin, E. V. Colapinto, G. N. Fuller, H. P. Coakham, and D. D. Bigner. “Monoclonal antibody and F(ab')2 fragment delivery to tumor in patients with glioma: comparison of intracarotid and intravenous administration.” Cancer Res 50, no. 13 (July 1, 1990): 4105–10.Link to Item
-
Humphrey, P. A., A. J. Wong, B. Vogelstein, M. R. Zalutsky, G. N. Fuller, G. E. Archer, H. S. Friedman, M. M. Kwatra, S. H. Bigner, and D. D. Bigner. “Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma.” Proc Natl Acad Sci U S A 87, no. 11 (June 1990): 4207–11. https://doi.org/10.1073/pnas.87.11.4207.Full Text Link to Item
-
Wasson, J. C., R. L. Saylors, P. Zeltzer, H. S. Friedman, S. H. Bigner, P. C. Burger, D. D. Bigner, A. T. Look, E. C. Douglass, and G. M. Brodeur. “Oncogene amplification in pediatric brain tumors.” Cancer Res 50, no. 10 (May 15, 1990): 2987–90.Link to Item
-
Oakes, W. J., H. S. Friedman, S. H. Bigner, N. H. Bullock, and D. D. Bigner. “Successful laboratory growth and analysis of CUSA-obtained medulloblastoma samples. Technical note.” J Neurosurg 72, no. 5 (May 1990): 821–23. https://doi.org/10.3171/jns.1990.72.5.0821.Full Text Link to Item
-
Fuller, G. N., P. C. Burger, S. C. Schold, A. Preisinqer, A. J. Wong, P. P. Bigner, B. Vogelstein, and S. H. Bigner. “GENE AMPLIFICATION IN HUMAN GLIOMAS.” Journal of Neuropathology and Experimental Neurology 49, no. 3 (May 1990): 320–320. https://doi.org/10.1097/00005072-199005000-00183.Full Text
-
Longee, D. C., X. He, C. J. Wikstrand, G. N. Fuller, S. H. Bigner, P. Fredman, J. -. E. Månsson, L. Svennerholm, and D. D. Bigner. “EXPRESSION OF GD2 BY TUMOR CELL LINES OF NEUROECTODERMAL ORIGIN AND HUMAN GLIOMAS AS DEFINED BY AN EPITOPE-DEFINED ANTI-GD2 MONOCLONAL ANTIBODY.” Journal of Neuropathology and Experimental Neurology 49, no. 3 (May 1990): 320–320. https://doi.org/10.1097/00005072-199005000-00184.Full Text
-
Lopes, M. B. S., A. Frankfurter, G. M. Zientek, C. D. Katsetos, H. S. Friedman, D. D. Biqner, and M. M. Herman. “NEURON-ASSOCIATED MICROTUBULE PROTEINS IN THE U-251 MALIGNANT GLIOMA CELL LINE.” Journal of Neuropathology and Experimental Neurology 49, no. 3 (May 1990): 272–272. https://doi.org/10.1097/00005072-199005000-00041.Full Text
-
Karlsson, G., J. E. Månsson, C. Wikstrand, D. Bigner, and L. Svennerholm. “Characterization of the binding epitope of the monoclonal antibody DMAb-1 to ganglioside GM2.” Biochim Biophys Acta 1043, no. 3 (April 17, 1990): 267–72. https://doi.org/10.1016/0005-2760(90)90026-t.Full Text Link to Item
-
Bigner, S. H., H. S. Friedman, B. Vogelstein, W. J. Oakes, and D. D. Bigner. “Amplification of the c-myc gene in human medulloblastoma cell lines and xenografts.” Cancer Res 50, no. 8 (April 15, 1990): 2347–50.Link to Item
-
Friedman, H. S., O. M. Colvin, K. Aisaka, J. Popp, E. H. Bossen, K. A. Reimer, J. B. Powell, J. Hilton, S. S. Gross, and R. Levi. “Glutathione protects cardiac and skeletal muscle from cyclophosphamide-induced toxicity.” Cancer Res 50, no. 8 (April 15, 1990): 2455–62.Link to Item
-
SKAPEK, S. X., A. F. VANDELLEN, D. P. MCMAHON, S. T. BERG, O. W. GRIFFITH, D. D. BIGNER, and W. S. FRIEDMAN. “MELPHALAN (L-PAM)-INDUCED TOXICITY IN NUDE-MICE PRETREATED WITH BUTHIONINE SULFOXIMINE (BSO).” Pediatric Research 27, no. 4 (April 1, 1990): A150–A150.Link to Item
-
Fuchs, H. E., G. E. Archer, O. M. Colvin, S. H. Bigner, J. M. Schuster, G. N. Fuller, L. H. Muhlbaier, S. C. Schold, H. S. Friedman, and D. D. Bigner. “Activity of intrathecal 4-hydroperoxycyclophosphamide in a nude rat model of human neoplastic meningitis.” Cancer Res 50, no. 6 (March 15, 1990): 1954–59.Link to Item
-
Colapinto, E. V., M. R. Zalutsky, G. E. Archer, M. A. Noska, H. S. Friedman, S. Carrel, and D. D. Bigner. “Radioimmunotherapy of intracerebral human glioma xenografts with 131I-labeled F(ab')2 fragments of monoclonal antibody Mel-14.” Cancer Res 50, no. 6 (March 15, 1990): 1822–27.Link to Item
-
Cope, D. A., M. W. Dewhirst, H. S. Friedman, D. D. Bigner, and M. R. Zalutsky. “Enhanced delivery of a monoclonal antibody F(ab')2 fragment to subcutaneous human glioma xenografts using local hyperthermia.” Cancer Res 50, no. 6 (March 15, 1990): 1803–9.Link to Item
-
Fekete, I., O. W. Griffith, K. E. Schlageter, D. D. Bigner, H. S. Friedman, and D. R. Groothuis. “Rate of buthionine sulfoximine entry into brain and xenotransplanted human gliomas.” Cancer Res 50, no. 4 (February 15, 1990): 1251–56.Link to Item
-
Ibayashi, N., M. M. Herman, J. C. Boyd, D. V. Caccamo, H. S. Friedman, D. D. Bigner, and L. J. Rubinstein. “Kinetics and glial fibrillary acidic (GFA) protein production in a transplantable human giant cell glioblastoma (D-212 MG) of near haploid karyotype maintained in an organ culture system. An immunohistochemistry study.” Neuropathol Appl Neurobiol 16, no. 1 (February 1990): 27–37. https://doi.org/10.1111/j.1365-2990.1990.tb00929.x.Full Text Link to Item
-
Lippitz, B. E., E. C. Halperin, O. W. Griffith, O. M. Colvin, G. Honore, C. B. Ostertag, D. D. Bigner, and H. S. Friedman. “L-buthionine-sulfoximine-mediated radiosensitization in experimental interstitial radiotherapy of intracerebral D-54 MG glioma xenografts in athymic mice.” Neurosurgery 26, no. 2 (February 1990): 255–60. https://doi.org/10.1097/00006123-199002000-00012.Full Text Link to Item
-
Lilley, E. R., M. C. Rosenberg, G. B. Elion, O. M. Colvin, D. D. Bigner, and H. S. Friedman. “Synergistic interactions between cyclophosphamide or melphalan and VP-16 in a human rhabdomyosarcoma xenograft.” Cancer Res 50, no. 2 (January 15, 1990): 284–87.Link to Item
-
Bigner, S. H., B. Vogelstein, J. Mark, H. S. Friedman, and D. D. Bigner. “Cytogenetics and molecular genetics: their status and role in understanding the behavior of central nervous system neoplasms.” Monogr Pathol, no. 32 (1990): 30–40.Link to Item
-
Brent, T. P., M. von Wronski, C. N. Pegram, and D. D. Bigner. “Immunoaffinity purification of human O6-alkylguanine-DNA alkyltransferase using newly developed monoclonal antibodies.” Cancer Res 50, no. 1 (January 1, 1990): 58–61.Link to Item
-
Lippitz, B. E., M. Kiessling, C. B. Ostertag, and D. D. Bigner. “Significance of monoclonal antibodies in diagnosis and therapy of tumors of the central nervous system.” Nervenarzt 61, no. 10 (1990): 587–96.
-
Shoup, S. A., W. W. Johnston, H. F. Siegler, J. W. Tello, J. Schlom, D. D. Bigner, and S. H. Bigner. “A panel of antibodies useful in the cytologic diagnosis of metastatic melanoma.” Acta Cytol 34, no. 3 (1990): 385–92.Link to Item
-
ROSENBERG, M. C., O. M. COLVIN, O. W. GRIFFITH, S. H. BIGNER, G. B. ELION, J. K. HORTON, E. LILLEY, D. D. BIGNER, and H. S. FRIEDMAN. “ESTABLISHMENT OF A MELPHALAN-RESISTANT RHABDOMYOSARCOMA XENOGRAFT WITH CROSS-RESISTANCE TO VINCRISTINE AND ENHANCED SENSITIVITY FOLLOWING BUTHIONINE SULFOXIMINE-MEDIATED GLUTATHIONE DEPLETION.” Cancer Research 49, no. 24 (December 15, 1989): 6917–22.Link to Item
-
Rosenberg, M. C., E. Lilley, H. S. Friedman, S. H. Bigner, D. D. Bigner, G. B. Elion, O. M. Colvin, O. W. Griffith, and J. K. Horton. “Establishment of a Melphalan-Resistant Rhabdomyosarcoma Xenograft with Cross-Resistance to Vincristine and Enhanced Sensitivity Following Buthionine Sulfoximine-Mediated Glutathione Depletion.” Cancer Research 49 (December 15, 1989): 6917–22.
-
Rosenberg, M. C., O. M. Colvin, O. W. Griffith, S. H. Bigner, G. B. Elion, J. K. Horton, E. Lilley, D. D. Bigner, and H. S. Friedman. “Establishment of a melphalan-resistant rhabdomyosarcoma xenograft with cross-resistance to vincristine and enhanced sensitivity following buthionine sulfoximine-mediated glutathione depletion.” Cancer Res 49, no. 24 Pt 1 (December 15, 1989): 6917–22.Link to Item
-
Hennawi, Y. el-, G. Y. Gillespie, M. S. Mahaley, M. A. Varia, D. D. Bigner, and C. Stanton. “A controlled study of efficacy of interstitial or external irradiation in a virus-induced brain-tumor model in rats.” J Neurosurg 71, no. 6 (December 1989): 898–902. https://doi.org/10.3171/jns.1989.71.6.0898.Full Text Link to Item
-
VRIONIS, F. D., C. J. WIKSTRAND, P. FREDMAN, J. E. MANSSON, L. SVENNERHOLM, and D. D. BIGNER. “5 NEW EPITOPE-DEFINED MONOCLONAL-ANTIBODIES REACTIVE WITH GM2 AND HUMAN GLIOMA AND MEDULLOBLASTOMA CELL-LINES.” Cancer Research 49, no. 23 (December 1, 1989): 6645–51.Link to Item
-
Vrionis, F. D., C. J. Wikstrand, P. Fredman, J. E. Månsson, L. Svennerholm, and D. D. Bigner. “Five new epitope-defined monoclonal antibodies reactive with GM2 and human glioma and medulloblastoma cell lines.” Cancer Res 49, no. 23 (December 1, 1989): 6645–51.Link to Item
-
Zalutsky, M. R., M. A. Noska, E. V. Colapinto, P. K. Garg, and D. D. Bigner. “Enhanced tumor localization and in vivo stability of a monoclonal antibody radioiodinated using N-succinimidyl 3-(tri-n-butylstannyl)benzoate.” Cancer Res 49, no. 20 (October 15, 1989): 5543–49.Link to Item
-
BIGNER, S. H., B. VOGELSTEIN, J. MARK, and D. D. BIGNER. “CYTOGENETICS AND GENE AMPLIFICATION IN MALIGNANT HUMAN-BRAIN TUMORS.” Cancer Genetics and Cytogenetics 41, no. 2 (September 1, 1989): 226–226.Link to Item
-
Ibayashi, N., M. M. Herman, J. C. Boyd, D. D. Bigner, H. S. Friedman, V. P. Collins, L. A. Donoso, and L. J. Rubinstein. “Relationship of the demonstration of intermediate filament protein to kinetics of three human neuroepithelial tumor cell lines. Lack of neural-related proteins in most cells in S phase: a double-labeled immunohistochemical study on matrix cultures.” Lab Invest 61, no. 3 (September 1989): 310–18.Link to Item
-
Zalutsky, M. R., P. K. Garg, H. S. Friedman, and D. D. Bigner. “Labeling monoclonal antibodies and F(ab')2 fragments with the alpha-particle-emitting nuclide astatine-211: preservation of immunoreactivity and in vivo localizing capacity.” Proc Natl Acad Sci U S A 86, no. 18 (September 1989): 7149–53. https://doi.org/10.1073/pnas.86.18.7149.Full Text Link to Item
-
Fredman, P., J. E. Månsson, C. J. Wikstrand, F. D. Vrionis, B. M. Rynmark, D. D. Bigner, and L. Svennerholm. “A new ganglioside of the lactotetraose series, GalNAc-3'-isoLM1, detected in human meconium.” J Biol Chem 264, no. 21 (July 25, 1989): 12122–25.Link to Item
-
Bigner, S. H., S. C. Schold, H. S. Friedman, J. Mark, and D. D. Bigner. “Chromosomal composition of malignant human gliomas through serial subcutaneous transplantation in athymic mice.” Cancer Genet Cytogenet 40, no. 1 (July 1, 1989): 111–20. https://doi.org/10.1016/0165-4608(89)90152-0.Full Text Link to Item
-
Friedman, H. S., S. C. Schold, M. S. Mahaley, O. M. Colvin, W. J. Oakes, N. A. Vick, P. C. Burger, S. H. Bigner, M. Borowitz, and E. C. Halperin. “Phase II treatment of medulloblastoma and pineoblastoma with melphalan: clinical therapy based on experimental models of human medulloblastoma.” J Clin Oncol 7, no. 7 (July 1989): 904–11. https://doi.org/10.1200/JCO.1989.7.7.904.Full Text Link to Item
-
Lightner, V. A., F. Gumkowski, D. D. Bigner, and H. P. Erickson. “Tenascin/hexabrachion in human skin: biochemical identification and localization by light and electron microscopy.” J Cell Biol 108, no. 6 (June 1989): 2483–93. https://doi.org/10.1083/jcb.108.6.2483.Full Text Link to Item
-
Zalutsky, M. R., R. P. Moseley, H. B. Coakham, R. E. Coleman, and D. D. Bigner. “Pharmacokinetics and tumor localization of 131I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies.” Cancer Res 49, no. 10 (May 15, 1989): 2807–13.Link to Item
-
He, X., C. J. Wikstrand, P. Fredman, J. -. E. Månsson, L. Svennerholm, and D. D. Bigner. “DISTRIBUTION OF GANGLIOSIDE GD3 IN CULTURED HUMAN TUMOR CELLS OF NEUROECTODERMAL ORIGIN AS DEFINED BY ANTI-GD3 MONOCLONAL ANTIBODIES.” Journal of Neuropathology and Experimental Neurology 48, no. 3 (May 1989): 305–305. https://doi.org/10.1097/00005072-198905000-00018.Full Text
-
Vrionis, F. D., C. J. Wikstrand, P. Fredman, J. -. E. Mansson, L. Svennerholm, and D. D. Bigner. “DETERMINATION OF GM2 IN CULTURED HUMAN GLIOMA, MEDULLOBLASTOMA AND NEUROBLASTOMA CELLS WITH EPITOPE-DEFINED MONOCLONAL ANTIBODIES (MAbs).” Journal of Neuropathology and Experimental Neurology 48, no. 3 (May 1989): 356–356. https://doi.org/10.1097/00005072-198905000-00171.Full Text
-
Friedman, H. S., O. M. Colvin, O. W. Griffith, B. Lippitz, G. B. Elion, S. C. Schold, J. Hilton, and D. D. Bigner. “Increased melphalan activity in intracranial human medulloblastoma and glioma xenografts following buthionine sulfoximine-mediated glutathione depletion.” J Natl Cancer Inst 81, no. 7 (April 5, 1989): 524–27. https://doi.org/10.1093/jnci/81.7.524.Full Text Link to Item
-
Schold, S. C., T. P. Brent, E. von Hofe, H. S. Friedman, S. Mitra, D. D. Bigner, J. A. Swenberg, and P. Kleihues. “O6-alkylguanine-DNA alkyltransferase and sensitivity to procarbazine in human brain-tumor xenografts.” J Neurosurg 70, no. 4 (April 1989): 573–77. https://doi.org/10.3171/jns.1989.70.4.0573.Full Text Link to Item
-
He, X. M., S. X. Skapek, C. J. Wikstrand, H. S. Friedman, J. Q. Trojanowski, J. T. Kemshead, H. B. Coakham, S. H. Bigner, and D. D. Bigner. “Phenotypic analysis of four human medulloblastoma cell lines and transplantable xenografts.” J Neuropathol Exp Neurol 48, no. 1 (January 1989): 48–68. https://doi.org/10.1097/00005072-198901000-00005.Full Text Link to Item
-
Jr, S. C. S., T. P. Brent, E. V. Hofe, H. S. Friedman, S. Mitra, D. D. Bigner, J. A. Swenberg, and P. Kleihues. “O6-Alkylguanine-DNA alkyltransferase and sensitivity to procarbazine in human brain-tumor xenografts.” Journal of Neurosurgery 70, no. 4 (1989): 573–77.
-
Wronski, M. A. von, D. D. Bigner, and T. P. Brent. “Expression of O6-alkylguanine-DNA alkyltransferase in Mer+ and Mer- human cell extracts probed with specific monoclonal antibodies.” Cancer Commun 1, no. 5 (1989): 323–27. https://doi.org/10.3727/095535489820874878.Full Text Link to Item
-
Garg, P. K., G. E. Archer, D. D. Bigner, and M. R. Zalutsky. “Synthesis of radioiodinated N-succinimidyl iodobenzoate: optimization for use in antibody labelling.” Int J Rad Appl Instrum A 40, no. 6 (1989): 485–90. https://doi.org/10.1016/0883-2889(89)90131-7.Full Text Link to Item
-
Gottfries, J., J. E. Mansson, P. Fredman, C. J. Wikstrand, H. S. Friedman, D. D. Bigner, and L. Svennerholm. “Ganglioside mapping of a human medulloblastoma xenograft.” Acta Neuropathol 77, no. 3 (1989): 283–88. https://doi.org/10.1007/BF00687580.Full Text Link to Item
-
He, X., C. J. Wikstrand, P. Fredman, J. E. Månsson, L. Svennerholm, and D. D. Bigner. “GD3 expression by cultured human tumor cells of neuroectodermal origin.” Acta Neuropathol 79, no. 3 (1989): 317–25. https://doi.org/10.1007/BF00294668.Full Text Link to Item
-
Skapek, S. X., O. M. Colvin, O. W. Griffith, D. R. Groothuis, E. V. Colapinto, Y. Lee, J. Hilton, G. B. Elion, D. D. Bigner, and H. S. Friedman. “Buthionine sulfoximine-mediated depletion of glutathione in intracranial human glioma-derived xenografts.” Biochem Pharmacol 37, no. 22 (November 15, 1988): 4313–17. https://doi.org/10.1016/0006-2952(88)90612-0.Full Text Link to Item
-
Colapinto, E. V., P. A. Humphrey, M. R. Zalutsky, D. R. Groothuis, H. S. Friedman, N. de Tribolet, S. Carrel, and D. D. Bigner. “Comparative localization of murine monoclonal antibody Me1-14 F(ab')2 fragment and whole IgG2a in human glioma xenografts.” Cancer Res 48, no. 20 (October 15, 1988): 5701–7.Link to Item
-
Friedman, H. S., S. X. Skapek, O. M. Colvin, G. B. Elion, M. R. Blum, P. M. Savina, J. Hilton, S. C. Schold, J. Kurtzberg, and D. D. Bigner. “Melphalan transport, glutathione levels, and glutathione-S-transferase activity in human medulloblastoma.” Cancer Res 48, no. 19 (October 1, 1988): 5397–5402.Link to Item
-
SHOUP, S. A., J. W. TELLO, H. F. SEIGLER, W. W. JOHNSTON, J. SCHLOM, D. D. BIGNER, and S. H. BIGNER. “THE IMMUNOCYTOCHEMICAL DIAGNOSIS OF METASTATIC MELANOMA IN CYTOLOGIC SPECIMENS.” Acta Cytologica 32, no. 5 (September 1, 1988): 781–781.Link to Item
-
GARG, P. K., H. FRIEDMAN, S. SLADE, D. D. BIGNER, and M. R. ZALUTSKY. “ASTATINE-211 LABELED MONOCLONAL-ANTIBODY - A POTENTIAL AGENT FOR RADIOIMMUNOTHERAPY.” European Journal of Nuclear Medicine 14, no. 5–6 (August 1, 1988): 245–245.Link to Item
-
Friedman, H. S., O. M. Colvin, S. X. Skapek, S. M. Ludeman, G. B. Elion, S. C. Schold, P. F. Jacobsen, L. H. Muhlbaier, and D. D. Bigner. “Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents.” Cancer Res 48, no. 15 (August 1, 1988): 4189–95.Link to Item
-
Skapek, S. X., O. M. Colvin, O. W. Griffith, G. B. Elion, D. D. Bigner, and H. S. Friedman. “Enhanced melphalan cytotoxicity following buthionine sulfoximine-mediated glutathione depletion in a human medulloblastoma xenograft in athymic mice.” Cancer Res 48, no. 10 (May 15, 1988): 2764–67.Link to Item
-
Lee, Y., D. E. Bullard, P. A. Humphrey, E. V. Colapinto, H. S. Friedman, M. R. Zalutsky, R. E. Coleman, and D. D. Bigner. “Treatment of intracranial human glioma xenografts with 131I-labeled anti-tenascin monoclonal antibody 81C6.” Cancer Res 48, no. 10 (May 15, 1988): 2904–10.Link to Item
-
Bigner, S. H., P. C. Burger, A. J. Wong, M. H. Werner, S. R. Hamilton, L. H. Muhlbaier, B. Vogelstein, and D. D. Bigner. “Gene amplification in malignant human gliomas: clinical and histopathologic aspects.” J Neuropathol Exp Neurol 47, no. 3 (May 1988): 191–205. https://doi.org/10.1097/00005072-198805000-00001.Full Text Link to Item
-
HE, X., C. J. WIKSTRAND, H. S. FRIEDMAN, J. Q. TROJANOWSKI, S. H. BIGNER, and D. D. BIGNER. “ANTIGENIC PHENOTYPES OF 4 HUMAN MEDULLOBLASTOMA CELL-LINES AND XENOGRAFTS.” Journal of Neuropathology and Experimental Neurology 47, no. 3 (May 1, 1988): 374–374.Link to Item
-
IBAYASHI, N., M. M. HERMAN, L. J. RUBINSTEIN, D. D. BIGNER, H. S. FRIEDMAN, V. P. COLLINS, and L. A. DONOSO. “INTERMEDIATE FILAMENT EXPRESSION OF 3 CULTURED HUMAN NEUROEPITHELIAL TUMOR-CELL LINES (MEDULLOBLASTOMA, RETINOBLASTOMA AND MALIGNANT ASTROCYTOMA) IN S-PHASE.” Journal of Neuropathology and Experimental Neurology 47, no. 3 (May 1, 1988): 349–349.Link to Item
-
Humphrey, P. A., A. J. Wong, B. Vogelstein, H. S. Friedman, M. H. Werner, D. D. Bigner, and S. H. Bigner. “Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts.” Cancer Res 48, no. 8 (April 15, 1988): 2231–38.Link to Item
-
Friedman, H. S., P. C. Burger, S. H. Bigner, J. Q. Trojanowski, G. M. Brodeur, X. M. He, C. J. Wikstrand, J. Kurtzberg, M. E. Berens, and E. C. Halperin. “Phenotypic and genotypic analysis of a human medulloblastoma cell line and transplantable xenograft (D341 Med) demonstrating amplification of c-myc.” Am J Pathol 130, no. 3 (March 1988): 472–84.Link to Item
-
HUMPHREY, P. A., A. J. WONG, B. VOGELSTEIN, H. S. FRIEDMAN, D. D. BIGNER, and S. H. BIGNER. “LOSS OF EPIDERMAL GROWTH-FACTOR RECEPTOR GENE AMPLIFICATION AS MALIGNANT HUMAN GLIOMAS ESTABLISH IN CULTURE.” Proceedings of the American Association for Cancer Research 29 (March 1, 1988): 78–78.Link to Item
-
SKAPEK, S. X., O. M. COLVIN, O. W. GRIFFITH, D. R. GROOTHUIS, J. HILTON, G. B. ELION, D. D. BIGNER, and H. S. FRIEDMAN. “SELECTIVE BUTHIONINE SULFOXIMINE (BSO)-MEDIATED DEPLETION OF GLUTATHIONE (GSH) IN AN INTRACRANIAL HUMAN GLIOMA-DERIVED XENOGRAFT.” Proceedings of the American Association for Cancer Research 29 (March 1, 1988): 357–357.Link to Item
-
WINICK, N., H. FREIDMAN, D. BIGNER, X. PERYEA, A. STRECKFUSS, and B. KAMEN. “METHOTREXATE (MTX), SCHEDULE DEPENDENT DRUG ACCUMULATION.” Proceedings of the American Association for Cancer Research 29 (March 1, 1988): 288–288.Link to Item
-
Lee, Y. S., D. E. Bullard, M. R. Zalutsky, R. E. Coleman, C. J. Wikstrand, H. S. Friedman, E. V. Colapinto, and D. D. Bigner. “Therapeutic efficacy of antiglioma mesenchymal extracellular matrix 131I-radiolabeled murine monoclonal antibody in a human glioma xenograft model.” Cancer Res 48, no. 3 (February 1, 1988): 559–66.Link to Item
-
Bigner, S. H., J. Mark, P. C. Burger, M. S. Mahaley, D. E. Bullard, L. H. Muhlbaier, and D. D. Bigner. “Specific chromosomal abnormalities in malignant human gliomas.” Cancer Res 48, no. 2 (January 15, 1988): 405–11.Link to Item
-
BIGNER, S. H., B. VOGELSTEIN, and D. D. BIGNER. “CHROMOSOMAL-ABNORMALITIES AND GENE AMPLIFICATION IN MALIGNANT GLIOMAS.” Isi Atlas of Science Biochemistry 1, no. 4 (January 1, 1988): 333–36.Link to Item
-
Bigner, S. H., J. Mark, H. S. Friedman, J. A. Biegel, and D. D. Bigner. “Structural chromosomal abnormalities in human medulloblastoma.” Cancer Genet Cytogenet 30, no. 1 (January 1988): 91–101. https://doi.org/10.1016/0165-4608(88)90096-9.Full Text Link to Item
-
Lee, Y. S., D. E. Bullard, M. R. Zalutsky, R. E. Coleman, C. J. Wikstrand, H. S. Friedman, E. V. Colapinto, and D. Bigner. “Therapeutic Efficacy of Antiglioma Mesenchymal Extracellular Matrix 131I-Radiolabeled Murine Monoclonal Antibody in a Human Glioma Xenograft Model.” Cancer Research 48, no. 3 (January 1, 1988): 584–88.
-
Vrionis, F. D., C. J. Wikstrand, and D. D. Bigner. “Relevance for neurobiology and neurooncology of antigens of malignant gliomas as defined by monoclonal antibodies.” Ann N Y Acad Sci 540 (1988): 64–77. https://doi.org/10.1111/j.1749-6632.1988.tb27052.x.Full Text Link to Item
-
Werner, M. H., P. A. Humphrey, D. D. Bigner, and S. H. Bigner. “Growth effects of epidermal growth factor (EGF) and a monoclonal antibody against the EGF receptor on four glioma cell lines.” Acta Neuropathol 77, no. 2 (1988): 196–201. https://doi.org/10.1007/BF00687431.Full Text Link to Item
-
Colapinto, E. V., Y. S. Lee, P. A. Humphrey, M. R. Zalutsky, H. S. Friedman, D. E. Bullard, and D. D. Bigner. “The localisation of radiolabelled murine monoclonal antibody 81C6 and its Fab fragment in human glioma xenografts in athymic mice.” Br J Neurosurg 2, no. 2 (1988): 179–91. https://doi.org/10.3109/02688698808992668.Full Text Link to Item
-
Warnke, P. C., P. Molnar, D. D. Bigner, D. H. Heistad, and D. R. Groothuis. “Intravenous adenosine selectively increases blood flow to xenotransplanted intracerebral gliomas.” Neurology 37, no. 12 (December 1987): 1870–73. https://doi.org/10.1212/wnl.37.12.1870.Full Text Link to Item
-
Bigner, S. H., A. J. Wong, J. Mark, L. H. Muhlbaier, K. W. Kinzler, B. Vogelstein, and D. D. Bigner. “Relationship between gene amplification and chromosomal deviations in malignant human gliomas.” Cancer Genet Cytogenet 29, no. 1 (November 1987): 165–70. https://doi.org/10.1016/0165-4608(87)90045-8.Full Text Link to Item
-
McComb, R. D., J. M. Moul, and D. D. Bigner. “Distribution of type VI collagen in human gliomas: comparison with fibronectin and glioma-mesenchymal matrix glycoprotein.” J Neuropathol Exp Neurol 46, no. 6 (November 1987): 623–33. https://doi.org/10.1097/00005072-198711000-00002.Full Text Link to Item
-
Bigner, S. H., R. Bjerkvig, O. D. Laerum, L. H. Muhlbaier, and D. D. Bigner. “DNA content and chromosomes in permanent cultured cell lines derived from malignant human gliomas.” Anal Quant Cytol Histol 9, no. 5 (October 1987): 435–44.Link to Item
-
Wong, A. J., S. H. Bigner, D. D. Bigner, K. W. Kinzler, S. R. Hamilton, and B. Vogelstein. “Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification.” Proc Natl Acad Sci U S A 84, no. 19 (October 1987): 6899–6903. https://doi.org/10.1073/pnas.84.19.6899.Full Text Link to Item
-
Schold, S. C., H. S. Friedman, and D. D. Bigner. “Therapeutic profile of the human glioma line D-54 MG in athymic mice.” Cancer Treat Rep 71, no. 9 (September 1987): 849–50.Link to Item
-
Bigner, S. H., A. J. Wong, J. Mark, K. W. Kinzler, B. Vogelstein, and D. D. Bigner. “13 Chromosomes and gene amplification in malignant human gliomas (MHG).” Cancer Genetics and Cytogenetics 28, no. 1 (September 1987): 32–32. https://doi.org/10.1016/0165-4608(87)90292-5.Full Text
-
Blasberg, R. G., H. Nakagawa, M. A. Bourdon, D. R. Groothuis, C. S. Patlak, and D. D. Bigner. “Regional localization of a glioma-associated antigen defined by monoclonal antibody 81C6 in vivo: kinetics and implications for diagnosis and therapy.” Cancer Res 47, no. 16 (August 15, 1987): 4432–43.Link to Item
-
Vriesendorp, F. J., C. Peagram, D. D. Bigner, and D. R. Groothuis. “Concurrent measurements of blood flow and transcapillary transport in xenotransplanted human gliomas in immunosuppressed rats.” J Natl Cancer Inst 79, no. 1 (July 1987): 123–30.Link to Item
-
Bigner, S. H., P. C. Burger, A. J. Wong, K. K. Kinzier, S. R. Hamilton, B. Vogelstein, and D. D. Bigner. “MORPHOLOGIC CHARACTERISTICS OF MALIGNANT HUMAN GLIOMAS (MHG) WITH GENE AMPLIFICATION.” Journal of Neuropathology and Experimental Neurology 46, no. 3 (May 1987): 373–373. https://doi.org/10.1097/00005072-198705000-00130.Full Text
-
McLendon, R. E., P. C. Burger, S. H. Bigner, and D. D. Bigner. “PRIMARY CENTRAL NERVOUS SYSTEM NEOPLASMS IN FISCHER-344 RATS RECEIVING CHRONIC LIFETIME EXPOSURE TO ACRYLONITRILE (ACN).” Journal of Neuropathology and Experimental Neurology 46, no. 3 (May 1987): 389–389. https://doi.org/10.1097/00005072-198705000-00178.Full Text
-
Wikstrand, C. J., R. E. McLendon, S. Carrel, J. T. Kemshead, J. P. Mach, H. B. Coakham, N. de Tribolet, D. E. Bullard, M. R. Zalutsky, and D. D. Bigner. “Comparative localization of glioma-reactive monoclonal antibodies in vivo in an athymic mouse human glioma xenograft model.” J Neuroimmunol 15, no. 1 (May 1987): 37–56. https://doi.org/10.1016/0165-5728(87)90005-1.Full Text Link to Item
-
Kinzler, K. W., S. H. Bigner, D. D. Bigner, J. M. Trent, M. L. Law, S. J. O’Brien, A. J. Wong, and B. Vogelstein. “Identification of an amplified, highly expressed gene in a human glioma.” Science 236, no. 4797 (April 3, 1987): 70–73. https://doi.org/10.1126/science.3563490.Full Text Link to Item
-
Lee, Y. S., D. E. Bullard, C. J. Wikstrand, M. R. Zalutsky, L. H. Muhlbaier, and D. D. Bigner. “Comparison of monoclonal antibody delivery to intracranial glioma xenografts by intravenous and intracarotid administration.” Cancer Res 47, no. 7 (April 1, 1987): 1941–46.Link to Item
-
Warnke, P. C., H. S. Friedman, D. D. Bigner, and D. R. Groothuis. “Simultaneous measurements of blood flow and blood-to-tissue transport in xenotransplanted medulloblastomas.” Cancer Res 47, no. 6 (March 15, 1987): 1687–90.Link to Item
-
HUMPHREY, P. A., A. J. WONG, H. S. FRIEDMAN, M. H. WERNER, B. VOGELSTEIN, D. D. BIGNER, and S. H. BIGNER. “AMPLIFICATION AND EXPRESSION OF THE EPIDERMAL GROWTH-FACTOR RECEPTOR (EGFR) GENE IN HUMAN GLIOMA (HGL) XENOGRAFTS.” Proceedings of the American Association for Cancer Research 28 (March 1, 1987): 23–23.Link to Item
-
LEE, Y. S., D. E. BULLARD, H. S. FRIEDMAN, C. J. WIKSTRAND, R. E. COLEMAN, M. ZALUTSKY, L. H. MUHLBAIER, and D. D. BIGNER. “EXPERIMENTAL RADIOTHERAPY OF SUBCUTANEOUS (SC) AND INTRACRANIAL (IC) HUMAN GLIOMA (HGL) XENOGRAFTS IN RODENTS WITH I-131 MONOCLONAL-ANTIBODY (MAB) 81C6.” Proceedings of the American Association for Cancer Research 28 (March 1, 1987): 392–392.Link to Item
-
SCHOLD, S. C., H. S. FRIEDMAN, G. B. ELION, S. MITRA, and D. D. BIGNER. “THERAPEUTIC SYNERGY OF THIOPURINES AND ALKYLATING DRUGS IN A HUMAN GLIOMA XENOGRAFT.” Proceedings of the American Association for Cancer Research 28 (March 1, 1987): 416–416.Link to Item
-
FRIEDMAN, H. S., O. M. COLVIN, J. HILTON, S. C. SCHOLD, G. B. ELION, S. X. SKAPEK, M. R. BLUM, P. M. SAVINA, L. H. MUHLBAIER, and D. D. BIGNER. “MELPHALAN CYTOTOXICITY AND RESISTANCE IN MEDULLOBLASTOMA (MBT).” Proceedings of the American Association for Cancer Research 28 (March 1, 1987): 447–447.Link to Item
-
Trojanowski, J. Q., H. S. Friedman, P. C. Burger, and D. D. Bigner. “A rapidly dividing human medulloblastoma cell line (D283 MED) expresses all three neurofilament subunits.” Am J Pathol 126, no. 2 (February 1987): 358–63.Link to Item
-
Beckman, W. C., S. K. Powers, J. T. Brown, G. Y. Gillespie, D. D. Bigner, and J. L. Camps. “Differential retention of rhodamine 123 by avian sarcoma virus-induced glioma and normal brain tissue of the rat in vivo.” Cancer 59, no. 2 (January 15, 1987): 266–70. https://doi.org/10.1002/1097-0142(19870115)59:2<266::aid-cncr2820590215>3.0.co;2-6.Full Text Link to Item
-
Bigner, S. H., J. Mark, and D. D. Bigner. “Chromosomal progression of malignant human gliomas from biopsy to establishment as permanent lines in vitro.” Cancer Genet Cytogenet 24, no. 1 (January 1987): 163–76. https://doi.org/10.1016/0165-4608(87)90094-x.Full Text Link to Item
-
KINZLER, K. W., S. H. BIGNER, D. D. BIGNER, J. M. TRENT, M. L. LAW, S. J. OBRIEN, A. J. WONG, and B. VOGELSTEIN. “IDENTIFICATION OF AN AMPLIFIED, HIGHLY EXPRESSED GENE IN A HUMAN GLIOMA.” Cytogenetics and Cell Genetics 46, no. 1–4 (January 1, 1987): 639–639.Link to Item
-
Biegel, J. A., D. S. Leslie, D. D. Bigner, and S. H. Bigner. “Hydroxyurea synchronization increases mitotic yield in human glioma cell lines.” Acta Neuropathol 73, no. 3 (1987): 309–12. https://doi.org/10.1007/BF00686628.Full Text Link to Item
-
Britt, R. H., B. E. Lyons, D. R. Enzmann, E. L. Saxer, S. H. Bigner, and D. D. Bigner. “Correlation of neuropathologic findings, computerized tomographic and high-resolution ultrasound scans of canine avian sarcoma virus-induced brain tumors.” J Neurooncol 4, no. 3 (1987): 243–68. https://doi.org/10.1007/BF00150616.Full Text Link to Item
-
El-Hennawi, Y., G. Y. Gillespie, M. A. Varia, P. Watkins, M. S. Mahaley, and D. D. Bigner. “Effect of methylprednisolone on radiotherapy of F344 rats with avian sarcoma virus induced gliomas.” J Neurooncol 4, no. 3 (1987): 309–13. https://doi.org/10.1007/BF00150620.Full Text Link to Item
-
Hennawi, Y. el-, G. Y. Gillespie, M. S. Mahaley, and D. D. Bigner. “Treatment of autochthonous rat brain tumors with steroid plus heparin: a brief report.” J Neurooncol 5, no. 2 (1987): 161–62. https://doi.org/10.1007/BF02571304.Full Text Link to Item
-
Ridder, L. I. de, O. D. Laerum, S. J. Mørk, and D. D. Bigner. “Invasiveness of human glioma cell lines in vitro: relation to tumorigenicity in athymic mice.” Acta Neuropathol 72, no. 3 (1987): 207–13. https://doi.org/10.1007/BF00691091.Full Text Link to Item
-
Vick, W. W., C. J. Wikstrand, D. E. Bullard, J. Kemshead, H. B. Coakham, J. Schlom, W. W. Johnston, D. D. Bigner, and S. H. Bigner. “The use of a panel of monoclonal antibodies in the evaluation of cytologic specimens from the central nervous system.” Acta Cytol 31, no. 6 (1987): 815–24.Link to Item
-
Lee, Y. S., C. J. Wikstrand, and D. D. Bigner. “Glioma-associated antigens defined by monoclonal antibodies against an avian sarcoma virus-induced rat astrocytoma.” J Neuroimmunol 13, no. 2 (December 1986): 183–202. https://doi.org/10.1016/0165-5728(86)90064-0.Full Text Link to Item
-
Lee, Y. S., T. J. Matthews, S. Pizzo, J. L. Abernethy, and D. D. Bigner. “Partial purification and characterization of a murine glioma-associated antigen defined by syngeneic rat monoclonal antibodies.” J Neuroimmunol 13, no. 2 (December 1986): 203–16. https://doi.org/10.1016/0165-5728(86)90065-2.Full Text Link to Item
-
Bullard, D. E., C. J. Wikstrand, P. A. Humphrey, Y. S. Lee, R. E. Coleman, M. Zalutsky, and D. D. Bigner. “Specific imaging of human brain tumor xenografts utilizing radiolabelled monoclonal antibodies (MAbs).” Nuklearmedizin 25, no. 6 (December 1986): 210–15.Link to Item
-
Lee, Y. S., S. H. Bigner, L. F. Eng, P. Molnar, A. Kuruvilla, D. R. Groothuis, and D. D. Bigner. “A glial fibrillary acidic protein-expressing and tumorigenic cell line derived from an avian sarcoma virus-induced rat astrocytoma.” J Neuropathol Exp Neurol 45, no. 6 (November 1986): 704–20. https://doi.org/10.1097/00005072-198611000-00008.Full Text Link to Item
-
McLendon, R. E., P. C. Burger, C. N. Pegram, L. F. Eng, and D. D. Bigner. “The immunohistochemical application of three anti-GFAP monoclonal antibodies to formalin-fixed, paraffin-embedded, normal and neoplastic brain tissues.” J Neuropathol Exp Neurol 45, no. 6 (November 1986): 692–703. https://doi.org/10.1097/00005072-198611000-00007.Full Text Link to Item
-
Wikstrand, C. J., R. E. McLendon, D. E. Bullard, P. Fredman, L. Svennerholm, and D. D. Bigner. “Production and characterization of two human glioma xenograft-localizing monoclonal antibodies.” Cancer Res 46, no. 11 (November 1986): 5933–40.Link to Item
-
BIGNER, S. H., W. W. VICK, C. J. WIKSTRAND, D. E. BULLARD, J. KEMSHEAD, J. SCHLOM, W. W. JOHNSTON, and D. D. BIGNER. “APPLICATION OF A PANEL OF MONOCLONAL-ANTIBODIES TO CYTOLOGIC SPECIMENS FROM THE CENTRAL-NERVOUS-SYSTEM.” Acta Cytologica 30, no. 5 (September 1, 1986): 577–577.Link to Item
-
“Brain tumors in man and animals: report of a workshop.” Environ Health Perspect 68 (September 1986): 155–73. https://doi.org/10.1289/ehp.68-1474266.Full Text Link to Item
-
Bigner, S. H., J. Mark, D. E. Bullard, M. S. Mahaley, and D. D. Bigner. “Chromosomal evolution in malignant human gliomas starts with specific and usually numerical deviations.” Cancer Genet Cytogenet 22, no. 2 (June 1986): 121–35. https://doi.org/10.1016/0165-4608(86)90172-x.Full Text Link to Item
-
Friedman, H. S., O. M. Colvin, S. M. Ludeman, S. C. Schold, V. L. Boyd, L. H. Mulhbaier, and D. D. Bigner. “Experimental chemotherapy of human medulloblastoma with classical alkylators.” Cancer Res 46, no. 6 (June 1986): 2827–33.Link to Item
-
Månsson, J. E., P. Fredman, D. D. Bigner, K. Molin, B. Rosengren, H. S. Friedman, and L. Svennerholm. “Characterization of new gangliosides of the lactotetraose series in murine xenografts of a human glioma cell line.” Febs Lett 201, no. 1 (May 26, 1986): 109–13. https://doi.org/10.1016/0014-5793(86)80580-4.Full Text Link to Item
-
Fredman, P., P. A. Humphrey, L. Svennerholm, and P. P. Bigner. “HUMAN GLIOMA (HGL) XENOGRAFTS AND ESTABLISHED HGL CELL LINES AS ANALYTICAL AND PREPARATIVE SOURCES OF GANGLIOSIDES.” Journal of Neuropathology and Experimental Neurology 45, no. 3 (May 1986): 324–324. https://doi.org/10.1097/00005072-198605000-00036.Full Text
-
McLendon, R. E., C. J. Wikstrand, M. A. Bourdon, and D. P. Bigner. “IMMUNOPEROXIDASE HISTOCHEMISTRY (IPH) OF ANTIGLIOMA MONOCLONAL ANTI-BODIES (MABʼS) ON NORMAL AND NEOPLASTIC CENTRAL NERVOUS SYSTEM TISSUES (CNS).” Journal of Neuropathology and Experimental Neurology 45, no. 3 (May 1986): 318–318. https://doi.org/10.1097/00005072-198605000-00016.Full Text
-
BIEGEL, J. A., S. H. BIGNER, J. MARK, H. S. FRIEDMAN, and D. D. BIGNER. “KARYOTYPIC FINDINGS IN 6 CASES OF HUMAN MEDULLOBLASTOMA.” Proceedings of the American Association for Cancer Research 27 (March 1, 1986): 36–36.Link to Item
-
Bullard, D. E., G. Y. Gillespie, M. S. Mahaley, and D. D. Bigner. “Immunobiology of human gliomas.” Semin Oncol 13, no. 1 (March 1986): 94–109.Link to Item
-
Clifford Schold, S., M. D. Walker, C. B. Wilson, and D. D. Bigner. “Summary of the sixth international conference on brain tumor research and therapy.” Journal of Neuro Oncology 4, no. 1 (March 1, 1986): 3–4. https://doi.org/10.1007/BF02157995.Full Text
-
WIKSTRAND, C. J., J. P. MACH, S. CARREL, N. DETRIBOLET, H. S. FRIEDMAN, D. E. BULLARD, P. A. HUMPHREY, and D. D. BIGNER. “LOCALIZATION OF ANTI-HUMAN GLIOMA MONOCLONAL-ANTIBODIES (MABS) IN SUBCUTANEOUS (SC) AND INTRACEREBRAL (IC) GLIOMA XENOGRAFTS.” Proceedings of the American Association for Cancer Research 27 (March 1, 1986): 330–330.Link to Item
-
FRIEDMAN, H. S., O. M. COLVIN, S. M. LUDEMAN, S. C. SCHOLD, V. L. BOYD, L. H. MUHLBAIER, and D. D. BIGNER. “CHEMOTHERAPY OF HUMAN MEDULLOBLASTOMA WITH CLASSICAL ALKYLATORS.” Proceedings of the American Association for Cancer Research 27 (March 1, 1986): 381–381.Link to Item
-
Friedman, H. S., M. S. Mahaley, S. C. Schold, N. A. Vick, J. M. Falletta, D. E. Bullard, B. J. D’Souza, J. D. Khandekar, S. Lew, and W. J. Oakes. “Efficacy of vincristine and cyclophosphamide in the therapy of recurrent medulloblastoma.” Neurosurgery 18, no. 3 (March 1986): 335–40. https://doi.org/10.1227/00006123-198603000-00014.Full Text Link to Item
-
Bigner, D. D., S. H. Bigner, P. C. Burger, J. D. Shelburne, and H. S. Friedman. “Primary brain tumours in Fischer 344 rats chronically exposed to acrylonitrile in their drinking-water.” Food Chem Toxicol 24, no. 2 (February 1986): 129–37. https://doi.org/10.1016/0278-6915(86)90347-9.Full Text Link to Item
-
Bullard, D. E., C. J. Adams, R. E. Coleman, and D. D. Bigner. “In vivo imaging of intracranial human glioma xenografts comparing specific with nonspecific radiolabeled monoclonal antibodies.” J Neurosurg 64, no. 2 (February 1986): 257–62. https://doi.org/10.3171/jns.1986.64.2.0257.Full Text Link to Item
-
BIEGEL, J. A., S. H. BIGNER, D. S. LESLIE, and D. D. BIGNER. “SYNCHRONIZATION OF HUMAN GLIOMA CELL-LINES WITH HYDROXYUREA.” Journal of Neuro Oncology 4, no. 1 (January 1, 1986): 95–95.Link to Item
-
BIGNER, D. D., C. J. WIKSTRAND, D. E. BULLARD, and P. A. HUMPHREY. “MOUSE MONOCLONAL-ANTIBODIES TO HUMAN GLIOMA-CELLS.” Journal of Neuro Oncology 4, no. 1 (January 1, 1986): 101–101.Link to Item
-
BIGNER, D. D., S. H. BIGNER, P. C. BURGER, J. D. SHELBURNE, and H. S. FRIEDMAN. “ACRYLONITRILE NEUROONCOGENESIS IN F344 RATS.” Journal of Neuro Oncology 4, no. 1 (January 1, 1986): 94–94.Link to Item
-
BIGNER, S. H., J. MARK, K. W. KINZLER, B. VOGELSTEIN, S. C. SCHOLD, and D. D. BIGNER. “CHROMOSOMES AND GENE AMPLIFICATION IN MALIGNANT HUMAN GLIOMAS.” Journal of Neuro Oncology 4, no. 1 (January 1, 1986): 92–92.Link to Item
-
BIGNER, S. H., J. MARK, and D. D. BIGNER. “SPECIFIC ABNORMALITIES OF 9P IN MALIGNANT HUMAN GLIOMAS (MHG).” Cancer Genetics and Cytogenetics 19, no. 1–2 (January 1, 1986): 183–183.Link to Item
-
Bigner, S. H., H. S. Friedman, J. A. Biegel, C. J. Wikstrand, J. Mark, R. Gebhardt, L. F. Eng, and D. D. Bigner. “Specific chromosomal abnormalities characterize four established cell lines derived from malignant human gliomas.” Acta Neuropathol 72, no. 1 (1986): 86–97. https://doi.org/10.1007/BF00687952.Full Text Link to Item
-
Friedman, H. S., S. C. Schold, and D. D. Bigner. “Chemotherapy of subcutaneous and intracranial human medulloblastoma xenografts in athymic nude mice.” Cancer Res 46, no. 1 (January 1986): 224–28.Link to Item
-
HUMPHREY, P. A., C. N. PEGRAM, C. J. WIKSTRAND, D. E. BULLARD, and D. D. BIGNER. “UTILIZATION OF PURIFIED, RADIOLABELED MONOCLONAL-ANTIBODY FAB FRAGMENTS FOR INVIVO LOCALIZATION IN MALIGNANT GLIOMAS.” Journal of Neuro Oncology 4, no. 1 (January 1, 1986): 107–107.Link to Item
-
MCLENDON, R. E., P. C. BURGER, C. J. WIKSTRAND, C. N. PEGRAM, L. F. ENG, and D. D. BIGNER. “THE HISTOCHEMICAL-LOCALIZATION OF GLIAL FIBRILLARY ACIDIC PROTEIN (GFAP) IN HUMAN CENTRAL-NERVOUS-SYSTEM (CNS) NEOPLASMS BY MONOCLONAL-ANTIBODIES (MCAS).” Journal of Neuro Oncology 4, no. 1 (January 1, 1986): 96–96.Link to Item
-
SCHOLD, S. C., M. S. MAHALEY, H. S. FRIEDMAN, N. A. VICK, D. E. BULLARD, P. C. BURGER, J. G. CAIRNCROSS, et al. “COOPERATIVE STUDIES OF CHEMOTHERAPY FOR GLIOMAS AND MEDULLOBLASTOMAS.” Journal of Neuro Oncology 4, no. 1 (January 1, 1986): 108–108.Link to Item
-
WIKSTRAND, C. J., P. A. HUMPHREY, D. E. BULLARD, and D. D. BIGNER. “CHARACTERIZATION OF LOCALIZING GLIOMA-REACTIVE MONOCLONAL-ANTIBODIES (MABS).” Journal of Neuro Oncology 4, no. 1 (January 1, 1986): 107–107.Link to Item
-
Lee, Y. S., T. J. Matthews, and D. D. Bigner. “Restricted specificity monoclonal antibodies against murine astrocytomas produced by syngeneic immunization and rat-mouse fusion.” Journal of Neuroimmunology 10, no. 2 (December 1985): 173–173. https://doi.org/10.1016/0165-5728(85)90008-6.Full Text
-
McComb, R. D., and D. D. Bigner. “Extracellular matrix antigens in human neuroectodermal tunmors as defined by monoclonal antibodies.” Journal of Neuroimmunology 10, no. 2 (December 1985): 180–180. https://doi.org/10.1016/0165-5728(85)90022-0.Full Text
-
Panther, L. A., G. L. Baumbach, D. D. Bigner, D. Piegors, D. R. Groothuis, and D. D. Heistad. “Vasoactive drugs produce selective changes in flow to experimental brain tumors.” Ann Neurol 18, no. 6 (December 1985): 712–15. https://doi.org/10.1002/ana.410180614.Full Text Link to Item
-
Wikstrand, C. J., and D. D. Bigner. “New anti-glioma monoclonal antibodies (MCA) rapidly selected for stability and specificity.” Journal of Neuroimmunology 10, no. 2 (December 1985): 176–176. https://doi.org/10.1016/0165-5728(85)90013-x.Full Text
-
Bullard, D. E., S. H. Bigner, and D. D. Bigner. “Comparison of intravenous versus intracarotid therapy with 1,3-bis(2-chloroethyl)-1-nitrosourea in a rat brain tumor model.” Cancer Res 45, no. 11 Pt 1 (November 1985): 5240–45.Link to Item
-
Friedman, H. S., P. C. Burger, S. H. Bigner, J. Q. Trojanowski, C. J. Wikstrand, E. C. Halperin, and D. D. Bigner. “Establishment and characterization of the human medulloblastoma cell line and transplantable xenograft D283 Med.” J Neuropathol Exp Neurol 44, no. 6 (November 1985): 592–605. https://doi.org/10.1097/00005072-198511000-00005.Full Text Link to Item
-
Lee, Y., and D. D. Bigner. “Aspects of immunobiology and immunotherapy and uses of monoclonal antibodies and biologic immune modifiers in human gliomas.” Neurol Clin 3, no. 4 (November 1985): 901–17.Link to Item
-
Bullard, D. E., S. H. Bigner, and D. D. Bigner. “Comparison of Intravenous versus Intracarotid Therapy with 1,3-Bis(2-chloroethyi)-1-nitrosourea in a Rat Brain Tumor Model.” Cancer Research 45 (November 1, 1985): 5240–45.
-
Bigner, S. H., J. Mark, S. C. Schold, L. F. Eng, and D. D. Bigner. “A serially transplantable human giant cell glioblastoma that maintains a near-haploid stem line.” Cancer Genet Cytogenet 18, no. 2 (October 1985): 141–53. https://doi.org/10.1016/0165-4608(85)90064-0.Full Text Link to Item
-
Campbell, G. L., R. Bartel, H. S. Freidman, and D. D. Bigner. “Effect of glutamate analogues on brain tumor cell lines.” J Neurochem 45, no. 4 (October 1985): 1186–92. https://doi.org/10.1111/j.1471-4159.1985.tb05540.x.Full Text Link to Item
-
Dranoff, G., G. B. Elion, H. S. Friedman, G. L. Campbell, and D. D. Bigner. “Influence of glutamine on the growth of human glioma and medulloblastoma in culture.” Cancer Res 45, no. 9 (September 1985): 4077–81.Link to Item
-
Dranoff, G., G. B. Elion, H. S. Friedman, and D. D. Bigner. “Combination chemotherapy in vitro exploiting glutamine metabolism of human glioma and medulloblastoma.” Cancer Res 45, no. 9 (September 1985): 4082–86.Link to Item
-
Bullard, D. E., and D. D. Bigner. “Applications of monoclonal antibodies in the diagnosis and treatment of primary brain tumors.” J Neurosurg 63, no. 1 (July 1985): 2–16. https://doi.org/10.3171/jns.1985.63.1.0002.Full Text Link to Item
-
Hatfield, J. S., R. P. Skoff, H. Maisel, L. Eng, and D. D. Bigner. “The lens epithelium contains glial fibrillary acidic protein (GFAP).” J Neuroimmunol 8, no. 4–6 (June 1985): 347–57. https://doi.org/10.1016/s0165-5728(85)80072-2.Full Text Link to Item
-
McComb, R. D., and D. D. Bigner. “Immunolocalization of laminin in neoplasms of the central and peripheral nervous systems.” J Neuropathol Exp Neurol 44, no. 3 (May 1985): 242–53. https://doi.org/10.1097/00005072-198505000-00003.Full Text Link to Item
-
Wikstrand, C. J., F. C. Grahmann, R. D. McComb, and D. D. Bigner. “Antigenic heterogeneity of human anaplastic gliomas and glioma-derived cell lines defined by monoclonal antibodies.” J Neuropathol Exp Neurol 44, no. 3 (May 1985): 229–41. https://doi.org/10.1097/00005072-198505000-00002.Full Text Link to Item
-
Bigner, S. H., S. C. Schold, J. Mark, and D. P. Bigner. “CYTOGENETIC ANALYSIS OF MALIGNANT HUMAN GLIOMAS (MHG) DURING ESTABLISH-MENT IN CULTURE AND THROUGH SERIAL TRANSPLANTATION IN ATHYMIC MICE.” Journal of Neuropathology and Experimental Neurology 44, no. 3 (May 1985): 315–315. https://doi.org/10.1097/00005072-198505000-00034.Full Text
-
Friedman, H. S., P. C. Burger, S. H. Bigner, J. O. Trojanowski, E. D. Halperin, and D. D. Bigner. “ESTABLISHMENT AND PRELIMINARY CHARACTERIZATION OF THE HUMAN MEDULLOBLASTOMA CELL LINE AND TRANSPLANTABLE XENOGRAFT D283 MED.” Journal of Neuropathology and Experimental Neurology 44, no. 3 (May 1985): 310–310. https://doi.org/10.1097/00005072-198505000-00018.Full Text
-
McComb, R. D., J. P. David, and P. P. Bigner. “DISTRIBUTION OF TYPE VI COLLAGEN IN NEUROEPITHELIAL NEOPLASMS.” Journal of Neuropathology and Experimental Neurology 44, no. 3 (May 1985): 313–313. https://doi.org/10.1097/00005072-198505000-00028.Full Text
-
McLendon, R. E., P. C. Burger, L. F. Eng, C. J. Wikstrand, C. N. Pegram, and D. D. Bigner. “PRODUCTION AND CHARACTERIZATION OF 3 MONOCLONAL ANTIBODIES (MAs) TO GLIAL FIBRILLARY ACIDIC PROTEIN (GFAP).” Journal of Neuropathology and Experimental Neurology 44, no. 3 (May 1985): 331–331. https://doi.org/10.1097/00005072-198505000-00083.Full Text
-
Bullard, D. E., D. G. Thomas, J. L. Darling, C. J. Wikstrand, J. V. Diengdoh, R. O. Barnard, J. G. Bodmer, and D. D. Bigner. “A preliminary study utilizing viable HLA mismatched cultured glioma cells as adjuvant therapy for patients with malignant gliomas.” Br J Cancer 51, no. 2 (February 1985): 283–89. https://doi.org/10.1038/bjc.1985.41.Full Text Link to Item
-
BIGNER, D. D., C. J. WIKSTRAND, D. E. BULLARD, and R. E. COLEMAN. “MONOCLONAL-ANTIBODIES FOR IMMUNOHISTOCHEMISTRY AND INVIVO TUMOR-LOCALIZATION FOR IMAGING AND TREATMENT IN NEUROONCOLOGY.” Acta Neurochirurgica 78, no. 3–4 (January 1, 1985): 164–164.Link to Item
-
BIGNER, S. H., R. E. MCLENDON, D. W. MENSI, C. J. WIKSTRAND, C. N. PEGRAM, W. W. JOHNSTON, and D. D. BIGNER. “EXPRESSION OF GLIAL FIBRILLARY ACIDIC PROTEIN IN CYTOLOGIC SPECIMENS FROM THE CENTRAL NERVOUS-SYSTEM AS DEMONSTRATED BY MONOCLONAL-ANTIBODIES.” Acta Cytologica 29, no. 5 (January 1, 1985): 919–20.Link to Item
-
BIGNER, S. H., S. C. SCHOLD, J. MARK, and D. D. BIGNER. “CHROMOSOMAL ANALYSIS OF HUMAN GLIOMAS THROUGH SERIAL TRANSPLANTATION IN ATHYMIC NUDE-MICE.” Proceedings of the American Association for Cancer Research 26, no. MAR (January 1, 1985): 32–32.Link to Item
-
BULLARD, D. E., S. H. BIGNER, and D. D. BIGNER. “COMPARISON OF INTRAVENOUS VERSUS INTRACAROTID THERAPY WITH 1,3-BIS(2-CHLOROETHYL)-1-NITROSOUREA IN A RAT-BRAIN TUMOR-MODEL.” Cancer Research 45, no. 11 (January 1, 1985): 5240–45.Link to Item
-
Bigner, S. H., S. C. Schold, J. Mark, and D. D. Bigner. “Chromosomal analysis of human gliomas through serial transplantation in athymic nude mice.” Proceedings of the American Association for Cancer Research VOL. 26 (January 1, 1985).
-
DRANOFF, G., G. B. ELION, H. S. FRIEDMAN, and D. D. BIGNER. “GLUTAMINE BASED COMBINATION CHEMOTHERAPY IN CULTURE FOR HUMAN GLIOMA AND MEDULLOBLASTOMA.” Proceedings of the American Association for Cancer Research 26, no. MAR (January 1, 1985): 323–323.Link to Item
-
Dranoff, G., G. B. Elion, H. S. Friedman, and D. D. Bigner. “Glutamine based combination chemotherapy in culture for human glioma and medulloblastoma.” Proceedings of the American Association for Cancer Research VOL. 26 (January 1, 1985).
-
FRIEDMAN, H. S., J. KURTZBERG, and D. D. BIGNER. “INVITRO VERSUS INVIVO CORRELATIONS OF CHEMOSENSITIVITY OF HUMAN MEDULLOBLASTOMA - REPLY.” Cancer Research 45, no. 12 (January 1, 1985): 6538–6538.Link to Item
-
Ohmiya, K., M. Shirai, Y. Kurachi, and S. Shimizu. “Isolation and properties of beta-glucosidase from Ruminococcus albus.” J Bacteriol 161, no. 1 (January 1985): 432–34. https://doi.org/10.1128/jb.161.1.432-434.1985.Full Text Link to Item
-
Bourdon, M. A., T. J. Matthews, S. V. Pizzo, and D. D. Bigner. “Immunochemical and biochemical characterization of a glioma-associated extracellular matrix glycoprotein.” J Cell Biochem 28, no. 3 (1985): 183–95. https://doi.org/10.1002/jcb.240280302.Full Text Link to Item
-
Britt, R. H., B. E. Lyons, L. F. Eng, S. H. Bigner, and D. D. Bigner. “Immunohistochemical study of glial fibrillary acidic protein in avian sarcoma virus-induced gliomas in dogs.” J Neurooncol 3, no. 1 (1985): 53–59. https://doi.org/10.1007/BF00165172.Full Text Link to Item
-
FRIEDMAN, H. S., S. M. LUDEMAN, S. C. SCHOLD, V. L. BOYD, L. H. MUHLBAIER, and D. D. BIGNER. “SENSITIVITY OF HUMAN MEDULLOBLASTOMA (MED) TO CLASSICAL ALKYLATORS.” Proceedings of the American Association for Cancer Research 26, no. MAR (January 1, 1985): 330–330.Link to Item
-
McComb, R. D., and D. D. Bigner. “Immunolocalization of monoclonal antibody-defined extracellular matrix antigens in human brain tumors.” J Neurooncol 3, no. 2 (1985): 181–86. https://doi.org/10.1007/BF02228895.Full Text Link to Item
-
Pegram, C. N., L. F. Eng, C. J. Wikstrand, R. D. McComb, Y. L. Lee, and D. D. Bigner. “Monoclonal antibodies reactive with epitopes restricted to glial fibrillary acidic proteins of several species.” Neurochem Pathol 3, no. 2 (1985): 119–38. https://doi.org/10.1007/BF02834285.Full Text Link to Item
-
Ostertag, C. B., P. Warnke, P. Kleihues, and D. D. Bigner. “Iodine-125 interstitial irradiation of virally induced dog brain tumours.” Neurol Res 6, no. 4 (December 1984): 176–80. https://doi.org/10.1080/01616412.1984.11739685.Full Text Link to Item
-
Bullard, D. E., M. Bourdon, and D. D. Bigner. “Comparison of various methods for delivering radiolabeled monoclonal antibody to normal rat brain.” J Neurosurg 61, no. 5 (November 1984): 901–11. https://doi.org/10.3171/jns.1984.61.5.0901.Full Text Link to Item
-
Friedman, H. S., S. C. Schold, L. H. Muhlbaier, T. D. Bjornsson, and D. D. Bigner. “In vitro versus in vivo correlations of chemosensitivity of human medulloblastoma.” Cancer Res 44, no. 11 (November 1984): 5145–49.Link to Item
-
Dranoff, G., and D. D. Bigner. “A word of caution in the use of neuron-specific enolase expression in tumor diagnosis.” Arch Pathol Lab Med 108, no. 7 (July 1984): 535.Link to Item
-
Schold, S. C., H. S. Friedman, T. D. Bjornsson, and D. D. Bigner. “Treatment of human glioma and medulloblastoma tumor lines in athymic mice with diaziquone and diaziquone-based drug combinations.” Cancer Res 44, no. 6 (June 1984): 2352–57.Link to Item
-
Wikstrand, C. J., S. H. Bigner, and D. D. Bigner. “Characterization of three restricted specificity monoclonal antibodies raised against the human glioma cell line D-54 MG.” J Neuroimmunol 6, no. 3 (June 1984): 169–86. https://doi.org/10.1016/0165-5728(84)90004-3.Full Text Link to Item
-
Adams, C., P. Bullard, M. Demons, S. Bigner, and D. Bigner. “132 HETEROTRANSPLANTATION OF D-54 MG HUMAN GLIOMA LINE IN CYCLOSPORINE-ANTITHYMOCYTE SERUM (CY-ATS) TREATED FISCHER 344 RATS.” Journal of Neuropathology and Experimental Neurology 43, no. 3 (May 1984): 337–337. https://doi.org/10.1097/00005072-198405000-00138.Full Text
-
Bigner, S. H., P. C. Burger, J. Mark, D. E. Bullard, and D. D. Bigner. “128 RELATIONSHIP BETWEEN KARYOTYPE AND HISTOLOGIC PARAMETERS OF MALIGNANT HUMAN GLIOMAS (MHG).” Journal of Neuropathology and Experimental Neurology 43, no. 3 (May 1984): 335–335. https://doi.org/10.1097/00005072-198405000-00134.Full Text
-
Bourdon, M. A., T. J. Matthews, S. V. Pizzo, and D. D. Bigner. “24 IMMUNOCHEMICAL AND BIOCHEMICAL ANALYSIS OF THE HUMAN GLIOMA EXTRACELLULAR MATRIX GLYCOPROTEIN (GMEM).” Journal of Neuropathology and Experimental Neurology 43, no. 3 (May 1984): 301–301. https://doi.org/10.1097/00005072-198405000-00033.Full Text
-
Dranoff, G., G. B. Elion, G. L. Campbell, H. S. Friedman, and P. P. Bigner. “130 INFLUENCE OF GLUTAMINE ON GROWTH OF HUMAN MEDULLOBLASTOMA IN CULTURE.” Journal of Neuropathology and Experimental Neurology 43, no. 3 (May 1984): 336–336. https://doi.org/10.1097/00005072-198405000-00136.Full Text
-
Lee, Y. S., C. N. Pegram, and D. D. Bigner. “25 GLIOMA-ASSOCIATED ANTIGEN DEFINED BY MONOCLONAL ANTIBODIES (MAs) AGAINST AN AVIAN SARCOMA VIRUS (ASV)-INDUCED RAT ASTROCYTOMA CELL LINE.” Journal of Neuropathology and Experimental Neurology 43, no. 3 (May 1984): 301–301. https://doi.org/10.1097/00005072-198405000-00034.Full Text
-
McComb, R. D., M. A. Bourdon, and P. P. Bigner. “131 EXTRACELLULAR MATRIX (ECM) ANTIGEN DEFINED BY A MONOCLONAL ANTIBODY (MA) RAISED AGAINST THE MEDULLOBLASTOMA-DERIVED CELL LINE TE-671.” Journal of Neuropathology and Experimental Neurology 43, no. 3 (May 1984): 336–336. https://doi.org/10.1097/00005072-198405000-00137.Full Text
-
Bullard, D. E., and D. D. Bigner. “Blood-brain barrier disruption in immature Fischer 344 rats.” J Neurosurg 60, no. 4 (April 1984): 743–50. https://doi.org/10.3171/jns.1984.60.4.0743.Full Text Link to Item
-
Bullard, D. E., S. C. Saris, and D. D. Bigner. “Carotid artery injections in 40- to 99-g Fischer rats: technical note and evaluation of blood flow by various injection techniques.” Neurosurgery 14, no. 4 (April 1984): 406–11. https://doi.org/10.1227/00006123-198404000-00003.Full Text
-
Saris, S. C., S. H. Bigner, and D. D. Bigner. “Intracerebral transplantation of a human glioma line in immunosuppressed rats.” J Neurosurg 60, no. 3 (March 1984): 582–88. https://doi.org/10.3171/jns.1984.60.3.0582.Full Text Link to Item
-
ADAMS, C., D. BULLARD, S. BIGNER, and D. BIGNER. “INTRACEREBRAL TRANSPLANTATION OF D-54 MG HUMAN GLIOMA LINE IN IMMUNOSUPPRESSED RATS.” Journal of Neuro Oncology 2, no. 3 (January 1, 1984): 268–268.Link to Item
-
BIGNER, S. H., J. MARK, and D. D. BIGNER. “KARYOTYPIC EVOLUTION OF HUMAN GLIOBLASTOMA-MULTIFORME (HGM) DURING ESTABLISHMENT IN CULTURE.” Proceedings of the American Association for Cancer Research 25, no. MAR (January 1, 1984): 36–36.Link to Item
-
BIGNER, S. H., P. C. BURGER, J. MARK, M. S. MAHALEY, D. E. BULLARD, and D. D. BIGNER. “KARYOTYPIC AND HISTOLOGIC ANALYSIS OF MALIGNANT HUMAN GLIOMAS (MHG).” Journal of Neuro Oncology 2, no. 3 (January 1, 1984): 264–264.Link to Item
-
BRITT, R., B. LYONS, D. ENZMANN, E. SAXER, S. BIGNER, and D. BIGNER. “CORRELATION OF NEUROPATHOLOGIC FINDINGS, COMPUTERIZED TOMOGRAPHIC AND HIGH-RESOLUTION ULTRASOUND SCANS OF CANINE AVIAN-SARCOMA VIRUS-INDUCED BRAIN-TUMORS.” Journal of Neuro Oncology 2, no. 3 (January 1, 1984): 272–272.Link to Item
-
Bigner, S. H., J. Mark, M. S. Mahaley, and D. D. Bigner. “Patterns of the early, gross chromosomal changes in malignant human gliomas.” Hereditas 101, no. 1 (1984): 103–13. https://doi.org/10.1111/j.1601-5223.1984.tb00455.x.Full Text Link to Item
-
Bourdon, M. A., R. E. Coleman, and D. D. Bigner. “The potential of monoclonal antibodies as carriers of radiation and drugs for immunodetection and therapy of brain tumors.” Prog Exp Tumor Res 28 (1984): 79–101. https://doi.org/10.1159/000408239.Full Text Link to Item
-
DRANOFF, G., G. B. ELION, H. S. FRIEDMAN, and D. D. BIGNER. “GLUTAMINE REQUIREMENTS OF HUMAN GLIOMA AND MEDULLOBLASTOMA IN CULTURE.” Journal of Neuro Oncology 2, no. 3 (January 1, 1984): 264–264.Link to Item
-
FRIEDMAN, H. S., S. C. SCHOLD, L. H. MUHLBAIER, and D. D. BIGNER. “INVITRO AND INVIVO CHEMOSENSITIVITY OF HUMAN MEDULLOBLASTOMA.” Proceedings of the American Association for Cancer Research 25, no. MAR (January 1, 1984): 376–376.Link to Item
-
GROOTHUIS, D., J. FISCHER, D. BIGNER, and N. VICK. “THE EFFECTS OF DEXAMETHASONE ON BLOOD-FLOW AND CAPILLARY-PERMEABILITY IN AN EXPERIMENTAL BRAIN-TUMOR.” Journal of Neuro Oncology 2, no. 3 (January 1, 1984): 274–274.Link to Item
-
HEISTAD, D. D., L. PANTHER, G. L. BAUMBACH, and D. D. BIGNER. “RESPONSIVENESS OF EXPERIMENTAL BRAIN-TUMORS TO VASOACTIVE STIMULI.” Clinical Research 32, no. 2 (January 1, 1984): A541–A541.Link to Item
-
MCCOMB, R. D., and D. D. BIGNER. “IMMUNOLOCALIZATION OF MONOCLONAL ANTIBODY-DEFINED EXTRACELLULAR-MATRIX COMPONENTS IN MALIGNANT GLIOMAS AND MEDULLOBLASTOMAS.” Journal of Neuro Oncology 2, no. 3 (January 1, 1984): 274–274.Link to Item
-
MCCOMB, R. D., and D. D. BIGNER. “LAMININ LOCALIZATION IN NORMAL HUMAN CENTRAL NERVOUS-SYSTEM AND MALIGNANT GLIOMAS.” Laboratory Investigation 50, no. 1 (January 1, 1984): A37–38.Link to Item
-
PANTHER, L., G. L. BAUMBACH, D. D. BIGNER, D. J. PIEGORS, and D. D. HEISTAD. “REGULATION OF BLOOD-FLOW IN EXPERIMENTAL BRAIN-TUMORS.” Stroke 15, no. 1 (January 1, 1984): 193–193.Link to Item
-
WIKSTRAND, C. J., F. C. GRAHMANN, R. D. MCCOMB, and D. D. BIGNER. “ANTIGENIC HETEROGENEITY OF HUMAN GLIOMA TISSUE AND CELL-LINES (HGL) DEFINED BY MONOCLONAL-ANTIBODIES (MAS).” Journal of Neuro Oncology 2, no. 3 (January 1, 1984): 267–267.Link to Item
-
Bourdon, M. A., R. E. Coleman, R. G. Blasberg, D. R. Groothuis, and D. D. Bigner. “Monoclonal antibody localization in subcutaneous and intracranial human glioma xenografts: paired-label and imaging analysis.” Anticancer Res 4, no. 3 (1984): 133–40.Link to Item
-
FRIEDMAN, H. S., S. H. BIGNER, S. C. SCHOLD, P. C. BURGER, T. D. BJORNSSON, E. C. HALPERIN, M. A. VARIA, L. H. MUHLBAIER, and D. D. BIGNER. “THE USE OF HUMAN MEDULLOBLASTOMA MODELS TO DESIGN RATIONAL THERAPY.” Journal of Neuro Oncology 2, no. 3 (January 1, 1984): 286–286.Link to Item
-
McComb, R. D., and D. D. Bigner. “The biology of malignant gliomas--a comprehensive survey.” Clin Neuropathol 3, no. 3 (1984): 93–106.Link to Item
-
Rottenberg, D. A., J. Z. Ginos, K. J. Kearfott, L. Junck, and D. D. Bigner. “In vivo measurement of regional brain tissue pH using positron emission tomography.” Ann Neurol 15 Suppl (1984): S98-102. https://doi.org/10.1002/ana.410150718.Full Text Link to Item
-
Bigner, S. H., J. Mark, and D. D. Bigner. “Chromosomal composition of four permanent cultured cell lines derived from human gliomas.” Cancer Genet Cytogenet 10, no. 4 (December 1983): 335–49. https://doi.org/10.1016/0165-4608(83)90091-2.Full Text Link to Item
-
Friedman, H. S., S. H. Bigner, R. D. McComb, S. C. Schold, J. F. Pasternak, D. R. Groothuis, and D. D. Bigner. “A model for human medulloblastoma. Growth, morphology, and chromosomal analysis in vitro and in athymic mice.” J Neuropathol Exp Neurol 42, no. 5 (September 1983): 485–503. https://doi.org/10.1097/00005072-198309000-00001.Full Text Link to Item
-
Schold, S. C., and D. D. Bigner. “Treatment of five subcutaneous human glioma tumor lines in athymic mice with carmustine, procarbazine, and mithramycin.” Cancer Treat Rep 67, no. 9 (September 1983): 811–19.Link to Item
-
Mahaley, M. S., D. D. Bigner, L. F. Dudka, P. R. Wilds, D. H. Williams, T. W. Bouldin, J. N. Whitaker, and J. M. Bynum. “Immunobiology of primary intracranial tumors. Part 7: Active immunization of patients with anaplastic human glioma cells: a pilot study.” J Neurosurg 59, no. 2 (August 1983): 201–7. https://doi.org/10.3171/jns.1983.59.2.0201.Full Text Link to Item
-
Mahaley, M. S., G. Y. Gillespie, R. P. Gillespie, P. J. Watkins, D. D. Bigner, C. J. Wikstrand, J. M. MacQueen, and F. Sanfilippo. “Immunobiology of primary intracranial tumors. Part 8: Serological responses to active immunization of patients with anaplastic gliomas.” J Neurosurg 59, no. 2 (August 1983): 208–16. https://doi.org/10.3171/jns.1983.59.2.0208.Full Text Link to Item
-
Friedman, H. S., S. C. Schold, M. Varia, and D. D. Bigner. “Chemotherapy and radiation therapy of human medulloblastoma in athymic nude mice.” Cancer Res 43, no. 7 (July 1983): 3088–93.Link to Item
-
Groothuis, D. R., J. F. Pasternak, J. M. Fischer, R. G. Blasberg, D. D. Bigner, and N. A. Vick. “Regional measurements of blood flow in experimental RG-2 rat gliomas.” Cancer Res 43, no. 7 (July 1983): 3362–67.Link to Item
-
Groothuis, D. R., J. M. Fischer, J. F. Pasternak, R. G. Blasberg, N. A. Vick, and D. D. Bigner. “Regional measurements of blood-to-tissue transport in experimental RG-2 rat gliomas.” Cancer Res 43, no. 7 (July 1983): 3368–73.Link to Item
-
Wikstrand, C. J., S. H. Bigner, and D. D. Bigner. “Demonstration of complex antigenic heterogeneity in a human glioma cell line and eight derived clones by specific monoclonal antibodies.” Cancer Res 43, no. 7 (July 1983): 3327–34.Link to Item
-
Bourdon, M. A., C. J. Wikstrand, H. Furthmayr, T. J. Matthews, and D. D. Bigner. “Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody.” Cancer Res 43, no. 6 (June 1983): 2796–2805.Link to Item
-
Groothuis, D., R. G. Blasberg, P. Molnar, D. Bigner, and J. D. Fenstermacher. “Regional blood flow in avian sarcoma virus (ASV)-induced brain tumors.” Neurology 33, no. 6 (June 1983): 686–96. https://doi.org/10.1212/wnl.33.6.686.Full Text Link to Item
-
Molnar, P., R. G. Blasberg, D. Groothuis, D. Bigner, and J. D. Fenstermacher. “Regional blood-to-tissue transport in avian sarcoma virus (ASV)-induced brain tumors.” Neurology 33, no. 6 (June 1983): 702–11. https://doi.org/10.1212/wnl.33.6.702.Full Text Link to Item
-
Schold, S. C., C. E. Rawlings, S. H. Bigner, and D. D. Bigner. “Intracerebral growth of a human glioma tumor line in athymic mice and treatment with procarbazine, 1,3-bis(2-chloroethyl)-1-nitrosourea, aziridinylbenzoquinone, and cis-platinum.” Neurosurgery 12, no. 6 (June 1983): 672–77. https://doi.org/10.1227/00006123-198306000-00014.Full Text Link to Item
-
Mahaley, M. S., P. A. Aronin, A. J. Michael, and D. Bigner. “Prevention of glioma induction in rats by simultaneous intracerebral inoculation of avian sarcoma virus plus bacillus Calmette-Guerin cell-wall preparation.” Surg Neurol 19, no. 5 (May 1983): 453–55. https://doi.org/10.1016/0090-3019(83)90145-3.Full Text Link to Item
-
Bourdon, M. A., H. Nakagawa, R. Biasberg, and D. D. Bigner. “9 MONOCLONAL ANTIBODY LOCALIZATION IN HUMAN GLIOMA INTRACRANIAL XENOGRAFTS.” Journal of Neuropathology and Experimental Neurology 42, no. 3 (May 1983): 308–308. https://doi.org/10.1097/00005072-198305000-00019.Full Text
-
Bullard, D. E., M. Clemons, C. Pegram, M. A. Bourdon, and D. D. Bigner. “139 ENTRY OF (125I) MONOCLONAL ANTIBODY (MA)FROM BLOOD INTO BRAIN.” Journal of Neuropathology and Experimental Neurology 42, no. 3 (May 1983): 351–351. https://doi.org/10.1097/00005072-198305000-00145.Full Text
-
Grahmann, F. C., C. J. Wikstrand, and D. D. Bigner. “115 MONOCLONAL ANTIBODIES (MA) AGAINST HUMAN GLIOSARCOMA DERIVED CELL LINE D-32MGCL 2.” Journal of Neuropathology and Experimental Neurology 42, no. 3 (May 1983): 343–343. https://doi.org/10.1097/00005072-198305000-00122.Full Text
-
McComb, R. D., C. J. Wikstrand, M. A. Bourdon, S. H. Bigner, and D. D. Bigner. “10 ANTIGENIC HETEROGENEITY OF HUMAN MALIGNANT GLIOMAS (MGs) DEMONSTRATED BY REACTIVITY WITH 10 MONOCLONAL ANTIBODIES (MCAs).” Journal of Neuropathology and Experimental Neurology 42, no. 3 (May 1983): 308–308. https://doi.org/10.1097/00005072-198305000-00020.Full Text
-
Bigbee, J. W., D. D. Bigner, C. Pegram, and L. F. Eng. “Study of glial fibrillary acidic protein in a human glioma cell line grown in culture and as a solid tumor.” J Neurochem 40, no. 2 (February 1983): 460–67. https://doi.org/10.1111/j.1471-4159.1983.tb11305.x.Full Text Link to Item
-
Groothuis, D. R., J. F. Pasternak, J. M. Fischer, D. D. Bigner, and N. A. Vick. “Spatial distribution of proliferating cells in avian sarcoma virus-induced gliomas.” Cancer Res 43, no. 2 (February 1983): 456–59.Link to Item
-
Bigbee, J. W., D. D. Bigner, and L. F. Eng. “Glial fibrillary acidic protein synthesized in vitro using messenger RNA from a human glioma cell line.” J Neuropathol Exp Neurol 42, no. 1 (January 1983): 80–86. https://doi.org/10.1097/00005072-198301000-00007.Full Text Link to Item
-
Schold, S. C., D. E. Bullard, S. H. Bigner, T. R. Jones, and D. D. Bigner. “Growth, morphology, and serial transplantation of anaplastic human gliomas in athymic mice.” J Neurooncol 1, no. 1 (1983): 5–14. https://doi.org/10.1007/BF00153635.Full Text Link to Item
-
“Workshop on monoclonal antibodies against gliomas and other neuroectoderm-derived tumors.” J Neuroimmunol 3, no. 3 (November 1982): 237–43. https://doi.org/10.1016/0165-5728(82)90026-1.Full Text Link to Item
-
McComb, R. D., T. R. Jones, S. V. Pizzo, and D. D. Bigner. “Immunohistochemical detection of factor VIII/von Willebrand factor in hyperplastic endothelial cells in glioblastoma multiforme and mixed glioma-sarcoma.” J Neuropathol Exp Neurol 41, no. 5 (September 1982): 479–89.Link to Item
-
Wikstrand, C. J., M. A. Bourdon, C. N. Pegram, and D. D. Bigner. “Human fetal brain antigen expression common to tumors of neuroectodermal tissue origin.” J Neuroimmunol 3, no. 1 (August 1982): 43–62. https://doi.org/10.1016/0165-5728(82)90017-0.Full Text Link to Item
-
Neuwelt, E. A., P. A. Barnett, D. D. Bigner, and E. P. Frenkel. “Effects of adrenal cortical steroids and osmotic blood-brain barrier opening on methotrexate delivery to gliomas in the rodent: the factor of the blood-brain barrier.” Proc Natl Acad Sci U S A 79, no. 14 (July 1982): 4420–23. https://doi.org/10.1073/pnas.79.14.4420.Full Text Link to Item
-
Strauss, M. M., S. H. Bigner, and D. D. Bigner. “Experimental allergic encephalomyelitis in Lewis rats bearing avian sarcoma virus-induced brain tumors.” J Neuroimmunol 2, no. 3–4 (June 1982): 283–94. https://doi.org/10.1016/0165-5728(82)90061-3.Full Text Link to Item
-
Bourdon, M. A., C. J. Wikstrand, R. E. Coleman, and D. D. Bigner. “SPECIFICITY AND TUMOR LOCALIZATION OF A MONOCLONAL ANTIBODY (MA) DEFINING A HUMAN GLIOMA ASSOCIATED EXTRACELLULAR MATRIX ANTIGEN.” Journal of Neuropathology and Experimental Neurology 41, no. 3 (May 1982): 367–367. https://doi.org/10.1097/00005072-198205000-00088.Full Text
-
McComb, R. D., T. R. Jones, S. V. Pizzo, and D. D. Bigner. “Specificity and sensitivity of immunohistochemical detection of factor VIII/von Willebrand factor antigen in formalin-fixed paraffin-embedded tissue.” J Histochem Cytochem 30, no. 4 (April 1982): 371–77. https://doi.org/10.1177/30.4.6801111.Full Text Link to Item
-
Groothuis, D. R., J. M. Fischer, G. Lapin, D. D. Bigner, and N. A. Vick. “Permeability of different experimental brain tumor models to horseradish peroxidase.” J Neuropathol Exp Neurol 41, no. 2 (March 1982): 164–85. https://doi.org/10.1097/00005072-198203000-00006.Full Text Link to Item
-
BIGNER, D. D., M. A. BOURDON, C. N. PEGRAM, L. F. ENG, R. E. COLEMAN, and C. J. WIKSTRAND. “LOCALIZATION OF GLIOMA-ASSOCIATED ANTIGENS AT THE CELLULAR, TISSUE, AND WHOLE-BODY LEVEL WITH MONOCLONAL-ANTIBODIES (MCA).” Journal of Neuroimmunology 3, no. 3 (January 1, 1982): 237–38.Link to Item
-
Friedman, H. S., S. C. Schold, S. H. Bigner, and D. D. Bigner. “Growth, morphology, and chemotherapeutic response of medulloblastoma in athymic mice.” Annals of Neurology 12, no. 2 (January 1, 1982): 212.
-
Friedman, H. S., S. H. Bigner, S. C. Schold, and D. D. Bigner. “Growth, morphology, and chemotherapeutic response of medulloblastoma (MBT) in athymic mice.” Pediatric Research 16, no. 4 II (January 1, 1982).
-
Jones, T. R., E. Ruoslahti, S. C. Schold, and D. D. Bigner. “Fibronectin and glial fibrillary acidic protein expression in normal human brain and anaplastic human gliomas.” Cancer Res 42, no. 1 (January 1982): 168–77.Link to Item
-
SCHOLD, S. C., H. S. FRIEDMAN, T. D. BJORNSSON, D. G. SHAND, and D. D. BIGNER. “TREATMENT OF HUMAN-BRAIN TUMORS IN ATHYMIC MICE WITH AZIRIDINYLBENZOQUINONE (AZQ).” Proceedings of the American Association for Cancer Research 23, no. MAR (January 1, 1982): 176–176.Link to Item
-
Serano, R. D., C. W. Sigel, C. A. Nichol, and D. D. Bigner. “Evaluation of the lipid-soluble diaminopyrimidines, metoprine and etoprine, in the avian sarcoma virus rat glioma model.” Cancer Treat Rep 66, no. 1 (January 1982): 99–106.Link to Item
-
WIKSTRAND, C. J., S. P. BIGNER, and D. D. BIGNER. “ANTIGENIC HETEROGENEITY OF AN ESTABLISHED HUMAN GLIOMA CELL-LINE (HGCL) AND 8 SINGLE CELL DERIVED CLONES AS DEFINED BY SPECIFIC ANTI-GLIOMA MONOCLONALANTIBODIES (MCA).” Proceedings of the American Association for Cancer Research 23, no. MAR (January 1, 1982): 271–271.Link to Item
-
WIKSTRAND, C. J., and D. D. BIGNER. “MONOCLONAL-ANTIBODY (MCA) DEFINITION OF SHARED NEUROECTODERMAL TUMOR FETAL ANTIGENS.” Journal of Neuroimmunology 3, no. 3 (January 1, 1982): 240–41.Link to Item
-
Wikstrand, C. J., and D. D. Bigner. “Expression of human fetal brain antigens by human tumors of neuroectodermal origin as defined by monoclonal antibodies.” Cancer Res 42, no. 1 (January 1982): 267–75.Link to Item
-
McComb, R. D., T. R. Jones, S. V. Pizzo, and D. D. Bigner. “Localization of factor VIII/von Willebrand factor and glial fibrillary acidic protein in the hemangioblastoma: implications for stromal cell histogenesis.” Acta Neuropathol 56, no. 3 (1982): 207–13. https://doi.org/10.1007/BF00690637.Full Text Link to Item
-
Jones, T. R., S. H. Bigner, S. C. Schold, L. F. Eng, and D. D. Bigner. “Anaplastic human gliomas grown in athymic mice. Morphology and glial fibrillary acidic protein expression.” Am J Pathol 105, no. 3 (December 1981): 316–27.Link to Item
-
Roszman, T. L., W. H. Brooks, W. R. Markesbery, G. J. Aziz, and D. D. Bigner. “Lymphocyte subpopulations and responsiveness in rats bearing intracranial tumors induced by avian sarcoma virus.” J Neurosurg 55, no. 4 (October 1981): 554–59. https://doi.org/10.3171/jns.1981.55.4.0554.Full Text Link to Item
-
Bigner, D. D. “Biology of gliomas: potential clinical implications of glioma cellular heterogeneity.” Neurosurgery 9, no. 3 (September 1981): 320–26.Link to Item
-
Wikstrand, C. J., and D. D. Bigner. “Hyperimmunization of non-human primates with BCG-CW and cultured human glioma-derived cells. Production of reactive antisera and absence of EAE induction.” J Neuroimmunol 1, no. 3 (September 1981): 249–60. https://doi.org/10.1016/0165-5728(81)90029-1.Full Text Link to Item
-
Groothuis, D. R., M. A. Mikhael, J. M. Fischer, J. F. Pasternak, T. Fouts, D. D. Bigner, and N. A. Vick. “Computed tomography of virally induced canine brain tumors: a preliminary report.” J Comput Assist Tomogr 5, no. 4 (August 1981): 538–43. https://doi.org/10.1097/00004728-198108000-00015.Full Text Link to Item
-
Bigner, S. H., D. E. Bullard, C. N. Pegram, C. J. Wikstrand, and D. D. Bigner. “Relationship of in vitro morphologic and growth characteristics of established human glioma-derived cell lines to their tumorigenicity in athymic nude mice.” J Neuropathol Exp Neurol 40, no. 4 (July 1981): 390–409. https://doi.org/10.1097/00005072-198107000-00004.Full Text Link to Item
-
Bullard, D. E., S. C. Schold, S. H. Bigner, and D. D. Bigner. “Growth and chemotherapeutic response in athymic mice of tumors arising from human glioma-derived cell lines.” J Neuropathol Exp Neurol 40, no. 4 (July 1981): 410–27. https://doi.org/10.1097/00005072-198107000-00005.Full Text Link to Item
-
Bigner, D. D., O. M. Pitts, and C. J. Wikstrand. “Induction of lethal experimental allergic encephalomyelitis in nonhuman primates and guinea pigs with human glioblastoma multiforme tissue.” J Neurosurg 55, no. 1 (July 1981): 32–42. https://doi.org/10.3171/jns.1981.55.1.0032.Full Text Link to Item
-
Bigner, D. D., S. H. Bigner, J. Pontén, B. Westermark, M. S. Mahaley, E. Ruoslahti, H. Herschman, L. F. Eng, and C. J. Wikstrand. “Heterogeneity of Genotypic and phenotypic characteristics of fifteen permanent cell lines derived from human gliomas.” J Neuropathol Exp Neurol 40, no. 3 (May 1981): 201–29. https://doi.org/10.1097/00005072-198105000-00001.Full Text Link to Item
-
Bullard, D. E., S. H. Bigner, and D. D. Bigner. “The morphologic response of cell lines derived from human gliomas to dibutyryl adenosine 3':5'-cyclic monophosphate.” J Neuropathol Exp Neurol 40, no. 3 (May 1981): 230–46. https://doi.org/10.1097/00005072-198105000-00002.Full Text Link to Item
-
Jones, T. R., K. J. Kao, S. V. Pizzo, and D. D. Bigner. “Endothelial cell surface expression and binding of factor VIII/von Willebrand factor.” Am J Pathol 103, no. 2 (May 1981): 304–8.Link to Item
-
Groothuis, D. R., J. M. Fischer, J. Pasternak, D. Bigner, and N. A. Vick. “190 QUANTITATIVE AUTORADIOGRAPHIC MEASUREMENTS OF BLOOD FLOW AND PERMEABILITY IN EXPERIMENTAL RG-2 RAT GLIOMAS.” Journal of Neuropathology and Experimental Neurology 40, no. 3 (May 1981): 362–362. https://doi.org/10.1097/00005072-198105000-00197.Full Text
-
McComb, R. D., T. R. Jones, S. V. Pizzo, and D. D. Bigner. “113 IMMUNOPEROXIDASE DETECTION OF FACTOR VIII/VON WILLEBRAND FACTOR (FVIII/vWF) IN GLIOBLASTOMA MULTIFORME (GBM), MIXED GLIOMA-SARCOMA (GS), HEMAN-GIOBLASTOMA (HBL), AND MENINGEAL HEMANGIOPERICYTOMA (HP).” Journal of Neuropathology and Experimental Neurology 40, no. 3 (May 1981): 336–336. https://doi.org/10.1097/00005072-198105000-00120.Full Text
-
Takeshita, I., S. Bigner, J. Liou, O. E. Brown, D. Sedwick, and D. D. Bigner. “112 A THYMIDINE-KINASE (TK) DEFICIENT 5-BROMO 2ʼDEOXYURIDINE (BUDR) RESISTANT HUMAN GLIOMA (HGL)-DERIVED PERMANENT CELL LINE THAT EXPRESSES GLIAL FIBRILLARY ACIDIC PROTEIN (GFAP).” Journal of Neuropathology and Experimental Neurology 40, no. 3 (May 1981): 336–336. https://doi.org/10.1097/00005072-198105000-00119.Full Text
-
BOURDON, M. A., C. J. WIKSTRAND, C. N. PEGRAM, and D. D. BIGNER. “A GLIOMA-MESENCHYMAL EXTRACELLULAR-MATRIX (GMEM) ANTIGEN DEFINED BY MONOCLONAL-ANTIBODY.” Federation Proceedings 40, no. 3 (January 1, 1981): 821–821.Link to Item
-
Bigner, D. D., C. Schold, S. H. Bigner, D. E. Bullard, and C. Wikstrand. “How heterogeneous are gliomas?” Cancer Treat Rep 65 Suppl 2 (1981): 45–49.Link to Item
-
Groothuis, D. R., J. M. Fischer, N. A. Vick, and D. D. Bigner. “Comparative permeability of different glioma models to horseradish peroxidase.” Cancer Treat Rep 65 Suppl 2 (1981): 13–18.Link to Item
-
Groothuis, D. R., M. A. Mikhael, J. M. Fischer, J. F. Pasternak, T. Fouts, D. D. Bigner, and N. A. Vick. “Computed tomography of virally induced canine brain tumors: A preliminary report.” Journal of Computer Assisted Tomography 5, no. 4 (January 1, 1981): 529–37.
-
MCCOMB, R. D., T. R. JONES, S. V. PIZZO, and D. D. BIGNER. “FACTOR-VIII-VONWILLEBRAND FACTOR (FVIII-VWF) EXPRESSION IN HEMANGIOBLASTOMAS (HBL) AS DETECTED BY PEROXIDASE-ANTIPEROXIDASE (PAP) IMMUNOHISTOCHEMISTRY.” Laboratory Investigation 44, no. 1 (January 1, 1981): A41–42.Link to Item
-
Neuwelt, E. A., E. Frenkel, D. Bigner, and P. Barnett. “The effects of osmotic modification of the blood-brain barrier and adrenal steroid administration on methotrexate delivery to rodent gliomas.” Neurosurgery 9, no. 4 (January 1, 1981): 471–72.
-
RAYMOND, U., M. A. VARIA, M. S. MAHALEY, P. STEINBOK, J. GROCE, J. L. MAHALEY, J. H. WRENN, S. LIPPER, C. N. PEGRAM, and D. D. BIGNER. “THERAPEUTIC EFFICACY OF THE BCNU ADJUVANT THERAPY AND RADIATION IN THE TREATMENT OF MALIGNANT BRAIN-TUMORS IN RATS.” Radiation Research 87, no. 2 (January 1, 1981): 437–38.Link to Item
-
SCHOLD, C., D. BULLARD, S. BIGNER, L. ENG, and D. BIGNER. “SERIAL TRANSPLANTATION OF ANAPLASTIC HUMAN GLIOMAS (HGL) IN ATHYMIC MICE.” Proceedings of the American Association for Cancer Research 22, no. MAR (January 1, 1981): 61–61.Link to Item
-
Steinbok, P., M. S. Mahaley, R. U, M. A. Varia, S. Lipper, J. Mahaley, J. G. Dalzell, and D. D. Bigner. “Treatment of autochthonous rat brain tumors with fractionated radiotherapy. The effects of graded radiation doses and of combined therapy with BCNU or steroids.” J Neurosurg 53, no. 1 (July 1980): 68–72. https://doi.org/10.3171/jns.1980.53.1.0068.Full Text Link to Item
-
Bigner, S. H., T. R. Jones, R. D. Serano, H. R. Herschman, and D. D. Bigner. “MORPHOLOGIC AND FUNCTIONAL CHARACTERISTICS OF A PERMANENT CELL LINE DERIVED FROM A CEREBELLAR HEMANGIOBLASTOMA.” Journal of Neuropathology and Experimental Neurology 39, no. 3 (May 1980): 341–341. https://doi.org/10.1097/00005072-198005000-00020.Full Text
-
Jones, T. R., E. Ruoslahti, S. C. Schold, L. F. Eng, and D. P. Bigner. “85 FIBRONECTIN (FN) AND GLIAL FIBRILLARY ACIDIC PROTEIN (GFAP) EXPRESSION IN HUMAN ANAPLASTIC GLIOMAS (HG1) GROWN IN ATHYMIC “NUDE” MICE.” Journal of Neuropathology and Experimental Neurology 39, no. 3 (May 1980): 365–365. https://doi.org/10.1097/00005072-198005000-00093.Full Text
-
Groothuis, D. R., J. M. Fischer, N. A. Vick, and D. D. Bigner. “Experimental gliomas: an autoradiographic study of the endothelial component.” Neurology 30, no. 3 (March 1980): 297–301. https://doi.org/10.1212/wnl.30.3.297.Full Text Link to Item
-
Wikstrand, C. J., and D. D. Bigner. “Immunobiologic aspects of the brain and human gliomas. A review.” Am J Pathol 98, no. 2 (February 1980): 517–68.Link to Item
-
BIGNER, S. H., D. E. BULLARD, C. SCHOLD, and D. D. BIGNER. “MORPHOLOGY OF ANAPLASTIC HUMAN GLIOMAS (AHG) GROWN SUBCUTANEOUSLY IN ATHYMIC NUDE-MICE.” Laboratory Investigation 42, no. 1 (January 1, 1980): 103–103.Link to Item
-
MAHESH, R. U., A. VARIA, M. S. MAHALEY, P. STEINBOK, J. L. MAHALEY, D. C. ZINN, P. ARONIN, A. MICHAEL, S. LIPPER, and D. D. BIGNER. “FRACTIONATED DOSES OF PHOTON IRRADIATION ON AUTOCHTHONOUS RAT-BRAIN TUMOR.” Radiation Research 83, no. 2 (January 1, 1980): 490–490.Link to Item
-
Steinbok, P., M. S. Mahaley, S. Lipper, J. G. Dalzell, C. Pegram, and D. Bigner. “Failure of intracerebral BCG cell wall preparation to prevent glioma induction by avian sarcoma virus in rats.” Cancer Immunology Immunotherapy 8, no. 1 (January 1, 1980): 55–59. https://doi.org/10.1007/BF00206355.Full Text
-
Wikstrand, C. J., and D. D. Bigner. “Immunobiologic aspects of the brain and human gliomas. A review.” American Journal of Pathology 98, no. 2 (January 1, 1980): 515–67.
-
Serano, R. D., C. N. Pegram, and D. D. Bigner. “Tumorigenic cell culture lines from a spontaneous VM/Dk murine astrocytoma (SMA).” Acta Neuropathol 51, no. 1 (1980): 53–64. https://doi.org/10.1007/BF00688850.Full Text Link to Item
-
Steinbok, P., M. S. Mahaley, R. U, D. C. Zinn, S. Lipper, J. L. Mahaley, and D. D. Bigner. “Synergism between BCNU and irradiation in the treatment of anaplastic gliomas. An in vivo study using the avian sarcoma virus-induced glioma model.” J Neurosurg 51, no. 5 (November 1979): 581–86. https://doi.org/10.3171/jns.1979.51.5.0581.Full Text Link to Item
-
Wikstrand, C. J., and D. D. Bigner. “Surface antigens of human glioma cells shared with normal adult and fetal brain.” Cancer Res 39, no. 8 (August 1979): 3235–43.Link to Item
-
Sylvia, A. L., G. G. Somjen, D. D. Bigner, and M. Rosenthal. “Redox properties of cytochrome oxidase and vascular reactivity of astrocytomas and neuroblastomas in vivo.” J Neurochem 32, no. 5 (May 1979): 1371–77. https://doi.org/10.1111/j.1471-4159.1979.tb11074.x.Full Text Link to Item
-
Bullard, D. E., and D. D. Bigner. “THE USE OF ATHYMIC ‘NUDE’ MICE FOR THE IN VIVO STUDY OF HUMAN NERVOUS SYSTEM TUMORS.” Journal of Neuropathology and Experimental Neurology 38, no. 3 (May 1979): 306–306. https://doi.org/10.1097/00005072-197905000-00024.Full Text
-
Jones, T. R., K. J. Kao, S. V. Pizzo, and D. D. Bigner. “FACTOR VIII-A MARKER OF ENDOTHELIAL CELLS IN NORMAL BRAIN AND GLIOMAS.” Journal of Neuropathology and Experimental Neurology 38, no. 3 (May 1979): 324–324. https://doi.org/10.1097/00005072-197905000-00080.Full Text
-
Serano, R. D., and D. D. Bigner. “VIRALLY INDUCED AUTOCHTHONOUS ASTROCYTOMAS IN THE MONGOLIAN GERBIL (MERIONES UNGUICULATUS).” Journal of Neuropathology and Experimental Neurology 38, no. 3 (May 1979): 340–340. https://doi.org/10.1097/00005072-197905000-00126.Full Text
-
Bullard, D. E., and D. D. Bigner. “Heterotransplantation of human craniopharyngiomas in athymic "nude" mice.” Neurosurgery 4, no. 4 (April 1979): 308–14. https://doi.org/10.1227/00006123-197904000-00006.Full Text
-
Duch, D. S., D. D. Bigner, S. W. Bowers, and C. A. Nichol. “Dihydrofolate reductase in primary brain tumors, cell cultures of central nervous system origin, and normal brain during fetal and neonatal growth.” Cancer Res 39, no. 2 Pt 1 (February 1979): 487–91.Link to Item
-
Duch, D. S., S. W. Bowers, and C. A. Nichol. “Dihydrofolate Reductase in Primary Brain Tumors, Cell Cultures of Central Nervous System Origin, and Normal Brain during Fetal and Neonatal Growth.” Cancer Research 39 (February 1, 1979): 487–91.
-
DUCH, D. S., D. D. BIGNER, S. W. BOWERS, and C. A. NICHOL. “DIHYDROFOLATE-REDUCTASE IN PRIMARY BRAIN TUMORS, CELL-CULTURES OF CENTRAL NERVOUS-SYSTEM ORIGIN, AND NORMAL BRAIN DURING FETAL AND NEONATAL GROWTH.” Cancer Research 39, no. 2 (January 1, 1979): 487–91.Link to Item
-
Preissig, S. H., C. N. Pegram, and D. D. Bigner. “Cytopathologic characteristics of permanent cell lines derived from anaplastic human gliomas.” Acta Cytol 23, no. 5 (1979): 412–19.Link to Item
-
Bigner, D. D., and C. J. Wikstrand. “FETAL AND ADULT BRAIN-ASSOCIATED SURFACE ANTIGENS OF HUMAN GLIOMA (HGL) CELL LINES AND CLONES.” Journal of Neuropathology and Experimental Neurology 37, no. 5 (September 1978): 591–591. https://doi.org/10.1097/00005072-197809000-00071.Full Text
-
Bullard, D., S. Preissig, C. Pregram, and D. Bigner. “IN VITRO RESPONSE OF CELLS DERIVED FROM HUMAN GLIOMAS (HGL) TO DIBUTYRYL ADENOSINE 3′:5′-CYCLIC MONOPHOSPHATE (cAMP).” Journal of Neuropathology and Experimental Neurology 37, no. 5 (September 1978): 596–596. https://doi.org/10.1097/00005072-197809000-00086.Full Text
-
Groothuis, D. R., N. A. Vick, and D. D. Bigner. “EXPERIMENTAL GLIOMAS: STUDIES AT THE MARGINAL ZONE.” Journal of Neuropathology and Experimental Neurology 37, no. 5 (September 1978): 619–619. https://doi.org/10.1097/00005072-197809000-00157.Full Text
-
Preissig, S. H., D. E. Bullard, C. N. Pegram, and P. P. Bigner. “RELATIONSHIP OF MORPHOLOGIC AND CELL BIOLOGIC CHARACTERISTICS OF HUMAN GLIOMAS (HCL) IN CELL CULTURE TO TUMORIGENICITY IN NUDE MICE.” Journal of Neuropathology and Experimental Neurology 37, no. 5 (September 1978): 674–674. https://doi.org/10.1097/00005072-197809000-00321.Full Text
-
Serano, R. D., C. N. Pegram, H. Fraser, A. G. Dickinson, and D. D. Bigner. “ESTABLISHED TUMORIGENIC CELL LINES FROM A SPONTANEOUS MURINE (VM/Dk) ASTROCYTOMA (SMA).” Journal of Neuropathology and Experimental Neurology 37, no. 5 (September 1978): 689–689. https://doi.org/10.1097/00005072-197809000-00353.Full Text
-
Copeland, D. D., and D. D. Bigner. “Glial-mesenchymal tropism of in vivo avian sarcoma virus neuro-oncogenesis in rats.” Acta Neuropathol 41, no. 1 (January 19, 1978): 23–25. https://doi.org/10.1007/BF00689552.Full Text Link to Item
-
MEYERS, M. E., T. L. ROSZMAN, W. H. BROOKS, and D. D. BIGNER. “EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS (EAE) IN RATS WITH PRIMARY GLIOMAS INDUCED WITH AVIAN-SARCOMA VIRUS (ASV).” Federation Proceedings 37, no. 3 (January 1, 1978): 413–413.Link to Item
-
PREISSIG, S. H., D. E. BULLARD, and D. D. BIGNER. “CYTOPATHOLOGIC STUDIES OF PERMANENT CULTURED CELL LINES DERIVED FROM ANAPLASTIC HUMAN GLIOMAS (HGL).” Acta Cytologica 22, no. 6 (January 1, 1978): 598–598.Link to Item
-
Roszman, T. L., W. H. Brooks, W. R. Markesbery, and D. D. Bigner. “General immunocompetence of rats bearing avian sarcoma virus-induced intracranial tumors.” Cancer Res 38, no. 1 (January 1978): 74–77.Link to Item
-
WIKSTRAND, C. J., and D. D. BIGNER. “ORGAN-SPECIFIC, FETAL BRAIN, AND POSSIBLE IDIOTYPIC ANTIGENS OF HUMAN GLIAL BRAIN TUMOR (HGBT) CELLS.” Proceedings of the American Association for Cancer Research 19, no. MAR (January 1, 1978): 161–161.Link to Item
-
Wikstrand, C. J., M. S. Mahaley, and D. D. Bigner. “Surface antigenic characteristics of human glial brain tumor cells.” Cancer Res 37, no. 12 (December 1977): 4267–75.Link to Item
-
Vick, N. A., M. J. Lin, and D. D. Bigner. “The role of the subependymal plate in glial tumorigenesis.” Acta Neuropathol 40, no. 1 (September 26, 1977): 63–71. https://doi.org/10.1007/BF00688574.Full Text Link to Item
-
Harwood, S. E., D. D. Bigner, W. Wechsler, and E. D. Day. “Antigens shared by rat schwannomas, neuroblastomas, and a testicular interstitial cell carcinoma.” Cancer Res 37, no. 9 (September 1977): 3379–84.Link to Item
-
Vick, N. A., J. D. Khandekar, and D. D. Bigner. “Chemotherapy of brain tumors.” Arch Neurol 34, no. 9 (September 1977): 523–26. https://doi.org/10.1001/archneur.1977.00500210025002.Full Text Link to Item
-
Cloyd, M. W., and D. D. Bigner. “Surface morphology of normal and neoplastic rat cells.” Am J Pathol 88, no. 1 (July 1977): 29–52.Link to Item
-
Mahaley, M. S., R. E. Gentry, and D. D. Bigner. “Immunobiology of primary intracranial tumors.” J Neurosurg 47, no. 1 (July 1977): 35–43. https://doi.org/10.3171/jns.1977.47.1.0035.Full Text Link to Item
-
Copeland, D. D., and D. D. Bigner. “Influence of age at inoculation on avian oncornavirus-induced brain tumor incidence, tumor morphology, and postinoculation survival in F344 rats.” Cancer Res 37, no. 6 (June 1977): 1657–61.Link to Item
-
Bigner, D. D., W. R. Markesberry, C. N. Pegram, B. Westermark, and J. Pontén. “PROGRESSIVE NEOPLASTIC GROWTH IN NUDE MICE OF CULTURED CELL LINES DERIVED FROM HUMAN GLIOMAS.” Journal of Neuropathology and Experimental Neurology 36, no. 3 (May 1977): 593–593. https://doi.org/10.1097/00005072-197705000-00027.Full Text
-
Copeland, D. D., and D. D. Bigner. “The role of the subependymal plate in avian sarcoma virus brain tumor induction: comparison of incipient tumors in neonatal and adult rats.” Acta Neuropathol 38, no. 1 (April 29, 1977): 1–6. https://doi.org/10.1007/BF00691268.Full Text Link to Item
-
Mahaley, M. S., W. H. Brooks, T. L. Roszman, D. D. Bigner, L. Dudka, and S. Richardson. “Immunobiology of primary intracranial tumors. Part 1: studies of the cellular and humoral general immune competence of brain-tumor patients.” J Neurosurg 46, no. 4 (April 1977): 467–76. https://doi.org/10.3171/jns.1977.46.4.0467.Full Text Link to Item
-
Cloyd, M. W., D. P. Bolognesi, and D. D. Bigner. “Immunofluorescent analysis of expression of the RNA tumor virus major glycoprotein, gp71, on surfaces of virus-producing murine and other mammalian species cell lines.” Cancer Res 37, no. 3 (March 1977): 922–30.Link to Item
-
Cloyd, M. W., D. P. Bolognesi, and D. D. Bigner. “Immunofluorescent analysis of expression of the RNA tumor virus major glycoprotein, gp71, on the surfaces of normal murine cells.” Cancer Res 37, no. 3 (March 1977): 931–38.Link to Item
-
Bigner, D. D., and C. B. Wilson. “Workshop on cancer of the brain.” Journal of Neurosurgery 47, no. 6 (January 1, 1977): 923–32. https://doi.org/10.3171/jns.1977.47.6.0923.Full Text
-
COPELAND, D. D., and D. D. BIGNER. “EFFECTS OF AGE ON INDUCTION OF INTRACRANIAL NEOPLASMS IN F-344 RATS BY INTRACEREBRAL INOCULATION OF AVIAN-SARCOMA VIRUS.” American Journal of Pathology 86, no. 2 (January 1, 1977): A67–68.Link to Item
-
Cloyd, M. W., and D. D. Bigner. “Contained indirect viable-cell membrane immunofluorescence microassay for surface antigen analysis of cells infected with hazardous viruses.” J Clin Microbiol 5, no. 1 (January 1977): 86–90. https://doi.org/10.1128/jcm.5.1.86-90.1977.Full Text Link to Item
-
DUCH, D. S., S. W. BOWERS, D. D. BIGNER, and C. A. NICHOL. “DIHYDROFOLATE-REDUCTASE LEVELS IN NORMAL BRAIN AND PRIMARY CNS TUMORS RELEVANT TO BRAIN TUMOR CHEMOTHERAPY.” Proceedings of the American Association for Cancer Research 18, no. MAR (January 1, 1977): 177–177.Link to Item
-
Duch, D. S., S. W. Bowers, D. D. Bigner, and C. A. Nichol. “Dihydrofolate reductase levels in normal brain and primary CNS tumors relevant to brain tumor chemotherapy.” Proceedings of the American Association for Cancer Research Vol.18 (January 1, 1977).
-
HARWOOD, S. E., D. D. BIGNER, and E. D. DAY. “3 ANTIGENS OF NITROSOUREA-INDUCED (NU) RAT SCHWANNOMAS.” Proceedings of the American Association for Cancer Research 18, no. MAR (January 1, 1977): 90–90.Link to Item
-
Harwood, S. E., D. D. Bigner, and E. D. Day. “Three antigens of nitrosourea induced (NU) rat schwannomas.” Proceedings of the American Association for Cancer Research Vol.18 (January 1, 1977).
-
Jr, M. S. M., R. E. Gentry, and D. D. Bigner. “Immunobiology of primary intracranial tumors. Part 2: The evaluation of chemotherapy and immunotherapy protocols using the avian sarcoma virus glioma model.” Journal of Neurosurgery 47, no. 1 (1977): 35–43.
-
WIKSTRAND, C. J., M. S. MAHALEY, and D. D. BIGNER. “COMMON SURFACE ANTIGEN(S) [HGL] OF HUMAN GLIAL BRAIN TUMOR [HGBT] CELLS.” Proceedings of the American Association for Cancer Research 18, no. MAR (January 1, 1977): 120–120.Link to Item
-
Harwood, S. E., D. D. Bigner, W. Wechsler, and E. D. Day. “Sequential adsorption analysis of antibodies to neuroectodermal cells by an indirect quantitative method.” J Natl Cancer Inst 56, no. 6 (June 1976): 1201–5. https://doi.org/10.1093/jnci/56.6.1201.Full Text Link to Item
-
Adams, D. O., R. W. Gilbert, and D. D. Bigner. “Cellular immunity in rats with primary brain tumors: inhibition of macrophage migration by soluble extracts of avian sarcoma virus-induced tumors.” J Natl Cancer Inst 56, no. 6 (June 1976): 1119–23. https://doi.org/10.1093/jnci/56.6.1119.Full Text Link to Item
-
Copeland, Dana D., and Darell D. Bioner. “MORPHOLOGIC FEATURES OF AVIAN SARCOMA VIRUS TRANSFORMED RAT NEUROECTODERMAL CELLS IN GELATIN FOAM MATRIX CULTURE.” Journal of Neuropathology and Experimental Neurology 35, no. 3 (May 1976): 356–356. https://doi.org/10.1097/00005072-197605000-00121.Full Text
-
Vick, N. A., D. D. Bigner, and J. Lin. “GLIAL TUMORIGENESIS.” Journal of Neuropathology and Experimental Neurology 35, no. 3 (May 1976): 358–358. https://doi.org/10.1097/00005072-197605000-00125.Full Text
-
Copeland, D. D., F. A. Talley, and D. D. Bigner. “The fine structure of intracranial neoplasms induced by the inoculation of avian sarcoma virus in neonatal and adult rats.” Am J Pathol 83, no. 1 (April 1976): 149–76.Link to Item
-
BIGNER, D. D., O. M. PITTS, M. S. MAHALEY, and E. D. DAY. “INDUCTION OF LETHAL EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS (EAE) IN NON-HUMAN PRIMATES WITH HUMAN GLIOBLASTOMA MULTIFORME (GBM).” Proceedings of the American Association for Cancer Research 17, no. MAR (January 1, 1976): 123–123.Link to Item
-
Bigner, D. D., and C. N. Pegram. “Virus-induced experimental brain tumors and putative associations of viruses with human brain tumors: a review.” Adv Neurol 15 (1976): 57–83.Link to Item
-
CLOYD, M. W., D. P. BOLOGNESI, P. J. FISCHINGER, and D. D. BIGNER. “ANTIGENIC EXPRESSION OF MURINE LEUKEMIA-VIRUS GP71 ON MURINE AND HETEROLOGOUS SPECIES CELLS.” Federation Proceedings 35, no. 3 (January 1, 1976): 736–736.Link to Item
-
Cloyd, M. W., D. P. Bolognesi, P. J. Fischinger, and D. D. Bigner. “The antigenic expression of murine leukemia virus GP71 on murine and heterologous species cells.” Federation Proceedings 35, no. 3 (January 1, 1976).
-
HARWOOD, S. E., D. D. BIGNER, and E. D. DAY. “ANALYSIS OF ANTIBODIES TO SURFACE ANTIGENS ON NEUROECTODERMAL TUMOR-CELLS USING AN INDIRECT SEQUENTIAL ADSORPTION RADIOIMMUNOASSAY.” Proceedings of the American Association for Cancer Research 17, no. MAR (January 1, 1976): 66–66.Link to Item
-
Copeland, D. D., F. S. Vogel, and D. D. Bigner. “The induction of intractranial neoplasms by the inoculation of avian sarcoma virus in perinatal and adult rats.” J Neuropathol Exp Neurol 34, no. 4 (July 1975): 340–58. https://doi.org/10.1097/00005072-197507000-00004.Full Text Link to Item
-
Cloyd, M. W., P. C. Burger, and D. D. Bigner. “R-type virus-like particles in avian sarcoma virus-induced rat central nervous system tumors.” J Natl Cancer Inst 54, no. 6 (June 1975): 1479–82. https://doi.org/10.1093/jnci/54.6.1479.Full Text Link to Item
-
Bigner, D. D., D. J. Self, and J. Frey. “Refinement of the avian oncornavirus induced primary rat brain tumor model for therapeutic screening.” Recent Results in Cancer Research Vol.51 (January 1, 1975): 20–34. https://doi.org/10.1007/978-3-642-80916-3_4.Full Text
-
CLOYD, M. W., P. C. BURGER, and D. D. BIGNER. “VIRUS-LIKE PARTICLES OBSERVED IN RAT CENTRAL NERVOUS-SYSTEM (CNS) TUMORS INDUCED WITH BRATISLAVA-77 AVIAN-SARCOMA VIRUS (B77-ASV).” Journal of Neuropathology and Experimental Neurology 34, no. 1 (January 1, 1975): 99–99.Link to Item
-
COPELAND, D. D., F. S. VOGEL, D. J. SELF, and D. D. BIGNER. “INCIDENCE AND MORPHOLOGY OF INTRACRANIAL TUMORS INDUCED BY BRATISLAVA-77 STRAIN OF AVIAN-SARCOMA VIRUS IN PERINATAL AND ADULT RATS.” Journal of Neuropathology and Experimental Neurology 34, no. 1 (January 1, 1975): 100–100.Link to Item
-
GILBERT, R. W., D. O. ADAMS, and D. D. BIGNER. “CELLULAR IMMUNITY TO SOLUBILIZED TUMOR ANTIGENS IN INBRED RATS BEARING AUTOCHTHONOUS VIRALLY INDUCED GLIOMAS.” Journal of Neuropathology and Experimental Neurology 34, no. 1 (January 1, 1975): 95–95.Link to Item
-
SWENBERG, J. A., D. D. BIGNER, T. L. HALL, and P. R. HARBACH. “ADDITIVE ONCOGENIC EFFECTS OF AVIAN-SARCOMA VIRUS AND ETHYLNITROSOUREA.” Journal of Neuropathology and Experimental Neurology 34, no. 1 (January 1, 1975): 99–99.Link to Item
-
VICK, N. A., and D. D. BIGNER. “GLIOMAS INDUCED BY AVIAN-SARCOMA VIRUS (ASV) - EARLY AND SEQUENTIAL STRUCTURAL EVENTS OF NEOPLASTIC TRANSFORMATION INVIVO.” Journal of Neuropathology and Experimental Neurology 34, no. 1 (January 1, 1975): 99–100.Link to Item
-
Grant, J. P., D. D. Bigner, P. J. Fischinger, and D. P. Bolognesi. “Expression of murine leukemia virus structural antigens on the surface of chemically induced murine sarcomas.” Proc Natl Acad Sci U S A 71, no. 12 (December 1974): 5037–41. https://doi.org/10.1073/pnas.71.12.5037.Full Text Link to Item
-
Self, D. J., K. F. Pettiss, and D. D. Bigner. “Improved techniques for staining and enumerating focus formation in viral infectivity assays.” Appl Microbiol 28, no. 1 (July 1974): 156–57. https://doi.org/10.1128/am.28.1.156-157.1974.Full Text Link to Item
-
Swenberg, J. A., D. Bigner, and T. L. Hall. “Experimental chemotherapy of viral induced brain tumors.” Proceedings of the American Association for Cancer Research Vol. 15 (January 1, 1974).
-
Day, E. D., and D. D. Bigner. “Specificity, cross-reactivity, and affinity of 125I-labeled antiglioma antibodies for monolayers of cultured glioma cells.” Cancer Res 33, no. 10 (October 1973): 2362–72.Link to Item
-
Burger, P. C., D. D. Bigner, and D. J. Self. “Morphologic observations of brain tumors in PD4 hamsters induced by four strains of avian sarcoma virus.” Acta Neuropathol 26, no. 1 (1973): 1–21. https://doi.org/10.1007/BF00685520.Full Text Link to Item
-
Wilfong, R. F., D. D. Bigner, D. J. Self, and W. Wechsler. “Brain tumor types induced by the Schmidt-Ruppin strain of Rous sarcoma virus in inbred Fischer rats.” Acta Neuropathol 25, no. 3 (1973): 196–206. https://doi.org/10.1007/BF00685199.Full Text Link to Item
-
Bigner, D. D., J. P. Kvedar, B. A. Thomas, C. Shaffer, N. A. Vick, W. K. Engel, and E. D. Day. “Factors influencing the cell type of brain tumors induced in dogs by Schmidt-Ruppin Rous sarcoma virus.” J Neuropathol Exp Neurol 31, no. 4 (October 1972): 583–95. https://doi.org/10.1097/00005072-197210000-00003.Full Text Link to Item
-
Sipe, J. C., N. A. Vick, and D. D. Bigner. “Grey matter edema: the marginal zone of autochthonous virally-induced gliomas.” J Neurol Sci 17, no. 2 (October 1972): 185–91. https://doi.org/10.1016/0022-510x(72)90139-6.Full Text Link to Item
-
Vick, N. A., and D. D. Bigner. “Microvascular abnormalities in virally-induced canine brain tumors. Structural bases for altered blood-brain barrier function.” J Neurol Sci 17, no. 1 (September 1972): 29–39. https://doi.org/10.1016/0022-510x(72)90019-6.Full Text Link to Item
-
Wilfong, R. F., D. D. Bigner, and W. Wechsler. “Susceptibility of inbred Fischer rats to brain tumor induction by Rous sarcoma virus.” Naturwissenschaften 59, no. 8 (August 1972): 371–72. https://doi.org/10.1007/BF00617927.Full Text Link to Item
-
Bigner, D. D., N. A. Vick, J. P. Kvedar, M. S. Mahaley, and E. D. Day. “Virus-cell relationships in dog brain tumors induced with Schmidt-Ruppin Rous sarcoma virus.” Prog Exp Tumor Res 17 (1972): 40–58. https://doi.org/10.1159/000393667.Full Text Link to Item
-
Vick, N. A., and D. D. Bigner. “Some structural aspects of dog brain tumors induced with the Schmidt-Ruppin strain of the Rous sarcoma virus.” Prog Exp Tumor Res 17 (1972): 59–73. https://doi.org/10.1159/000393668.Full Text Link to Item
-
Vick, N. A., D. D. Bigner, and J. P. Kvedar. “The fine structure of canine gliomas and intracranial sarcomas induced by the Schmidt-Ruppin strain of the Rous sarcoma virus.” J Neuropathol Exp Neurol 30, no. 3 (July 1971): 354–67. https://doi.org/10.1097/00005072-197107000-00004.Full Text Link to Item
-
Bigner, D. D., W. H. Olson, and D. E. McFarlin. “Peripheral polyneuropathy, high and low molecular weight IgM, and amyloidosis.” Arch Neurol 24, no. 4 (April 1971): 365–73. https://doi.org/10.1001/archneur.1971.00480340097011.Full Text Link to Item
-
Bigner, D. D., N. A. Vick, J. P. Kvedar, and W. K. Engel. “Correlated virological and ultrastructural study of Schmidt-Ruppin Rous sarcoma virus-induced dog brain tumors.” J Neuropathol Exp Neurol 30, no. 1 (January 1971): 122–23.Link to Item
-
Bigner, D. D., and D. E. McFarlin. “Neurological disorders with abnormalities of immunoglobulin metabolism.” Res Publ Assoc Res Nerv Ment Dis 49 (1971): 260–74.Link to Item
-
Brightman, M. W., T. S. Reese, N. A. Vick, and D. D. Bigner. “A mechanism underlying the lack of a blood-brain barrier to peroxidase in virally induced brain tumors.” J Neuropathol Exp Neurol 30, no. 1 (January 1971): 139–40.Link to Item
-
Bigner, D. D., J. P. Kvedar, N. A. Vick, and W. K. Engel. “An improved method of preparing Schmidt-Ruppin Rous sarcoma virus for brain tumor induction in mammals.” Neurology 20, no. 4 (April 1970): 413.Link to Item
-
Bigner, D. D., G. L. Odom, M. S. Mahaley, and E. D. Day. “Brain tumors induced in dogs by the Schmidt-Ruppin strain of Rous sarcoma virus. Neuropathological and immunological observations.” J Neuropathol Exp Neurol 28, no. 4 (October 1969): 648–80. https://doi.org/10.1097/00005072-196910000-00006.Full Text Link to Item
-
Bigner, D. D., R. B. Fritz, and E. D. Day. “Cerebral physiology in dogs after brain-tumor induction with Schmidt-Ruppin Rous sarcoma virus: experiences with radioiodinated normal and antiviral immunoglobulin G.” J Natl Cancer Inst 43, no. 3 (September 1969): 565–73.Link to Item
-
Mahaley, M. S., E. D. Day, and D. Bigner. “PROBLEMS INHERENT TO THE IN VIVO LOCALIZATION OF ANTI‐BRAIN TUMOR ANTIBODIES.” Annals of the New York Academy of Sciences 159, no. 2 (January 1, 1969): 451–60. https://doi.org/10.1111/j.1749-6632.1969.tb48295.x.Full Text
-
-
Book Sections
-
Chandramohan, V., J. H. Sampson, I. H. Pastan, and D. D. Bigner. “Immunotoxin Therapy for Brain Tumors.” In Translational Immunotherapy of Brain Tumors, 227–60, 2017. https://doi.org/10.1016/B978-0-12-802420-1.00010-7.Full Text
-
Chandramohan, V., L. Sanchez-Perez, Y. He, C. J. Pirozzi, K. L. Congdon, and D. D. Bigner. “Preclinical Immunotherapeutic Animal Models for Brain Tumors.” In Translational Immunotherapy of Brain Tumors, 111–47, 2017. https://doi.org/10.1016/B978-0-12-802420-1.00006-5.Full Text
-
Buckley, A. F., R. E. McLendon, C. J. Wikstrand, and D. D. Bigner. “Biomarker discovery in central nervous system neoplasms: Past, present and future.” In Tumors of the Central Nervous System: Astrocytomas, Hemangioblastomas, and Gangliogliomas, 5:107–19, 2012. https://doi.org/10.1007/978-94-007-2019-0_13.Full Text
-
-
Other Articles
-
Kirby, R., J. Moul, and M. Brawer. “Editorial.” Prostate Cancer and Prostatic Diseases, October 14, 2001. https://doi.org/10.1038/sj.pcan.4500537.Full Text
-
Rasheed, B. K., R. E. McLendon, H. S. Friedman, A. H. Friedman, H. E. Fuchs, D. D. Bigner, and S. H. Bigner. “Chromosome 10 deletion mapping in human gliomas: a common deletion region in 10q25.” Oncogene, June 1, 1995.Link to Item
-
-
Conference Papers
-
Batich, Kristen, Duane Mitchell, Patrick Healy, James Herndon, Gloria Broadwater, Gunn Michael, Min-Nung Huang, et al. “CTIM-10. REPRODUCIBILITY OF CLINICAL TRIALS USING CMV-TARGETED DENDRITIC CELL VACCINES IN PATIENTS WITH GLIOBLASTOMA.” In Neuro Oncology, 23:vi51–vi51. Oxford University Press (OUP), 2021. https://doi.org/10.1093/neuonc/noab196.202.Full Text Open Access Copy Link to Item
-
Beasley, Georgia, Nellie Farrow, Karenia Landa, Maria Angelica Seilm, Sin-Ho Jung, Darell Bigner, Andrea True Kelly, Smita Nair, Matthias Gromeier, and April Salama. “302 A phase I trial of intratumoral PVSRIPO in patients with unresectable treatment refractory melanoma.” In Regular and Young Investigator Award Abstracts. BMJ Publishing Group Ltd, 2020. https://doi.org/10.1136/jitc-2020-sitc2020.0302.Full Text
-
Chandramohan, Vidyalakshmi, Tyler Evangelous, Eric S. Lipp, Bhavna Hora, Darell D. Bigner, Roger E. McLendon, and David M. Ashley. “ANALYSIS OF IMMUNE SIGNATURES IN PEDIATRIC GLIOBLASTOMAS FOR PATIENT STRATIFICATION TO IMMUNOTHERAPY.” In Neuro Oncology, 22:365–365, 2020.Link to Item
-
Mosaheb, Mubeen, Daniel Landi, Elena Dobrikova, Michael Brown, Yuanfan Yang, Jana Cable, Hideho Okada, et al. “GENETICALLY STABLE POLIOVIRUS VECTOR CARRYING H3.3K27M ANTIGEN FOR TREATMENT OF DIFFUSE MIDLINE GLIOMA BY INTRAMUSCULAR INJECTION.” In Neuro Oncology, 22:472–472, 2020.Link to Item
-
Yang, Yuanfan, Michael Brown, Matthias Gromeier, and Darell Bigner. “ONCOLYTIC POLIOVIRUS AS A PROBE FOR MECHANISMS OF IMMUNE RESISTANCE IN GLIOBLASTOMA.” In Neuro Oncology, 22:231–231, 2020.Link to Item
-
Desjardins, Annick, Matthias Gromeier, James Emmett Herndon, Dina Randazzo, Stevie Threatt, Eric S. Lipp, Elizabeth S. Miller, et al. “Oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG): Experience with retreatment of survivors from the phase I trial.” In Journal of Clinical Oncology, 37:101s-101s. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/JCO.2019.37.15_suppl.2060.Full Text Link to Item
-
Desjardins, Annick, Dina Randazzo, Vidya Chandramohan, Katherine Peters, Margaret Johnson, Leslie Thomas, Stevie Threatt, et al. “DOSE ESCALATION TRIAL OF D2C7 IMMUNOTOXIN (D2C7-IT) ADMINISTERED INTRATUMORALLY VIA CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMA (MG).” In Neuro Oncology, 20:vi9–vi9. OXFORD UNIV PRESS INC, 2018. https://doi.org/10.1093/neuonc/noy148.031.Full Text Link to Item
-
Ashley, David, Annick Desjardins, Matthias Gromeier, Andrea Muscat, James Herndon, Allan Friedman, Henry Friedman, et al. “INTRATUMORAL ADMINISTRATION OF AN ONCOLYTIC POLIO/RHINOVIRUS RECOMBINANT (PVSRIPO) IN MALIGNANT GLIOMA PATIENTS: ASSESSMENT OF MUTATIONAL RESPONSE CORRELATES.” In Neuro Oncology, 20:7–7. OXFORD UNIV PRESS INC, 2018.Link to Item
-
Bowie, Michelle, David Ashley, Janell Hostettler, Michael Brown, Jeffrey Bryant, Darell Bigner, Matthias Gromeier, and Smita Nair. “DYSFUNCTIONAL STING PATHWAY SIGNALING COMPROMISES INNATE IMMUNITY IN GLIOBLASTOMA.” In Neuro Oncology, 20:127–28. OXFORD UNIV PRESS INC, 2018.Link to Item
-
Diplas, Bill H., Matthew S. Waitkus, Xujun He, Jackie Brosnan-Cashman, Heng Liu, Lee Chen, Zhaohui Wang, et al. “THE GENOMIC LANDSCAPE OF TRIPLE-NEGATIVE GLIOBLASTOMA.” In Neuro Oncology, 20:102–3. OXFORD UNIV PRESS INC, 2018.Link to Item
-
Diplas, Bill, Matthew Waitkus, Xujun He, Jackie Brosnan-Cashman, Heng Liu, Lee Chen, Zhaohui Wang, et al. “THE GENOMIC LANDSCAPE OF TRIPLE-NEGATIVE GLIOBLASTOMA.” In Neuro Oncology, 20:112–112. OXFORD UNIV PRESS INC, 2018.Link to Item
-
Keir, Stephen, Matthew Waitkus, Martin Roskoski, Henry Friedman, Darell Bigner, Hai Yan, and David Ashley. “ESTABLISHMENT AND PRELIMINARY EVALUATION OF BEVACIZUMAB-RESISTANT GLIOMA XENOGRAFT MODELS.” In Neuro Oncology, 20:275–275. OXFORD UNIV PRESS INC, 2018.Link to Item
-
Thompson, Eric, Daniel Landi, David Ashley, Steve Keir, and Darell Bigner. “BEVACIZUMAB, IRINOTECAN, TEMOZOLOMIDE, TYROSINE KINASE INHIBITION, AND MEK INHIBITION ARE EFFECTIVE AGAINST PLEOMORPHIC XANTHOASTROCYTOMA REGARDLESS OF V600E STATUS.” In Neuro Oncology, 20:102–102. OXFORD UNIV PRESS INC, 2018.Link to Item
-
Thompson, Eric, Michael Brown, Elena Dobrikova, Vijay Ramaswamy, Michael Taylor, Roger McLendon, Vidya Chandramohan, Darell Bigner, and Matthias Gromeier. “POLIOVIRUS RECEPTOR (CD155) EXPRESSION IN PEDIATRIC BRAIN TUMORS MEDIATES ONCOLYSIS OF MEDULLOBLASTOMA AND PLEOMORPHIC XANTHOASTROCYTOMA.” In Neuro Oncology, 20:213–213. OXFORD UNIV PRESS INC, 2018.Link to Item
-
Dombrowski, Stephen, Thamara Abou-Antoun, Anthony Mansour, Rewa Arar, Mohammad Movassaghi, Erin Murphy, Shuvojit Banerjee, et al. “Abstract A47: Inhibition of histone methyltransferase with novel epipolythiodioxopiperazines (ETP) alkaloids in pediatric high-grade glioma.” In Cancer Research, 78:A47–A47. American Association for Cancer Research (AACR), 2018. https://doi.org/10.1158/1538-7445.pedca17-a47.Full Text
-
Brown, Michael C., Eda K. Holl, David Boczkowski, Elena Dobrikova, Mubeen Mosaheb, Vidya Chandramohan, Darell D. Bigner, Matthias Gromeier, and Smita K. Nair. “Abstract A79: Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of antigen-presenting cells and tumor antigen-specific CTLs.” In Cancer Immunology Research, 6:A79–A79. American Association for Cancer Research (AACR), 2018. https://doi.org/10.1158/2326-6074.tumimm17-a79.Full Text
-
Landa, Karenia, Eda Holl, Michael Brown, James Herndon, Lars Grimm, Jeremy Force, Darell Bigner, Shelley Hwang, Matthias Gromeier, and Smita Nair. “Abstract LB-302: Oncolytic poliovirus-mediated inflammation and immunity in breast cancer.” In Cancer Research, Vol. 78. American Association for Cancer Research (AACR), 2018. https://doi.org/10.1158/1538-7445.am2018-lb-302.Full Text
-
Ashley, David M., Eric M. Thompson, Daniel Landi, Annick Desjardins, Allan H. Friedman, Stevie Threatt, James E. Herndon, et al. “PHASE 1B STUDY POLIO VACCINE SABIN-RHINOVIRUS POLIOVIRUS (PVSRIPO) FOR RECURRENT MALIGNANT GLIOMA IN CHILDREN.” In Neuro Oncology, 20:93–93. OXFORD UNIV PRESS INC, 2018.Link to Item
-
Gururangan, Sridharan, Gerald Grant, Tim Driscoll, Gerald Archer, James Herndon, Henry Friedman, Joanne Kurtzberg, Darell Bigner, John Sampson, and Duane Mitchell. “RE-MATCH PROTOCOL: PHASE I STUDY OF AUTOLOGOUS TUMOR SPECIFIC LYMPHOCYTE TRANSFER (ALT) plus DC VACCINE (DCV) DURING RECOVERY FROM MYELOABLATIVE CHEMOTHERAPY (MAC) AND AUTOLOGOUS STEM CELL RESCUE (HDC plus ASCR) OR NON-MYELOABLATIVE CHEMOTHERAPY (NMAC) IN PATIENTS WITH RECURRENT CENTRAL PNETS (R-PNET).” In Neuro Oncology, 20:104–104. OXFORD UNIV PRESS INC, 2018.Link to Item
-
Landi, Daniel, Eric Thompson, Roger McLendon, Annick Desjardins, Vidya Chandramohan, David Ashley, and Darell Bigner. “TARGETING EGFR IN HYPOMUTATED PEDIATRIC BRAIN TUMORS USING THE D2C7 IMMUNOTOXIN.” In Neuro Oncology, 20:103–103. OXFORD UNIV PRESS INC, 2018.Link to Item
-
Roskoski, Martin, Danuta Gasinski, Henry Friedman, Darell Bigner, and Stephen Keir. “EVALUATION OF COBIMETINIB, A MEK INHIBITOR, IN LOW-GRADE PEDIATRIC BRAIN TUMORS.” In Neuro Oncology, 20:104–5. OXFORD UNIV PRESS INC, 2018.Link to Item
-
Kurachi, Y., H. Yamamoto, Y. Nose, S. Shimizu, Y. Tateno, T. Yonemura, and M. Furukawa. “Failure mode analysis of GaN-HEMT under high temperature operation.” In Ieee International Reliability Physics Symposium Proceedings, 2018-March:PWB.31-PWB.34, 2018. https://doi.org/10.1109/IRPS.2018.8353706.Full Text
-
Tateno, Y., Y. Kurachi, H. Yamamoto, and T. Nakabayashi. “Investigation of the pulsed-IV degradation mechanism of GaN-HEMT under high temperature storage tests.” In Ieee International Reliability Physics Symposium Proceedings, 2018-March:PWB.21-PWB.25, 2018. https://doi.org/10.1109/IRPS.2018.8353705.Full Text
-
Force, Jeremy, Eda Holl, Michael Brown, Paul Kelly Marcom, Lars Grimm, David Boczkowski, Victoria Frazier, et al. “Recombinant oncolytic poliovirus combined with checkpoint blockade for breast cancer therapy.” In Journal of Clinical Oncology, 36:e12641–e12641. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.e12641.Full Text
-
Desjardins, Annick, John H. Sampson, Gordana Vlahovic, Katherine B. Peters, Dina Randazzo, Stevie Threatt, James Emmett Herndon, et al. “Dose finding study of the intratumoral administration of the oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG).” In Journal of Clinical Oncology, 35:e13533–e13533. American Society of Clinical Oncology (ASCO), 2017. https://doi.org/10.1200/jco.2017.35.15_suppl.e13533.Full Text Link to Item
-
Randazzo, Dina, Annick Desjardins, Vidyalakshmi Chandramohan, John H. Sampson, Katherine B. Peters, Gordana Vlahovic, Stevie Threatt, et al. “Phase 1 single-center, dose escalation study of D2C7-IT administered intratumorally via convection-enhanced delivery for adult patients with recurrent malignant glioma.” In Journal of Clinical Oncology, 35:e13532–e13532. American Society of Clinical Oncology (ASCO), 2017. https://doi.org/10.1200/JCO.2017.35.15_suppl.e13532.Full Text Link to Item
-
Bao, Xuhui, Stephen T. Keir, Smita K. Nair, Ira Pastan, Darell D. Bigner, and Vidyalakshmi Chandramohan. “A combinatorial immunotherapy for malignant brain tumors: D2C7 immunotoxin and immune checkpoint inhibitors.” In Journal of Clinical Oncology, 35:102–102. American Society of Clinical Oncology (ASCO), 2017. https://doi.org/10.1200/jco.2017.35.7_suppl.102.Full Text
-
Yu, Xin, Stephen T. Keir, Scott Szafranski, Steven Clayton, Ira Pastan, Darell D. Bigner, and Vidyalakshmi Chandramohan. “Immunotoxin and bcl-2 inhibitor combination therapy targeting chondroitin sulfate proteoglycan 4.” In Journal of Clinical Oncology, 35:74–74. American Society of Clinical Oncology (ASCO), 2017. https://doi.org/10.1200/jco.2017.35.7_suppl.74.Full Text
-
Xie, L., M. Fan, Z. Zhang, V. Chandramohan, I. Pastan, D. D. Bigner, and X. Bao. “Anti-Podoplanin Immunotoxin Therapy For Lung Cancer Treatment.” In American Journal of Respiratory and Critical Care Medicine, Vol. 195. AMER THORACIC SOC, 2017.Link to Item
-
Desjardins, Annick, Dina Randazzo, Vidya Chandramohan, John Sampson, Katherine Peters, Gordana Vlahovic, Stevie Threatt, et al. “PHASE I DOSE ESCALATION STUDY OF D2C7-IT ADMINISTERED INTRATUMORALLY VIA CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMA (MG).” In Neuro Oncology, 18:21–22. OXFORD UNIV PRESS INC, 2016.Link to Item
-
Gedeon, Patrick C., Teilo H. Schaller, Carter M. Suryadevara, Bryan D. Choi, Elizabeth A. Reap, Gary E. Archer, Luis Sanchez-Perez, Darell D. Bigner, and John H. Sampson. “A FULLY-HUMAN EGFRvIII-TARGETED BISPECIFIC ANTIBODY REDIRECTS HUMAN T CELLS TO SPECIFICALLY LYSE MALIGNANT GLIOMA.” In Neuro Oncology, 18:96–96. OXFORD UNIV PRESS INC, 2016.Link to Item
-
Holl, E., M. Brown, D. Boczkowski, D. Bigner, M. Gromeier, and S. Nair. “POLIO VIRUS THERAPY HAS IMMUNOSTIMULATORY PROPERTIES THAT ARE ACTIVE AGAINST SOLID TUMORS.” In Cytokine, 87:61–62. ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD, 2016.Link to Item
-
Svalina, Matthew N., Ken Kikuchi, Jinu Abraham, Sangeet Lal, Monika A. Davare, Teagan P. Settelmeyer, Michael C. Young, et al. “IGF1R as a Key Target in High Risk, Metastatic Medulloblastoma.” In Sci Rep, 6:27012, 2016. https://doi.org/10.1038/srep27012.Full Text Link to Item
-
Desjardins, Annick, John H. Sampson, Katherine B. Peters, Gordana Vlahovic, Dina Randazzo, Stevie Threatt, James Emmett Herndon, et al. “Patient survival on the dose escalation phase of the Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG) clinical trial compared to historical controls.” In Journal of Clinical Oncology, 34:2061–2061. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.2061.Full Text Link to Item
-
Vlahovic, Gordana, Gerald E. Archer, Elizabeth Reap, Annick Desjardins, Katherine B. Peters, Dina Randazzo, Patrick Healy, et al. “Phase I trial of combination of antitumor immunotherapy targeted against cytomegalovirus (CMV) plus regulatory T-cell inhibition in patients with newly-diagnosed glioblastoma multiforme (GBM).” In Journal of Clinical Oncology, 34:e13518–e13518. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.e13518.Full Text Link to Item
-
Dombrowski, Stephen, Thamara Abou-Antoun, Stephen Mack, Xiao-Nan Li, Peter Houghton, Darell Bigner, Jeremy Rich, and Violette Recinos. “INHIBITION OF EPIGENETIC REGULATION AS A THERAPY FOR PEDIATRIC HIGH GRADE GLIOMA.” In Neuro Oncology, 17:11–11. OXFORD UNIV PRESS INC, 2015.Link to Item
-
Desjardins, Annick, John H. Sampson, Katherine B. Peters, Gordana Vlahovic, Dina Randazzo, Stevie Threatt, James Emmett Herndon, et al. “Oncolytic polio/rhinovirus recombinant (PVSRIPO) against recurrent glioblastoma (GBM): Optimal dose determination.” In Journal of Clinical Oncology, 33:2068–2068. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.15_suppl.2068.Full Text
-
Vlahovic, Gordana, Gerald E. Archer, Denise Lally-Goss, Elizabeth Reap, Annick Desjardins, Katherine B. Peters, Dina Randazzo, et al. “Phase I study of combination of antitumor immunotherapy targeted against cytomegalovirus (CMV) plus regulatory T-cell inhibition in patients with newly diagnosed glioblastoma multiforme (GBM).” In Journal of Clinical Oncology, 33:e13030–e13030. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.15_suppl.e13030.Full Text
-
Keir, Stephen T., B Ahmed Rasheed, Katherine A. Hoadley, Martin A. Roskoski, Danuta Gasinski, Madan M. Kwatra, Henry S. Friedman, and Dare D. Bigner. “Identification and treatment data of xenografts representing TCGA-defined glioblastoma subtypes.” In Cancer Research, Vol. 75, 2015. https://doi.org/10.1158/1538-7445.AM2015-2435A.Full Text Link to Item
-
Pirozzi, Christopher J., Catherine Y. Wang, Austin B. Carpenter, Huishan Zhu, Paula K. Greer, Roger E. McLendon, Darell D. Bigner, Yiping He, and Hai Yan. “Abstract 63: Driving brain tumorigenesis: Generation of a mutant IDH1 mouse model of progressive glioma.” In Cancer Research, 74:63–63. American Association for Cancer Research (AACR), 2014. https://doi.org/10.1158/1538-7445.am2014-63.Full Text
-
Kuan, C. -. T., I. H. Pastan, and D. D. Bigner. “NEXT-GENERATION RECOMBINANT IMMUNOTOXINS FOR GLIOBLASTOMAS AND MELANOMAS TREATMENT.” In Neuro Oncology, 16:iii43–iii43. Oxford University Press (OUP), 2014. https://doi.org/10.1093/neuonc/nou209.6.Full Text
-
Vaidyanathan, Ganesan, Sri Gururangan, Darell Bigner, and Michael Zalutsky. “PRE-CLINICAL EFFICACY STUDY OF INTRA-THECAL (IT) (LU)-L-177-DOTA-TATE (SOMATOSTATIN ANALOGUE) IN ATHYMIC RATS WITH LEPTOMENINGEAL DISEASE (LMD) FROM MEDULLOBLASTOMA (MBL).” In Neuro Oncology, 16:71–71. OXFORD UNIV PRESS INC, 2014.Link to Item
-
Desjardins, Annick, John Howard Sampson, Katherine B. Peters, Tulika Ranjan, Gordana Vlahovic, Jason Watts, Stevie Threatt, et al. “Phase I study of the intratumoral administration of an oncolytic polio/rhinovirus recombinant (PVSRIPO) in recurrent glioblastoma (GBM).” In Journal of Clinical Oncology, 32:TPS2106–TPS2106. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.tps2106.Full Text
-
Vlahovic, Gordana, Gerald E. Archer, Denise Lally-Goss, Sharon Norman, Annick Desjardins, Katherine B. Peters, Tulika Ranjan, et al. “Regulatory T-cell inhibition plus antitumor immunotherapy targeted against cytomegalovirus (CMV) in patients with newly diagnosed glioblastoma multiforme (GBM).” In Journal of Clinical Oncology, 32:3069–3069. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.3069.Full Text
-
Desjardins, Annick, J. H. Sampson, K. B. Peters, T. Ranjan, G. Vlahovic, S. Threatt, J. E. Herndon, et al. “Intratumoral administration of an Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) in recurrent glioblastoma(GBM): Preliminary results of the Phase I clinical trial.” In Cancer Research, Vol. 74, 2014. https://doi.org/10.1158/1538-7445.AM2014-CT416.Full Text Link to Item
-
Guo, Changcun, Lee H. Chen, Yafen Huang, Chun-chi Chang, Ping Wang, Christopher J. Pirozzi, Xiaoxia Qin, et al. “MLL2 maintains neoplastic cell growth and global histone H3 lysine 4 monomethylation.” In Cancer Research, Vol. 74, 2014. https://doi.org/10.1158/1538-7445.AM2014-LB-82.Full Text Link to Item
-
Han, Lei, Kai-Liang Zhang, Jun-Xia Zhang, Liang Zeng, Chun-Hui Di, Brian Fee, Miriam Rivas, et al. “AJAP1 is dysregulated at an early stage of gliomagenesis and suppresses invasion through cytoskeleton reorganization.” In Cancer Research, Vol. 74, 2014. https://doi.org/10.1158/1538-7445.AM2014-1561.Full Text Link to Item
-
Keir, Stephen T., B Ahmed Rasheed, Katherine A. Hoadley, Martin A. Roskoski, Danuta Gasinski, Patrick J. Killela, Hai Yan, Madan M. Kwatra, Henry S. Friedman, and Darell D. Bigner. “Establishment, identification and treatment data of TCGA glioblatoma xenograft subtypes.” In Cancer Research, Vol. 74, 2014. https://doi.org/10.1158/1538-7445.AM2014-838.Full Text
-
Choi, Bryan, Patrick C. Gedeon, James Herndon, Luis Sanchez-Perez, Duane Mitchell, Darell Bigner, and John Sampson. “A BISPECIFIC ANTIBODY REDIRECTS REGULATORY T CELLS TO KILL TUMOR CELLS THROUGH GRANZYME-DEPENDENT CYTOTOXICITY.” In Neuro Oncology, 15:68–69. OXFORD UNIV PRESS INC, 2013.Link to Item
-
Desjardins, Annick, John Sampson, Katherine Peters, Tulika Ranjan, Gordana Vlahovic, Stevie Threatt, James Herndon, et al. “PHASE 1 STUDY OF AN ONCOLYTIC POLIO/RHINOVIRUS RECOMBINANT (PVSRIPO) AGAINST RECURRENT GLIOBLASTOMA.” In Neuro Oncology, 15:107–8. OXFORD UNIV PRESS INC, 2013.Link to Item
-
Reap, Elizabeth, Gerald Archer, Luis Sanchez-Perez, Pamela Norberg, Robert Schmittling, Smita Nair, Xiuyu Cui, et al. “TARGETING IDH1 MUTATIONS USING PEPTIDE VACCINES IN BRAIN TUMORS.” In Neuro Oncology, 15:71–71. OXFORD UNIV PRESS INC, 2013.Link to Item
-
Vlahovic, Gordana, Annick Desjardins, Katy Peters, Tulika Ranjan, James Herndon, Allan Friedman, Henry Friedman, et al. “FEASIBILITY AND SAFETY STUDY OF GBM STEM CELL TUMOR AMPLIFIED RNA IMMUNOTHERAPY IN RECURRENT GLIOBLASTOMA.” In Neuro Oncology, 15:73–74. OXFORD UNIV PRESS INC, 2013.Link to Item
-
Killela, Patrick, Zachary Reitman, Yuchen Jiao, Roger McLendon, Bert Vogelstein, Darell Bigner, Luis Diaz, and Hai Yan. “Frequent ATRX, CIC, FUBP1 and IDH1 Mutations Refine the Classification of Malignant Gliomas.” In Journal of Neuropathology and Experimental Neurology, 72:542–542. LIPPINCOTT WILLIAMS & WILKINS, 2013.Link to Item
-
Desjardins, Annick, John Howard Sampson, Katherine B. Peters, Tulika Ranjan, Gordana Vlahovic, Stevie Threatt, James Emmett Herndon, et al. “Dose-finding and safety study of an oncolytic polio/rhinovirus recombinant against recurrent glioblastoma.” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013.Link to Item
-
Ranjan, Tulika, Katherine B. Peters, Gordana Vlahovic, Lloyd M. Alderson, James Emmett Herndon, Frances McSherry, Stevie Threatt, et al. “Phase II trial for patients with newly diagnosed glioblastoma (GBM) treated with carmustine wafers followed by concurrent radiation therapy (RT), temozolomide (TMZ), and bevacizumab (BV), then followed by TMZ and BV post-RT.” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013.Link to Item
-
Keir, Stephen T., Martin A. Roskoski, Sabrina Wagner, Ralph Tiedt, Darell D. Bigner, and Henry S. Friedman. “Abstract 2079: Antitumoral activity of INC280 against adult glioblastoma brain tumors xenografts.” In Cancer Research, 73:2079–2079. American Association for Cancer Research (AACR), 2013. https://doi.org/10.1158/1538-7445.am2013-2079.Full Text
-
Chandramohan, Vidyalakshmi, Stephen T. Keir, Xuhui Bao, Ira H. Pastan, Chien-Tsun Kuan, and Darell D. Bigner. “DEVELOPMENT OF A NOVEL, SINGLE-CHAIN, TRISPECIFIC IMMUNOTOXIN, D2C7-Mel-14-PE38KDEL FOR TARGETED PEDIATRIC BRAIN TUMOR THERAPY.” In Neuro Oncology, 15:7–7. OXFORD UNIV PRESS INC, 2013.Link to Item
-
Flores, Catherine, Christina Pham, David Snyder, Luis Sanchez-Perez, Darell Bigner, John Sampson, and Duane Mitchell. “NOVEL ROLE FOR ENHANCING IMMUNOTHERAPY AGAINST PEDIATRIC BRAIN TUMORS USING HEMATOPOIETIC STEM CELLS.” In Neuro Oncology, 15:42–42. OXFORD UNIV PRESS INC, 2013.Link to Item
-
Gromeier, Matthias, Annick Desjardins, John H. Sampson, Stevie J. E. Threatt, James E. Herndon, Allan Friedman, Henry S. Friedman, and Darell D. Bigner. “ONCOLYTIC POLIOVIRUS IMMUNOTHERAPY OF PRIMARY CNS TUMORS.” In Neuro Oncology, 15:20–20. OXFORD UNIV PRESS INC, 2013.Link to Item
-
Guo, Changcun, Chun-Chi Chang, Matthew Wortham, Lee Chen, Dawn Kernagis, Xiaoxia Qin, Young-wook Cho, et al. “GLOBAL IDENTIFICATION OF MLL2-TARGETED LOCI REVEALS MLL2'S ROLE IN DIVERSE SIGNALING PATHWAYS.” In Neuro Oncology, 15:9–9. OXFORD UNIV PRESS INC, 2013.Link to Item
-
Gururangan, Sridharan, Gerald Grant, Tim Driscoll, Gerald Archer, James Herndon, Henry Friedman, Joanne Kurtzberg, Darell Bigner, John Sampson, and Duane Mitchell. “A PHASE I/II STUDY OF ADOPTIVE T-CELL THERAPY (ALT) AND DC VACCINATION (DCV) DURING RECOVERY FROM MYELOABLATIVE CHEMOTHERAPY AND HEMATOPOIETIC STEM CELL TRANSPLANTATION (HDC plus ASCR) OR NON-MYELOABLATIVE CONDITIONING (NMA) IN PATIENTS (PTS) WITH RECURRENT CENTRAL PNETS (RE-MATCH PROTOCOL).” In Neuro Oncology, 15:46–47. OXFORD UNIV PRESS INC, 2013.Link to Item
-
Keir, Stephen, Charles Pegram, Eric Lipp, Ahmed Rasheed, Vidyalakshmi Chandramohan, Chien-Tsun Kuan, Madan Kwatra, Hai Yan, and Darell Bigner. “ESTABLISHMENT OF SEVEN NEW PERMANENT PEDIATRIC BRAIN TUMOR LINES.” In Neuro Oncology, 15:10–10. OXFORD UNIV PRESS INC, 2013.Link to Item
-
Kuan, Chien-Tsun, Vidyalakshmi Chandramohan, Stephen Keir, Ira Pastan, and Darell Bigner. “GENERATION OF ANTI-PDGFR alpha IMMUNOTOXINS FOR BRAINSTEM GLIOMA TREATMENT.” In Neuro Oncology, 15:39–40. OXFORD UNIV PRESS INC, 2013.Link to Item
-
Pham, Christina D., Yanxin Pei, Catherine Flores, David Snyder, Darell D. Bigner, John H. Sampson, Robert J. Wechsler-Reya, and Duane A. Mitchell. “DEVELOPMENTALLY REGULATED ANTIGENS FOR IMMUNOLOGIC TARGETING OF MEDULLOBLASTOMA SUBTYPES.” In Neuro Oncology, 15:42–43. OXFORD UNIV PRESS INC, 2013.Link to Item
-
Sayour, Elias, Christina Pham, Luis Sanchez-Perez, David Snyder, Catherine Flores, Hanna Kemeny, Weihua Xie, et al. “RNA NANOPARTICLE VACCINES RE-DIRECT HOST-IMMUNITY AGAINST INTRACRANIAL MALIGNANCIES.” In Neuro Oncology, 15:36–36. OXFORD UNIV PRESS INC, 2013.Link to Item
-
Wortham, Matthew, Zach Reitman, Yiping He, Darell Bigner, and Hai Yan. “ABERRANT Otx2 EXPRESSION ENHANCES MIGRATION AND INDUCES ECTOPIC PROLIFERATION OF HINDBRAIN NEURONAL PROGENITOR CELLS.” In Neuro Oncology, 15:2–2. OXFORD UNIV PRESS INC, 2013.Link to Item
-
Desjardins, Annick, John Howard Sampson, Katherine B. Peters, Tulika Ranjan, Gordana Vlahovic, Stevie Threatt, James Emmett Herndon, et al. “Dose-finding and safety study of an oncolytic polio/rhinovirus recombinant against recurrent glioblastoma.” In Journal of Clinical Oncology, Vol. 31, 2013.Link to Item
-
Keir, Stephen T., Martin A. Roskoski, Michael Kragh, Mikkel W. Pederson, Helle J. Jacobsen, Ivan D. Horak, Henry S. Friedman, and Darell D. Bigner. “Efficacy of Sym004, a novel anti-EGFR antibody mixture, against EGFRvIII positive glioblastoma xenografts.” In Cancer Research, Vol. 73, 2013. https://doi.org/10.1158/1538-7445.AM2013-4322.Full Text Link to Item
-
Shao, H., J. Chung, L. Balaj, A. Charest, D. D. Bigner, B. S. Carter, F. H. Hochberg, X. O. Breakefield, R. Weissleder, and H. Lee. “443 Protein Typing of Circulating Microvesicles Allows Real-time Monitoring of Glioblastoma Therapy.” In European Journal of Cancer, 48:137–38. Elsevier BV, 2012. https://doi.org/10.1016/s0959-8049(12)72241-4.Full Text
-
Archer, Gary E., Weihua Xie, Pamela Norberg, Anjelika Dechkovskaia, Allan Friedman, Darell D. Bigner, Duane A. Mitchell, John H. Sampson, and David Boczkowski. “FEASIBILITY OF AMPLIFIED CD133((+)) BRAIN TUMOR STEM CELL RNA-PULSED DENDRITIC CELLS FOR THE TREATMENT OF PATIENTS WITH RECURRENT GLIOBLASTOMA.” In Neuro Oncology, 14:49–49. OXFORD UNIV PRESS INC, 2012.Link to Item
-
Brown, Kristine E., Stephen T. Keir, John H. Sampson, Darell D. Bigner, and Madan M. Kwatra. “NEUROKININ-1 RECEPTOR: A POTENTIAL TARGET TO INHIBIT PEDIATRIC GLIOBLASTOMAS.” In Neuro Oncology, 14:17–18. OXFORD UNIV PRESS INC, 2012.Link to Item
-
Choi, Bryan D., Chien-Tsun Kuan, Mingqing Cai, Darell D. Bigner, and John H. Sampson. “INTRAVENOUS TREATMENT WITH AN ENDOTHELIAL GROWTH FACTOR RECEPTOR VIII-TARGETED BISPECIFIC ANTIBODY SUCCESSFULLY TREATS WELL-ESTABLISHED BRAIN TUMORS.” In Neuro Oncology, 14:38–39. OXFORD UNIV PRESS INC, 2012.Link to Item
-
Desjardins, Annick, Katherine B. Peters, James E. Herndon, Leigh Ann Bailey, Lloyd M. Alderson, Tulika Ranjan, John H. Sampson, et al. “NEWLY DIAGNOSED GLIOBLASTOMA TREATED WITH GLIADEL (R) FOLLOWED BY RADIATION THERAPY (RT), TEMOZOLOMIDE AND BEVACIZUMAB, AND POST-RT BEVACIZUMAB AND TEMOZOLOMIDE: A PHASE II STUDY.” In Neuro Oncology, 14:104–104. OXFORD UNIV PRESS INC, 2012.Link to Item
-
Flores, Catherine T., David Snyder, Luis Sanchez-Perez, Christina Pham, Henry Friedman, Darell D. Bigner, John H. Sampson, and Duane A. Mitchell. “ROLE OF HEMATOPOIETIC STEM CELLS IN ENHANCING THE ANTI-TUMOR EFFICACY OF ADOPTIVE CELLULAR THERAPY.” In Neuro Oncology, 14:35–35. OXFORD UNIV PRESS INC, 2012.Link to Item
-
Keir, Stephen T., Henry S. Friedman, and Darell D. Bigner. “EZN-2208, A NOVEL PEGYLATED SN38 DRUG CONJUGATE, MARKEDLY INHIBITS TUMOR GROWTH IN COMPARISON TO IRINOTECAN.” In Neuro Oncology, 14:29–29. OXFORD UNIV PRESS INC, 2012.Link to Item
-
Mitchell, Duane A., Gary Archer, Darrel Bigner, Henry Friedman, Denise Lally-Goss, Beth Perry, James Herndon, et al. “DENDRITIC CELL VACCINES TARGETING HUMAN CYTOMEGALOVIRUS IN GLIOBLASTOMA REVEAL LYMPH NODE HOMING AS A MAJOR AXIS FOR CLINICAL INTERVENTION.” In Neuro Oncology, 14:47–47. OXFORD UNIV PRESS INC, 2012.Link to Item
-
Mitchell, Duane A., Sridharan Gururangan Gururangan, Gerald Grant, Tim Driscoll, Gary Archer, Jennifer King, Dave Boczkowski, et al. “ADOPTIVE CELLULAR THERAPY TARGETING RECURRENT MEDULLOBLASTOMA AND PRIMITIVE NEUROECTODERMAL TUMORS AFTER MYELOABLATIVE AND NON-MYELOABLATIVE CONDITIONING.” In Neuro Oncology, 14:49–49. OXFORD UNIV PRESS INC, 2012.Link to Item
-
Nair, Smita, Robert Schmittling, David Boczkowski, Gerald Archer, Darell D. Bigner, John H. Sampson, and Duane A. Mitchell. “TARGETING CYTOMEGALOVIRUS ANTIGENS FOR GLIOBLASTOMA IMMUNOTHERAPY.” In Neuro Oncology, 14:32–32. OXFORD UNIV PRESS INC, 2012.Link to Item
-
Pham, Christina D., Catherine Flores, David Snyder, Darrel D. Bigner, John H. Sampson, and Duane A. Mitchell. “DEVELOPMENT OF IMMUNOCOMPETENT SYNGENEIC MODELS OF MEDULLOBLASTOMA FOR EVALUATION OF IMMUNOTHERAPY.” In Neuro Oncology, 14:163–163. OXFORD UNIV PRESS INC, 2012.Link to Item
-
Sanchez-Perez, Luis, Bryan Choi, David Snyder, Xiuyu Cui, Robert J. Schmittling, Catherine Flores, Laura Johnson, et al. “MYELOABLATIVE TEMOZOLOMIDE INCREASES ANTIGEN-SPECIFIC CD8(+) T-CELL VACCINE RESPONSES AND IS REQUIRED FOR EFFICACIOUS IMMUNOTHERAPY AGAINST INTRACEREBRAL TUMORS.” In Neuro Oncology, 14:40–40. OXFORD UNIV PRESS INC, 2012.Link to Item
-
Sayour, Elias J., Luis Sanchez-Perez, Christina Pham, David Snyder, Weihua Xie, Xiuyu Cui, Darell D. Bigner, John H. Sampson, and Duane A. Mitchell. “DEVELOPING RNA NANOPARTICLE VACCINES TARGETING PEDIATRIC AND ADULT BRAIN TUMORS.” In Neuro Oncology, 14:39–39. OXFORD UNIV PRESS INC, 2012.Link to Item
-
Sayour, Elias J., Pat McLendon, Renee Reynolds, Darell D. Bigner, John H. Sampson, Roger McLendon, and Duane A. Mitchell. “ASSESSMENT OF INTRATUMORAL TREGS AND CLINICAL OUTCOMES IN PRIMARY AND RECURRENT GLIOBLASTOMA.” In Neuro Oncology, 14:39–39. OXFORD UNIV PRESS INC, 2012.Link to Item
-
Keir, Stephen, Julia Saling, Martin Roskoski, Henry Friedman, and Darell Bigner. “EFFICACY OF COMBINATION THERAPY WITH PONATINIB (AP24534) +/- BEVACIZUMAB AGAINST PEDIATRIC GLIOBLASTOMA.” In Neuro Oncology, 14:57–57. OXFORD UNIV PRESS INC, 2012.Link to Item
-
Antoun, Gamil R., R. McLendon, H. Friedman, A. Friedman, D. Bigner, and F. Ali-Osman. “The mutational status of the p53 tumor suppressor gene is a determinant of GSTP1 expression and mediates GSTP1-dependent drug resistance in human glioblastoma.” In Cancer Research, Vol. 72, 2012. https://doi.org/10.1158/1538-7445.AM2012-1177.Full Text Link to Item
-
Hedegaard, Chris J., Charles N. Pegram, Darell D. Bigner, and Hans S. Poulsen. “Internalization of the dual-specific immunotoxin D2C7-(scdsFv)-PE38KDEL in malignant glioma cell lines.” In Cancer Research, Vol. 72, 2012. https://doi.org/10.1158/1538-7445.AM2012-2732.Full Text Link to Item
-
Wortham, Matthew, Genglin Jin, Julia Lailai Sun, Dare D. Bigner, and Hai Yan. “The medulloblastoma oncogene Otx2 enhances migration and permits ectopic proliferation of neuronal progenitor cells of the cerebellum and brainstem.” In Cancer Research, Vol. 72, 2012. https://doi.org/10.1158/1538-7445.AM2012-3352.Full Text Link to Item
-
Batinic-Haberle, Ines, Stephen T. Keir, Zrinka Rajic, Artak Tovmasyan, and Darell D. Bigner. “Lipophilic Mn Porphyrins in the Treatment of Brain Tumors.” In Free Radical Biology and Medicine, 51:S119–20. Elsevier BV, 2011. https://doi.org/10.1016/j.freeradbiomed.2011.10.309.Full Text
-
Ayriss, Joanne, Ralph Reisfeld, Chien-Tsun Kuan, Steve Keir, Ira Pastan, and Darell Bigner. “MEL-14 AND 9.2.27 IMMUNOTOXINS: PROMISING THERAPEUTICS FOR PEDIATRIC GLIOMA.” In Neuro Oncology, 13:I6–7. OXFORD UNIV PRESS INC, 2011.Link to Item
-
Buckley, Anne, Danielle Miltz, Brent Asrican, Darell Bigner, and Chay Kuo. “CHEMICAL SCREEN FOR PROLIFERATION AND MIGRATION EFFECTS ON SVZ NEURAL STEM CELLS AND BRAIN TUMOR CELLS.” In Neuro Oncology, 13:I21–22. OXFORD UNIV PRESS INC, 2011.Link to Item
-
Buckley, Anne, Patricia Paez-Gonzalez, Cassie Ludwig, Alexander Lazarides, Darell Bigner, and Chay Kuo. “MAPPING MONOCILIATED AND MULTICILIATED FOURTH VENTRICULAR WALL CELLS AS THE ORIGIN OF CLASSIC PEDIATRIC MEDULLOBLASTOMAS.” In Neuro Oncology, 13:I14–I14. OXFORD UNIV PRESS INC, 2011.Link to Item
-
Cai, Mingqing, Bryan Choi, John Sampson, Chien-Tsun Kuan, and Darell Bigner. “A BISPECIFIC T-CELL ENGAGER EFFECTIVELY ERADICATES EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION VARIANT III (EGFRvIII)-EXPRESSING GLIOBLASTOMA MULTIFORME.” In Neuro Oncology, 13:I9–10. OXFORD UNIV PRESS INC, 2011.Link to Item
-
Cao, Xinyu, Hu Zhu, Darell Bigner, Francis Ali-Osman, and Hui-Wen Lo. “GAIN-OF-FUNCTION tGLI1 TRANSCRIPTION FACTOR AUGMENTS ANCHORAGE-INDEPENDENT GROWTH OF MEDULLOBLASTOMA CELLS AND CONFERS THEIR RESISTANCE TO SMO INHIBITORS.” In Neuro Oncology, 13:I9–I9. OXFORD UNIV PRESS INC, 2011.Link to Item
-
Cao, Xinyu, Hu Zhu, Darell Bigner, Francis Ali-Osman, and Hui-Wen Lo. “EGFR AND EGFRvIII UNDERGO STRESS- AND EGFR KINASE INHIBITOR-INDUCED MITOCHONDRIAL TRANSLOCALIZATION IN GLIOBLASTOMA: A POTENTIAL MECHANISM OF EGFR- AND EGFRvIII-DRIVEN ANTAGONISM OF APOPTOSIS AND DRUG RESPONSE.” In Neuro Oncology, 13:I8–9. OXFORD UNIV PRESS INC, 2011.Link to Item
-
Chandramohan, Vidyalakshmi, Mika Kato Kaneko, Yukinari Kato, Charles N. Pegram, Stephen T. Keir, Ira H. Pastan, Chien-Tsun Kuan, and Darell D. Bigner. “CONSTRUCTION OF A NOVEL ANTIPODOPLANIN (NZ-1) IMMUNOTOXIN FOR BRAIN TUMOR THERAPY.” In Neuro Oncology, 13:I26–I26. OXFORD UNIV PRESS INC, 2011.Link to Item
-
Gururangan, Sridharan, Gerald Grant, Timothy Driscoll, Herbert Fuchs, Renee Reynolds, Smita Nair, Laura Johnson, et al. “ADOPTIVE CELLULAR THERAPY DURING RECOVERY FROM TREATMENT-INDUCED LYMPHOPENIA IN PEDIATRIC PATIENTS WITH RECURRENT MEDULLOBLASTOMA AND PNETs.” In Neuro Oncology, 13:I34–I34. OXFORD UNIV PRESS INC, 2011.Link to Item
-
Keir, Stephen, Darell Bigner, and Henry Friedman. “DOES TUMOR MICROVASCULATURE IMPACT RESPONSE TO BEVACIZUMAB IN COMBINATION WITH TEMOZOLOMIDE AGAINST BRAIN TUMOR XENOGRAFTS?” In Neuro Oncology, 13:I20–I20. OXFORD UNIV PRESS INC, 2011.Link to Item
-
Keir, Stephen, David Reardon, Henry Friedman, and Darell Bigner. “EFFICACY OF AP24534 (PONATINIB) +/- BEVACIZUMAB AGAINST PEDIATRIC GLIOBLASTOMA.” In Neuro Oncology, 13:I7–I7. OXFORD UNIV PRESS INC, 2011.Link to Item
-
Keir, Stephen, Henry Friedman, and Darell Bigner. “EFFICACY OF BEVACIZUMAB +/- TEMOZOLOMIDE AGAINST PEDIATRIC GLIOMAS.” In Neuro Oncology, 13:I6–I6. OXFORD UNIV PRESS INC, 2011.Link to Item
-
Keir, Stephen, Sri Gururangan, David Reardon, Darell Bigner, and Henry Friedman. “INHIBITION OF TUMOR GROWTH IN PEDIATRIC BRAIN TUMOR XENOGRAFTS TREATED WITH LBH589 (PANOBINOSTAT).” In Neuro Oncology, 13:I4–I4. OXFORD UNIV PRESS INC, 2011.Link to Item
-
Kuan, Chien-Tsun, Jianjun Li, Vidyalakshmi Chandramohan, Jinli Chang, and Darell Bigner. “ESTABLISHMENT OF AND PROOF OF CONCEPT FOR A HUMAN PEDIATRIC BRAINSTEM GLIOMA XENOGRAFT MODEL.” In Neuro Oncology, 13:I7–I7. OXFORD UNIV PRESS INC, 2011.Link to Item
-
Parsons, Donald W., Hai Yan, Darell D. Bigner, Michael D. Taylor, Tom Curran, Mitchel S. Berger, and Victor E. Velculescu. “THE GENETIC LANDSCAPE OF MEDULLOBLASTOMA.” In Neuro Oncology, 13:I28–29. OXFORD UNIV PRESS INC, 2011.Link to Item
-
Piao, Hailan, Charles N. Pegram, Chien-Tsun Kuan, and Darell D. Bigner. “GANGLIOSIDE EXPRESSION IN PEDIATRIC BRAIN TUMOR CELL LINES AND DEVELOPMENT OF ANTIGANGLIOSIDE scFv BY AFFINITY MATURATION.” In Neuro Oncology, 13:I7–I7. OXFORD UNIV PRESS INC, 2011.Link to Item
-
Reitman, Zachary J., Genglin Jin, Edward D. Karoly, Ivan Spasojevic, Jian Yang, Kenneth W. Kinzler, Yiping He, Darell D. Bigner, Bert Vogelstein, and Hai Yan. “METABOLOMIC PROFILING OF A GLIOMA CELL LINE EXPRESSING IDH1 AND IDH2 MUTANTS.” In Neuro Oncology, 13:I22–23. OXFORD UNIV PRESS INC, 2011.Link to Item
-
Vaidyanathan, Ganesan, Jianjun Li, Darell D. Bigner, and Michael R. Zalutsky. “TARGETED RADIOTHERAPY OF MEDULLOBLASTOMA USING SOMATOSTATIN RECEPTOR AVID RADIOLABELED PEPTIDES.” In Neuro Oncology, 13:I27–I27. OXFORD UNIV PRESS INC, 2011.Link to Item
-
Wortham, Matthew, David C. Adamson, Qun Shi, Paul Northcott, Chunhui Di, Christopher Duncan, Jianjun Li, et al. “OTX2 IS A PREVALENT BUT TARGETABLE ONCOGENE IN Shh-INDEPENDENT MEDULLOBLASTOMAS.” In Neuro Oncology, 13:I30–I30. OXFORD UNIV PRESS INC, 2011.Link to Item
-
Zhu, Hu, Xinyu Cao, Steve Keir, Darell Bigner, Francis Ali-Osman, and Hui-Wen Lo. “UPREGULATION OF VEGF-A GENE EXPRESSION BY THE tGLI1 TRANSCRIPTION FACTOR CONTRIBUTES TO GLIOBLASTOMA ANGIOGENESIS.” In Neuro Oncology, 13:I15–16. OXFORD UNIV PRESS INC, 2011.Link to Item
-
Yan, Hai, Zachary J. Reitman, Genglin Jin, Ivan Spasojevic, Yiping He, Dare D. Bigner, Edward D. Karoly, Jian Yang, Kenneth W. Kinzler, and Bert Vogelstein. “Profiling the effects of IDH1 and IDH2 mutants on the glioma cell metabolome.” In Cancer Research, Vol. 71, 2011. https://doi.org/10.1158/1538-7445.AM2011-LB-257.Full Text Link to Item
-
Karakoula, Katherine, Darell D. Bigner, Steven Keir, David G. Thomas, John Darling, and Tracy Warr. “GENOME-WIDE PROFILING OF PAEDIATRIC CNS TUMOR XENOGRAFTS BY EXPRESSION AND HIGH-RESOLUTION CGH MICROARRAYS.” In Neuro Oncology, 12:84–84. OXFORD UNIV PRESS INC, 2010.Link to Item
-
Keir, Stephen T., David A. Reardon, Mark Watson, Gordon C. Shore, Darell D. Bigner, and Henry S. Friedman. “ACTIVITY OF GMX1777 AGAINST A PANEL OF BRAIN TUMOR XENOGRAFTS.” In Neuro Oncology, 12:99–99. OXFORD UNIV PRESS INC, 2010.Link to Item
-
Keir, Stephen T., Sri Gururangan, David A. Reardon, Darell D. Bigner, and Henry S. Friedman. “EFFICACY OF LBH589 (PANOBINOSTAT) AGAINST A PANEL OF PEDIATRIC BRAIN TUMOR XENOGRAFTS.” In Neuro Oncology, 12:99–99. OXFORD UNIV PRESS INC, 2010.Link to Item
-
Karakoula, A., D. Bigner, S. Keir, D. Thomas, and T. Warr. “GENETIC PROFILING IN TUMOUR XENOGRAFTS FROM PAEDIATRIC GLIOMAS BY EXPRESSION AND HIGH RESOLUTION COMPARATIVE GENOMIC HYBRIDISATION MICROARRAYS.” In Neuro Oncology, 12:3–3. OXFORD UNIV PRESS INC, 2010.Link to Item
-
Ali-Osman, Francis, Kouros Owzar, Bartley Adams, Eric Lipp, James Herdon, Dora Illyasova, Faith Davis, et al. “GENETIC DIVERSITY ASSOCIATED WITH SURVIVAL IN MALIGNANT GLIOMAS IDENTIFIED BY LINKAGE DISEQUILIBRIUM-BASED ANALYSIS OF HAPLOTYPE BLOCK REGIONS OF DNA REPAIR GENES.” In Neuro Oncology, 11:891–891. OXFORD UNIV PRESS INC, 2009.Link to Item
-
Davis, Faith G., Dora Il’yasova, Kristin M. Rankin, Bridget J. McCarthy, Serap Erdal, Juliana F. M. Lewis, Umaima Al-Alem, and Darell Bigner. “Environmental Exposures and Adult Brain Cancers.” In Epidemiology, 20:S149–S149. Ovid Technologies (Wolters Kluwer Health), 2009. https://doi.org/10.1097/01.ede.0000362509.72737.c1.Full Text
-
Heimberger, A. B., G. E. Archer, D. A. Mitchell, D. D. Bigner, R. J. Schmittling, J. E. Herndon, T. Davis, et al. “Epidermal growth factor receptor variant III (EGFRvIII) vaccine ( CDX-110) in GBM.” In Journal of Clinical Oncology, Vol. 27. AMER SOC CLINICAL ONCOLOGY, 2009.Link to Item
-
Herndon, J., J. Vredenburgh, D. Reardon, A. Desjardins, K. Peters, S. Gururangan, J. Norfleet, A. Friedman, D. Bigner, and H. S. Friedman. “Phase I trial of vendetanib and oral etoposide for recurrent malignant gliomas.” In Journal of Clinical Oncology, Vol. 27. AMER SOC CLINICAL ONCOLOGY, 2009.Link to Item
-
Peters, K., A. Desjardins, D. A. Reardon, S. Perry, J. E. Herndon, L. Bailey, A. H. Friedman, H. S. Friedman, D. D. Bigner, and J. J. Vredenburgh. “Temozolomide (TMZ) and bevacizumab (BV) as initial treatment for unresectable or multifocal glioblastoma multiforme (GBM).” In Journal of Clinical Oncology, Vol. 27. AMER SOC CLINICAL ONCOLOGY, 2009.Link to Item
-
Sampson, J. H., G. E. Archer, D. D. Bigner, R. J. Schmittling, J. E. Herndon, T. Davis, H. S. Friedman, T. Keler, D. A. Reardon, and D. A. Mitchell. “Effect of daclizumab on T-Reg counts and EGFRvIII-specific immune responses in GBM.” In Journal of Clinical Oncology, Vol. 27. AMER SOC CLINICAL ONCOLOGY, 2009.Link to Item
-
Kato, Yukinari, Kazuhiko Mishima, Mika Kaneko, Michael Zalutsky, Chien-Tsun Kuan, and Darell Bigner. “Podoplanin is a novel antibody-based therapeutic target for glioblastoma.” In Cancer Research, Vol. 69. AMER ASSOC CANCER RESEARCH, 2009.Link to Item
-
Mitchell, Duane A., Gary E. Archer, Darell D. Bigner, Henry S. Friedman, Denise Lally-Goss, Beth Perry, James E. Herndon, et al. “RNA Transfected Dendritic Cell Vaccines Targeting Human Cytomegalovirus Antigens in Patients with Glioblastoma.” In Molecular Therapy, 17:S93–S93. NATURE PUBLISHING GROUP, 2009.Link to Item
-
Davis, F. G., B. J. McCarthy, S. Erdal, D. Il’yasova, J. Mendes, K. Rankin, and D. Bigner. “Environmental Exposures and Adult Brain Cancers.” In Epidemiology, 19:S276–S276. LIPPINCOTT WILLIAMS & WILKINS, 2008.Link to Item
-
Archer, Gary, Amy Heimberger, Darell Bigner, Tom Davis, Henry Friedman, Alan Friedman, Tibor Keler, et al. “THE POSITIVE INFLUENCE OF TEMOZOLOMIDE ON THE HUMORAL AND CELL-MEDIATED (DTH) RESPONSES TO EGFRVIII-TARGETED VACCINE (CDX-110) IN PATIENTS WITH GBM.” In Neuro Oncology, 10:810–810. OXFORD UNIV PRESS INC, 2008.Link to Item
-
Duncan, Chris, Rebecca Leary, Jordan Cummins, Chunhui Di, Tian-Li Wang, Darell Bigner, Levy Kopelovich, Bert Vogelstein, Victor Velculescu, and Hai Yan. “IDENTIFICATION OF MICROBIAL DNAS IN BRAIN TUMORS.” In Neuro Oncology, 10:800–800. OXFORD UNIV PRESS INC, 2008.Link to Item
-
Killela, Patrick, Chris Duncan, Roger Mclendon, Darell Bigner, and Hai Yan. “GENOMIC LANDSCAPE OF GLIOBLASTOMA.” In Neuro Oncology, 10:800–801. OXFORD UNIV PRESS INC, 2008.Link to Item
-
Mitchell, Duane, Gary Archer, Darell Bigner, Henry Friedman, Denise Lally-Goss, Beth Perry, James Herndon, et al. “EFFICACY AND IMMUNOLOGIC EFFECTS OF RNA-PULSED DENDRITIC CELL VACCINES TARGETING HUMAN CYTOMEGALOVIRUS ANTIGENS IN PATIENTS WITH GLIOBLASTOMA.” In Neuro Oncology, 10:814–814. OXFORD UNIV PRESS INC, 2008.Link to Item
-
Okamura, Tatsunori, Simendra Singh, Darell Bigner, and Francis Ali-Osman. “LIGAND-DEPENDENT ACTIVATION OF THE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INDUCES EARLY DRUG RESISTANCE IN BRAIN TUMOR CELLS VIA ACTIVATION OF ITS DOWNSTREAM TARGET GLUTATHIONE S-TRANSFERASE P1.” In Neuro Oncology, 10:782–782. OXFORD UNIV PRESS INC, 2008.Link to Item
-
Reardon, D., A. Ezrin, Brian Brohman, J. Karjalainen, H. Dulude, J. Warren, M. Zalutsky, and D. Bigner. “AN UPDATE ON THE EFFECTS OF NEURADIAB ON PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM).” In Neuro Oncology, 10:845–845. OXFORD UNIV PRESS INC, 2008.Link to Item
-
Silber, Joachim, Tristan Felix, Sujatmi Hariono, Nalin Gupta, C David James, Darell Bigner, and Graeme Hodgson. “MIR-124 INHIBITS CDK6 AND INDUCES G(1) CELL CYCLE ARREST IN MEDULLOBLASTOMA CELLS.” In Neuro Oncology, 10:872–73. OXFORD UNIV PRESS INC, 2008.Link to Item
-
Vredenburgh, James, Annick Desjardins, David Reardon, Jeremy Rich, John Kirkpatrick, Sridharan Gururangan, Leighann Bailey, Allan Friedman, Darell Bigner, and Henry Friedman. “BEVACIZUMAB IN COMBINATION WITH TEMOZOLOMIDE AND RADIATION THERAPY FOLLOWED BY BEVACIZUMAB, TEMOZOLOMIDE, AND IRINOTECAN FOR NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME.” In Neuro Oncology, 10:836–37. OXFORD UNIV PRESS INC, 2008.Link to Item
-
Chandramohan, Vidyalakshmi, Charles N. Pegram, Scott E. Szafranski, Stephen T. Keir, Ira Pastan, Chien-Tsun Kuan, and Darell D. Bigner. “Dual-specific antibody, D2C7 (SCDSFV)-PE38KDEL for brain tumor therapy.” In Neuro Oncology, 10:379–379. DUKE UNIV PRESS, 2008.Link to Item
-
Chandramohan, Vidyalakshmi, Charles N. Pegram, Stephen T. Keir, Chien-Tsun Kuan, and Darell D. Bigner. “Identification of antigens on cancer stem cells for brain tumor therapy.” In Neuro Oncology, 10:384–384. DUKE UNIV PRESS, 2008.Link to Item
-
Chang, Jinli, Jianjun Li, Nidhi Srivastava, Stephen T. Keir, C David James, Darell D. Bigner, and Chien-Tsun Kuan. “In vivo bioluminescence imaging of luciferase-expressing pediatric brain tumor xenografts in rodent models.” In Neuro Oncology, 10:509–509. DUKE UNIV PRESS, 2008.Link to Item
-
Piao, Hailan, Charles N. Pegram, Darell D. Bigner, and Chien-Tsun Kuan. “Ganglioside expression in pediatric brain tumor xenograft lines.” In Neuro Oncology, 10:381–82. DUKE UNIV PRESS, 2008.Link to Item
-
Srivastava, Nidhi, Tracy Warr, Charles Pegram, Stephen Keir, Ahmed Rasheed, Roger Mclendon, Chien-Tsun Kuan, and Darell Bigner. “Establishment and characterization of cell lines and transplantable xenografts from pediatric brain tumors.” In Neuro Oncology, 10:380–380. DUKE UNIV PRESS, 2008.Link to Item
-
Yan, Hai, Cory Adamson, Qun Shi, Chunhui Di, Chris Duncan, Roger Mclendon, and Darell Bigner. “The oncogenic role of OTX2 in medulloblastoma pathogenesis and its clinical implications as a tumor marker and therapeutic target.” In Neuro Oncology, 10:390–390. DUKE UNIV PRESS, 2008.Link to Item
-
Mitchell, Duane, Gary Archer, Darell Bigner, Annick Desjardins, Allan Friedman, Henry Friedman, Denise Lally-Goss, et al. “Efficacy and immunologic effects of RNA-pulsed dendritic cell vaccines targeting human cytomegalovirus antigens in patients with glioblastoma.” In Cancer Research, Vol. 68. AMER ASSOC CANCER RESEARCH, 2008.Link to Item
-
Archer, Gary, Duane Mitchell, Amy Heimberger, Henry Friedman, David Reardon, James Vredenburgh, Mark Gilbert, et al. “Temozolomide therapy induces an increase in regulatory T-cells without abbrogating a specific tumor.” In Neuro Oncology, 9:509–509. DUKE UNIV PRESS, 2007.Link to Item
-
Graner, Michael, Anjelika Dechkovskaia, Ling Wang, Ian Cumming, and Darell Bigner. “Characterization of brain tumor exosomes: Biology, biochemistry, immumology.” In Neuro Oncology, 9:501–501. DUKE UNIV PRESS, 2007.Link to Item
-
Li, Jianjun, Gerald Grant, Charles Pegram, and Darell Bigner. “In vivo characterization of the blood-brain and blood-tumor barrier in orthotopic xenograft tumors derived from adult and pediatric malignant gliomas.” In Neuro Oncology, 9:486–87. DUKE UNIV PRESS, 2007.Link to Item
-
Mitchell, Duane, Gary Archer, Darell Bigner, Allan Friedman, Henry Friedman, David Reardon, James Vredenburgh, James Herndon, Roger McLendon, and John Sampson. “RNA-loaded dendritic cells targeting cytomegalovirus in patients with malignant glioma.” In Neuro Oncology, 9:509–509. DUKE UNIV PRESS, 2007.Link to Item
-
Northcott, Paul, Yukiko Nakahara, John Peacock, David Ellison, Sidney Croul, Lars Feuk, Paul Kongkham, et al. “Multiple recurrent genetic events converge on proper control of histone 3 lysine 9 methylation in pediatric medulloblastoma.” In Neuro Oncology, 9:554–554. OXFORD UNIV PRESS INC, 2007.Link to Item
-
Northcott, Paul, Yukiko Nakahara, John Peacock, David Ellison, Sidney Croul, Lars Feuk, Paul Kongkham, et al. “Identification of known and novel recurrent amplified oncogenes in pediatric medulloblastoma.” In Neuro Oncology, 9:554–554. OXFORD UNIV PRESS INC, 2007.Link to Item
-
Yan, Hai, Qun Shi, Chunhui Di, Chris Duncan, and Darell Bigner. “Deregulation of an extraordinarily important developmental gene promotes medulloblastoma tumorigenesis.” In Neuro Oncology, 9:555–555. DUKE UNIV PRESS, 2007.Link to Item
-
Sampson, J. H., K. D. Aldape, M. R. Gilbert, S. J. Hassenbusch, R. Sawaya, B. Schmittling, G. E. Archer, et al. “Temozolomide as a vaccine adjuvant in GBM.” In Journal of Clinical Oncology, Vol. 25. AMER SOC CLINICAL ONCOLOGY, 2007.Link to Item
-
Davis, F. G., S. Erdal, B. J. Mccarthy, G. Rauscher, J. Mendes, L. Rosul, and D. Bigner. “Assessing Human Exposure to Animal Neurocarcinogens: A Pilot Study.” In Epidemiology, 17:S189–90. Ovid Technologies (Wolters Kluwer Health), 2006. https://doi.org/10.1097/00001648-200611001-00481.Full Text
-
Bao, Shideng, Qiulian Wu, Sith Sathornsumetee, Yueling Hao, Zhizhong Li, Anita B. Hjelmeland, Qing Shi, Roger E. McLendon, Darell D. Bigner, and Jeremy N. Rich. “Glioma cancer stem cells promote tumor angiogenesis through vascular endothelial growth factor.” In Neuro Oncology, 8:392–392. DUKE UNIV PRESS, 2006.Link to Item
-
Erdal, S., J. Mendes, D. D. Bigner, and F. Davis. “Exposure assessment methodology in a brain cancer epidemiology study.” In Neuro Oncology, 8:406–406. DUKE UNIV PRESS, 2006.Link to Item
-
Hjelmeland, Anita B., Katie Lattimore, Brian Fee, Sarah Wickman, Stephen T. Keir, Mark D. Hjelmeland, David Batt, et al. “The combination of novel low-molecular-weight inhibitors of Raf (LBT 613) and TOR (RAD001, everolimus) decreases glioma proliferation and invasion.” In Neuro Oncology, 8:412–412. DUKE UNIV PRESS, 2006.Link to Item
-
Okamura, Tatsunori, Timothy Haystead, Darell D. Bigner, and Francis Ali-Osman. “Glutathione S-transferase P1 (GSTP1) is a novel downstream target of Akt in human gliomas.” In Neuro Oncology, 8:400–400. DUKE UNIV PRESS, 2006.Link to Item
-
Reardon, D., G. Akabani, A. Friedman, H. Friedman, J. Herndon, R. McLendon, J. Quinn, et al. “Patient-specific murine I-131-labeled anti-tenascin monoclonal antibody 81C6 radioimmunotherapy for delivering a 44-GY boost to the resection cavity periphery of patients with newly diagnosed primary malignant brain tumors: A feasibility pilot study.” In Neuro Oncology, 8:489–489. DUKE UNIV PRESS, 2006.Link to Item
-
Sathornsumetee, Sith, Anita B. Hjelmeland, Stephen T. Keir, Roger E. McLendon, David Batt, Timothy Ramsey, Naeem Yusuff, et al. “AAL881, a novel small molecule inhibitor of RAF and VEGFR activities, blocks growth of malignant glioma.” In Neuro Oncology, 8:417–417. DUKE UNIV PRESS, 2006.Link to Item
-
Shi, Qing, Anita B. Hjelmeland, Stephen T. Keir, Sarah K. Wickman, Guanghong Wu, Dowdy Jackson, Osamu Ohmori, Darell D. Bigner, Henry S. Friedman, and Jeremy N. Rich. “A novel low-molecular-weight inhibitor of focal adhesion kinase, inhibits glioma growth.” In Neuro Oncology, 8:417–417. DUKE UNIV PRESS, 2006.Link to Item
-
Shi, Qing, Shideng Bao, Anita B. Hjelmeland, Darell D. Bigner, and Jeremy N. Rich. “Secreted protein acidic and rich in cysteine (SPARC) induces glioma invasion and survival through activation of focal adhesion kinase and integrin-linked kinase.” In Neuro Oncology, 8:401–401. DUKE UNIV PRESS, 2006.Link to Item
-
Vredenburgh, James, Annick Desjardins, James E. Herndon, David Reardon, Jennifer Quinn, Sith Sathornsumetee, Sridharan Gururangan, Allan Friedman, Darell Bigner, and Henry Friedman. “Bevacizumab and irinotecan is an effective treatment for malignant gliomas.” In Neuro Oncology, 8:454–454. DUKE UNIV PRESS, 2006.Link to Item
-
Gregory, S. G., N. V. Johnson, J. J. Connelly, J. Virgadamo, R. E. McLendon, J. M. Vance, and D. D. Bigner. “Characterizing genomic rearrangements in oligodendroglioma using whole genome tilepath hrCGH arrays.” In Neuro Oncology, 8:421–421. DUKE UNIV PRESS, 2006.Link to Item
-
Parrett, Timothy J., Ozlem Yapicier, Bernd W. Scheithauer, Michael W. Graner, Darell D. Bigner, and Buge Oz. “EGFR membrane expression is associated with poor outcome in ependymomas.” In Brain Pathology, 16:S27–S27. BLACKWELL PUBLISHING, 2006.Link to Item
-
Heimberger, A. B., S. F. Hussain, K. Aldape, R. Sawaya, G. A. Archer, H. Friedman, D. Reardon, A. Friedman, D. Bigner, and J. H. Sampson. “Tumor-specific peptide vaccination in newly-diagnosed patients with GBM.” In Journal of Clinical Oncology, 24:107S-107S. AMER SOC CLINICAL ONCOLOGY, 2006.Link to Item
-
Adamson, D Cory, Chunhui Di, Qun Shi, Roger E. McLendon, Darell D. Bigner, and Hai Yan. “Prognostic significance of OTX2 in medulloblastoma.” In Cancer Research, Vol. 66. AMER ASSOC CANCER RESEARCH, 2006.Link to Item
-
Ali-Osman, Francis, James E Henderson Ii, Bartley Adams, Gamil Antoun, Henry Friedman, David Reardon, Roger McClendon, and Darell D. Bigner. “Genetic polymorphism of the Epidermal Growth Factor (EGF) gene in glioma patients: Distribution and correlation with Survival.” In Cancer Research, Vol. 66. AMER ASSOC CANCER RESEARCH, 2006.Link to Item
-
Antoun, Gamil, Pamela Gasdaska, Andrew Parker, Bartley Adams, Henry Friedman, Roger McLendon, Darell Bigner, and Francis Ali-Osman. “Identification of methylation hotspots in the GSTP1 region associated with transcriptional silencing of the GSTP1 gene in human gliomas.” In Cancer Research, Vol. 66. AMER ASSOC CANCER RESEARCH, 2006.Link to Item
-
Cui, Bo, Stewart P. Johnson, Francis Ali-Osman, Darell D. Bigner, and Henry S. Friedman. “Constitutive phosphorylation of Chk1 at serine 317 in a medulloblastoma cell line is sensitive to the inhibition of the phosphatidyalinositol-3-kinase-related kinase (PIKK) pathway.” In Cancer Research, Vol. 66. AMER ASSOC CANCER RESEARCH, 2006.Link to Item
-
Graner, Michael W., R Ian Cumming, Emily M. Thomas, Shelley Davis, Timothy J. Parrett, Ling Wang, Nichole Satterwhite, Vince Guerriero, and Darell D. Bigner. “Characterization of the HSP70 co-chaperone HspBP1 in brain tumors.” In Cancer Research, Vol. 66. AMER ASSOC CANCER RESEARCH, 2006.Link to Item
-
Maxwell, Jill A., Stewart P. Johnson, Roger E. McLendon, Francis Ali-Osman, Jennifer A. Quinn, Allan H. Friedman, James E. Herndon, et al. “O-6-alkylguanine-DNA alkyltransferase (AGT) and microsatellite instability (MSI) analyses in malignant glioma.” In Cancer Research, Vol. 66. AMER ASSOC CANCER RESEARCH, 2006.Link to Item
-
Okamura, Tatsunori, Simendra Singh, Timothy Haystead, Darell D. Bigner, and Francis Ali-Osman. “EGFR phosphorylates Glutathione S-Transferase P1 (GSTP1), a novel downstream target, in human glioma cells.” In Cancer Research, Vol. 66. AMER ASSOC CANCER RESEARCH, 2006.Link to Item
-
Shi, Qing, Shideng Bao, Darell D. Bigner, and Jeremy N. Rich. “Secreted protein acidic and rich in cysteine (SPARC) activates focal adhesion kinase and integrin-linked kinase to induce AKT-dependent glioma survival and invasion.” In Cancer Research, Vol. 66. AMER ASSOC CANCER RESEARCH, 2006.Link to Item
-
Shi, Qun, Chunhui Di, Chris Duncan, David C. Adamson, Roger McLendon, Darell D. Bigner, and Hai Yan. “Molecular characterization of the role of OTX2 in medulloblastoma pathogenesis.” In Cancer Research, Vol. 66. AMER ASSOC CANCER RESEARCH, 2006.Link to Item
-
Wakiya, Kenji, Chien-Tsun Kuan, and Darell D. Bigner. “Targeting of malignant gliomas with GPNMB-specific single-chain antibody fragment (scFv) and recombinant immunotoxin.” In Cancer Research, Vol. 66. AMER ASSOC CANCER RESEARCH, 2006.Link to Item
-
Johnson, Nicole V., Jessica J. Connelly, Josh Virigadamo, Roger E. McLendon, Jeffrey M. Vance, Darell D. Bigner, and Simon G. Gregory. “Characterizing oligodendroglioma rearrangements using whole genome hrCGH arrays.” In Cancer Research, Vol. 66. AMER ASSOC CANCER RESEARCH, 2006.Link to Item
-
Sathorn-sumetee, S., A. B. Hjelmeland, M. D. Hjelmeland, Q. Shi, A. Prager, J. L. Hart, D. D. Bigner, X. F. Wang, C. D. Kontos, and J. N. Rich. “PI3K and TGF beta pathways interact functionally and therapeutically to regulate cellular motility and invasion in malignant glioma.” In Clinical Cancer Research, 11:9134S-9134S. AMER ASSOC CANCER RESEARCH, 2005.Link to Item
-
Adamson, D. C., D. K. Broderick, C. Di, Y. R. Samuels, R. E. McLendon, D. W. Fults, V. E. Velculescu, A. Rasheed, D. D. Bigner, and H. Yan. “PIK3CA is mutated in oligodendrogliomas, astrocytomas, and medulloblastomas and associated with chromosome 1p, 19q LOH in oligodendrogliomas.” In Neuro Oncology, 7:345–345. DUKE UNIV PRESS, 2005.Link to Item
-
Ali-Osman, F., H. Lo, G. Antoun, A. Friedman, H. Friedman, and D. Bigner. “A novel mechanism of PKA- and PKC-dependent drug resistance in human gliomas involving phosphorylation and metabolic activation of glutathione S-transferase P1 (GSTP1).” In Neuro Oncology, 7:377–377. DUKE UNIV PRESS, 2005.Link to Item
-
Ali-Osman, F., J. E. Herndon, L. Stephenson, F. Davis, B. McCarthy, D. Reardon, A. Friedman, R. McClendon, H. Friedman, and D. D. Bigner. “Prevalence and prognostic significance of polymorphisms at the glutathione S-transferase M1, M3, P1, and T1 gene loci in human astrocytomas.” In Neuro Oncology, 7:304–304. DUKE UNIV PRESS, 2005.Link to Item
-
Archer, G., D. Bigner, A. Friedman, H. Friedman, K. Penne, A. Paolino, D. Smith, D. Reardon, and J. Sampson. “Immunologic targeting of the tumor-specific antigen contained in the deletion mutation of the epidermal growth factor receptor (EGFRvIII) with peptide loaded dendritic cells in patients with malignant gliomas.” In Neuro Oncology, 7:350–350. DUKE UNIV PRESS, 2005.Link to Item
-
Boskovitz, A., C. Pegram, K. Peixoto, M. R. Zalutsky, and D. D. Bigner. “Pre-clinical evaluation of D2C7, a monoclonal antibody reactive for both the wild type and variant III mutant epidermal growth factor receptor, for radioimmunotherapy of malignant gliomas.” In Neuro Oncology, 7:370–370. DUKE UNIV PRESS, 2005.Link to Item
-
Desjardins, A., J. Quinn, D. Reardon, J. Rich, S. Sathornsumetee, J. Vredenburgh, A. Walker, S. Tourt-Uhlig, D. Bigner, and H. Friedman. “Temozolomide (TMZ) with O6-benzylguanine (BG) plus CPT-11 in the treatment of recurrent malignant glioma: A phase I trial.” In Neuro Oncology, 7:320–320. DUKE UNIV PRESS, 2005.Link to Item
-
Desjardins, A., J. Quinn, D. Reardon, J. Rich, S. Sathornsumetee, J. Vredenburgh, A. Walker, S. Tourt-Uhlig, D. Bigner, and H. Friedman. “Temozolomide (TMZ) with O6-benzylguanine (BG) for TMZ-resistant malignant glioma: A phase 2 trial.” In Neuro Oncology, 7:401–401. DUKE UNIV PRESS, 2005.Link to Item
-
Desjardins, A., J. Vredenburgh, M. Badruddoja, J. Quinn, D. Reardon, J. Rich, S. Sathornsumetee, K. Penne, D. Bigner, and H. Friedman. “Phase II study of cloretazine for the treatment of adults with recurrent malignant glioma.” In Neuro Oncology, 7:317–317. DUKE UNIV PRESS, 2005.Link to Item
-
Hjelmeland, A., M. Hjelmeland, C. Kontos, D. Bigner, X. Wang, and J. Rich. “The PTEN tumor suppressor gene shifts cellular responses to transforming growth factor-beta towards tumor suppression in malignant gliomas.” In Neuro Oncology, 7:298–298. DUKE UNIV PRESS, 2005.Link to Item
-
Kuan, C., K. Wakiya, J. M. Dowell, J. Herndon, G. J. Riggins, M. Graner, C. J. Wikstrand, and D. D. Bigner. “GPNMB: A new target for human high-grade gliomas (HGL) immunotherapy.” In Neuro Oncology, 7:369–369. DUKE UNIV PRESS, 2005.Link to Item
-
Reardon, D. A., J. Quinn, J. Rich, J. Vredenburgh, A. Desjardins, S. Sathornsumetee, A. Salvado, Z. Nikolova, D. Bigner, and H. Friedman. “Imatinib mesylate (Gleevec) plus hydroxyurea: An effective regimen in the treatment of recurrent malignant glioma: Phase 2 study results.” In Neuro Oncology, 7:291–291. DUKE UNIV PRESS, 2005.Link to Item
-
Reardon, D. A., J. Rich, J. Quinn, J. Vredenburgh, A. Desjardins, S. Sathornsumetee, S. Gururangan, P. Lyons, D. Bigner, and H. Friedman. “Phase I study results of Gefitinib (iressa; ZD1839) plus rapamycin in the treatment of patients with recurrent malignant glioma.” In Neuro Oncology, 7:312–312. DUKE UNIV PRESS, 2005.Link to Item
-
Reardon, D., G. Akabani, A. Friedman, H. Friedman, R. McLendon, J. Quinn, J. Rich, J. Vredenburgh, M. Zalutsky, and D. Bigner. “An update of phase 2 trial results: Patients with recurrent malignant glioma treated with iodine 131-labeled murine antitenascin monoclonal antibody 81C6 into the resection cavity.” In Neuro Oncology, 7:311–311. DUKE UNIV PRESS, 2005.Link to Item
-
Reese, E., A. Hjelmeland, R. McLendon, E. Holland, D. Bigner, X. Wang, and J. Rich. “Expression levels of the transforming growth factor-beta mediator SMAD3 determines glioma phenotype in a genetically defined human glioma model and a transgenic murine glioma model.” In Neuro Oncology, 7:301–301. DUKE UNIV PRESS, 2005.Link to Item
-
Rich, J., Q. Shi, M. Hjelmeland, R. Goudar, S. Keir, R. McLendon, E. Reese, et al. “Low-molecular-weight EGFR/KDR tyrosine kinase inhibitor offers combinatorial benefit with a rapamycin derivative based on PTEN status.” In Neuro Oncology, 7:343–44. DUKE UNIV PRESS, 2005.Link to Item
-
Rich, J., S. Keir, S. Sathornsumetee, D. Reardon, D. Bigner, and H. Friedman. “Comination of imatinib mesylate (STI-571, Gleevec) and temozolomide (temodar) displays increased activity against glioma xenografts.” In Neuro Oncology, 7:387–387. DUKE UNIV PRESS, 2005.Link to Item
-
Sathornsumetee, S., D. Batt, M. Kieran, S. Kier, T. Ramsey, N. Yusuff, D. Reardon, D. Bigner, H. Friedman, and J. Rich. “Targeting malignant gliomas with a low-molecular-weight Raf/vascular endothelial growth factor receptor inhibitor.” In Neuro Oncology, 7:379–379. DUKE UNIV PRESS, 2005.Link to Item
-
Shi, Q., S. Bao, D. Bigner, and J. Rich. “VEGF cooperates with secreted protein acidic and rich in cysteine (SPARC) to activate intracellular glioma survival pathways.” In Neuro Oncology, 7:286–286. DUKE UNIV PRESS, 2005.Link to Item
-
Rich, J., C. Hans, B. Jones, R. McLendon, B. Rasheed, A. Dobra, H. Dressman, D. Bigner, J. Nevins, and M. West. “Gene expression profiling links invasion-related genes to poor survival in older glioblastoma patients.” In Neuro Oncology, 7:293–293. DUKE UNIV PRESS, 2005.Link to Item
-
Friedman, H. S., J. Quinn, J. Rich, J. Vredenburgh, A. Desjardins, S. Sathornsumetee, A. Salvado, Z. Nikolova, D. Bigner, and D. Reardon. “Efficacy of imatinib mesylate plus hydroxyurea regimen in the treatment of recurrent malignant glioma: Phase II study results.” In Journal of Clinical Oncology, 23:117S-117S. AMER SOC CLINICAL ONCOLOGY, 2005.Link to Item
-
Rich, J. N., D. A. Reardon, J. A. Quinn, J. J. Vredenburgh, A. Desjardins, S. Sathornsumetee, S. Gururangan, P. Lyons, D. D. Bigner, and H. S. Friedman. “A phase I trial of gefitinib (ZD1 839) plus rapamycin for patients with recurrent malignant glioma.” In Journal of Clinical Oncology, 23:130S-130S. AMER SOC CLINICAL ONCOLOGY, 2005.Link to Item
-
Vredenburgh, J. J., D. Reardon, G. Akabani, A. Friedman, H. Friedman, R. McLendon, J. Quinn, J. Rich, M. Zalutsky, and D. Bigner. “Results of a phase II study of 131 iodine-labeled anti-tenascin murine monoclonal antibody B1C6 (m81C6) administered to deliver a targeted radiation boost dose of 44 Gy to the surgically created cystic resection cavity perimeter in the treatment of patients with newly diagnosed primary and metastatic brain tumors.” In Journal of Clinical Oncology, 23:116S-116S. AMER SOC CLINICAL ONCOLOGY, 2005.Link to Item
-
Archer, G. E., D. Bigner, A. Friedman, H. Friedman, K. Penne, D. Lally-Batts, A. Paolino, S. Tourt-Uhlig, D. Reardon, and J. Sampson. “Dendritic cell vaccine for intracranial tumors I (DC Victori trial).” In Neuro Oncology, 6:341–341. DUKE UNIV PRESS, 2004.Link to Item
-
Boskovitz, A., G. Vaidyanathan, G. E. Archer, H. Ochiai, T. Okamura, J. H. Sampson, D. D. Bigner, and M. R. Zalutsky. “Medulloblastoma neoplastic meningitis targeted radiotherapy with intrathecal alpha-emitter At-211-labeled thymidine analogue.” In Neuro Oncology, 6:403–403. DUKE UNIV PRESS, 2004.Link to Item
-
Erdal, S., D. D. Bigner, and F. G. Davis. “Theoretical estimation of dermal exposure to known and suspected animal neurocarcinogens.” In Neuro Oncology, 6:326–27. DUKE UNIV PRESS, 2004.Link to Item
-
Gondar, R. K., M. D. Hjelmeland, S. T. Keir, C. A. Conrad, R. E. McLendon, C. J. Wikstrand, P. Traxler, et al. “Inhibition of receptor tyrosine kinases and mammalian target of rapamycin offers combinatorial benefit in tumor control.” In Neuro Oncology, 6:407–407. DUKE UNIV PRESS, 2004.Link to Item
-
Hjelmeland, M., A. Hjelmeland, S. Sathornsumetee, M. H. Herbstreith, N. J. Laping, D. D. Bigner, X. F. Wang, and J. N. Rich. “SB-431542, a small molecule transforming growth factor-B-receptor antagonist, inhibits human glioma cell line proliferation and motility.” In Neuro Oncology, 6:408–408. DUKE UNIV PRESS, 2004.Link to Item
-
Kuan, C. T., C. J. Wikstrand, T. S. Davis, M. R. Zalutsky, and D. D. Bigner. “Monoclonal antibodies (MABS) against somatostatin receptor 2A (SSTR2A) as potential medulloblastoma therapeutic reagents.” In Neuro Oncology, 6:409–409. DUKE UNIV PRESS, 2004.Link to Item
-
Mitchell, D. A., C. Learn, R. Schmittling, A. Friedman, R. E. McLendon, D. D. Bigner, and J. H. Sampson. “Detection and immunologic recognition of cytomegalovirus antigens expressed within malignant gliomas.” In Neuro Oncology, 6:343–343. DUKE UNIV PRESS, 2004.Link to Item
-
Reardon, D., A. Friedman, J. Herndon, J. Quinn, J. Rich, J. Vredenburgh, M. Badruddoja, et al. “Phase II trial of imatinib mesylate plus hydroxyurea in the treatment of patients with malignant glioma.” In Neuro Oncology, 6:381–381. DUKE UNIV PRESS, 2004.Link to Item
-
Reardon, D., G. Akabani, A. Friedman, H. Friedman, J. Herndon, R. McLendon, J. Quinn, et al. “Phase II study of 131-iodine-labeled anti-tenascin murine monoclonal antibody 81C6 (M81C6) administered to deliver a targeted radiation boost dose of 44 Gy to the surgically created cystic resection cavity perimeter in the treatment of patients with newly diagnosed primary and metastatic brain tumors.” In Neuro Oncology, 6:381–381. DUKE UNIV PRESS, 2004.Link to Item
-
Rich, J. N., D. Loncar, S. Sathornsumetee, S. Keir, C. Wheeler, I. Dimery, D. D. Bigner, and H. S. Friedman. “ZD6474, a vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor, inhibits growth of multiple primary central nervous system tumor types.” In Neuro Oncology, 6:413–413. DUKE UNIV PRESS, 2004.Link to Item
-
Sampson, J. H., A. H. Friedman, D. A. Reardon, H. Friedman, J. M. Provenzale, D. D. Bigner, M. Brady, et al. “Convection-enhanced delivery of IL13-PE38QQR in malignant glioma: Comparison of observed and predicted drug distribution.” In Neuro Oncology, 6:381–82. DUKE UNIV PRESS, 2004.Link to Item
-
Wikstrand, C. J., C. T. Kuan, K. Wakiya, R. I. Cumming, K. Lamszus, M. Westphal, and D. D. Bigner. “Immunotherapeutic target antigen phenotypes of pediatric vs. adult central nervous system (CNS) tumor biopsies, xenografts, and cultured cells.” In Neuro Oncology, 6:415–16. DUKE UNIV PRESS, 2004.Link to Item
-
Yan, H., C. H. Di, D. Broderick, R. McLendon, S. Gururangan, D. Friedman, and D. Bigner. “Molecular genomics of medulloblastoma.” In Neuro Oncology, 6:416–416. DUKE UNIV PRESS, 2004.Link to Item
-
Akabani, G., D. A. Rizzieri, M. R. Zalutsky, R. E. Coleman, S. D. Metzler, J. E. Bowsher, B. Toaso, et al. “Phase I trial study of [131]I-labeled chimeric 81C6 mAb for the treatment of patients with non-Hodgkin's lymphoma.” In European Journal of Nuclear Medicine and Molecular Imaging, 31:S222–S222. SPRINGER, 2004.Link to Item
-
Badruddoja, M. A., D. A. Reardon, G. Akabani, A. H. Friedman, H. S. Friedman, J. N. Rich, J. A. Quinn, K. Penne, J. J. Vredenburgh, and D. D. Bigner. “Phase II trial of iodine 131-labeled murine anti-tenascin monoclonal anti-body 81C6 (M81C6) via surgically created resection cavity in the treatment of patients with recurrent malignant brain tumors.” In Journal of Clinical Oncology, 22:124S-124S. AMER SOC CLINICAL ONCOLOGY, 2004.Link to Item
-
Yung, A., J. Vredenburgh, T. Cloughesy, B. J. Klencke, P. S. Mischel, D. D. Bigner, K. Aldape, S. Vanderburg, and M. Prados. “Erlotinib HCL for glioblastoma multiforme in first relapse, a phase II trial.” In Journal of Clinical Oncology, 22:120S-120S. AMER SOC CLINICAL ONCOLOGY, 2004.Link to Item
-
Goudar, R., S. Keir, M. Hjelmeland, C. Conrad, P. Traxler, H. Lane, X. F. Wang, D. D. Bigner, H. S. Friedman, and J. N. Rich. “Combination therapy of inhibitors of the epidermal growth factor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition.” In Clinical Cancer Research, 9:6090S-6090S. AMER ASSOC CANCER RESEARCH, 2003.Link to Item
-
Hjelmeland, M. D., M. Herbstreith, S. Sathornsumetee, A. Hjelmeland, N. J. Laping, D. D. Bigner, X. F. Wang, and J. N. Rich. “SB431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma xenograft malignant phenotype.” In Clinical Cancer Research, 9:6236S-6236S. AMER ASSOC CANCER RESEARCH, 2003.Link to Item
-
Rich, J. N., D. Loncar, S. Keir, C. Wheeler, I. Dimery, D. D. Bigner, and H. S. Friedman. “ZD6474, a vascular endothelial growth factor receptor 2 (VEGFR-2) inhibitor, inhibits growth of multiple primary central nervous system tumor types.” In Clinical Cancer Research, 9:6143S-6143S. AMER ASSOC CANCER RESEARCH, 2003.Link to Item
-
Rizzieri, D. A., G. Akabani, M. Zalutsky, R. E. Coleman, B. Toaso, E. Anderson, A. Lagoo, et al. “Phase I trial with pharmocokinetics, dosimetry, toxicity and response of anti-stromal therapy using I-131 labeled chimeric anti-tenascin therapy for lymphoma.” In Blood, 102:635A-636A. AMER SOC HEMATOLOGY, 2003.Link to Item
-
Akabani, G., S. Metzler, D. A. Reardon, D. D. Bigner, and J. H. Sampson. “Convection enhanced delivery of TP-38 immunotoxin for the therapy of brain tumors: Assessment of delivery and distribution by means of registered SPECT and MRI.” In Journal of Nuclear Medicine, 44:117P-117P. SOC NUCLEAR MEDICINE INC, 2003.Link to Item
-
McLendon, R. E., R. N. Wiltshire, J. E. Herndon, A. Lloyd, H. S. Friedman, D. D. Bigner, and S. H. Bigner. “Sub-classification of glioblastoma defined by comparative genomic hybridization alterations.” In Journal of Neuropathology and Experimental Neurology, 62:542–542. AMER ASSN NEUROPATHOLOGISTS INC, 2003.Link to Item
-
Rich, J. N., C. H. Guo, R. E. McLendon, D. D. Bigner, X. F. Wang, and C. M. Counter. “Biological model for assessing the role in glioma formation of genes differentially expressed in human gliomas.” In Annals of Neurology, 50:S31–S31. WILEY-LISS, 2001.Link to Item
-
Archer, G. E., J. M. Schuster, H. E. Fuchs, A. Guaspari, D. P. Bigner, H. S. Friedman, and R. E. McLendon. “NEUROPATHOLOGY OF MULTIPLE VERSUS SINGLE DOSE INTRATHECAL MELPHALAN IN RATS.” In Journal of Neuropathology and Experimental Neurology, 52:298–298. Oxford University Press (OUP), 1993. https://doi.org/10.1097/00005072-199305000-00152.Full Text
-
Fuchs, H. E., G. E. Archer, J. M. Schuster, O. M. Colvin, S. H. Bigner, L. H. Muhlbaier, H. S. Friedman, and D. D. Bigner. “A NUDE RAT MODEL OF LEPTOMENINGEAL TUMOR DISSEMINATION (LTD) OF HUMAN MEDULLOBLASTOMA.” In Journal of Neuropathology and Experimental Neurology, 48:356–356. Oxford University Press (OUP), 1989. https://doi.org/10.1097/00005072-198905000-00173.Full Text
-
-
Preprints
-
Yang, Yuanfan, Michael Brown, Gao Zhang, Kevin Stevenson, Malte Mohme, Reb Kornahrens, Darell Bigner, David Ashley, Giselle López, and Matthias Gromeier. “Polio Virotherapy of Malignant Glioma Engages the Tumor Myeloid Infiltrate and Induces Diffuse Microglia Activation.” BioRxiv, 2022. https://doi.org/10.1101/2022.04.19.488771.Full Text
-
-
Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.